¥xÆW¥¼¤W¥«ªÑ²¼ °]¸gºô 

¥¼¤W¥«  

¥¼¤W¥«ªÑ²¼¦æ±¡,¿³ÂdªÑ²¼¶R½æ,¥¼¤W¥«ÂdªÑ²¼¬d¸ß,§Ö³t´x´¤¥¼¤W¥«ªÑ²¼¶R½æ¯ß°Ê

Åwªï¨Ó¨ì¥²´Iºô ¤â¾÷ª© ¥[¤J·|­û µn¤J ­º­¶
¥¼¤W¥«ÂdªÑ²¼¦æ±¡¬d¸ß,¥¼¤W¥«ªÑ²¼¶R½æ¹L¤á,¿³ÂdªÑ²¼¦æ±¡¬d¸ß¡ã§K¥I¶O±M½u¡G0800-035-178
°Q½×°Ï>¥xÆW¯E¹©¥Í§Þ
½Ð¤j®a¨Ó²q·Q"¯E¹©¤½¥q¦b¥¬¤°»ò     µoªí·s¸ÜÃD ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GS.H10000301  µoªí®É¶¡:2013/4/22 ¤U¤È 10:23:12
À°¦£""·|­û¡G²q·Q10136148""¶K­Ó¤å³¹¡A¦]¬°¥L¥»¤H¤£ª¾¹D¸Ó«ç»ò¶K¨ì¿³Âdª©¨Ó~~~

³o¬O¤@½g§¹¥þ©M¯E¹©µLÃöªº¤å³¹

¦ý¦n¹³¤S¦³©ÒÃöÁp ¦]¬°¯E¹©¤]¦P¼Ë¦bµo®i³o®M§Þ³N

¦b³o­Ó²{ª÷¼W¸êªºªÑ»ù½pÀq´Á(²qªº)

¤]³\¤j®a¨Ó°Ê°Ê¸£ ¸Ñ¸ÑªÑ»ùªº´e

´N¦p¦P¼ÐÃD

±z·Q¨ì¤°»ò©O?

½Ð¤j®a¦h¦h±·³õ ÁÂÁ±z!

¥Íª«¼Ð°O(Biomarker)¬O§ÜÀù¥P¤¦(Anticancer Drug)¡H

ª¾Ãѳq°Tµû½×²Ä60´Á

³z¹L°ò¦]ÀË´úµo²{Àù¯g¬O¥i¦æªº¡C¦ý¬O­±¹ï¦h¦p¤û¤òªº¦UºØ¥Íª«¼Ð°O¡A¤â¤W¨S¦³¨¬°÷¬ã¨s¸g¶Oªº¬ã¨s¤H­û¡A­n§â¥Íª«¼Ð°O¤ÀªR§Þ³N±a¶i¥«³õ¦¨¬°¯e¯f¶EÂ_ªº¤@Àô¡A¹ê¦b§xÃø¡C

°ò¦]ÅéÂå¾Ç¤£Â_¶i¨B¡A¤Î®Éµo²{¨Ã¥Bºë½T´x±±Àù¯gªº¦­´Á¼x¥ü¤£¦A»»¤£¥i¤Î¡C¬ã¨s¡u¤À¤l¥Íª«¼Ð°O¡v(molecular biomarker)¡A¥i¥HÀ°§U§Ú­Ìµo²{¯e¯fªºªì´Á¯g­Ô¡A¤]¥i§Y®É¶i¦æ¦³®ÄªºªvÀø¡CµM¦Ó¡A³o­Ó¹Ú·Q¦Ü¤µ¤´¥¼¹ê²{¡C

¥þ¥@¬Éªº¹êÅç«Ç³£¦b¿n·¥´M§ä¥i¥Î¨Ó°»´ú¯e¯fªº¥Íª«¼Ð°O¡C¦ý¬O­n§â³oºØ¥Íª«¼Ð°Oª¾Ãѵo®i¨ì¯à°÷¥Î©ó¯e¯f¶EÂ_¡AÁÙ¦³¤@¬qªø¸ô­n¨«¡C¬ü°ê¬F©²ªº¥DºÞ¾÷Ãö¥Ø«eÁÙ¨S¦³§å­ã¥ô¦ó¤@¶µ¥Î©ó¦­´Á°»´ú¯e¯fªº¶EÂ_¸ÕÅçªk¡C

©¬´µÂå®v¡]Harvey Pass¡^»¡¡A¥Íª«¼Ð°O³Ì­«­nªº¥\¯à¡AÀ³¸Ó­n¯à«ü©úÀ³·í±Ä¦æªºªvÀø¤èªk©Î¯e¯fªº¯f²zª¬ªp¡C

ÂåÃIJ£·~Æ[¹î®a»¡¡A­n½T©w¬YºØ¥Íª«¼Ð°O¬O§_¥i¥HÀ°§U§Ú­Ì°»´ú¯e¯f¡A¤Q¤À§xÃø¡A¨S¦³¤H¯à«OÃÒ³o¨Ç¥Íª«¼Ð°O·|Åܦ¨¯à°÷¦æ¾P¤W¥«ªº¯e¯fÀË´ú§Þ³N¡C¦¹¥~¡AÁÙ¦b¹êÅ綥¬qªº¥Íª«¼Ð°OºØÃþÁc¦h¡A­n¿ï¥X¤@­Ó³Ì¦³µo®i¼ç¤Oªº¼Ð°O¡A¤]¤£®e©ö¡C

Âå®v³£§Æ±æ³oºØ¥Íª«¼Ð°OÀË´ú¯à°÷À°§U¥L­Ì§ä¨ì¹ï¯S©w¯f±w¦³®ÄªºÀøµ{¡C°ÝÃD¦b©ó¡A·í³o¨Ç¥Íª«¼Ð°O¥u¯à¥Î©ó¯f±¡¶EÂ_«oµLªk©ú½T«ü¥XªvÀø¤èªk®É¡AÂå®v¬O§_Ä@·N±Ä¥Î¡C

¬ü°ê¯Ã¬ù¤j¾ÇÂå¾Ç¤¤¤ß±Mªù¬ã¨s¶¡¥ÖÀù¡]mesothelioma¡A¯Ý¸¡µÄ¤ºÅ¨²Õ´ªº´c©Ê¸~½F¡^¥Íª«¼Ð°OªºÂå®v©¬´µ¡]Harvey Pass¡^»¡¡A¥Íª«¼Ð°O³Ì­«­nªº¥\¯à¡AÀ³¸Ó­n¯à«ü©úÀ³·í±Ä¦æªºªvÀø¤èªk©Î¯e¯fªº¯f²zª¬ªp¡C

¤C¦~«e¡A¬ü°ê°ê®aÀù¯g¬ã¨s©Ò¦¨¥ß¤F¡u¦­´Á°»´ú¬ã¨sºô¡v¡]EDRN¡^¡A§Æ±æÂǦ¹½T»{¥Íª«¼Ð°O§Þ³Nªº¥i¾a«×¡A«Ø¥ß¤@®MÀË´ú»PÅçÃҥͪ«¼Ð°O¬O§_¦³®Äªº¬yµ{¬[ºc¡C³o­Ó¤uµ{¬Û·í¯E¤j¡A¦]¬°¯e¯f¶EÂ_ÀË´ú³q±`»Ý­n¦P®É¹B¥Î¦n´XºØ¤£¦Pªº¥Íª«¼Ð°O¡A¤~¯à½T«OÀË´úµ²ªG¦b²Î­p¤W¬O¦³ÅãµÛ·N¸q¡C

´ú¸Õ¶i¦æ¤¤

EDRN³o­Óºô¸ô´£¥X¤@­Ó¦p¦óµû§P¥Íª«¼Ð°O¬O§_¦³®Äªº¯ó®×¡A¤]«ü¥X¤F¦UºØ¦³Ãö¼h­±¡CEDRN¦b¦¨¤d¤W¸UºØ¼ç¦b¥Íª«¼Ð°O¤¤¿ï¥X¤F¤@¦Ê¤ÜºØ¡A³o¨Ç¥Íª«¼Ð°O¤]¦U¦b¤£¦Pªº¬ãµo¶¥¬q¡C

³o¤@¦Ê¤ÜºØ¥Íª«¼Ð°O¡A¬O¶¡¥ÖÀù¡B¨xÀù¡B»H¯ÖÀù¡BÄáÅ@¸¢Àù»PªÍÀù³o¤­ºØÀù¯gªº¥Íª«¼Ð°O¡A¦³ªº¤´¦b¬ãµoªº²Ä¤T¶¥¬q¡A¦³ªº¤w¸g¶i¤J³Ì«á¶¥¬q¡A¨Ã¥B³z¹L¤j³W¼Òªº¤HÅé¸ÕÅçÁA¸Ñ¨ä°»´ú¯e¯fªº®ÄªG¦p¦ó¡C

¬ü°ê°¨¨½Äõ¦{¥Íª«¬ì§Þ¤½¥qCangen Biotechnologies¤]°Ñ»P¤FEDRN­pµe¡A¥L­Ì§Ó¦b¦¨¬°²Ä¤@­Ó§âDNA¬°°ò¦ªº»H¯ÖÀù¦­´Á°»´ú§Þ³N±À¤W¥«³õªº¤½¥q¡C¸Ó¤½¥qªí¥Ü¡A¥L­Ì¹ï¦Û¤v¬ãµo¡B¥H¤Q¤­­ÓDNA¤ù¬q²Õ¦¨ªºÀËÅç¤u¨ã«Ü¦³«H¤ß¡A³oºØÀËÅç¤u¨ã¥i¥H¤ñ¨ä¥L¶EÂ_¤è¦¡§ó¦­µo²{¸~½F¡C

¤£¹L¡AÁöµMÂå®v¥i¥H¥Î³oºØ¤u¨ã§ó¦­µo²{¸~½F¡A¤j³¡¤Àªº»H¯ÖÀù±wªÌÁÙ¬O±o¸g¾ú¤â³N¡C´«¨¥¤§¡A³oºØ·sªºÀËÅç¤u¨ã¹ï©ó»H¯ÖÀù¯f±wªº¦s¬¡²v¥u¦³»´·L¼vÅT¡C

Cangen¤½¥q¬ã¨s³¡ªù¥DºÞ¦ãºqªi¡]Eddy Agbo¡^»¡¡A³z¹L¥Íª«¼Ð°O§ä¥X¥i¥HªvÀøªì´Á¸~½Fªº·sÃĪ«Àøªk¡A¬O¥L­Ì¥¼¨Óªº¬D¾Ô¡CµM¦Ó¡A¥Ñ©ó³oºØ·s¦¡ÃĪ«ÀøªkÁÙ¨S°Ý¥@¡A¬ü°êªºÂå®v»P¤ä¥IÂåÀø·ÓÅ@¾÷ºc¶O¥Îªº«OÀI¤½¥q¡A¹ï¥Íª«¼Ð°Oªº¿³½ì·|«Ü¦³­­¡C

»sÃIJ£·~¸ê·½Â×´I¡A¤]³\¯à¨Ï¥DºÞ¾÷Ãö§å­ã¥Íª«¼Ð°OÀË´ú§Þ³N¡C¤£¹L¡AÃļt¤ñ¸ûÃö¤ßªº¡A¬O¦p¦ó³z¹L¥Íª«¼Ð°OÁA¸Ñ±wªÌ¾A¤£¾A¦X¨Ï¥Î¬YºØÃĪ«¡AÃļt¹ï¦­´Á°»´ú¿³½ì¯Ê¯Ê¡C

¥[¦{Genentech¤½¥q¬ãµo¥X§Ü¨ÅÀùÃĪ«Herceptin¡A¬O­Ó¦¨¥\®×¨Ò¡CHerceptin¦®¦bªvÀø¨º¨ÇÅ餺¹L«×ªí²{¬YºØ¨üÅ骺¨ÅÀù±wªÌ¡C¥ú¬O¥h¦~¡AHerceptin´N½æ¤F¤Q¤T»õ¬ü¤¸¡C

microRNAs

¦è¶®¹ÏºÖ·ç¼w»®ª÷´ËÀù¯g¬ã¨s¤¤¤ß¤À¤l¥Íª«¾Ç®a«¢«n³\¡]Sam Hanash¡^»¡¡A¤j®a³£§Æ±æ¬Ý¨ì¥Íª«¼Ð°O§Þ³N¥X²{À¸¼@©Êªº¦¨¥\¡C«¢«n³\»¡¡A²~ÀV¤£¦b©ó¹êÅç«Ç¸Ìªº¬ì¾Ç¬O§_¥ý¶i¡A¦Ó¬O¬ã¨s¤H­û­n¦p¦ó¦b¨º»ò¦hºØ°ò¦]¡B³J¥Õ½è»P·LRNA¡]microRNAs¡^¤¤¥h¿¾¦sµ×¡A§ä¥XÁ{§É¤W¦³¹ê¥Î»ù­Èªº¥Íª«¼Ð°O¡C¥L»{¬°¡A¥Ø«eªºª¬ªp´N¹³¬O¬ü°ê¦è³¡©Ý¯î®É¥N¡A¨C­Ó¤H³£¯à«Å¥Ü¾Ö¦³¤@¤ù¤g¦a¡A¨C­Ó¾ÇªÌ¤]³£¯à«ÅºÙµo²{¬YºØ¥Íª«¼Ð°O¡C

¥ß¤U¼Ð¬ñ

EDRN¶O¤F¤@µf¥\¤Ò´M§ä³Ì¦³¼ç¤Oªº¥Íª«¼Ð°O¡A¦nÅý³o¨Ç¥Íª«¼Ð°O¶i¤JÁ{§É¸ÕÅ綥¬q¡CEDRN¤w¯à´£¨Ñ¥Î©ó¬ã¨sªÍÀù¡B¨ÅÀù¡B§Z±_Àù¡BÄáÅ@¸¢Àù©Mµ²¸zÀùµ¥Àù¯g¥Íª«¼Ð°OªºÀù¤Æ²Ó­M²Õ´¡B¦å²M»P¦å²G¼Ë¥»¡C¬ì¾Ç®a¥i¥H¥Î³o¨Ç§÷®Æªì¨BÀËÅç¥Íª«¼Ð°Oªº¥i¾aµ{«×¡C

EDRN¤]«Ø¥ß¤FÅçÃҥͪ«¼Ð°O´ú¸Õ®ÄªGªº«~ºÞ¼Ð·Ç¡A¦³¤@¾ã®M§e²{¸ê®Æªº¼Ð·Ç¨t²Î¡CEDRNÁÙ»P¬ü°ê°ê®aÀù¯g¬ã¨s©Òªº¨ä¥L¹Î¶¤µÛ¤â«Ø¥ß¤@­Ó¤j³W¼Òªº¤HÅé¥Íª«¼Ë¥»Àx¦s®w¡]human biosample collection¡^¡C

±M®a»{¬°¡A³o¨Ç¨BÆJ½T¹ê¦³¨ä¥²­n¡A¦ý¬O³o¨Ç§@ªk¤£¤@©w¯à§â¥Íª«¼Ð°O´ú¸Õ±a¨ì¥«³õ¤W¡C¦b³Â¦{¥¬¬¥¼w¬ã¨s©Ò¡]Broad Institute¡^¬ã¨s³J¥Õ½èÅ骺¦N¥ß¯S¡]Mi

·|­û¡G²q·Q10136148  µoªí®É¶¡:2015/12/20 ¤U¤È 10:36:54²Ä 1517 ½g¦^À³
Faith ¤j

ÁÂÁ±z!

«¢! «¢! «¢! ¯uªº¤ß±¡«Ü´Î

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2015/12/19 ¤U¤È 09:48:21²Ä 1516 ½g¦^À³
²q·Q¤j

ÁÂÁ±z

¤j¹Ù£¸©w­n«O­«¨­Åé

µ¥¸Ñª¼¡BÅý¤K°êÁp­x¨Ó©ïÃâ

¥ú¥Î·Qªº´N§Ô¤£¦í°½¯º¤F

§Æ±æ²q·Q¤j¨C¤Ñ¤]¯à¶}Ãh¤j¯º´X¦^¡ãÅ¥»¡¹ï°·±d«Ü¦³À°§U©O¡I^_^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2015/12/19 ¤U¤È 07:57:00²Ä 1515 ½g¦^À³
ÁÂÁÂ

Faith ¤j

¥­¤ß¦Ó½× ¤j ¨â¦ìªºÃö¤ß

¸g¹L´X¥G¤@¦~ªº¬ÝÂåÀˬd ²{¦b¹ï¦Û¤vªº¨­¤ßª¬ªp ¤ñ¥¼µo¯f«e¤F¸Ñ

¦]¬°¤p§Ì±q¦~»´¨ì¦~ªì¥¼µo¯f«e ¤£¹B°Êªº¤é¤l ©}«ü¥i¼Æ

µo¯f¤§ªì ±`¶]«æ¶E ´X¦¸ªº¦å²GÀˬd ³£¥¿±`

§Ú¤Ó¤Ó´N»¡§Ú¥i¯à¬O®£·W¯g(¦]¦oªB¤Í¤¤¦³¤H¦³¦¹¯gª¬)

¦ý¤p§Ì©MCliff ¤jªº·Qªk¤@¼Ë ¤£¯à«_µM¤£Àˬd¨­Åé ´Nª½±µ¬Ýºë¯«¬ì

©Ò¥H¦b¤@³s¦êªºÀˬd¤§«á ¤~¶}©l±µ¨üºë¯«¬ìªvÀø

¤§«eªº¤K­Ó¤ë®É¶¡ ³£¦Y¤ß«ß½Õ¾ã©M§ÜµJ¼{ªºÃÄ

µM¦Ó¸ÓÃÄÁö¬O·í¤¤³Ì»´ªº ¤ß²v¤]±±¨îªºÁÙ¦n ¦ý°Æ§@¥Î´N¬O¤ß²v¹LºC ¨C¤ÀÄÁ¦b50¤W¤U

¦³®É¨ÌµM¯Ý´e ÀYµÈ ´«Àô¹Ò´N¤£µÎªA

¦³¤@¦¸¦b¦¨¤j°µ²Ä¤G¦¸¹B°Ê¤ß¹q¹Ï ¦]Âå®v¬°¤F¯u¹ê¤F¸Ñ¤ßŦ¥¼¦YÃĪºª¬ªp ³W©w§Ú24¤p®É«e¤£­n¦YÃÄ

µ²ªG§Ú´N¶}©lµJ¼{ µ¥¤W¨ì¾÷¾¹ ®Ú¥»ÁÙ¥¼¶}©l´ú¸Õ ¤p§Ìªº¤ß¸õ´N¤wöt¨ì150 ¤£¾A¦A´ú

²{¦bºë¯«¬ì¥ÎÃĤwªñ¨â­Ó¤ë ¤ßŦ¤º¬ì¥ÎÃÄ ¤w°±¦Y¤ß«ß¤£¾ãÃÄ ¥u¦Yªü¥q¤ÇÆF

·Pı¤W¦n¹³¦³®ÄªG ¯Ý´eÀYµÈªº±¡ªp¤Ö«Ü¦h ¤ß²v¤]±±¨îªº¤£¿ù ¬ù¦b65~70¶¡

¦P®É ¦b¹B°Ê«áªº½w©M®É¶¡¤]ÁYµu«Ü¦h

´Á«Ý¦b«e­±´X¦ì¯E¤Í©Ò´£¨Ñªº¥\ªk©ÎÀøªk ¦b½m²ß¤W­y¹D«á

¯à°÷¥h°£¹ïÃĪ«ªº¨Ì¿à

ÁÂÁ¤j®aªºÃö¤ß

¤j®a¤]­n¦n¦n«O¾i¦Û¤vªº¨­Åé ¨É¨ü°·±d¤S¦³°]´Iªº¤H¥Í

ÁÂÁ¤j®a!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥­¤ß¦Ó½×10139639  µoªí®É¶¡:2015/12/19 ¤U¤È 02:28:58²Ä 1514 ½g¦^À³
²q·Q¤j¡A

ÂåÀø¯gª¬§Ú¤£À´¡A¤£¹L¦pªG¦èÂåµLªk¸Ñ¨M°ÝÃD

¬O§_¸Õ¸Õ¶Ç²Î¤¤Âå©Î¥Á«UÀøªk¡H

¥ò´º¤j¥X°ê²`³y³o»ò¤[¡A¸Ó¦^°ê¤F¡A¯à§_´£¨Ñ«Øij¡H

Á`¤§§Æ±æ±z¨­Åé±d°·¡A¤£¨ü¯fµh©ÒÂZ¡Aª©¤W¯E¹©ªº¦P¾Ç¤]¤@¼Ë¡A³o¼Ë¦pªG¬Y¦~·í¯E¹©5112®É¡A¤j®a´N¨Ó¶}­Ó²±¤jªº¦P¾Ç·|§a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2015/12/19 ¤W¤È 07:24:22²Ä 1513 ½g¦^À³
²q·Q¤j

¤p§Ì¤§«e¬Ý±z´y­zªºª¬ªp

£¸ª½¹ï±zªº¤ßŦ¸õ°Ê·P¨ì¼~¤ß

¬Q¤é¤Í¤H¨ì®a§@«È¡A²á¨ì°·±d¡A¤]²á¨ì¤ßŦ°ÝÃD

·Pı¡u¤ß©ÐŸ°Ê¡v¬O¤@¯ë¤H¤ñ¸û¤Öµo²{ªº¡A¥H¤U¦³¨Ç¸ê®Æ¨Ñ±z°Ñ¦Ò

¤ß«ß¤£¾ã¤£ªvÀø¡@·í¤ß¸£¤¤­·¡Ï¤ßŦ°IºÜ

°·±dÂåÀøºô

11¤ë21¤é¶g¤» ¤W¤È8:16

¡i2016»O¥_´í¥´¤½¯q°¨©ÔªQ¡j

¡]°·±dÂåÀøºô¡þ°OªÌ³\ºÓ¿o³ø¾É¡^¥x¥_ºaÁ`¬ã¨s¹Î¶¤µo²{¡A¦]¤ß©ÐŸ°Ê©Ò¤Þ°_ªº¤¤­·­·ÀI¡A¤ñ¦è¤è¤HÁÙ°ª¡I¬ã¨s«ü¥X¡A¦b¥xÆW¡A¤ß©ÐŸ°Êªº¯f±w¥u­n±a¦³¤@­Ó¤¤­·ªº¦MÀI¦]¤l¡A¤¤­·¾÷²v´N¤É°ª¬ù3%¡A¬O¦è¤è¤Hªº2­¿¥H¤W¡A¦Ó¨ä¤¤¡A­·ÀI³Ì°ªªº´N¬O65·³¥H¤WªºªøªÌ¤Î¿}§¿¯f±wªÌ¡C

¥x¥_ºaÁ`¤ßŦ¤º¬ìÂå®v»¯¤l¤Zªí¥Ü¡A¤ß©ÐŸ°Ê¬OÁ{§É¤W³Ì±`¨£ªº¤ß«ß¤£¾ã¡A¥Ø«eµo¥Í­ì¦]¤£©ú¡C©Ò¿×¤ß©ÐŸ°Ê«Y«ü¤ß©Ð§Ö³t¦Ó¤£³W«ßªº¸õ°Ê¡A¥i©Èªº¬O¡A¦]¤ß©ÐµLªk¦³®Ä¦a¦¬ÁY¡A¤@¥¹µo¥Í¤ß©ÐŸ°Ê®É¡A¤ß©Ð¤ºªº¦å²G¬y°Ê¤£¨Î¡A®e©ö¾®µ²¦¨¦å®ê¡A­Y¬O¦å®êÀHµÛ¦å²G¬y¦V¸£³¡¡A¥i¯à·|ªý¶ë¦í¸£³¡¦åºÞ¦Ó¤Þ°_¸£¤¤­·¡C

¥_Á`¤ß«ß¤£¾ã¬ã¨s¹Î¶¤¦¨­û¡B·sÃÄÁ{§É¸ÕÅ礤¤ß¥D¥ô¦¿±á®¦±Ð±Âªí¥Ü¡AÁöµM¼Ú¬üªºªvÀø«ü¤Þ§¡«Øij­n¨Ï¥ÎÃĪ«¨Ó±±¨î¯f±wªº¤ß¸õ³t²v¡A¦ý¥Ø«eµL¥ô¦óªº¤åÄm©ú½T«ü¥X¤ß²v±±¨î¥i¥H§ïµ½¯f±wªº¹w«á¡C

¤ß©ÐŸ°Ê¤£±±¨î¡@©ö¤¤­·¡B¤ßŦ°IºÜ

¥Ø«e¥xÆW¤ß©ÐŸ°Ê²±¦æ²v¬ù1%¡A¥þ¥x¬ù¦³23¸U¦W¤ß©ÐŸ°Êªº¯f±w¡A¦Ó¤ß©ÐŸ°Ê¤]±`¦X¨Ö¤ß¸õ¹L³t°ÝÃD¡A­Y¤£±±¨î¯fªp¡AÅý¤ßŦ­t¾á¤j¡A®e©ö¦³°IºÜªº¦MÀI¡A¦]¦¹¡AÂå®v«ü¥X¡A±±¨î¦í¤ßŦ¸õ°Êªº³t«×¡A¥i¹w¨¾¤¤­·¡A¤]¥iÁקK¤ßŦ­t¾á¹L¤j¡C¦¹¬ã¨s¤w¥Zµn©ó¤ßŦ¾Ç¬É­«¶q¯Åªº´Á¥ZJ Am Coll Cardiol»PCirculation¡A°ê»ÚÂå¾Ç´CÅéMedscape§ó¬O±MÃD³ø¾É¡C

ÃĪ«±±¨î¤ß¸õ¡@¥i­°§C¦º¤`­·ÀI

2013¦~®É´¿¥H¤ß©ÐŸ°Ê¹q¿N³N¬°¥DÃDºaÀò¥Íµ¦·|SNQª÷¼úªº¥_ºa¤º¬ì³¡³¯¾A¦w¥D¥ô¬O¬ã¨s¹Î¶¤ªº»â¾ÉªÌ¡A¥D¥ôªí¥Ü¡A¬ã¨s¹Î¶¤¦b¨â¦~¶¡¡A¤ÀªR¤Fªñ30¸U¦W¤ß©ÐŸ°Ê±wªÌ¡A¬ã¨s¤£¦P¤ß²v±±¨îÃĪ«¹ï©ó¯f±w¹w«áªº¼vÅT»P¤¤­·¾÷²v¡C¬ã¨sµ²ªGÃÒ¹ê¡A±µ¨ü¤A«¬ªýÂ_¾¯¨Ó±±¨î¤ß¸õ³t«×ªº¯f±w¡A¬Û¸û©ó¨S¦³¨Ï¥Î¥ô¦ó¤ß²v±±¨îÃĪ«ªº²Õ§O¡A¦º¤`ªº­·ÀI¬ù¤U­°24%¡C¦Ó¨Ï¥Î¤ò¦a¶À¨Ó±±¨î¤ß²vªº±wªÌ¡A¤£¦ýµLªk¦³®ÄªvÀø¤ß«ß¤£¾ã¡A¤Ï¦Ó´£°ª¦º¤`­·ÀI¡]¬ù12%¡^¡C

ªøªÌ¡B¿}§¿¯f°ª­·ÀI¡@ÂåÆ~¿n·¥ªvÀø

¦P®É¡A¥_ºa¹Î¶¤§óµo²{¡A¥xÆW¤ß©ÐŸ°Ê±wªÌªº¤¤­·­·ÀI¦ü¥G¤ñ¦è¤è¤H°ª¡A¥u­n±a¦³¤@­Ó¤¤­·ªº¦MÀI¦]¤l¡A¸£¤¤­·­·ÀI±Û§Y¼W¥[2.55%¨ì2.75%¡A¬O¦è¤è¤Hªº2­¿¥H¤W¡A¨ä¤¤¡A¤S¥H¦~¬ö¶W¹L65·³¤Î¿}§¿¯f±wªÌªº­·ÀI³Ì°ª¡C»¯¤l¤ZÂå®v©IÆ~¡A­Y¦³¤W­z±¡ªpªº±wªÌ¡AÀ³ªø´Á±µ¨ü¤fªA§Ü¾®¦åÃĪ«ªvÀø¡A¥H¹w¨¾¤¤­·ªºµo¥Í¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2015/12/18 ¤U¤È 08:24:48²Ä 1512 ½g¦^À³
´µ¤p¤å¤j

ÁÂÁ±z´£¥Ü½m¥\¤ßªk ©ÎÅý¨S¤°¼z®Úªº¤p§Ì¤ñ¸û®e©ö¶i¤Jª¬ªp

·PÁ±zªº¤À¨É

QQ¤j

ÁÂÁ±zªº¸É¥R

¤p§Ì·|¸ÕµÛ±q¤j®aªº¤èªk¤¤¥hÅé·| §ä¥X¾A¦X¤p§ÌÅé½è¯fªpªº¤è¦¡ «ù«í½m²ß

ÁÂÁ¤j®aªºÃöÃh

¦A¦¸¯¬ºÖ¤j®a¨­¤ß°·±d ¤ß·Q¨Æ¦¨

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GQQ10140589  µoªí®É¶¡:2015/12/18 ¤U¤È 12:45:18²Ä 1511 ½g¦^À³
²q·Q¤j:

©êºp! §Ñ°O´£¤Î«á¨Ó§Ú¨Ï¥Î¦å¿}µ§¨ú¥N©ñ¦å¤ù. ¸û¦³®Ä²v, ¬}¤f¤]¸û¤p.

¤w¼Æ¦~¨S¦³³o¡¨¦å½ÄÀY¡¨ªº§xÂZ¤F.

¥t¤p©_¤j©Ò»¡ªº­ì©lÂI, ­Y¤£¤è«K«ö¼¯®É, ¥ÎÂåÀø¯Åªº»·¬õ¥~½u·Ó®g¤]«Ü¦n.

®ÄªG¦U¦³¤d¬î. ¦Ü©ó3¸U¥ñ¯Sªº¹q¦ìªvÀø´È¹ï©ó¨­Å骺¯«¸g½Õ¾ãªø´Á¤U¨Ó·|

¦³À°§U. ³o¨Ç³£¬O­Ó¤H¤Î¿Ë¤Í¸gÅç¤À¨É¨Ñ±z°Ñ¦Ò.

´µ¤p¤å¤j:

+ 1

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G´µ¤p¤å10139040  µoªí®É¶¡:2015/12/18 ¤W¤È 08:10:56²Ä 1510 ½g¦^À³
²q·Q¤j

¥H¤U¬O¤p§Ì©Ò±µÄ²ªº¨ä¤¤¤@ªù®ð¥\¡A°w¹ï®ð¥\ºAªº»¡©ú¡A¥i°Ñ¦Ò¬Ý¬Ý

®ð¥\ºA¡G¤w¶i¤J©ÀÀY±M¤@¡A¤ß«Ü¦wÀR¡A¦w©wªº½m®ðª¬ºA¡AºÙ¬°¡i®ð¥\ºA¡j¡C³oºØª¬ºA·|¨ÏÂø©À¦ÛµM®ø¥¢¡A¦p¦P¶i¤J¤F¤£¦Pªº®É¶¡¡BªÅ¶¡¦¸¤¸¡C

¡u§Ú­n¶}©l½m¥\¡A¶i¤J®ð¥\ºA¡vªº¦Û§Ú·t¥Ü¡A¥i¥H¨ó§U¶i¤J®ð¥\ºA

½m®ðªº®É­Ô¤ß«Ü¦wÀR¡B¦w©w¡A¤ß´N±Ó¾U¡A»E¶°®ðªº¯à¶q¤~·|ºë¯Â¡C¦Ó

¥B¼ô±x¤ñ¸ûºë·Lªº®ð·P«á¡A¤ß§ó®e©ö©w¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2015/12/17 ¤U¤È 10:38:00²Ä 1509 ½g¦^À³
·PÁ´X¦ì¤j¤j´£¨ÑÄ_¶Qªº·N¨£

¤p§Ì·|·ÓµÛ°µ°µ¬Ý

§Æ±æ¦hºÞ»ô¤U ¦­¤é«ì´_°·±d ÁÂÁ¤j®a!

JM¤j

±zªºÀR§¤«Øij ¨Ìºa¶§ªº¬ã¨s¦ü¥G¥i¥H¬¡µ¸°Æ¥æ·P¯«¸g §Ú·|¸ÕµÛ½m²ß¬Ý¬Ý

ÁÂÁ±z

Cliff ¤j

±z¯u¬O¸U¨Æ³q ³s¥\ªk³£¬ã¨s»á²` ¤@»y¹D¯}½m¥\ºëÀH

¡§®ð¥\ºAªºª¬ªp¤U¡A¨­¤ß¬O³B©ó»´ÃP¡B´r§Ö¡BÃP¡BÀR¡B¦ÛµM¡A¹ï©ó½Õ¸`¦Û«ß¯«¸g¡A­Ó¤H¸gÅçı±o¦³©ÒÀ°§U¡¨

«¢! ­ì¨Ó¤p§Ì¥H«e°µªº³£¬OÅé¾Þ

¤p§Ì¤]ı±o¦Û¤v¤ß«ß¤£¾ã¬O¯gª¬ ¤£¬O¯f¦]

§Ú¦³°µ¹B°Ê¤ß¹q¹Ï ¦ý¦]¤p§Ì¦h¦½Åé½è ¦½¬y¤Ó¦h ¼vÅT¶K¤ù»P¨­Å骺¶K¦X«×

¾É­P¹B°Ê¤ß¹q¹Ï ¤£¬Æ²z·Q ¤£©ö§PŪ

¥B·íªì¦]¦Û¤v­è°µ§¹PET/CT ¿ç®g¾¯¶q¤w§l¦¬¤£¤Ö ¤£´±¦A°µ¤ß¦ÙÄéª`³y¼v©Î64¤ÁCT«aª¬°Ê¯ßÀˬd

´N¦b¥b¦~«á ¦b¦¨¤j¦í°|Àˬd®É °µ¤F256¤ÁCT«aª¬°Ê¯ßÀˬd

¶t¤Æ«ü¼Æ 0.6 ÁÙ¦n ¦³¦h³B´³¶ô ¦³¨â³B¯U¯¶25 ~ 49 % ¾l¬Ò¤p©ó 25 % À³¤]ÁÙ¦n

¦Ü©ó¸~½FÀ£­¢¤¤¼Ï¯«¸gªººÃ¼{ §Ú¦³©çÀV´ÕX ¥ú ¨S²§¼Ë

©ç§C¾¯¶q¯Ý³¡CTªº³ø§i ¦³´£¤Î¡¨ Degenerative change of spine with spurs formation. ¡§ ³o­Ó¤£ª¾¦³µL¼vÅT?!

§Úªºª½Ä±©M§Ú¦Yºë¯«¬ìÃĪ«ªº·P¨ü ©Î³\ÁÙ¦³¨ä¥L­ì¦] ¦ý°Æ¥æ·P¯«¸g¤Ó®z À³¤]¬O­ì¦]ªº¤@Àô

ÁÂÁ±z

QQ¤j

·Q¤£¨ì±z¤]¦³¦P¼Ë¸gÅç ¤p§Ì¬Ý¹L¨â­Ó¯«¸g¤º¬ìÂå®v

ÀYÀV³¡MRI ÀV´ÕX ¥ú ÁÙ¦³ÀV°Ê¯ß¶W­µªi ³£¥¿±`

¦ýÀY³¡¯gª¬ÁÙ¬O¨S§ïµ½ ¤@­ÓÂå®v´Nª½±µ¸ò§Ú»¡ ¤£¬O³o¬ìªº°ÝÃD ½Ð§ä§O¬ì

¥t¤@¦ì»¡¥i¯àÀV³¡¦Ù¦×¤Óºò ¶}µ¹§Ú¦Ù¦×ÃP¦¢ÃÄ»I

¨C·í§Úı±oÀYµÈµÈ¤£µÎªA®É ¶î©ÙÀV³¡ ¦³½w¸Ñ¤§®Ä

¤Óµh­W¤F ¤£¬O¬ÝÂå­W ¦Ó¬O§ì¤£¨ì¯f¦]

ÁÂÁ±z

¦n¤ß¤j

±z¨£¥~¤F ¬O¤p§Ì­n¸ò±z¹Dºp¤~¬O

±z»¡¤ß¸Ìªºµ² ÄÝ©ó¤ßÆF¼h­±ªº°ÝÃD ¤p§Ì·|ÀR¤ß¦a·Q¤@·Q Äpµ²¦b­þ¸Ì

¥Í¯f¤~ª¾¨­¤ßÆF¥­¿ÅªºÃø³B

ÁÂÁ±z

¦h¦h ¤j

ÁÂÁ±zªº´£¿ô

¡§ ¯uªº­n¹ï¯g¤UÃÄ ¡¨ ³o¥¿¬O¤p§Ì·í¤U·Q´M¨Dªº

¬Ý¨ÓÁÙ­n¤@¬q®É¤é·Î¼õ ¤~¯à§ä¨ì¯u¥¿ªº¯f¦]

ÁÂÁ±zªº¯¬ºÖ

¯E§b ¤j

¤p§Ì¤]¬Ý¹L¥t¤@­Óºë¯«¬ìÂå®v

¥L¤]»¡§Ú¬O®£·W¯g

¤£¹L¦Y¤F¶}ªºÃÄ ´X¥G¾ã¤Ñ©ü¨I¨I ´N¤£´±¦A¦Y¤F

©Î³\¬O®£·W¯g ¦]§Úªº¯gª¬¤Ó¹³®Ñ¤W´y¼gªº

¥u¯à¤@¨B¤@¨B¨Ó¬d

ÁÂÁ±z

¦Ñ´­ ¤j

ÁÂÁ±zµ¹ªº«Øij ³o¨â¶µ¤p§Ì¤]³£°µ¤FÀˬd

¤p§Ì¬Q¤é¨S»¡²M·¡ ·Ð³Ò±z¦A¦¸¥mÀ{ ¯u¹L·N¤£¥h

ÁÂÁ±zªºÃö¤ß©M¯¬ºÖ

¤p©_¤j

³Â·Ð±zªá³o»ò¦h®É¶¡ ¸ò¤p§Ì»¡©ú±zªº¸gÅç©MÀøªk

§Ú·|ÂùºÞ»ô¤U¸Õ¸Õ¬Ý ºÉ¤O¦a°õ¦æ

§Æ±æ¯à°U±zªººÖ ¦³®Ä ¬Æ©Î²¬Â¡

ÁÂÁ±z

¦A¦¸·PÁ¤j®aªºÃöÃh ¤p§Ì»Ê·P¤­¤º

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2015/12/17 ¤U¤È 02:29:14²Ä 1508 ½g¦^À³
²q·Q¤j¡A

¥H¤U¬°¤F¨³³t¡B½T¹ê¦aªí¹F¤p§Ìªº·Qªk¡A¤å¦r¤º®e´N¤£°µ¹L¦hªº­×¹¢¡C

¥H¤U¬O¬°¤F¯S®í¥Øªº(²q·Q¤j«ì´_°·±d)©Ò°µªº¤Á½R°Q½×¡A»P¬ì¾Ç«D¬ì¾ÇµLÃö¡B»P»ù­ÈÆ[µLÃö¡B»P¹ï¤¤Âå©Î¦èÂ媺°¾¦nµLÃö¡A­Y¯E¤Í¦³¿³½ì¥i¦Û¦æ¬ã¨s¡A­Y¨S¦³¿³½ì´Nª½±µ¸õ¹L¡A¤p§Ìªº°ß¤@¥Øªº¬O²q·Q¤j«ì´_°·±d¡C

½t°_¡G¤p§Ì¦~»´®É³ßÅw¹B°Ê¡A¹B°ÊÃø§K·|¦³¨Ç¹B°Ê¶Ë®`¡A¦ý¦~»´®ð©ô¡A¶K­Ó»IÃĹL¤@°}¤l¤]´N¤£Ãª¨Æ¤F¡C¸g¹L¤F¤Q´X¦~¡Aº¥º¥²£¥Í¤F«á¿ò¯g¡A¨Ò¦p¤[¯¸Áv³¡»Äµh¡B¥k¸}½ï±`ÁôÁô°µµh¡A¤Ñ®ð¤£¨Î®É¯S§OÄY­«¡B¸y³¡§¤¤[¤F©ö»Äµh¡B¯ÝµÄ¦³®É·|¦³´eµh¡Aµh°_¨Ó§Ï©»¤ßªÈµ²°_¨Óªº·Pı¡C»Äµh¤¤Â媺³B²z¤èªk´N¬O°w¨b©M¼ö¼Åµh³B¡A¦èÂå¤j¦h¥Î¤îµh¾¯©Î¦Ù¦×ÃP¦¢¾¯¥H¤Î«Øij´_«Ø¡A»ÄµhÁöµM§xÂZ¡A¦ý¹ï¥Í©R¤]¨S¤°«Â¯Ù¡A¤]´N»P¤§©M¥­¦@³B¡C¦ý¯ÝµÄ´eµh´N«DÀˬd¤£¥i¡A¦èÂåÀˬd¤ßŦ¤@¤Á¥¿±`¡AÂå¥Í§PÂ_À³¸Ó¬O¯Ý¦Ù©âµh¤Þ°_ªº·Pı¡Aµ¹­ÓÃĦY¡A¤]¤£µh¤F¡A¦ý¤@°}¤l´N·|§xÂZ¤@¤U¡C

¦ý¤p§Ì­Ó©Ê¡A·Q¬°³o¨Ç§xÂZ§äµª®×¡A¥u­n¹ï¨­Åé¨S¦³«I¤J¦¡ªºªvÀø¤è¦¡¡A·|§â¥¦·í°µ¦Û¤v¨­Å骺¹êÅç¨Ó¸Õ¸Õ¬Ý¡C¦]½t»Ú·|±µÄ²¨ì¤F¡y­ì©lÂI¡z¡A¨ä²z½×ÄAÂФ¤¦èÂå²z½×¡A»¡¯uªº¡A¨ü¹L¬ì¾Ç¹êÅç«ä·Q±Ð¨|ªº¤H¤@¶}©l«ÜÃø±µ¨ü³o¼Ëªº¤@­ÓÀøªk¡A¦ý¦]¬°¥¦´N¬O±q¤j¶qªº±wªÌ¨­¤WÂk¯Ç¥X¨Óªº¾Þ§@¦¡Àøªk¡A²³æÁ¿¡A°µ°µ¬Ý¡A«Ü§Ö´N¥i¥Hª¾¹D²z½×¹ï¤£¹ï¡A¤p§Ì´N¥ý§â¸£³U©ñªÅ¡A·ÓµÛ¥¦ªº¤èªk¥h¾Þ§@¡A³ºµM¾Þ§@¤F¤§«á¡Aªø¦~¤U¨Ó¨­Å骺³o¨Ç§xÂZºCºC®ø¥¢¤F¡A©ÎªÌ°¸¦³µo§@¡A¦ý¤]¥i¥H³z¹L¾Þ§@§â¤£µÎªAªº¯gª¬µ¹½w©M¤U¨Ó¡A¤§«á¡A¤p§Ì¯uªº¸ò³o¨Çªø¦~ªº§xÂZ©M¥­¦@³B¤F¡C

¤p§Ìª¾±z¬O¨ü¹L¬ì¾Ç°V½mªº¤H¡A¥O¤½¤l¤S¬O´NŪÂå¬ì¡A±Ë¥¿²Î¦èÂå¡AÂà¥tÃþÀøªk¡A¹ê¦b¬ð¤a¡A¦ý±z¤w°µ¤F¦èÂå¸Ô²ÓªºÀˬd¡A°£¤F¤ß¹q¹Ï©M¥i¯à°Æ¥æ·P¯«¸g¸û®z¥~¡A¨ä¥¦ªº¾¹©x²Õ´¬dµL²§ª¬¡A¡y¦b¥Ø«eªºªvÀø¤è¦¡¤£°µ¥ô¦ó§ïÅܪº±¡ªp¤U¡z¡A¡y¹ï¨­Åé¤]¨S¦³¥ô¦óªº«I¤J¦¡ªvÀøªº±¡ªp¤U¡z¡A¥Î¬ì¾Ç¹êÅ窺ºë¯«¨Ó¾Þ§@¤@­Ó¥i¯à¥i¥H¤j´T§ïµ½¯gª¬ªºÀøªk¡A¥H±zªº°l¨D·sª¾ªº­Ó©Ê¡A¥i¥H¹Á¸Õ¬Ý¬Ý¡C±z¤£¥Î§¹¥þ¬Û«H­ì©lÂIªº²z½×¡A­Y¯gª¬¯uªº¦n¤F¡A±z¤]¥i¥H§â³o­ÓÀøªkµ¹§Ñ±¼¡A¤p§Ì­«ÂI¥u§Æ±æ±zµ¹¦Û¤v©Mµ¹­ì©lÂI³o­ÓÀøªk¤@¦¸¾÷·|¡C

­ì©lÂI½t¦Û¤¤Âå®v±i°xº~©Ò³Ð¥ß¡A¥¦ªº²z½×­«ÂI¦b¤Hªº°·±d»Ý­n¨­Å餺¦bÀô¹Ò©M¥~¦bÀô¹Òªº¥­¿Å¡A·í¥¢¥h¥­¿Å®É¡A¨­Åé·|·Q¿ìªk¥h°µ½Õ¾ã¡AÁö¦³·l¶Ë¡A¦ý¤]¥¼¥²¥X²{¯gª¬¡A¦ý·í¤º¥~¦bªº·l¶Ë¤O¶q¤Ó¤j®É¡A¶W¹L¨­Å骺½Õ±±¯à¤O¡A¯gª¬´N¶]¥X¤F¡A¤]´N¬O¥X²{¤F¯fµhªº²{¶H¡C³o¨Ç¤º¥~¦bÀô¹Òªº·l¶Ë¡A·|ºCºC¤ÏÀ³¦b¨­Å骺©T©wªº­ì©lÂI¨­¤W¡Aº¥º¥¦a§Î¦¨¤F­ì©lµhÂI¡A¨­Åé­Y¦s¦b¤F­ì©lµhÂI¡A­Y¨­Å骺Åé¤O¤]°I®z(ºÙ¤§¬°¨­Å骺¼ö¯à¤£¨¬¡A¤p§ÌºÙ¤§¬°¥Í©R¤O´î®z)¡A¤@¸I¨ì¤º¥~¦bªº·l¶Ë¦]¯À¥X²{(¨Ò¦p¥Í®ð¡B´d¶Ë¡B¹L³Ò¡B¨ü´H¡B¤£·í¶¼­¹µ¥)¡A´N¥i¯àIJµo¯gª¬¥X²{¡C¦b¤¤Âå¡A³Ì±µªñ­ì©lÂI²z½×ªº¬O¡u¶Ë´H½×¡v©M®]«äÂ䪺¡uªü¬O¥Þ¡v¡A¦b¦èÂå³Ì±µªñªº¬O¡utrigger point¡v¡A¦ý¡uªü¬O¥Þ¡v©M¡utrigger point¡v¥u³B²z¯kµh¡A¤£³B²z¯e¯f¡A¦Ó­ì©lÂI¨âªÌ³£³B²z¡C

²³æ¨Ó»¡¡A­Y¤£¬O«æ©Êªº¥~¶Ë©ÎªÌ¬O²Óµß¯f¬rªº·P¬V¡A¤HÅ骺¤j³¡¤À¯kµh©M¯e¯f³£¬O¨­Å饢¥h¤F§¡¿Åª¬ºA©Ò¥X²{ªº²{¶H¡A¦Ó¨­Åé¤W¦³¼Æ­Ó©T©w¦ì¸mªº­ì©lÂI¡A³o¨Ç¤£¦Pªº­ì©lÂI´xºÞ¨­Å餣¦P¦ì¸mªº¯e¯f»P¯kµh¡A³B²z¯e¯f©Î¯kµh¬O±N­ì©lµhÂI¸g¹L«ö±À»P¼ö¼Åªº¾Þ§@¡A¥i¥H¨ë¿E¨­Å骺§K¬Ì¤O©M­×Å@¯à¤O¡A¨Ãµ¹¤©¾A·íªº¸É¥R¼ö¯à(¤¤Â媺­¹¸É)¡A¨­Åé±N¦A«ì´_§¡¿Åªºª¬ºA¡A¯kµh©M¯e¯f´N¦]¦Ó®ø¥¢¡C

±z©Ò»Ý­n°µªº¡A«Ü²³æ¡A

¤@¡B¸É¥R¼ö¯à¡A¼W¥[Åé¤O¡C¹B°Ê¡G¨Ò¦p§Ö¨«¡B®ð¥\¡B¥­¥Ï¥\³£¦æ¡C­¹¸É¡G¨Ò¦p¤Hçx´ö¡BÁ¤´ö¡B¤¤Â媺·Å¼ö©Ê­¹ª«¡B¤Ö¦Y´H²D©Ê­¹ª«¡C

¤G¡B¼ö¼Å¡CÃħ½¶R¤@­Ó§N¼ö¼Å¥Î³U¡A¤jªº¡A¥i¥H¸Ë¤ñ¸û¦h·Å¼ö¶}¤ô¡A¤@¤Ñ¨â¦¸¼ö¼Å±zªº­ì©lµhÂI¡A­I³¡ªº­ì©lµhÂI¥i¥H¨Ï¥Î´¡¹qªº¼ö¼Å¹Ô¡A¦b­ì©lÂI«ö±À¤§«á¦b­ì©lÂI¦ì¸m¼ö¼Å¡A·Å«×¥H·Å·xµÎ¾A¬°­ì«h¡C

¤T¡B¾Ç·|­ì©lÂIªº¦ì¸m¤Î«ö±Àªº¤èªk¡C³oÂI¥i¥H¤W­ì©lÂIªº©x¤èºô¯¸¡AùØÀY¦³±Ð¾Çªº¼v¤ù¡A±z¥i¥H¥ý±qÀY³¡­ì©lÂI©M¤W­I³¡­ì©lÂI¾Ç°_¡A¨ä¥¦ªº²z½×©M¨ä¥¦ªº³¡¦ì¦³®É¶¡¦AºCºC¬Ý¡C

±zªº¯gª¬¥D­n¦bÀY³¡©M¯Ý³¡¡B¤ßŦ¡B­G¡AÀY³¡¥ÑÀY³¡­ì©lÂI´xºÞ¡A¯Ý³¡¡B¤ßŦ¡B­G¥Ñ¤W­I³¡­ì©lÂI´xºÞ¡CÀY³¡­ì©lÂI¥D­n¬O¨â­Ó¦Õ¦·«á­±¤U½t¨â­Ó°©ÀY¥æ±µ³B¡A±i¤j¼L¤Ú®É¡A¦Õ¦·«á­±¤U½t¦³¤@­Ó¥W¬}³B´N¬OÀY³¡­ì©lÂI¡A¤p§Ì´±ªÖ©w¡A±z­Y§ä¨ì¥¿½Tªº¦ì¸m¡A¥Î­¹«ü«ü¸¡©ÎÃö¸`³B«öÀ£¡A¤@©w·|¦³¼@µhªº·Pı¡A¦ý¨º¥u¬O¥Ö¦×ªºµh¡A¤â«ü¤@©ñ¶}´N°±¤F¡A«Ü¹³¬O¤â«üÀY³QªùÀ£¨ì©ÎªÌ¤â«üÀY³QÅKºlÂñ¨ìªº·Pı¡A¯gª¬¶VÄY­«©Îµo§@ªºÀW²v¶V°ªªº¤H¡A«öÀ£­ì©lµhÂI·Pı´N¶Vµh¡A¦ý½Ð±z©ñ¤ß¡A­ì©lÂI¦b¸Ñ­å¾Ç¤W³£¬O°©ÀY®ÇÃ䪺²ÓÁ_©ÎªÌ¦Ù¦×¸s¡A¨S¦³­«­nªº¯«¸g¦åºÞ³q¹L¡A³oÂI±z¥i¥H½Ð¥O¤½¤l°µ½T»{¡C

«öÀ£­n½w¡A¥H¦Û¤v¯à©Ó¨ü¦ý¤S¥²¶·¦³¨Çµh¬°­ì«h¡A¦B­á¤T¤Ø«D¤@¤é¤§´H¡A±z¥Ø«eªº­ì©lµhÂIªºª¬ºA¤£¬Oµuµu´X¤Ñ§Î¦¨ªº¡A¦]¦¹¥²¶·ºCºC¨Ó¡A¨C¤Ñ«öÀ£¨â¦¸¡A«ö«á¼ö¼Å­ì©lµhÂI¡A§â¼@µhªº­ì©lµhÂIºCºC«ö¼¯¦¨¤£¤Óµhªº­ì©lÂI¡A¦b³o­Ó¹Lµ{¤¤¡A±zªº¯gª¬©M¤£µÎªAªºÀW²v·|ºCºC­°§C¡A±z­ì¥»ªºªvÀø©M¶E

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦Ñ´­10141055  µoªí®É¶¡:2015/12/17 ¤U¤È 02:00:05²Ä 1507 ½g¦^À³
²q·Q¤j

¡u¤@ÁϽk¶îªº24¤p®É¤ß¹q¹Ï¡v¡A¤ß¸õ´å°Ê©ó41¦Ü160¤U........¯uªº«Ü©_©Ç

¦p¶]¨B¤ß¹q¹Ï¡]Treadmill test ¡^70%~80%ªº¥i«H«×¤£¦æ

³Ì«áÁÙ¥i¦Ò¼{64¤ÁCT«aª¬°Ê¯ßÀˬd¦³90%ªº¥i«H«×

¯¬ºÖ±z¦­¤é±d´_

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¯E§b10139724  µoªí®É¶¡:2015/12/17 ¤U¤È 01:08:34²Ä 1506 ½g¦^À³
²q·Q¤j

±zªº¯gª¬«Ü¹³®£·W¯g,®e©ö¦b¶}¨®®Éµo§@,¥i¥H¸ß°Ý¤@¤UÂå¥Í

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦h¦h10137435  µoªí®É¶¡:2015/12/17 ¤W¤È 11:38:03²Ä 1505 ½g¦^À³
²q·Q¤j

¤p§Ì©ó15¦~«e¤]¦³ÄY­«¤ß«ß¤£¾ã °µ¤F¤@°ïÀˬd¤]¬d¤£¥X­ì¦]

¬O¦Y§¹¦P¨Æ³ß°s«á¹j¤éµo§@,·íªìÂå¥Í¶}ÃÄ(¦WºÙ:XÆQ»ÄX)§Ñ°O¤F

¦Y¤F§óºG,³s¨«¸ô³£µL¤O,¤W¯Z¯Ý¤fÁÙ­n¶K¦b®à½t¤u§@,¯uªº«Üµh­W

«á¨Ó´«Âå¥Í «Øij§Ú´î»´¥ÎÃÄ,¥»¤H«Ü¤Ö³Ü©@°Ø «ùÄò¥ÎÃĬù¤@¦~

º¥º¥¦n¤F ²{¦b¨C¤é³£³ÜªM®³ÅK´£¯«

ªñ¦~ÃhºÃ¬O³Ü³ß°s­¹ª«¤¤¬r¤Þ°_¥B¦Y¤F¹L²rªºÃħó¶Ë¤ßŦ~

¯uªº­n¹ï¯g¤UÃÄ §_«h§óºG ¨Ñ±z°Ñ¦Ò.

¯¬ºÖ ²q·Q¤j¦­¤é±d´_

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦n¤ßªº¯Q¾~10137878  µoªí®É¶¡:2015/12/17 ¤W¤È 10:43:13²Ä 1504 ½g¦^À³
²q·Q¤j

­º¥ý,¤§«e¦p¦³¹ï±z«_¥Ç¤§³B,¦b³o¸Ì¸ò±z½ß­Ó¤£¬O.

±z¸Ó°µªºÀˬd´X¥G³£°µ¤F,°£¤F¤ß¹q¹Ï¦³²§¼Ë¤§¥~,¸£³¡MRIÀ³¥i¥H±Æ°£¸£³¡¸~½F,¸¡³¡¶W­µªiÀ³¥iªì¨B±Æ°£¤@¨Ç±`ªø¦b¸¡µÄªº¤º¤Àªc¯«¸g½F,©â¦åÀˬd¤]¥i¥HÂç²M¤@¨Ç¤º¤Àªc¥¢½Õªº°ÝÃD,»{¦Pcliff¤j¤ßŦ¤è­±­n¦A¶i¤@¨B½T»{,¬Ý¬Ý¤ß«ß¤£¾ã¬O¦óºØ«¬ºA.

¦pªG¤ß¹q¹Ï¬O¤@°}¤@°}ªºÄu©Ê¤ß·i¹L³t,¦pªG³£¨S¸I¯ù.©@°Ø.µÒ.°s,¨º¯uªº«Ü¦³¥i¯à¬O¸ò¦Û«ß¯«¸g¥¢½Õ¦³Ãö«Y.

³oºØ±¡§Î±`±`¬O¤ß¸Ì¦³¤@­Óµ²¨S¦³¸Ñ¶}(§Ú¨S¦³«_¥Ç¤§·N,¥u¬O´£¨Ñ¥i¯à©Ê),

³o­Óµ²±`·|²o°Ê¤Hªº±¡ºü,±¡ºü´N·|²o°Ê¦Û«ß¯«¸g,³y¦¨¦h¼Ë©Êªº¯gª¬.

¦pªG¦³ªº¸Ü,½Ð¹Á¸Õ¥h§ä´M¨Ã­±¹ï³o­Óµ²,¦³¾÷·|¸Ñ¶}´N§V¤O¸Ñ,¨S¾÷·|¸Ñ¶}´NÂàÅܤ߹ҹÁ¸Õ©ñ¤U,«e´£¬O­n­±¹ï¥L,³o«Ü­«­n.

¸Ñ¶}©Î©ñ¤U¤§«á,¬Û«H¤ß±¡©Î¯gª¬±N·|¦³«Ü¤j§ïµ½.§Æ±æ¦³À°¨ì±z,¤]ÁÂÁ±z¤§«eªº«ü±Ð.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GQQ10140589  µoªí®É¶¡:2015/12/17 ¤W¤È 01:44:54²Ä 1503 ½g¦^À³
²q·Q¤j:

§Ú¤]´¿¦³¹L¡¨¦å©¹¸£³¡½Ä¡¨ªº·Pı, ·í®É¤]ÃhºÃ¬O§_­n¤¤­·. «á¨Ó©M¤@¦ì²¤À´¤¤Â媺ªB¤Í´£¤Î, «Øij§Ú¦pªG¦A¹J¨ì³oºØ±¡§Î, ¸Õ±N¤â«üÂW¯}©ñ¦å, ¥LÁÙ¯d¤F©ñ¦å¤ùµ¹§Ú. «á¨Ó§Ú¤S¸I¨ì³oª¬ªp, ¦ý¤]¤£ª¾­nÂW¨º«ü, ´N°®¯Ü±q¤¤«üÂW°_(¦³¥ý¥Î°sºëÀ¿«ø¤â«üÀY®ø¬r), ³°ÄòÂW¤F´X«ü±N¦åÀ½¥X¨Ó. ¬O¦³®ÄªG, ºCºC½w¸Ñ. Â_Â_ÄòÄò§Ú¥Î¹L³o¤èªk´X¦¸, ³£¦h¤Ö¹ï·í¤U¦³½w¸Ñªº¥\¯à. ³o¤w¬O¦h¦~«eªº¨Æ¤F. ³o¬O­Ó¤H¸gÅç, «D´£¨ÑÂåÀø°Ñ¦Ò.

¤£ª¾±z·ÓªºÀYÀV³¡MRI¬O§_·Ó¨ìÀV´Õ? ¦³¨S¦³¯«¸gÀ£­¢ªº²{¶H? ¤§©Ò¥H³o»ò°Ý¬O¦]¬°±zªºªì©l¯gª¬¡¨·|¯Ý´e ¤ß«ß¤£¾ã §l¤£¨ìªÅ®ð ¸£³¡·|©âµh ·w¯t¡¨µ¥©M§Ú¤j­ô³¡¤À¬ÛÃþ¦ü, ¥L¶´X°éÀˬd¥X¬OÀV´ÕÀ£­¢¯«¸gÃa¦º¡K ÃhºÃ³o¬O¦], ³y¦¨ºØºØ¯gª¬¬OªG. ÁöµMÂå¥Í·í®É­n¨D¥L¥ß§Y¶}¤M, ¦Ò¶q¨ì¥i¯àªº«á¿ò¯g, ¨S¨º»ò°µ¡K ¥Ø«eÁÙ¦b´_°·, ¦ý¤w³vº¥±d´_, ¯u¬O¸U©¯! ³o¤¤¶¡¹Lµ{«D¤T¨¥¨â»y¥i³¯­z¡K

­Ë¬O¥Lªº¹Lµ{¤¤¦³¨â¼Ëª«²zªvÀøªº¾÷¾¹À°¤F«Ü¤jªº¦£, ¤@¬OÂåÀø¯Åªº»·¬õ¥~½u¾÷, ¥Lª½±µ·Ó¤ßŦ¤ÎªÍŦ, ¹ï¯Ý´e¤Î©I§l¦³À°§U., ¥t¤@¬O3¸U¥ñ¯Sªº¤é¥»¹q¦ìªvÀø¾¹. ¶È´£¨Ñ±z°Ñ¦Ò, ±z¥i¥H¦Û¦æ¤Wºô·j´M¬ÛÃö¸ê®Æ¶i£¸¨B¤F¸Ñ.

¯¬±z¦­¤é±d´_ !

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GCliff10135274  µoªí®É¶¡:2015/12/17 ¤W¤È 12:20:14²Ä 1502 ½g¦^À³
²q·Q¤j¡G±zªº¯gª¬¹³´X­Ó¯e¯f¡A«o¤S¤£§¹¥þ¹³¡G

1.¤G¦yä²æ««¡G¥i¬O¤ßŦ¶W­µªi»¡¬O¥¿±`¡C

2.­G­¹¹D°f¬y¡GÁö°µ¹L­GÃè¡A¦ý­G­¹¹D°f¬y¬O°ÊºA©Êªº¯gª¬¡A°£«D¤w»G»k­¹¹D³y¦¨­¹¹D¼ìºÅ¡A§_«h¦³¥i¯à°µ¥X¨Óªºµ²ªG¬O³±©Ê¡F¦ý¸Ü»¡¦^¨Ó¡A¬JµM¬O»´·L°f¬y¡AÀ³¸Ó¤]ÁÙ¤£¦Ü©ó³y¦¨¨º»ò¦hªº¯gª¬¤~¹ï¡C

3.¤ß«ß¤£¾ã¡G¨º­Ó¥iºÃªº¡u¤@ÁϽk¶îªº24¤p®É¤ß¹q¹Ï¡v¡A¤ß¸õ´å°Ê©ó41¦Ü160¤U¡K¡A³o¶µ²§±`­È±o¦A°l¬d¤U¥h¡C·íµM¤´¦³¥i¯à¤ß«ß¤£¾ã¬Oµ²ªG¡]¯gª¬¡^¡A¤£¬O¯f¦]¡C¥t¥~¡A¦³¨S¦³¤ß¦Ù¯Ê®ñ¡A¦ó¤£¦w±Æ¶]¨B¤ß¹q¹Ï¡]Treadmill test ¡^«Kª¾¡H

4.¸~½FÀ£­¢¤¤¼Ï¯«¸g¡A³o¤@ÂI§Ú»¡¤£²M·¡¡A§ä¯«¸g¤º¬ìÂå®vÀ°±z¬d¤@¬d¡C

5.³Ì«á¡A¸U¯ë¬Ò¤£¬O¡A´N­n¦Ò¼{¦Û«ß¯«¸g¥¢½Õ¡A³o­Ó¥i¯à©Ê·íµM¦³¡A¥u¬O­n©ñ¦b³Ì«á¡A¥H§K©µ»~¯f±¡¡C

ÁÙ¦³¡A½m®ð¥\µL½×°Ê¥\¡]¤Ó·¥¡B¤ÖªL¡BªL·s¡B¦Ûµo¥\¡B¦U®a®ð¥\¡B·ìÏÉ¡B¥­¥Ï¥\¡B¥~¤¦¥\¡K¡^¡A©Î¬OÀR¥\¡]¥´§¤¡K¡^¡A¨ä¹ê³£¬O®í³~¦PÂk¡A¥u°Ý½m¥\ªº¤H¤@¥y¸Ü¡A±z¦³¨S¦³¶i¤J¡u®ð¥\ºA¡v¡H¦pªG¨S¦³ªº¸Ü¡A®{¦³©Û¦¡¦ÓµL®ð·P¡A¥ú¦³·N©À«oµL®ðªº¹B¦æ¡A¸ò°µÅé¾ÞµL²§¡C

®ð¥\ºA¤¶©óºÎ¯vºA»P²M¿ôºA¤§¶¡¡A¦U­Óª¬ºA·|§e²{¤£¦P«¬ºAªº¸£ªi¡C

ºÎ¯vºAªº¸£ªi¬O£c»P£_ªi¡FÀW²v¤p©ó7¦¸/¬í¡C

®ð¥\ºAªº¸£ªi¬O£\ªi¡FÀW²v8~13¦¸/¬í¡C

²M¿ôºAªº¸£ªi¬O£]ªi¡FÀW²v14~29¦¸/¬í¡C

©Ò¥H¦b®ð¥\ºAªºª¬ªp¤U¡A¨­¤ß¬O³B©ó»´ÃP¡B´r§Ö¡BÃP¡BÀR¡B¦ÛµM¡A¹ï©ó½Õ¸`¦Û«ß¯«¸g¡A­Ó¤H¸gÅçı±o¦³©ÒÀ°§U¡Aµ¹±z°Ñ¦Ò¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GJM10139061  µoªí®É¶¡:2015/12/17 ¤W¤È 12:17:08²Ä 1501 ½g¦^À³
¸Õ¸ÕÀR§¤??

http://www.chikung.org.tw/txt/paper/p15.htm

ÀR§¤½Õ®§¹ï¦Û«ß¯«¸g¬¡©Êªº®ÄÀ³

§@ªÌ¡þ³¢¥¿¨å ¥x¥_ºaÁ`©I§lªvÀø¬ì

¡@¡@¡@³¯°ª´­¡@¶§©ú¤j¾ÇÁ{§ÉÂå¾Ç¬ã¨s©Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2015/12/16 ¤U¤È 10:24:00²Ä 1500 ½g¦^À³
¤p©_¤j ·PÁ±zªºÃö¤ß

©Î³\¤p§Ì¸Ó³¯­z¯f±¡ Åý±z°Ñ¦Ò

¤µ¦~¤¸¤ë ¤p§Ì¶}¨®®É ¬ðı¦å©¹¸£³¡½Ä ¦n¹³§Ö¤¤­·ªº·Pı

²Ä¤G¦¸ ³oºØ·Pı§óÄY­« ¤£±o¤£°±¨®¥ð®§¥b¤p®É ¤§«á¹ï¶}¨®´N¦³À£¤O¤F

±q¦¹®i¶}¬ÝÂ媺¹Lµ{

­è¶}©l ·|¯Ý´e ¤ß«ß¤£¾ã §l¤£¨ìªÅ®ð ¸£³¡·|©âµh ·w¯t ©Ò¥H«æ¶E¦n´X¦¸

¸g«æ¶EÂå®vÂश¬Ý ¤ßŦ¤º¬ì °µ¤F24¤p®É¤ß¹q¹Ï ¤ßŦ¶W­µªi

24¤p®É¤ß¹q¹Ï¬O¤@ÁϽk¶î ¤ß²v¨C¤ÀÄÁ¦b41 ~ 160¶¡¸õ°Ê ¤ßŦ¶W­µªi«hµL²§¼Ë

Âå¥Í¶}¤ß«ß¤£¾ã©M§ÜµJ¼{ªºÃı±¨î

¤S¦]¸£³¡°ÝÃD ¬Ý¤F¯«¸g¤º¬ì ¦Û¶O°µ°·ÀË ¥]§t ÀYÀV³¡MRI ÀV°Ê¯ß¶W­µªi ÁÙ¦³¦å²G±`³WÀˬd ¸¡³¡¶W­µªiµ¥

¥u¦³Áx©T¾J ©M¨â¶µ¸~½F«ü¼Ð(CEA, CA-199)¤£¦X¥¿±`­È ¾l§¡¥¿±`

°·ÀË®aÂå¬ì¸ò§Ú¸ÑÄÀ»¡ÁÙ¦n ¦ý§Ú¦Û¤v¤S¶]¥h¦å²G¸~½F¬ì¿Ô¸ß

Âå®v»¡¨â­Ó­È°¾°ª¦³«Ü¦h­ì¦] °²¦p¾á¤ß «Øij¥h·ÓPET/CT

µ²ªG¬OªÍ³¡¦³¤@³B«GÂI §PŪÂå®v¥s§Ú¥h¯ÝµÄ¤º¬ì°lÂÜ ¤S¦Û¶O©ç¤F§C¾¯¶q¯Ý³¡CT(¸Ó«GÂI¥i¯à¬O¶t¤Æ)

§éÄˤF´X­Ó¤ë §Ú¤G©j§i¶D§Ú ¦o¦h¦~«e¤]¤ß«ß¤£¾ã ­ì¦]¬O­G­¹¹D°f¬y©Ò¤Þ°_

¤p§Ì¦³¤@¬q®É¶¡¤]­G­¹¹D°f¬yÄY­« ¤S·Ó¤F¸z­GÃè ¤]¥¿±`

¯u´o¤H ¦Y¤ß«ß¤£¾ã©M§ÜµJ¼{ªºÃÄ ¤w¦n´X­Ó¤ë

¦ý¦³¦¸§Ö¨«¤§«á(¥¼¥Í¯f¤§«e ¨C¤Ñ³£ºC¶]30¤ÀÄÁ) «o¯Ý´eÄY­« ¤ß²v½w©M³t«×¶WºC ¤@¤p®É«á¤~©M½w

§Ú¤S´«¤F§O®aÂå°|ªº¤ßŦ¤º¬ìÂå®v ¨º¤Ñ·f¤õ¨®´N·Pı¤£µÎªA(´«Àô¹Ò·|ıÀY·w²§¼Ë )

¬Ý§¹¤ß¹q¹Ï Âå®v«o»¡§Ú¦³¤ß¦Ù±ð¶ëªººÃ¼{ (¦ý·í®É§Ú¨S¦³¤ß¦Ù±ð¶ëªº¨å«¬¯gª¬ )

¥s§Ú¥h«æ¶E ÁÙ¤£­ã§Ú¦Û¤v¨«¸ô ­n§¤½ü´È

»¡¤]©_©Ç §¤¤W½ü´È §Ú¤Ó¤Ó±À§Ú¨S¦h»· §Ú¬ðµM·Pı·¥«×ªº¤£µÎªA Á٩ǧڤӤӫç»ò±À¨º»òºC

¨ì¤F«æ¶E³B §Ú«_§N¦½ «æ³Ý §l¤£¨ìªÅ®ð

Âå®vµ¹§Ú¦Þ¤U§t¤ù À¹®ñ®ð¸n ©â¦åÀˬd ©ç¯Ý³¡X¥ú

¬ù¹L¤F5¤ÀÄÁ Âå®v°Ý§Ú¦³¨S¦³¤ñ¸ûµÎªA §Ú»¡¨S¦³

«á¨Ó¥´ÂIºw ¤H´N¶}©l½w©M Àˬdµ²ªG¤]¥¿±` ¤U¤È·Ó¤ßŦ¶W­µªi¤]µL²§¼Ë

¦ý¬Oªù¶EÂå®v«o­n§Ú¦í°|Àˬd Àˬd§¹¤]ÁÙ¦n

·í±ßÂå®v¨Ó§Ú¯f©Ð ¸ò§Úªø½Í¬ù¤@¤p®É »¡§ÚÀˬdµ²ªG ¤£À³¦³³o¼Ëªº¯fªp²£¥Í

©ó¬O¥LÁÙ¬O¶}¤F¦P¼ËªºÃĵ¹§Ú ¥~¥[ªü¥q¤ÇÆF(100mg)

¤é¤l¤]´N³o¼ËÄ~Äò¹L ¦³¤@¤Ñ§Ú¤Ó¤Óªºªí©f´B¨Ó¬Ý§Ú©¨¤÷ ½Í¤Î¥L¤]¤ß«ß¤£¾ãªº¾ã­ÓÂåÀø¹Lµ{

¥L»¡¥L¬O¦Û«ß¯«¸g¥¢½Õ ¥s§Ú¥h¬Ý¹Å¸qªº¬Yºë¯«¬ìÂå®v¸Õ¸Õ¬Ý(¥L¦í®ç¶é «o¨Ó¹Å¸q¬Ý¯f)

§Ú¥´¹q¸Ü¥h¹w¬ù ¤@­Ó¦h¤ë¤~¬Ý¨ìÂå®v

¥¦¥Î»ö¾¹´ú¸Õ »¡§Ú¬O°Æ¥æ·P¯«¸g¤Ó®z ´N¶}Ãĵ¹§Ú ª½¨ì²{¦bÁÙ¦bªvÀø

²{¦bªº§Ú ¦­¤W¦Y¿P³Á¤ù ¤@ªM½­ªG¥Ä ¦b¤½¶é²`©I§l100¦¸ §Ö¨«¤@¤p®É ¥­¥Ï¥\1 ¦¸

¤U¤È§Ö¨«¤@¤p®É ¥­¥Ï¥\1 ¦¸

¥u¦b±ß¤W¬Ý²³¤j¤jªº¤j¤å¤Î¸ê®Æ

³o´N¬O¤p§Ì²{¦b¤j²¤ªº±¡ªp

§Úª¾¹D¤ß±¡¼ÖÆ[«Ü­«­n §Ú±`´£¿ô¦Û¤v­n¯º¤f±`¶} ¯uªº¤ß±¡´N¶}®Ô°_¨Ó

½Ð±z¤]¤£¥²«æ ¦³ªÅ¦A¼g«K¥i ½Ð§O¼õ©]¼g³á!

ÁÂÁ±z! ·P®¦!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·P°Ê£®10141081  µoªí®É¶¡:2015/12/16 ¤W¤È 08:50:03²Ä 1499 ½g¦^À³
²q·Q¤j,JM¤j,Faith¤j,

·PÁ¾ɤޡA¶WÆg¡I

²q·Q¤j¡A

¯¬¦­¤é±d´_¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2015/12/16 ¤W¤È 06:07:38²Ä 1498 ½g¦^À³
JM¤j

«z¡I¦n´Î³á¡I¯u¬O¤Ó·PÁ±z¤F¡I

±zÀ³¸Ó§ï¦W¥sJACKªº¡AHaHa!

±z£¸©w¬O¤p§Ìªº¸t½Ï¦Ñ¤½¤½...

ÁÂÁÂJM¤j¡IªÈ·P¤ß£°^_^¡ã

¯E¤Í­Ì

³o¸Ì¦³«Ü¦­«Ü¦­¥H«e¤j®a§V¤O¹Lªº¨¬¸ñ

·í®É¯uªº¬O£¸¸s¤H¦bºN¶H

¦ý¤j®aÃh©êµÛ¤@¥÷¹Ú·Q¡B¼ö±¡...

°²¤é¦³ªÅ¤£§«¨Ó³}³}

¤]§Æ±æ¦¹½gªº¯B¥XÅý²q·Q¤j°·±d§ó°·±d

¯¬ºÖ²q·Q¤j

ÁÂÁÂJM¤j

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GJM10139061  µoªí®É¶¡:2015/12/15 ¤U¤È 10:30:40²Ä 1497 ½g¦^À³
Faith¤j, ¨ÓÅo!!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G±Û«a10139522  µoªí®É¶¡:2015/1/31 ¤W¤È 11:55:13²Ä 1496 ½g¦^À³
Faith¤j:§Aªº»¡©ú¦Aºë±m¤£¹L¤F¡Aµ¹§A¤j¤jªºÆg¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2015/1/31 ¤W¤È 09:31:03²Ä 1495 ½g¦^À³
­D§b¤j¡Bµ½¤H¤j

·PÁ§A­Ìªº¤À¨É»P»¡©ú

²Î¾ã¤j®a¤ÀªRªº¸ê®Æ¡A¤]´N¬O»¡

1.¦b³Ì«á¤@¦ì¯f¤H¥´§¹²Ä9°w¤§«e¡A·í¤H¼Æ¹F¨ì¸Ó´Á¤¤¤ÀªR®É¡AÁÙ¬O¥²»Ý¶i¦æ

¦ý³Ì«á¤@¦ì¯f¤H¥´§¹9°w«á¡A§Y¨Ï¨ì¹F´Á¤¤¤ÀªR¤H¼Æ¡A¤]¤£·|¶i¦æ¡A´Nµ¥¸Ñª¼¤F

2.±Û«a¤j¤§«e´¿´£¹L¤@­Ó­«ÂI¡G

¯E¹©¤½¥q¦b¥Ó½Ð¤WÂd®É¡A´¿¥D°Ê»¡©ú¤£·|´Á¤¤¤ÀªR¡A³o¬O­Ó¦n®ø®§

3.¸g¾úªF¬v¨Æ¥ó«á¡A§Ú·Q¤j®a³£©È¡u¥N¤u¡v¡A©Ò¥H§Ú­Ì§O«æ¡A¶¶«Kµ¥¼í¶®

4.¨C¤Ñªº³Ì«á¤@µ§¥æ©öÁÙÆZ¦³½ìªº¡A¤j®a¥i¥HªY½à¤@°}¤l

5.´Á«Ýªk»¡·|¡A¦ý¤ß¤¤¤£«æµÛ¸Ñª¼¡A¥u¬O¬°³o¨Ç¯f±w¦³ÂI±{±¤

6.²{¦b¶}©l¡A¨C¹L¤@¤Ñ¡B¤@­Ó¤ë´N§â¯E¹©»P¯E¤Í©¹¦¨¥\±Àªñ

7.¦]¬°´o¤HªºIPO,«o¥i¯à³y¦¨¯E¹©¤WÂd«áªºÂêªÑ

¤j®a......«ç»ò¥i¥H¤£´¤ºò©O

¦pªG¦~©³ªÑ»ù¨ì¤F6-8¦Ê¡A¦³¤H¦b½|§A­Ì³o¨Ç¶R¦b3¡B4¦Êªº¯E¤Í

³o®É¡A´«§A­Ì²zª½®ð§§ªº§i¶D¥L­Ì¡u§A­Ìª¾¹D§Ú­Ì¬O«ç»ò¼õ¹L¨Óªº¶Ü¡H¡v

©Ò¥H

¤@°_

¥[ªo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gµ½¤H10137888  µoªí®É¶¡:2015/1/31 ¤W¤È 04:22:10²Ä 1494 ½g¦^À³
Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37 (visit 3, 4, 5, 7, 9, 11, 13, 15, and 18).

©ó2014-7-21§¹¦¨342¦ì¦¬®×, °²³]²Ä342¦ì¨ü¸ÕªÌ©ó2014-7-22¬I¥´²Ä¤@°w, ¬I¥´²Ä8°wªº²Ä25¶g¬°2015-1-6, ¬I¥´²Ä9°wªº²Ä37¶g¬°2015-3-31.

OBI-822/821¤G/¤T´ÁÂಾ©Ê¨ÅÀùÁ{§É¸ÕÅç, ³]©w¤G¶µ«ü¼Ð(endpoint)­n¹F¦¨,

1. Primary endpoint: PFS±q6­Ó¤ë´£°ª¨ì9­Ó¤ë, 2. Second endpoint: OS±q18­Ó¤ë´£°ª¨ì27­Ó¤ë.

ºâ¨ì¤µ¤Ñ, PFS¦­¤w¶W¹L9­Ó¤ë, ¦ý¬OOSÁÙ¨S¹F¨ì27­Ó¤ë, ©Ò¥H2015¦~Q3©ÎQ4¸Ñª¼, ¤£¥uPFS¶W¼Ð, OS¤]¯à¹F¼Ð.

§ó­«­nªº¥Ø¼Ð¬OÅýPFS¶W¶V¥Ø«e©Ò¦³ªº¨ÅÀùÃÄ, ¹F¨ì¥@¬É²Ä¤@ªº©_ÂÝ, ¬°¥xÆW«~µP¤Î¥xÆWªºÀù¯g·sÃĬãµo¥ß¤U¼Ð¬ñ.

¨ì¦~©³, ¼í¶®Ãļt¥i¯à§¹¦¨Åç¼t, ¥i¥H¶q²£OBI-822/821©M833/821.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­D§b10139065  µoªí®É¶¡:2015/1/30 ¤U¤È 11:50:06²Ä 1493 ½g¦^À³
1¡E«ö»O¥_ºa¥ÁÁ`Âå°|²Ä¤@¤HÅé¸ÕÅç©e­û·|²Ä 10 ¦¸·|ij¬ö¿ý ¤½§iª©

¶}·|®É¶¡¡G¤E¤Q¤E¦~¤Q¤@¤ë¤@¤é¤U¤È¤G®É¥¿ ¡y¥»¸ÕÅç©ó 176 ¨Æ¥óµo¥Í·|°õ¦æ¤@¦¸´Á¶¡¤ÀªR¡z¡A¨ä©Ò¹ïÀ³¤§ÅãµÛ¤ô·Ç¤§±Àºâ¤è¦¡À³¥H 176 °£¥H 284 ¦Ó«D 176 °£¥H 342¨Ó­pºâ¤§¡C¤p§Ì¥H¬°»O¥_ºa¥ÁÁ`Âå°|¬O¸ÕÅçÂå°|¡A·|¤£Â_¦¬¨ì·sªº¸ÕÅç­p¹º®Ñª©¥»v1.v2.v3....«ö·Ó­p¹º®Ñ«ü¥Ü°õ¦æ¡A¦pªG¤j®a¤£¬Û«H¸ÕÅç­p¹º®Ñ¥Õ¯È¶Â¦r¡A§Ú¤]¤£ª¾¹D¤j®a­n¬Û«H¤°»ò¡H

2.§Ú¦³po¹L¨ÌLachin¤½¦¡¡A¥i¥H¤Whttp://www.cct.cuhk.edu.hk/stat/survival/Lachin1981.htm#2¡C

3.¦A¡Eªþ¤W¶§©ú¤j¾Ç³¯®a¼zºÓ¤h½×¤å¡y±´°Q¨ÅÀùÁ{§É¸ÕÅ礧´Á¤¤¤ÀªR¡zhttp://140.113.39.130/cgi-bin/gs32/ymgsweb.cgi/login?o=dymcdr&s=id=%22GYF225229545%22.&searchmode=basic ùØ­±¦³¨Ç¾ú¦~¨Ó¨ÅÀùÁ{§É¸ÕÅçÁ{§É¤H¼Æ¤Î¨ä¤¤¤ÀªR¤H¼Æ¸ê®Æ¡A¬Ý¬Ý¬O¤£¬O¡y­è­è¦n¡z³£¬OÁ{§É¤H¼Æ¤@¥b¡A¦pªG¤£¬O´N¤£¥²¦Aª§½×¬O176¡H171¡H142¤H¡H§Ú»{¬°176¥u¬O­è¦n±µªñ342¤Hªº¤@¥b171¤H¡A±i¸³¤è«K¸ÑÄÀ´N»¡´Á¤¤¤ÀªR¤H¼Æ¬O¡y¦¬®×¡z¤H¼Æªº¤@¥b¡F¨º¤S¦³¤H·Q»¡À³¸Ó¬O¦³®Ä²Î­p¤H¼Æ284¤Hªº¤@¥b142¤H¡C§Ú¥u·Q»¡³o¤@¤Á³£©M¡y¤@¥b¡zµLÃö¡A¸ÕÅç©Ò»Ýªº¯f±w¼Æ¥Ø©M´Á¤¤¤ÀªRµo¥Í¨Æ¥ó¼Æ¬O¤½¥q¦b³]­p¸ÕÅç®É¹w¦ô¤ñ­ì¥»¼Ð·Ç¤Æ¾ÇªvÀøªº­·ÀI²v¦A¥[¤W¤@¨Ç¼Æ¦rºâ¥X¨Óªº¡A¦b³]­pÁ{§É¸ÕÅç®É´N©w¦n¤F«áÄò·|¨Ì¸ÕÅç¶i¦æ¶¶§Q»P§_¶i¦æ½Õ¾ã¡A¤p§Ì¨ÃµL­p¹º®Ñ¦ý­YµL¼W¦¬Á{§É¤H¼Æ«h´Á¤¤¤ÀªR¤H¼ÆÀ³¤£·|½Õ¾ã¡C

´N¹³Faith¤j»¡ªº¸Ó¦³®Ä¡B¸Ó´_µoªº³£®t¤£¦h¤F¤U­Ó¤ë¬Æ¦Ü3¤ë¶}©l´_µo¤H¼Æ·|ÁÍí©w¡AÂ÷´Á¤¤¤ÀªR©Î¸Ñª¼ªº¤é¤l¶V¨Ó¶Vªñ¡A§Ú·Q¦b¨S¦³§ó§ï¸ÕÅç­p¹ºªº«e´£¤U¡A¤j®a´N¥H»O¥_ºa¥ÁÁ`Âå°|²Ä¤@¤HÅé¸ÕÅç©e­û·|²Ä 10 ¦¸·|ij¬ö¿ý ¤½§iª©ªº176¤H¬°ª©¥»°µ¦UºØ±À½×¡A§_«hÅܼƤS¦h¤@­Ó¤j®a­n¤À2¡B3ºØ¼Æ¦r°µ°²³]¡A²¦³º´Á¤¤¤ÀªRÁÙ¬O¦³¥i¯àµo¥Í¤£ª¾¦U¦ì¤j¤j¥H¬°©O¡H­Y¦³§ó¦n·QªkÅwªï¤À¨É¡AÁÂÁ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2015/1/30 ¤U¤È 06:16:56²Ä 1492 ½g¦^À³
¹ï¤£°_

¤W¤@½g¿ù¦r

¬O"ÁÂ"(­äÁÂ)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2015/1/30 ¤U¤È 03:50:34²Ä 1491 ½g¦^À³
©ú¤Ñ¬O¤@¤ëªº³Ì«á¤@¤Ñ¤F

¤é¤l¤S©¹«e±À¤F¤@­Ó¤ë

¤@¤ëªºµ²§ô¥Nªí³Ì«á¤@§åªº¦¬®×¯f¤H¤w¸g¾ú6­Ó¤ë8°w

¸Ó¦³®Ä¡B¸Ó´_µoªº³£®t¤£¦h¤F

¤U­Ó¤ë¬Æ¦Ü3¤ë¶}©l´_µo¤H¼Æ·|ÁÍí©w

³Ìªñ¤@ª½«ä¦Ò¤@­Ó°ÝÃD

Ãö©ó´Á¤¤¤ÀªR¡A´Á¤¤¤ÀªR¥D­n¬O¤ÀªRÃĪ«ªº¦w¥þ©Ê

¥H¥Ø«e¨Ó¬Ý¡A¬O¨S¦³´Á¤¤¤ÀªRªº¥²­n©Ê¤F

¦ý¬O¸U¤@´_µo¤H¼Æ¹F142©Î176¡]¦³¯E¤Í´£¨ì§õ¤p©j»¡¬O142¡^

À³¸ÓÁÙ¬O­n´Á¤¤¤ÀªR§a

§Ú¬O°Ñ¦Ò°ò¨È¡A¥¦¤§«e¦¬§¹®×«á¡A¸Ñª¼¤Î³Q­¢´Á¤¤¤ÀªR¦P®É¶i¦æ

³oÂI¤£ª¾¤p§Ìªº»{ª¾¬O§_¥¿½T¡H

¦pªG½T¹ê¹F³o­Ó¤H¼Æ´N­n³Q­¢´Á¤¤¤ÀªR¡A¦Ó¯E¹©¤@ª½¤£»Ý´Á¤¤¤ÀªR

§q«J....,

¥t¥~¡A³ÌªñªºªÑ»ù¤j®a¨Sµo²{¬O¤@ºØÃÀ³N¶Ü¡H

¤W¤£¥h¤]¤U¤£¨Ó¡AÆZ¦³½ìªº

©ñªø½uªº¯E¤Í­Ì¡A§Ú­Ì´N¨Óµ¥µ¥¬Ý³o¤@ªi­n«ç»ò¨«§a

¡]¦pªG¬O¸g¾ú150-170¨º6­Ó¤ëªº¯E¤Í¡A¹ï§A§Ú¦Ó¨¥¡A¤@ÂI³£¤£Ãø¼õ¡A¤£¬O¶Ü¡H¡^

¶R¨ì455¥ª¥k¦Ó¹w³Æ°µªø½uªº¯E¤Í­Ì

±i¸³³£»¡¡G³o¬O¤@¤ä¤¤¼ú¾÷²v«Ü°ªªºªÑ²¼

§A­Ì«ç»ò¥i¥H¨S­@¤ß¡H¤£½ä½ä¬Ý©O¡H§Ú­Ì³£µ¥ªº¤ñ§A­Ì¤[¤F

§A­Ì¬Ý¦ü¶R¦b°ªÂI¡A¥i¤]Â÷¦¨¥\¶Vªñ¤£¬O¶Ü

µ¥¨ìªá¨à³£¬ª¤F¡AÀ³¸Ó«üµ¥¸Ñª¼¤é§a¡I«¢«¢

©¡®É¡A§Ú©È§Ú­Ì³£­nµ¥¨ìµo§Ý¤F¡I¦]¬°³o±i±m¨é...¤@©w­n´¤ºò

¤@°_

¥[ªo

§ë¸ê¬Ò¦³­·ÀI¡A¦ý§ë¸ê¤ñ§ë¾÷¦n¤Ó¦h¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2015/1/27 ¤U¤È 01:56:47²Ä 1490 ½g¦^À³
¤p©_¤j ÁÂÁ±z!

°w¹ï±zªº¦Ò¶q ¤p§Ì¸Õºâµ²ªG ¦C¦p ªí1

¨âªÌÁ`¥Í¦s¾÷²v¬ï¹L 0.5 ¤ô¥­½uªº±¡ªp

¤À§O¬° ³]­­¸ê®Æ¼Æ¬ù 100 ¤H ´c¤Æ¤H¼Æ 83~86 ¤H ¡Q ³]­­¸ê®Æ¼Æ¬ù 105 ¤H ´c¤Æ¤H¼Æ¬ù 83 ¤H

ÁöµM¦³ÂI®t§O ¦ý¹ï¦ôºâ ¤¤¦ìPFS ©Î³\¨S¤°»ò®t²§?

¤S­Y¦Ò¼{¥¢Áp¤H¼Æ( 11¤H ) ¸m«e©M¸m¤¤ªº¸Õºâµ²ªG ¤À§O¦C©ó ªí2 ¤Î ªí3

¤GªÌÁ`¥Í¦s¾÷²v¬ï¹L 0.5 ¤ô¥­½uªº±¡ªp

¤À§O¬° ³]­­¸ê®Æ¼Æ¬ù 90 ¤H ´c¤Æ¤H¼Æ 77 ~ 80 ¤H ¡Q ³]­­¸ê®Æ¼Æ¬ù 100 ¤H ´c¤Æ¤H¼Æ¬ù 80 ¤H

¥¦­Ìªº¤¤¦ìPFS¤]À³³£¤j©ó19­Ó¤ë ?

¤p©_¤j ±zªº³Ð·s«ä¦ÒÅÞ¿è¶WÆg Åý¤p§Ì±o¥HÂç²M«Ü¦h 822 ¤¤¦ìPFS ­pºâ¤W¤£½T©wªº¦a¤è

¥Î³o¼Ë«O¦uªº¦ô­p ­Ó¤H·Pı Áö¤£¤¤À³¤]¤£»·¤F!?

­Õ­Y¥¼¨Ó¦³·s»¡ªk©Î¸ê®Æ §Ú­Ì¦A¨Ó½Õ¾ã

ÁÂÁ±zªº«ü¾É!

¸Õºâªí 1

0 228 0 1.00000000 1.00000000

5 228 23 0.89912281 0.89912281

5 200 3 0.98500000 0.88563596

5 192 3 0.98437500 0.87179790

5 184 3 0.98369565 0.85758381

5 176 3 0.98295455 0.84296590

5 168 3 0.98214286 0.82791294

5 160 3 0.98125000 0.81238957

5 152 3 0.98026316 0.79635557

5 144 3 0.97916667 0.77976483

5 136 3 0.97794118 0.76256413

5 128 3 0.97656250 0.74469153

5 120 3 0.97500000 0.72607425

5 112 3 0.97321429 0.70662583

5 104 3 0.97115385 0.68624239

5 96 3 0.96875000 0.66479732

5 88 3 0.96590909 0.64213377

5 80 3 0.96250000 0.61805375

5 72 3 0.95833333 0.59230151

5 64 3 0.95312500 0.56453738

5 56 3 0.94642857 0.53429431

5 48 3 0.93750000 0.50090091

5 40 3 0.92500000 0.46333334

¸Õºâªí 2 ( ¥¢Áp¤H¼Æ11¤H ¸m©ó«e )

0 228 0 1.00000000 1.00000000

16 228 23 0.89912281 0.89912281

5 189 3 0.98412698 0.88485102

5 181 3 0.98342541 0.87018498

5 173 3 0.98265896 0.85509506

5 165 3 0.98181818 0.83954788

5 157 3 0.98089172 0.82350557

5 149 3 0.97986577 0.80692492

5 141 3 0.97872340 0.78975630

5 133 3 0.97744361 0.77194225

5 125 3 0.97600000 0.75341564

5 117 3 0.97435897 0.73409729

5 109 3 0.97247706 0.71389277

5 101 3 0.97029703 0.69268804

5 93 3 0.96774194 0.67034326

5 85 3 0.96470588 0.64668409

5 77 3 0.96103896 0.62148860

5 69 3 0.95652174 0.59446736

5 61 3 0.95081967 0.56523126

5 53 3 0.94339623 0.53323704

5 45 3 0.93333333 0.49768790

5 37 3 0.91891892 0.45733483

5 29 3 0.89655172 0.41002433

¸Õºâªí 3 ( ¥¢Áp¤H¼Æ11¤H ¸m©ó¤¤ )

0 228 0 1.00000000 1.00000000

5 228 23 0.89912281 0.89912281

5 200 3 0.98500000 0.88563596

5 192 3 0.98437500 0.87179790

5 184 3 0.98369565 0.85758381

5 176 3 0.98295455 0.84296590

5 168 3 0.98214286 0.82791294

5 160 3 0.98125000 0.81238957

5 152 3 0.98026316 0.79635557

5 144 3 0.97916667 0.77976483

16 136 3 0.97794118 0.76256413

5 117 3 0.97435897 0.74301120

5 109 3 0.97247706 0.72256135

5 101 3 0.97029703 0.70109914

5 93 3 0.96774194 0.67848303

5 85 3 0.96470588 0.65453657

5 77 3 0.96103896 0.62903515

5 69 3 0.95652174 0.60168580

5 61 3 0.95081967 0.57209469

5 53 3 0.94339623 0.53971197

5 45 3 0.93333333 0.50373117

5 37 3 0.91891892 0.46288811

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2015/1/27 ¤W¤È 10:11:25²Ä 1489 ½g¦^À³
²q·Q¤j¡A

¤p§Ì·Q¤F·Q¡AÁÙ¬O§â¸Õºâªí¥[¤J¥¢Ápªº¥i¯à¤H¼Æ¦n¤F

ÁöµM¸ÕÅç²ÕÃĦ³®Ä¡A±wªÌÀ³¸Ó¤ñ¸û¤£·|¥D°Ê¥¢Áp

¦ýÁÙ¬O¥[¤J¥¢Áp¤H¼Æ·|Åý¸Õºâªí¤ñ¸û§¹¾ã

´N¥Î5%¤j¬ù11¤H

©Ò¥H­Ë±À100¤H¡A°£¤F2013¦~7¤ë~2014¦~7¤ëªº86¦ì³]­­¥~¡A

¦A¥[¤W11¦ì¦b¤ñ¸ûµuªº®É¶¡´N¥¢Ápªº³]­­¤H¼Æ

©Ò¥H­Ë±À100¤H´N·|¸¨¦b2013¦~6¤ë

¥ý¥Î¦³§â´¤ªº°²³]¡Aµø±¡ªp»Ý­n¦A°µ½Õ¾ã¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü®¶10139782  µoªí®É¶¡:2015/1/27 ¤W¤È 07:49:37²Ä 1488 ½g¦^À³
¥i§_°Ý¤j¤j­Ì¤@­Ó·s¤âªº°ÝÃD

¥Ø«e¨ÅÀù¥½´ÁÀøªkªºPFS¬O´X­Ó¤ë©O?

ÁÂÁ±z

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2015/1/26 ¤U¤È 11:53:31²Ä 1487 ½g¦^À³
²q·Q¤j¡A

¤p§Ì¯u¨ØªA±z¡A­ì¥»ÁÙ¾á¤ß¤å¦rªºªí¹F·|µü¤£¹F·N¡I

¦A¤@ÂIÂI¤p¤pªº°Q½×¡A

228 0 1.00000000 1.00000000

0 228 23 0.89912281 0.89912281

5 205 3 0.98536585 0.88596491

5 197 3 0.98477157 0.87247306

5 189 3 0.98412698 0.85862428

5 181 3 0.98342541 0.84439294

5 173 3 0.98265896 0.82975029

±zªº¶¶§Ç¬O¥ý23¤H´c¤Æ¡AµM«á5¦ì³]­­¡A¦A¨Ó3¦ì´c¤Æ¡F¦A5¦ì³]­­¡AµM«á3¦ì´c¤Æ¡H

ÁÙ¬O¶¶§Ç¬O¥ý23¤H´c¤Æ¡AµM«á3¦ì´c¤Æ¡A¦A¨Ó5¦ì³]­­¡F¦A3¦ì´c¤Æ¡AµM«á5¦ì³]­­¡H

¦pªG¬O«eªÌ¡A¤p§Ìı±o¥H¤Uªººâ¦¡¤ñ¸û¥¿½T¡G

0 228 23 0.89912281 0.89912281

5 200 3 0.98500000 0.88596491 ...¥ý³]­­5¦ì¡A¦]¦¹·í´Á¤T¦ì´c¤Æ®É¡An at risk=205-5=200

5 192 3 0.98437500 0.87247306

5 184 3 0.98369560 0.85862428

5 176 3 0.98342541 0.84439294

5 168 3 0.98265896 0.82975029

­pºâ¾÷§Ú´N¨S¦³¥J²Ó«ö¤F¡C

¡y¤S¥Ñ¤p©_¤jµ¹ªº¦¬®×¶i«× ¥H³]­­¸ê®Æ¼Æ100 ­Ë±À®É¶¡ ¤j·§¸¨©ó 6 ¤ë©³ (¶Z²{¦b19 ­Ó¤ë)¡z

³]­­¸ê®Æ¼Æ100 ­Ë±À¡A2013¦~7¤ë¨ì2014¦~7¤ë¦@¦¬96¤H¡A¦©°£10%¬ù10¤H¦­¦­´c¤Æ¡A¦]¦¹2013¦~7¤ë¥H«áªº³]­­¤H¼Æ³Ì¦h¥u¦³86¤H¡A­n­Ë±À¨ì100¤H¡A¤j·§­n±À¨ì2013¦~ªº5¤ë¡A¶Z²{¦b¦³20­Ó¤ë¡Cm¤]´N¬O83~86¥X²{¤F¡A¦¹®É³o¦ì±wªÌªº´c¤Æ®É¶¡´N¬OT¡AT·|¤j©ó­Ë±Àªº²Ä100¦ì³]­­¸ê®Æ¡A¤]´N¬OT·|¤j©ó20­Ó¤ë¡A¦ÓT´N¬O¤¤¦ì¼ÆPFS¡A¤]´N¬O¤¤¦ì¼ÆPFS¤j©ó20­Ó¤ë¡C

¡y¦ý§Ú­Ì¤§«e¤S°²³]76¤H´c¤Æ¬°¸Ñª¼³]©wªº±ø¥ó ©|¥¼¹F83~86¤H¡z

¦b¦¹¨Ò¤¤¡A¸ÕÅç²Õ¦³83~86¤H´c¤Æ¡A¤~·|¹F¨ì¬ï¹L0.5¤ô¥­½u¡A¦pªG¤£¤p¤ß¤Ó¦­´¦¶}¡Aµo²{¸ÕÅç²Õ¥u¦³76¤H´c¤Æ¡AKM¨ç¼Æ·|¦Q¦b0.5¤ô¥­½u¤§¤W¡A³o®É´NÀª§¼¤F¡A­n»\°_¨Ó¦A­«·sµ¥¨ì¹F¨ì0.5¶Ü¡HÁÙ¬O¥Î³oºØ¹Ï«¬FDA¤]¥i¥H±µ¨ü¶Ü¡H

·PÁ²q·Q¤j±z»P¤p§Ìªº¬ä½R°Q½×¡A¤]¦]¬°³o¨Ç°Q½×¡A¤p§Ì¤~·|§â¦s¬¡¨ç¼Æ°µ³o»ò²`¤Jªº«ä¦Ò¡A§Ú·Q¡A¨ì¦¹¡A¤p§Ì¹ï©ó¦s¬¡¨ç¼Æªº»{ÃÑ»P±z¨S¦³¥ô¦ó®t²§¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2015/1/26 ¤U¤È 08:54:53²Ä 1486 ½g¦^À³
ÁÂÁ¤p©_¤j ¹Ç§AÅó±ø±ø¤jªº¸Ñ»¡

¤p©_¤j¶WÁo©ú ¯à°÷±Àºt¥X³o®M­pºâÅÞ¿è Åý¤HªY¸r

¤p§Ì¬Ý¤F¼Æ¦¸ ¤~²¤²¤Åé·|­Ó¤¤ºëÀH(¤£ª¾³o¦¸·|¤£·|¤S¤£À´¸ËÀ´ ¤S»~¸Ñ¤F?!)

¨Ì¤p©_¤j²Ä¤@¨Òªº°²³] ¸Õºâ¦p¤U

¨C­Óª½Ä檺Äæ¦ì¦WºÙ ¥Ñ¥ª¦Ü¥k¤À§O¬° ¡m ³]­­¸ê®Æ¼Æ ¡n,¡m n at risk §Y n( i ) ¡n,¡m d( i ) ¡n,¡m ¶¥¬q¦s¬¡¾÷²v §Y 1- d( i )/ n( i ) ¡n, ¡m Á`¦s¬¡¾÷²v ¡n

228 0 1.00000000 1.00000000

0 228 23 0.89912281 0.89912281

5 205 3 0.98536585 0.88596491

5 197 3 0.98477157 0.87247306

5 189 3 0.98412698 0.85862428

5 181 3 0.98342541 0.84439294

5 173 3 0.98265896 0.82975029

5 165 3 0.98181818 0.81466392

5 157 3 0.98089172 0.79909709

5 149 3 0.97986577 0.78300789

5 141 3 0.97872340 0.76634815

5 133 3 0.97744361 0.74906210

5 125 3 0.97600000 0.73108461

5 117 3 0.97435897 0.71233885

5 109 3 0.97247706 0.69273319

5 101 3 0.97029703 0.67215696

5 93 3 0.96774194 0.65047448

5 85 3 0.96470588 0.62751655

5 77 3 0.96103896 0.60306786

5 69 3 0.95652174 0.57684752

5 61 3 0.95081967 0.54847797

5 53 3 0.94339623 0.51743204

5 45 3 0.93333333 0.48293657

¥Ñ¦¹·§ºâªí ³]­­¸ê®Æ¼Æ¤j¬ù100 ´c¤Æ¤H¼Æ¬ù83~86 Á`¦s¬¡¾÷²v·|¬ï¹L0.5

¤S¥Ñ¤p©_¤jµ¹ªº¦¬®×¶i«× ¥H³]­­¸ê®Æ¼Æ100 ­Ë±À®É¶¡ ¤j·§¸¨©ó 6 ¤ë©³ (¶Z²{¦b19 ­Ó¤ë)

¦ý§Ú­Ì¤§«e¤S°²³]76¤H´c¤Æ¬°¸Ñª¼³]©wªº±ø¥ó ©|¥¼¹F83~86¤H

¦]¦¹±ÀÂ_ ¤¤¦ìPFS ¤j©ó19­Ó¤ë

³o­Ó¸ò¹Ç§AÅó±ø±ø¤jªº¦ôºâ¤è¦¡ ¦n¹³¤]«Ü±µªñ

¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!

¤]¦A¦¸·PÁ¤p©_¤j ¹Ç§AÅó±ø±ø¤jªº¤À¨É¸Ñ»¡

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¹Ç§AÅó±ø±ø10135894  µoªí®É¶¡:2015/1/26 ¤U¤È 04:09:19²Ä 1485 ½g¦^À³
Ãö©óKeplan-Meier¤èªk¡A¤p§Ì¦³¤@¨Ç·Qªk¡A¤]³\¤£¤@©w«Ü¥¿½T¡A½Ð¤F¸Ñ¦a¯E¤Í¤£§[«ü¥¿:

1.·í¦³³]­­¸ê®Æ®É¡A¦]¬°dt=0,·|³y¦¨¯AÀI²vH(t)=dt/L(t-1)=0 dtªí¥Ü°Ï¶¡¤º¦º¤`¤H¼Æ¡AL(t-1)ªí¥Ü°Ï¶¡ªì¦s¬¡¤H¼Æ

2.¦]¦¹¦s¬¡²vS(t)=S(t-1)*(1-H(t)) »P¤W¤@°Ï¶¡ºû«ù¤£ÅÜ, ¦ýL(t-1)¦]¬°²¾°£¦¹³]­­¤H¦Ó´î¤Ö

3.«á¨Ó·í¸Ó²Õ¦³±wªÌ´c¤Æ¡A¥Ñ©óL(t-1)¦AÄ~Äò´î¤Ö¡AH(t)·|¥[³t´î¤Ö(¦³ÂI¹³§â2ªº³¡¤À¤@¦¸¶^¨¬)

¤£ºÞ³]­­¸ê®Æ¦h¤Ö¡A¤]­n¦b1/2(¹êÅç²Õ¤H¼Æ-³]­­¤H¼Æ)ªþªñ®É¡AK-M·|¬Û¥æ¦b0.5

³o­Ó´Nªí¥Ü¤£¥Î¥h¦ô­p³]­­¤H¼Æ¦h¤Ö¡A¥Î¥­§¡¦¬®×¤H¦¬®×®É¶¡¨ì¥Ø«e®É¶¡¦@¸g¹L¦h¤Ö®É¶¡·í§@¦s¬¡´Á¬O¥i¥H°µ¬°°Ñ¦Òªº¡A

¤½¥q»¡2013¦~6¤ë¦¬¨ì±Nªñ200¤Hªº¸Ü¡A©Ò¥H²Ä172¤H¬O2013¦~6¤ë«e¦¬¨ìªº¡A

¦Ó¨ì2015¦~1¤ë¤´µM¨S¦³»Ý­n´Á¤¤¤ÀªR¡A¨ºÁ`PFS¦Ü¤Ö¬O19­Ó¤ë

¦]¬°¹êÅç»P¹ï·Ó²Õ2:1, °²³]¹ï·Ó²ÕPFS=9, ¹êÅç²ÕPFS=X, 2/3 * X + 1/3 * 9 = 19, X=24, ²{¦b¹êÅç²ÕPFS¤w¸g>24

¥Î«Ü²³æªººâªk¡A·íµM·|¦³»~®t¡A¶È¨Ñ°Ñ¦Ò

(¦³¨Ç¯E¤Í¥i¯à·|»{¬°§Ú·Q±o¤Ó²³æ¡A¥i¬O¨Æ¹ê¤W¡A½ÆÂøªº­pºâ¤½¦¡©¹©¹¥u¬O¨Ó¦Û¥X³Ì­ì©lªº¼Æ¦r¡A´N¬O"PFS"

,´N¦n¹³¹]²y±q¤ñÂÄÅK¶ð±¼¤U¨Ó¦]¬°ªÅ®ðªý¤O¥i¥H©¿µø, G­È«Ü±µªñ­«¤O±`¼Æ¡A¦Ð¤ò«h¤£¦æ¡A

¹ï©ó§Ú³o­Ó²¤Æ¼Ò«¬¦Ó¨¥¡A¦ý¬O¦pªG¹êÅç²ÕPFS=X, ¹ï·Ó²Õ=9...¨ä¾lªº³]­­¸ê®Æ¡A­Ó§O®t²§·|¦³¡A¦ý¬O¤]·|±µªñ²¤Æ¼Ò«¬)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2015/1/26 ¤U¤È 01:41:25²Ä 1484 ½g¦^À³
²q·Q¤j¡A

¨ä¹ê§Úªº·N«ä¤£¬O¤@©w¶W¦ô©Î§C¦ô¡A¦Ó¬OKM¨ç¼Æ°£«D¯uªº¸Ñª¼¡A¤£µM¥Î¦ôºâªº¥u¯à¦ô¤¤¦ì¼ÆPFS¦b¬Y­Ó½d³ò¡A§Ú©Ò°µªº¦ôºâ¬O¥Î«O¦uªº¤è¦¡¡A¤]´N¬O·|¤j©ó¦h¤Öªº¤è¦¡¡A¹ê»Úªº¼Æ¦r¥i¯à¤ñ§Ú¦ôºâªº¼Æ¦r¨Ó±o¦n¡C

´Nºâª¾¹DÁ`´c¤Æ¤H¼Æ¡A¥B¹ï·Ó²Õªº´c¤Æ¤H¼Æ¤]ª¾¹D¡A¤]´N¬O»¡¸ÕÅç²Õªº´c¤Æ¤H¼Æª¾¹D¤F¡A¦]¬°³]­­¸ê®Æ»P´c¤Æ¸ê®Æªº±Æ¦C²Õ¦X¦³¬Û·í¦hªº¥i¯à©Ê¡A¦P¼Ë¬O¹F¨ì0.5ªºÁ`¦s¬¡¾÷²v¡A·|¦³¤£¦Pªº²Õ¦X¤è¦¡¨Ó¹F¨ì¡A¤p§Ì¥u¥Î¤F¤@ºØ¥i¯à©Ê¨Ó±À¦ô¡Aºâ¬O¤ñ¸û«O¦uªº±À¦ôªk¡A²{¦b¬Ý¤F±zªº¸Õºâªí¡A¬ðµMÆF¾÷¤@°Ê¡A¦ó¤£­É¥Î±zªº¸Õºâªí¨Ó¦ôºâ¤£¦Pªº²Õ¦X¤è¦¡¡A¬Ý¬Ýµ²ªG·|«ç¼Ë¡A¤£ª¾±zı±o§´·í§_¡H

¬°¤F·¾³qªº¶¶ºZ¡A°²³]¼Æ¦r¥²¶·¤@­P¡A¥ý¥Î§Úªº¼Æ¦r¡A±z¦³³ßÅwªº¨ä¥¦°²³]¡A±z¦A­×§ï¡C­º¥ý¡A¥uºâ¸ÕÅç²Õ¡A¦¬®×¤H¼Æ¡A2012¦~©³«e66¦ì¡A2013¦~1~6¤ë¦¬66¦ì¡A2013¦~7~12¤ë¦¬40¦ì¡A2014¦~1~7¤ë¦¬56¦ì¡A822¥¼¯à²£¥Í§@¥Îªº±wªÌ¦û10%(³o¼Ë¤l¤ñ¸û¦n³B²z«Üµu®É¶¡´N´c¤Æªº·¥ºÝ­È)¡A822§@¥Î¦¨NEDªº±wªÌ¦û10%(³o¼Ë¤l¤ñ¸û¦n³B²z¥i¥Hºû«ù«Ü¤[®É¶¡³£¤£´c¤Æªº·¥ºÝ­È)¡C

¥ý·Q¹³1¤ë©³¸ÕÅç²Õ¹F¨ì0.5ªºÁ`¦s¬¡¾÷²vªº´c¤Æ¤H¼Æ¥X²{¤F¡A´N´¦¶}¬Ýµª®×¡A±z¥u·|¬Ý¨ì¨âºØ¼Æ¾Ú¡A´c¤Æªº¼Æ¾Ú©MÁÙ¨S´c¤Æªº³]­­¸ê®Æ(¥¢Ápªº³]­­¸ê®Æ³oùØ¥ý¤£³B²z¡A¦]¬°¥u­n¤H¼Æ¤£¦h¡A¼vÅT´N¤£¤j)¡A´c¤Æªº±wªÌ´N«ö·Ó´c¤Æ®É¶¡ªøµu°µ±Æ§Ç¡A´c¤Æªº±wªÌ¥i¯à¨Ó¦Û©ó¤W­zªº®É¶¡°Ï¹jªº¥ô¤@°Ï¬q¡A¦ý·Ó±`²z¡A±q¤ñ¸û¦­¦¬®×ªº°Ï¬qªº´c¤Æ¤H¼Æ·|¤ñ¸û¦h¡A¤ñ¸û±ß¦¬®×ªº°Ï¬q´c¤Æ¤H¼Æ·|¤ñ¸û¤Ö¡C´c¤Æ¤H¼Æ±Æ§Ç§¹«á¡A¹F¨ì´c¤Æ®É¶¡±Æ¦b³Ì¤[ªº¨º¤@­Ó¡A¤]´N¬O±zªº¨Ò¤l¤¤ªº²Ä76¦ì(±Æ§Ç«á)¡A¤]¥i¥H»¡´N¬O­è¦n¹F¨ì0.5ªºÁ`¦s¬¡¾÷²vªº¨º¤@¦ì¡A§Ú­ÌºÙ³o­Ó¼Æ¦r¬°m¡A¥Lªº´c¤Æ®É¶¡§Ú­Ì¥ÎT¨Óªí¥Ü¡C²{¦b³]­­¸ê®Æ­n¤À¨â²Õ¡A²Ä¤@²Õ¬O¤Ö¼Æ¦­¦­¥¢Ápªº³]­­¸ê®Æ¤Î¤ñ¸û±ß¦¬®×ªº±wªÌ¡A·í´¦¶}µª®×®É¡A¥u­n´c¤Æ®É¶¡¤´¥¼½T©w¥B¦b´¦¶}¨º¤@¨è¥¼´c¤Æ®É¶¡¤p©óTªº¡A³£­n±Æ¦b³o¤@²Õ¡A³o¤@²Õ¬O¥Î¨Ó­pºâÁ`¦s¬¡¾÷²v±q1­°¨ì0.5®É¦p¦ó¼vÅTm­Ó¤w´c¤Æ±wªÌ¨ä¾÷²v¤U­°ªº³t«×¡C¥t¥~¤@²Õ¬O´c¤Æ®É¶¡¤]¥¼½T©w¡A¦ý¬O¬O¦]¬°¦b¦­´Á¦¬®×¥BÃĮĵo´§±o«Ü¦n¡A¤@ª½³£¨S¦³´c¤Æ¡A¥L­Ìªº¥¼´c¤Æ®É¶¡¤j©óT¡A´N±Æ¦b²Ä¤G²Õ¡C¦­´Á¦¬®×ªº±wªÌ¡A¦pªG¤£¬OÅܦ¨¤w´c¤Æ¼Æ¾Ú¡A´N¬O·|¦¨¬°²Ä¤G²Õªº³]­­¸ê®Æ¡F±ß´Áªº¦¬®×±wªÌ¡A¦pªG¤£¬OÅܦ¨¤w´c¤Æ¼Æ¾Ú¡A´N·|¦¨¬°²Ä¤@²Õªº³]­­¸ê®Æ¡A¥¢Ápªº±wªÌ´X¥G¤j³¡¥÷³£¦b²Ä¤@²Õªº³]­­¸ê®Æ¡C²Ä¤@²Õªº³]­­¸ê®Æ»Pm­Ó¤w´c¤Æªº¼Æ¾Ú¦@¦P¨Ó¨M©w0.5ªºÁ`¦s¬¡¾÷²v¦ó®É¥X²{¡A¤]´N¬O»¡¤¤¦ì¼ÆPFS¦ó®É¥X²{¡A²Ä¤G²Õªº³]­­¸ê®Æ¡A¤£ºÞ¥L­Ì³]­­¦h¤[¡A¹ï¤¤¦ì¼ÆFPS¨S¦³¼vÅT¡C

§ÚÁ|¨â­Ó¨Ò¤l¡A±z¨Óºâºâ¬Ý¡C¥ý¥Î±zªºÁ|¨Ò¡A1¤ë©³¹F176¤H´c¤Æ¡A¨ä¤¤¹ï·Ó²Õ100¤H¡A¸ÕÅç²Õ76¤H¡A§Ú­Ì¨Óºâºâ¬Ý76¬O§_´N¬O¹F¨ì0.5ªºÁ`¦s¬¡¾÷²vªºm¨º­Ó¼Æ¦r¡A¥H¤Î¦pªG¹F¨ì¤F¡A¤¤¦ì¼ÆPFS¬O¦h¤Ö¡C

²Ä¤@­Ó¨Ò¤lªº°²³]¥Î³Ì«O¦uªº¤è¦¡¡A¤w´c¤Æªºm­Ó±wªÌ¥þ³¡¨Ó¦Û©ó2012¦~¦~©³«eªº66¦ì»P2013¦~1~6¤ëªº66¦ì¡AÁ`¦@³o132¦ì±wªÌ¤¤¡A¦]¦¹2014¦~1~7¤ëªº56¦ì»P2013¦~7~12¤ëªº40¦ì±wªÌ¡A°£¤F10% ªº¤ñ¨Ò¦¨¬°¤w´c¤Æ¼Æ¾Ú¥~¡A¨ä¥¦ªº86¤H³£¬O¥¼´c¤Æ®É¶¡¤p©óTªº³]­­¸ê®Æ¡C²{¦b¥Î³o86¦ì¤p©óTªº³]­­¸ê®Æ»Pm­Ó¤w´c¤Æ¸ê®Æ¨Ó°µºtºâ¡A¬Ý¬Ý¬O§_76¬O¤£¬O¯uªº¬Om¡Hm¥i¯à¤j©ó76¤]¥i¯à¤p©ó76¡A­n¥Î¤ñ¸û±µªñ¯u¹ê±¡ªpªº¤è¦¡¨Ó°µ¸Õºâ¡C¨Ì±zªº¸Õºâªí¡A±z¬O¥ý¦³28¦ì¤w´c¤Æ¼Æ¾Ú¡A±µ¤U¨Ó88¦ì³]­­¡A¦A±µ¤U¨Ó48¦ì¤w´c¤Æ¼Æ¾Ú¡A¦¹®É¦b¤w´c¤Æ¹F76¤H®É¹F¨ì0.5ªºÁ`¦s¬¡¾÷²v¡C²{¦b§Ú­Ì¥Î¥i¯à§ó¶Kªñ¨Æ¹êªº¤èªk¡A¥ý¦³228¤Hªº10%¤]´N¬O23¤H¤w´c¤Æ¡AµM«á±µ¤U¨Ó¤À°t³]­­¸ê®Æ86¤H»P76-23=53¤H¤w´c¤Æ¼Æ¾Ú¡A¥æ¤eµÛ¼vÅTKM¨ç¼Æ¤U­°ªº¾÷²v©M¹Ï«¬¡AÁ|­Ó¨Ò¡A«ö®É¶¡±Æ§Ç¡A¨C5­Ó³]­­¸ê®Æ´Nºò±µµÛ°t3­Ó¤w´c¤Æ¼Æ¾Ú¡A¦p¦¹5­Ó°t¤T­Ó¡AÅýKM¨ç¼Æ¤£Â_¤U­°¡Aª½¨ì0.5ªºÁ`¦s¬¡¾÷²v¥X²{¬°¤î¡A¬Ý¬Ý³]­­¸ê®Æ¹F¨ì´X¦ì¥H¤Îm¬O¦h¤Ö®É¡A0.5ªºÁ`¦s¬¡¾÷²v¥X²{¡C°²³]¯uªº¬O86¦ì³]­­¸ê®Æ»P76­Ó¤w´c¤Æ¼Æ¾Ú¥i¥H¹F¨ì0.5ªºÁ`¦s¬¡¾÷²v¡A¦]¬°²Ä86¦ì³]­­¸ê®Æªº¥¼´c¤Æ®É¶¡¬O±q2013¦~7¤ë¨ì2015¦~1¤ë¡A¦@¬O19­Ó¤ë¡A¤S¦]¬°T(²Äm­Ó¤w´c¤Æ±wªÌ¡A¥Lªº´c¤Æ®É¶¡´N¬O¤¤¦ì¼ÆPFS)¤@©w¤j©ó«e­±ªº86¦ìªº³]­­¸ê®Æªº¥ô¦ó¤@­Ó¡A¦]¦¹T¤j©ó19¡C

¥t¤@­Ó¨Ò¤l¬O·¥ºÝªº¨Ò¤l¡A´N¬O¤w´c¤Æªº¼Æ¾Ú³£¬O±q¦­¦¬®×ªº±wªÌ¨Óªº¡A°£¤F10%ªº822¥¼¯àµo´§ÃĮġA¥H¤Î10%ªº±wªÌÄÝ©óNEDªºª¬ªp·|«Ü¤[¤~´c¤Æªº¨Ò¥~¡C¥ý°²³]³o¤@­Ó¨Ò¤lªºm¤]¬O76¦ì¡A¦ý¦]¬°³o¤@¨Òªº²Ä¤@²Õ(«e­±¦³©w¸q¹L²Ä¤@²Õ©M²Ä¤G²Õ)³]­­¸ê®Æ·|¤ñ¤W¤@¨Ò¦h«Ü¦h¡A©Ò¥H³o¤@¨Òªºm¤@©w¤p©ó76¡A¹ê»Úªºm½Ð±z¸Õºâ¬Ý¬Ý¡C¤@¼Ë¥Î¸Õºâªí¨ÓºâKM¨ç¼Æ«ç»ò±q1¤U­°¨ì0.5¡AÁÙ¬O¥ý¦³23¤H«Ü§Ö´N´c¤Æ¤F¡A76-23=53¡A³Ì¦h53¤H¥þ³¡¨Ó¦Û©ó2012¦~¦~©³«e¦¬®×ªº±wªÌ¡A2012¦~¦~©³«e¦¬66¤H¡A¦³10%¬ù7¤H¬ONEDªº±wªÌ¡A³o7¦ìNEDªº±wªÌ·|«Ü¤[¤~´c¤Æ¡A¦]¦¹³Ì¦h53¤Hªº¤w´c¤Æ¼Æ¾Ú¥þ³¡¨Ó¦Û©ó66-7=59³o59¦ì±wªÌ¡A¤]´N¬O»¡¡A¦b2012¦~¦~©³¥H«á¦¬®×ªº66+40+56¤H=162¤H¡A°£¤F10%ÃĮĤ£¦nªº¤§¥~¡A¦b¦¹¨Ò¤¤¡A¥þ³¡¬O¥¼´c¤Æªº³]­­¸ê®Æ¡A2013¦~1¤ë¦¬®×ªº´N¬O25+­Ó¤ë¡A2013¦~5¤ë¦¬®×ªº´N¬O20+­Ó¤ë¡A¨Ì¦¹Ãþ±À

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2015/1/26 ¤W¤È 10:16:59²Ä 1483 ½g¦^À³
£«¬Â¤j¡A

ÁÂÁ±z´£¨Ñªº¸ê®Æ

¦ý¨Ì¾Ú©w¸q¡G

¡K³o類¥Hµo¥Í¡u¸~½F惡¤Æ¡v¬°Æ[¹î¨Æ¥óªºµû¦ô«ü¼Ð±`¥Îªº¦³Progression-free survival (PFS)©MTime to progression (TTP)¡A³o兩­Óµû¦ô«ü¼Ð©w¸qµy¦³不¦P¡APFS©w¸qªº¨Æ¥ó¥]¬A¡u¸~½F惡¤Æ¡v©M¡u¦º¤`¡v¡A¥HPFS¬°µû¦ô«ü¼Ðªº臨§É¸ÕÅç¡AÆ[¹î¨ü¸ÕªÌ±q¶i¤J¸ÕÅç¨ì¸~½Fµo¥Í惡¤Æ©Î¦º¤`ªº®É¶¡ªø度¡A¨ü¸ÕªÌ¥u­n¡u¸~½F惡¤Æ¡v©Î¡u¦º¤`¡v¤GªÌ¨ä¤@¥ýµo¥Í¡A«h¹F¨ì¬ã¨sªº²×ÂI¡A¦¹¤@Æ[¹î®É¶¡ªø度§Y¬O¸ÕÅç©Ò­n¦¬¶°¤ÀªRªº數¾Ú¡F¦ÓTTP©w¸qªº¨Æ¥ó¶È¦³¡u¸~½F惡¤Æ¡v¡A不¥]¬A¡u¦º¤`¡v¡K

¦º¤`ªÌ¡A¦pªG¥L¬O¥ý´c¤Æ¦A¦º¤`¡A¨º»ò¥LªºPFS©MOS³£¤w¸g¦b¤£¦Pªº®É¶¡½T©w¤F¡A¹ï³o­ÓÁ{§É¹êÅç°^Ämªº²Î­p¼Æ¾Ú¤£·|¦AÅܰʤF¡F¦pªG¥LÁÙ¨SÆ[¹î¨ì´c¤Æ´N¦º¤`¡A¨º»ò¥LªºPFS©MOS¬O¦P¤@­Ó®É¶¡¡A¤]½T©w¤F¡A¹ï³o­ÓÁ{§É¹êÅç°^Ämªº²Î­p¼Æ¾Ú¤]¤£·|¦AÅܰʤF¡C¦]¦¹¤p§Ìı±o¡y¦º¤`ªÌ¬O°h¥XÁ{§Éªº¡z³o¥y¸Ü§ï¦¨¡y¦º¤`ªÌ¤£¦A¹ïÁ{§É¹êÅ窺²Î­p¼Æ¦r²£¥ÍÅÜ°Ê¡z¤ñ¸û§´·í¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GBenjamin10139027  µoªí®É¶¡:2015/1/26 ¤W¤È 08:30:48²Ä 1482 ½g¦^À³
¦n¤[¨S¤W¨Ó¤F¡AµL·N¨£¤S¬Ý¨£¦³¤H¦b°Q½×ÃÒ©Òµ|¡C

½Í¨ìÃÒ©Òµ|¡Aµoı¤j®a¦³­Ó¿ù»~ªº·§©À¡A´N¬O"IPO¤£¨ì10±iªº¤H¤£¥Î½Ò"¡C

¨ä¹ê¡A¾Ú§Ú¤F¸Ñ¡A³o¬O¿ù»~ªº¡A¦Ó¬O"ÄÝ©Ó¾P¨ú±o¦U¸Óªì¦¸¤W¥«¡B¤WÂd¤½¥qªÑ²¼¼Æ¶q¦b 10,000 ªÑ¥H¤U"ªº¤~¤£½Ò¡C(½Ð°Ñ¦Ò¤U¤èªº°êµ|§½ºô¯¸)

http://www.mof.gov.tw/public/Attachment/3871541926.pdf

´«¥y¸Ü»¡¡AÀ³¸Ó¥u¦³¤½¥q­û¤u»{ÁÊ¥H¤Î¸ß°éªº¤H¤~¦³³o¸ê®æ¤~¬O¡A¦]¬°°£¦¹¥H¥~¡A¸Ó¤£ÄÝ©ó"ÄÝ©Ó¾P¨ú±o"¡C

­Y¦³¿ù»~¡A©|½Ð¤£§[«ü¥¿^^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2015/1/26 ¤W¤È 07:54:56²Ä 1481 ½g¦^À³
¹ï¤£°_! ¤S¬Ý¿ù¤F!

¬Ý¨Ó¯uªº¸Ó¦Ò¼{³¬¼L¤F ÁÂÁ¤j®a!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gµ½¤H10137888  µoªí®É¶¡:2015/1/25 ¤U¤È 11:49:16²Ä 1480 ½g¦^À³
·PÁ²q·Q¤j©M¤p©_¤jªº¥Î¤ß©M¸Ô²Ó¤ÀªR!

±q¤U­±¤G«h·s»D³ø¾É, palbociclibÁÙ¨S®³¨ìFDA·sÃĤW¥«³\¥i, ¥u¬OÀò±oÀu¥ý¼f¬d¸ê®æ, ¼f¬dºI¤î¤é´Á¬°2015-4-13.

¦b2015-4-13¤§«e, FDA·|¤½§i¬O§_³q¹L¼f¬d.

According to studies, inhibition of these proteins will slow down the growth of cancer.

½÷·çªºPalbociclib¥u¬O§í¨î©M­°§CÀù²Ó­Mªº¥Í´Þ¤O, ©Ò¥H¯à©µªøÀù²Ó­M´c¤Æªº®É¶¡. ¥¦¤£¯à®ø·ÀÀù(·F)²Ó­M.

µ¥¨ìÀù²Ó­M²£¥Í§ÜÃÄ©Ê, ¨ä¥Í´Þ¤O©MÂX´²¤O§ó±j, ©Ò¥HÁ`¦s¬¡´Á(OS)¼W¥[¤£¦h.

2014-10-16 CDK4/6¥«³õ¶}±Ò¦b±æ¡XFDAÀu¥ý¼f¬d½÷·ç¨Å¸¢Àù©ú¬PÃÄpalbociclib

½÷·ç(Pfizer)ªñ¤é«Å¥¬¡AFDA¤w±µ¨ü¼f¬dpalbociclib·sÃÄ¥Ó½Ð(NDA)¡A¦P®É¤w±Â¤©Àu¥ý¼f¬d¸ê®æ(Priority Review Status)¡A

¦}¤w«ü©w³B¤èÃĥΤ᦬¶Oªk(PDUFA)¥Ø¼Ð¤é´Á¬°2015¦~4¤ë13¤é¡CÀu¥ý¼f¬d¸ê®æ·N¨ýµÛFDA±N¦b6­Ó¤ë¤º§¹¦¨palbociclib NDAªº¼f¬d¡A¬Û¤ñ±`³Wªº10­Ó¤ë¼f¬d©P´ÁÁYµu¤F4­Ó¤ë¡C

¦pªGÀò§å¡Apalbociclib+µÜ¦±Ðü(letrozole)Áp¦XÀøªk§@¬°ER+/HER2-±ß´Á¨Å¸¢Àùªº¤@½uÀøªk¡A±N¬°¦¨¤d¤W¸UÂಾ©Ê¨Å¸¢Àù±wªÌ´£¨Ñ¤@­Ó­«­nªº·s¿ï¾Ü¡C

2015-1-11 Pfizer Inc. (NYSE:PFE) Expects Early Approval of Drug for Breast Cancer

Pfizer Inc. (NYSE:PFE) is working on a new drug for treatment of breast cancer. The drug is called palbociclib.

Pfizer Inc. (NYSE:PFE) is currently having talks with the FDA of US to get them to approve the drug early.

The FDA accepted the application of palbociclib in October 2014. The breast cancer drug was granted a high status ¡V Priority Review.

As a result, the time taken for reviewing the drug decreased to six months from 10.

Pfizer Inc. (NYSE:PFE) says that this decision by the FDA does not require a meeting of the advisory committee.

Spokesperson from FDA, Tara Goodin, said that palbociclib will be completely and thoroughly reviewed by the FDA, whether or not Oncologic Drugs Advisory Committee evaluates it.

Jefferies¡¦ analyst, Jeffrey Holford, said that Pfizer Inc. (NYSE:PFE) gave a statement that since the Advisory Committee is not meeting to approve the breast cancer drug,

therefore, Pfizer Inc. (NYSE:PFE) are confident that palbociclib will be approved by April. ½÷·ç¦Û«Hpalbociclib±N¦b2015¦~4¤ëÀò±o¼f§å.

FDA earlier gave an approval date of April 13. The statement by Pfizer Inc. (NYSE:PFE) suggests that the company would receive the approval that they seek by this date.

As a result of this announcement, the stocks of Pfizer Inc. (NYSE:PFE) increased by 2.04%. Palbociclib will be sold as Ibrace expectantly.

Letrozole is another drug for treatment of breast cancer, which has been approved by the FDA.

Ibrace and letrozole will be used as a combination together to treat breast cancer in women who have crossed their age for menopause.

The advanced breast cancer patients will be those who have not received earlier treatments. The proteins CDK 4 and 6 help in the growth and spreading of tumor cells.

Palbociclib targets these proteins. According to studies, inhibition of these proteins will slow down the growth of cancer.

In 2013, the FDA gave the drug a designation of Breakthrough Therapy. For many past years, the pharmaceutical companies have used

this approach of inhibiting the CDK proteins to treat cancer. But so far no such efforts by other companies have been successful.

The reason was that severe side-effects were noticed in patients that were being treated with drugs targeting all the CDK classes.

Pfizer Inc. (NYSE:PFE) was successful because it only targeted the CDK 4 and 6 proteins; not all of the classes. According to studies to investigate the drug,

palbociclib slowed down the cancer growth for over 20 months. The treatments that are available in the market are those that stall cancer spread for 10 months only.

Still, it is not known for how long the patients¡¦ survival is extended. Analysts estimate that palbociclib can potentially generate annual sales worth $3 billion.

Mr. Holford estimates that the annual sales will increase by $5 billion due to the drug. JPMorgan estimate that by 2020, the drug will bring home $4 billion.

Pfizer Inc. (NYSE:PFE) say that they are planning to bring the drug in the

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2015/1/25 ¤U¤È 10:32:59²Ä 1479 ½g¦^À³
²q·Q¤j

Palbociclib ÁÙ¨S¦³®³¨ìFDA ÃÄÃÒ

¦³¦nªºPFS ¨S¦³¦nªºOS ±N¥¢¥h·sÃĬãµoªº²×·¥¥Øªº»P»ù­È

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2015/1/25 ¤U¤È 08:11:37²Ä 1478 ½g¦^À³
¤p©_¤j

·PÁ±zªá¶O¤j¶qªº¤ß¤O®É¶¡¬°¤p§Ì¸Ô²Ó¦a¸Ñ»¡

¹ï©ó­pºâ ¤¤¦ìPFS ªºÃöÁä°ÝÃD --- ±ß¶i¸ÕÅ窺±wªÌ ¦b¸Ñª¼®É ¤´¥¼´c¤Æ ³o¨Ç¸ê®Æ«ç»ò³B²z

°O±o´¿´N±Ð©ó±z Áö±o±z¶}ÄÀ ¤p§Ì«o»~¸Ñ¦Ü¤µ

¤£µM¤]¤£·|¦b³o­ÓÄø°ÝÃD¤W¥´Âà

¤µÁö±o¥HÂç²M ´N¬O¥²¶·¥H³]­­¸ê®Æ¨Ó³B²z­pºâ

³o¤]Åã¥Ü ·í¸Ñª¼®É ¤£ºÞ¦³µL³Q­¢(2015.9 ©Î¤§«e) ³]­­¸ê®Æ¤H¼Æ´X¥G·|¶W¹L88¤H

«ö·Ó¸Õºâ ·í³]­­¥[´c¤Æ¤H¼Æ ¶W¹L(88+76) ¥Î©Ô»ôªk¥H¤é¾ä¤Ñ¦ôºâªº¤è¦¡¶Õ±N¶W¦ô °£«D¸ÕÅç²Õªº´c¤Æ¤H¼Æ¹é¹éµL´X(µL³Q­¢¸Ñª¼ªº±¡ªp)

³o¯uªº¤£¦nª± §Ë¿ùÆ[©À §C¦ôÅܶW¦ô ÁÙ¯u¥O¤HµLªk½Õ¾A!

©Î³\´N´Á«Ý¬Ý¬Ý 822ªº¤¤¦ìOS¥i¦³¶W¤Zªºªí²{?

³o¤]Åý¤H·Q°_ ¥Ñ½÷·ç¤½¥q¬ãµo¥B´£¦­Àò±oÃÄÃÒªº palbociclib

¥¦ªº¾AÀ³¯g¬OER(+) HER2(¡Ð)ªºMBC±wªÌ ¤p§Ì»{¬° Palbociclib ¬O822ªº¹ï¤âÃÄ

palbociclib ¬OCDK 4/6§í»s¾¯¡A¦®¦bªý¤î²Ó­M¶g´Á¶iµ{ §í¨î²Ó­M¼W´Þ©M²Ó­MDNAªº¦X¦¨

Palbociclib ¯à¥H¤G´Áªº¼Æ¾Ú ¦b¤£¨ì60¤Ñªº®É¶¡«KÀòÃÄÃÒ(2014.8.18 ~ 2014.10.13)

¬O palbociclib ÃĮİ÷¦n ÁÙ¬O½÷·ç°÷¤O?

¾Ú³ø¾É http://www.ascopost.com/issues/may-1,-2014/paloma-1-trial-finds-palbociclibletrozole-doubles-progression-free-survival-in-metastatic-breast-cancer.aspx

³o­Ó¦W¬°PALOMA-1 ªº¤G´Á¸ÕÅç ¤À¨â­Ó³¡¥÷

1. ER(+) HER2(¡Ð)¥B°±¸gªºMBC±wªÌ ¥¦ªº¤¤¦ìPFS ( palbociclib + letrozole ) :( letrozole ) ¬°26.1­Ó¤ë : 5.7­Ó¤ë ¡]P <0.0001¡^

2. ER(+) HER2(¡Ð)¥B¨ã¦³(CCND1 amplification and/or loss of p16) ªºMBC±wªÌ ¤¤¦ìPFS ( palbociclib + letrozole ) :( letrozole ) ¬°18.1­Ó¤ë : 11­Ó¤ë ¡]P <0.0046¡^

¨â³¡¥÷ªº¤¤¦ìPFS Á`­p ( palbociclib + letrozole ) :( letrozole ) ¬° 20.2­Ó¤ë : 10.2­Ó¤ë ¡] P = .0004¡^

¤¤¦ìOS ( palbociclib + letrozole ) :( letrozole ) ¬° 37.5­Ó¤ë : 33.3­Ó¤ë (µL²Î­p¾ÇÅãµÛ®t²§)

Á{§ÉÀò¯q²v ( §¹¥þ©M³¡¤À¤ÏÀ³¥[¤W¯e¯fí©w ) ¤À§O¬° 81 ¢H ©M 58 ¢H

¸ÕÅçµ²§ô®É ¤´¦bªvÀøªº±wªÌ ( palbociclib + letrozole ) 23 ¢H VS ³æ¿Wletrozole 10 ¢H ³Ì±`¨£ªº°±¤îªvÀø­ì¦]¬O¯e¯f¶i®i

³o¼Ëªº¼Æ¾Ú«Ü´Î¶Ü?

ÁöµM ¤¤¦ìPFS ¦³ÅãµÛ¦¨ªø ¦ý¬OÁ`¥Í¦s«ü¼ÐOS «oµLÅãµÛ§ïµ½ ±wªÌ¨Ã¥¼±q·sÃÄÀò±o¥Í¦s§Q¯q

¸ÕÅç²Õªº¥ÎÃÄÀW²v¬° 125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles

¦b¸ÕÅçµ²§ô®É ¸ÕÅç²Õ¤´¦bªvÀøªº±wªÌ ¦³ 23 ¢H ©ÎÅã¥Ü¥Xªñ77 %ªº±wªÌ¦³§ÜÃĩʪº°ÝÃD ¾É­PÃĪ«¥¢®Ä ²£¥Í¯e¯f¶i®i

±q³o­Ó¨Ò¤l ER(+) HER2(-)ªºMBC±wªÌ ©Î³\¸~½F´c©Ê¨S¦³¨º»ò°ª

¦]¬°HER2(¡Ð) ´_µo´c©Ê­°§C µL»Ý¨Ï¥ÎHerceptin ¤S¦]¬°ER(+) ©Ò¥H³æ¿W¨Ï¥Îletrozole ´N¥i§â¤¤¦ìOS©Ôªø¨ì33.3 ­Ó¤ë

¨º¤£¸T­n°Ý palbociclib ªº¨¤¦â¦b­þ¸Ì?

³o¼Ë¤]¯à¥Î¤G´Á¼Æ¾Ú¨Ó´£¦­Àò±oÃÄÃÒ ±M·~©M«D±M·~¤§¶¡ªº¬Ýªk³º¦p¦¹­~²§ Åý¤H¦³¹j¦æ¦p¹j¤s¤§¹Ä

©Î³\ 822 ªºÁ{§É¤T´Á¥i±Ä¶}©ñ¦¡¸ÕÅç ±N¨ä¤¤¤@²Õ¦bÀøµ{µ²§ô«á Ä~Äò©T©w¶g´Á¦a¬IÃÄ ª½¨ì¯e¯f¶i®i¬°¤î ¨ÓÆ[¹î822ªºÃĮķ¥­­

Ãö©ó¨ÅÀùªº¶Pº¸»XÀøªk ³o½g¤¶²ÐÁÙº¡¸Ô²Óªº https://www1.cgmh.org.tw/intr/intr5/c6210/breast%20cancer%20hormone%20therapy.html

¥H¤W»¡ªk ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!

°Ú«¢! ¹ï¤£°_ ¦Ñ¬O»~¾É¤j®a ¬Ý¨ÓÀ³¸Ó³¬¤W¼L¤Ú¤F

©¯¦n¦³¤p©_¤jªº«ü¾É ¤£µM»~¤H»~¤v ¤´¤£¦Ûª¾ ¬O¬°¸o¹L

«D±`ÁÂÁ¤p©_¤jªº«ü¾É ·P®¦!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý£«¬Â10136621  µoªí®É¶¡:2015/1/25 ¤U¤È 06:10:41²Ä 1477 ½g¦^À³
¤p©_¤j,Âå®v¿Ë±­説:¦º¤`ªÌ¬O°h¥XÁ{§Éªº,¨Ñ§A°Ñ¦Ò.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2015/1/25 ¤W¤È 01:31:39²Ä 1476 ½g¦^À³
²q·Q¤j¡A

¤p§ÌºÉ¤O¥h¸ÑÄÀ¬Ý¬Ý¡A­Y¦³Ã㤣¹F·N¤§³B¡A¦AÄ~Äò°Q½×¡C

¡y¸ÕÅç²Õ228¤Hªº³]­­¸ê®Æ·|¤j©ó88¤H¶Ü?¡z

§Ú·Q±z¥i¯à§â³]­­¸ê®Æ©w¸q¬°¥¢Ápªº±wªÌ¤F¡A¥¢Ápªº±wªÌ¥u¬O³]­­¸ê®Æªº¤@¤p³¡¤À¡A´¦¶}¬Ýµª®×®É¡A©|¥¼´c¤Æªº±wªÌ¤~¬O³]­­¸ê®Æªº³Ì¤j³¡¤À¡A°²³]¯E¹©²{¦b´¦¶}¬Ýµª®×¡AS¤p©j¥h¦~3¤ë¦¬®×¡A¨ì²{¦b¬ù¤Q­Ó¤ë¡A¤´¨S¦³´c¤Æ¡A²Î­p¼Æ¦r¬ö¿ý¬°10+­Ó¤ë¡A¦o¥i¯à¦A¹L¤@­Ó¤ë´N´c¤Æ¡A¤]¥i¯à36­Ó¤ë«á´c¤Æ¡A¦]¬°­n°µ²Î­p¤ÀªR¤F¡AS¤p©j´N¬Oµn°O¬°10+­Ó¤ë¡C¦pªG¦³¤@­Ó¥h¦~2¤ë¦¬®×ªº±wªÌ¡A¦o¨ì¥h¦~12¤ë«á±q¦¹¥¢Áp¡A¨º»ò¦o¤]¬Oµn°O¬°10+­Ó¤ë¡A¦ý³o¦ì10+­Ó¤ëªº±wªÌ»PS¤p©jªº10+­Ó¤ë¤£¤Ó¤@¼Ë¡A¦pªG¯E¹©±ß¤@ÂI¸Ñª¼¡AS¤p©jªº¼Æ¦rÁÙ·|ÅܤơA¦ý³o¦ì¥h¦~2¤ë¦¬®×ªº±wªÌ¡A¦o¬OÄÝ©ó¥¢Áp¤H¤f¡APFS¤ÀªR©MOS¤ÀªR³£¬O¬ö¿ý¬°10+­Ó¤ë¡A¤£·|¦A¦³¥ô¦óÅܤƤF¡C³q±`³o¼Ë¤l¦]¥¢Ápªº³]­­¸ê®Æ¦ûÁ`¸ÕÅç¤H¼Æªº¤ñ¨Ò¤£·|¤Ó°ª¡A¤j¬ù¤Q´X­Ó¦Ê¤À¤ñ¡A¦b¦¹342¤HªºÁ{§É¸ÕÅ礤¡A¯E¹©§ìªº¬O342-284=58¤H¡A¥u­n¥¢Áp¤H¤f¤£¶W¹L58¤H¡A³£¦b¸ÕÅ窺³]­p°²³]½d³ò¤º¡C(¯E¹©¬O§_§ì58¤H¬°¸ÕÅç³]­p¥i¯àªº¥¢Áp¤H¼Æ¡A¤p§Ì¤£¯à§¹¥þ½T©w¡A¬O¥Î±À´úªº¡A³oÂI°Ñ¦Ò´N¦n¡C)

¥Ñ¤W­zªº¸ÑÄÀ¡A¥ô¦ó®É­Ô´¦¶}µª®×¡A´N¥u¦³¤w´c¤Æ±wªÌªº´c¤Æ®É¶¡¸ê®Æ¡A¥H¤Î´c¤Æ®É¶¡¤´¥¼ª¾ªº³]­­¸ê®Æ¨âºØ¸ê®Æ¡A¥u¦³³o¨âºØ¼Æ¾Ú¡A¤w´c¤Æ±wªÌªº´c¤Æ®É¶¡¸ê®Æ¤w¸g¬O§¹¥þ½T©wªº¼Æ¾Ú¡A¤£ºÞ¦Aµ¥¦h¤[¡A¼Æ¦r³£¤£·|¦A§ïÅܤF¡C´c¤Æ®É¶¡¤´¥¼ª¾ªº³]­­¸ê®Æ¥i¥H¤À¦¨¤TÃþ¼Æ¾Ú¡A¤@Ãþ¬O¥¢Ápªº³]­­¸ê®Æ¡A³o­Ó¤]¤£·|¦AÀHµÛ®É¶¡ªº±À¶i¦Ó§ïÅܤF¡F¤@Ãþ¬O¦]¬°¤ñ¸û±ß¤~¶i¤J¦¬®×ªº¸ÕÅç²Õ±wªÌ¡A¦]¬°¶i¤J¸ÕÅç®É¶¡¤Óµu¡A¤j³¡¤À³£ÁÙ¨S´c¤Æ¡A¥h¦~1~7¤ë¦¬®×ªº¸ÕÅç²Õ±wªÌ³£¬OÄÝ©ó³o¤@Ãþ¡A­Y¦AÆ[¹î¤[¤@ÂIªº®É¶¡¡A¤~¯àª¾¹DÃĪ«¦b¥L­Ì¨­¤WªºÃĮĦp¦ó¡F¥t¤@Ãþ¬OÃĪ«¦b¥L­Ì¨­¤W§@¥Î±o¬Û·í¦nªº¦­´Á¦¬®×±wªÌ¡A¨Ò¦p¦b2012¦~¦~©³«e¦¬®×ªº¸ÕÅç²Õ±wªÌ¡A¥L­Ì¥þ³¡¸g¾ú¶W¹L24­Ó¤ë¥H¤Wªº®É¶¡¡A¦]¬°ÁÙ¨S´c¤Æ¡A²{¦b´¦¶}¬Ýµª®×¡AÁÙ¬O¨S´c¤Æ¡A¦]¦¹¤]¬Oµn°O¬°³]­­¸ê®Æ¡C

¦b±zªº¨Ò¤l¤¤¡A¡y°²­Y¸Ñª¼®ÉÁ`´c¤Æ¤H¼Æ¬O176 ¥B°²³]¹ï·Ó²Õ¦³100¤H´c¤Æ ¨º´N¬O¸ÕÅç²Õ¦³76 ¤H´c¤Æ¡z¡A¬JµM¸ÕÅç²Õ¦³76¤H´c¤Æ¡A¨º»ò¸ÕÅç²Õªº³]­­¸ê®Æ´N¬O228-76=152¤H¡A³o152¤H¦³¥¢Ápªº¡B¦³¸û±ß´Á¤~¶i¤J¸ÕÅ窺¡B¦³ÃĮĵo´§±o«Ü¦nªº¦­´Á¦¬®×±wªÌ¡A¥L­Ìªº´c¤Æ®É¶¡´N¬O¦b¸Ñª¼®É¨S¦³¿ìªk§¹¥þ½T©w¡A¦]¦¹ºÙ¬°³]­­¸ê®Æ¡A´N¦]¬°¦s¬¡¤ÀªR·|¦³«Ü¦hªº³]­­¸ê®Æ¡A©Ò¥H¤~¥ÎKM¨ç¼Æ¨Ó¸Ñ¨M¡C

¡y¥Î³o­Ó·í°ò¦ ¨Ó¸Õºâ·í³]­­¸ê®Æ¬O¦h¤Ö®É 822ªºÁ`¦s¬¡¾÷²v­è­è¦n·|¬ï¶V0.5

¸Õ¤F´X¦¸ ·í³]­­¸ê®Æ¤H¼Æ¹F88 ¤H (¸ÕÅç²Õ¦³76 ¤H´c¤Æ) Á`¦s¬¡¾÷²v­è­è¦n·|¬ï¶V0.5 (¸Õºâªí¦C©ó³Ì©³ºÝ ½Ð°Ñ¦Ò)

³o¬O§_ªí¥Ü ·í³]­­¸ê®Æ¤H¼Æ¬°88¤H®É 822ªº¤¤¦ìPFS©Î»P¤é¾ä¤Ñ©Òºâ±oªº¤Ñ¼Æ¬ù²¤¬Û·í( §â©Ò¦³±wªÌ¬Ý¦¨¦P®É¶i¤J¸ÕÅ窺·í¤é°_ºâ)

·í¸Ñª¼®É ³]­­¸ê®Æ¤H¼Æ¤Ö©ó88¤H®É ¤¤¦ìPFS·|¤ñ¤é¾ä¤Ñ©Òºâ±oªº¤Ñ¼ÆÁÙªø??? ¤Ï¤§ «h­n¥´§é??? ³o¼Ëªº»¡ªk¹ï¶Ü???¡z

§Ú¸ÕµÛ«ö·Ó±zªº¨Ò¤l¨Ó±À¡A±z¬Ý¬Ý¸ò±zªº·Qªk¤@¼Ë§_¡H

±zªº¸Õºâªíªººâªk¡A¦b¥[Åv¥­§¡¤èªk¤¤¡AÀ³¸Ó¸ÑŪ¬°¡A°²³]¦³76¤H´c¤Æ¤F¡A³o76¤H¥ý

«ö·Ó´c¤Æ®É¶¡°µ±Æ§Ç¡A§Ú­Ì°²³]´N¦b³o­Ó¤ë©³¹F¨ì76¤H´c¤Æ¡A©Ò¥H³o²Ä76¤Hªº´c¤Æ®É¶¡¬ö¿ý¬°20­Ó¤ë(±zªº¥[Åv¥­§¡¦b2013¦~5¤ë¡A¹ï¶Ü¡H)¡A¦]¦¹´N°²³]¥þ³¡ªº228¦ì¸ÕÅç²Õ±wªÌ³£¦b2013¦~5¤ë¦¬®×¡A¦]¬°¤ñ³o²Ä76­Ó¤H´c¤Æ®É¶¡¡A¤]´N¬O20­Ó¤ë¡AÁÙµuªº³]­­¸ê®Æ¦b¦¹¨Ò¤¤¬°88¤H¡A§Ú­Ì¥²¶·°²³]³o88¤H¥þ³¡¬O¥¢Áp¡A©ÎªÌ¦b²Ä¤@­Ó¤ë¥¢Áp¡B©ÎªÌ¦b²Ä­Ó¤G¤ë¥¢Áp¡B©ÎªÌ¦b²Ä19­Ó¤ë¥¢Áp¡A¨ä¾lªº228-88-76=64¤H³£ÁÙ¨S´c¤Æ¡A¥L­Ì¤]¬O³]­­¸ê®Æ¡A¬OÃĮĵo´§±o«Ü¦nªº±wªÌ¡A¦]¦¹¦b±zªº¥[Åv¥­§¡¤èªk¤¤¡A­Y¦b³o­Ó¤ë©³¹F¨ì76¤H¥B°µ¤F¸Ñª¼¡A¤¤¦ì¼ÆPFS´N¬O20­Ó¤ë¡A¦]¬°¤w¸g¹F¨ìÁ`¦s¬¡¾÷²v­è­è¦n¬ï¶V0.5¤F¡C

¦A¨Ó¬Ý¹ê»Úªº¡A¦ý¤]¬O³ÌÃø¦ôºâªº¤¤¦ì¼ÆPFS¡C¤@¼Ë¨Ì·Ó±zªº¨Ò¤l¡A²Ä76¤H´c¤Æ®É¡A¦³88­Ó³]­­¸ê®Æ¦b¸g¹L±Æ§Ç«áªº²Ä76¤Hªº´c¤Æ®É¶¡¤§«e¡A¦P®É¤]ªí¥Ü¦³64¦ì³]­­¸ê®Æ¬OÄÝ©óÃĮĵo´§±o«Ü¦n¡A¥L­Ì¸g¾ú¤F¶W¹L¸g±Æ§Ç«áªº³o²Ä76¤Hªº´c¤Æ®É¶¡«á¡A¤´³B©ó¥¼´c¤Æªºª¬ºA¡C­n«ç»ò¥h±Æ«e­±ªº88­Ó³]­­¸ê®Æ»P¤w¸g´c¤Æªº76¤Hªº¶¶§Ç¡H³o­Ó±Æªk¡A¦A«ç»ò±Æ¡A¨ä¹ê³£¥u¬O²q¡A¸ò¸Ñª¼ªº¼Æ¾Ú¥²¦³¤£¤pªº®t¶Z¡A§Ú­Ì¥u¯à±q³Ì¦³¥i¯à©Êªº±Àªk¥h²q¡C¥ý¥Î§Ú¥Îªº¼Æ¦r¡A2013¦~6¤ë©³«e¸ÕÅç²Õ¦¬®×132¤H¡A2013¦~¤U¥b¦~¸ÕÅç²Õ¦¬®×¤H¼Æ40¤H¡A2014¦~¸ÕÅç²Õ¦¬®×¤H¼Æ56¤H¡A¥H¤Î¦³10%ªº¸ÕÅç²Õ¬OÄÝ©ó822´X¥G¨S¦³µo´§ÃĮĪº±wªÌ¡C2013¦~¤U¥b¦~¸ÕÅç²Õ¦¬®×¤H¼Æ40¤H+2014¦~¸ÕÅç²Õ¦¬®×¤H¼Æ56¤H=96¤H¡A¬OÄÝ©ó¸û±ß¦¬®×ªº±wªÌ¡A¦©±¼10%ªº´X¥G¨S¦³µo´§ÃĮĪº¤w´c¤Æ±wªÌ¡A¤´¦³¬ù86¦ì±wªÌ¡A³o86¦ì±wªÌ©|¥¼´c¤Æ¡A¦ý¸g¾ú¸ÕÅç®É¶¡¤S¤ñ¸ûµu¡A¦]¦¹³Ì¥i¯à³£¬OÄÝ©ó¤W­zªº88­Ó³]­­¸ê®Æ¡A¨º¨Ì·Ó¤w´c¤Æ®É¶¡°µ±Æ§Çªº³o²Ä76¦ì¤w´c¤Æ±wªÌ¡A¦]¬°¥Lªº´c¤Æ®É¶¡¥²¶·¬O¤j©ó«e­±ªº²Ä88­Ó(«e­±88¦ì±Æ§Ç«á³Ì¤j¨º¤@­Ó¡A³Ì¦³¥i¯à¬O¦b2013¦~7¤ë¦¬®×ªº)¡A¦]¦¹³o¸g±Æ§Ç«áªº²Ä76¦ì´c¤Æ±wªÌ³Ì¦³¥i¯à¬O¦b2013¦~ªº6¤ë©³¤§«e¦¬®×ªº±wªÌ¡A¦]¬°¥L¸g¾ú¹Lªº¸ÕÅç®É¶¡¤@©w¤j©ó19­Ó¤ë(?IMG SRC="/WF_SQL_XSRF.html">

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2015/1/24 ¤W¤È 09:24:42²Ä 1475 ½g¦^À³
¤j®a¦n!

½Í¨ì822ªº¤¤¦ìPFS

¤p©_¤j¤w¸gÀ°§Ú­Ì³]ºâ«Ü¦h

²{¦b¤S¬Ý¨ì¤j®a¹ï©óÁ`´c¤Æ¤H¼Æ176¤Hªº°Q½× ¤£§K¦³¨Ç·Qªk

¦]¬°­Ó¤H¹ê¦bµLªkµû¦ô³o­Ó·Qªkªº¹ï©Î¿ù ©Î¬Oª¼ÂI¦b­þ

½Ð¤j®aÀ°¦£·Q·Q«ü¥¿ ¤£³Ó·P¿E ÁÂÁ¤j®a!

¤p§Ì¥H«e´¿¥Î¥[Åv¥­§¡¤è¦¡ ±N°Ñ»P¸ÕÅç±wªÌ ¬Ý¦¨¦b¬Y¤@®É¶¡ÂI¦P®É¶i¤J¸ÕÅç

¥Î­pºâ¤é¾ä¤Ñªº¤è¦¡ ¨Ó·§¦ô822 ªº¤¤¦ìPFS

¤£¹L³o­Ó¤è¦¡ ·|¨ü¨ì³]­­¸ê®Æ¤H¼Æªº¦h¹è ²£¥Í»~®t

¤µ¤é·Q¥Î¸Õºâªº¤è¦¡ ±N¥¦¶q¤Æ

°²­Y¸Ñª¼®ÉÁ`´c¤Æ¤H¼Æ¬O176 ¥B°²³]¹ï·Ó²Õ¦³100¤H´c¤Æ ¨º´N¬O¸ÕÅç²Õ¦³76 ¤H´c¤Æ

¥Î³o­Ó·í°ò¦ ¨Ó¸Õºâ·í³]­­¸ê®Æ¬O¦h¤Ö®É 822ªºÁ`¦s¬¡¾÷²v­è­è¦n·|¬ï¶V0.5

¸Õ¤F´X¦¸ ·í³]­­¸ê®Æ¤H¼Æ¹F88 ¤H (¸ÕÅç²Õ¦³76 ¤H´c¤Æ) Á`¦s¬¡¾÷²v­è­è¦n·|¬ï¶V0.5 (¸Õºâªí¦C©ó³Ì©³ºÝ ½Ð°Ñ¦Ò)

³o¬O§_ªí¥Ü ·í³]­­¸ê®Æ¤H¼Æ¬°88¤H®É 822ªº¤¤¦ìPFS©Î»P¤é¾ä¤Ñ©Òºâ±oªº¤Ñ¼Æ¬ù²¤¬Û·í( §â©Ò¦³±wªÌ¬Ý¦¨¦P®É¶i¤J¸ÕÅ窺·í¤é°_ºâ)

·í¸Ñª¼®É ³]­­¸ê®Æ¤H¼Æ¤Ö©ó88¤H®É ¤¤¦ìPFS·|¤ñ¤é¾ä¤Ñ©Òºâ±oªº¤Ñ¼ÆÁÙªø??? ¤Ï¤§ «h­n¥´§é??? ³o¼Ëªº»¡ªk¹ï¶Ü??? ½Ð¤j®aÀ°¦£·Q·Q ÁÂÁÂ!

§Ú¤]¦b·Q ¸ÕÅç²Õ228¤Hªº³]­­¸ê®Æ·|¤j©ó88¤H¶Ü?

¤]³\¦b¥xÆW¦]¦a¯U ¥æ³q¤è«K ¥¢Ápªº·|¤ñ¸û¤Ö ¦ýÀøµ{µ²§ô«áªº©w´ÁÀˬd ¥i¯à·|¦³±wªÌ·NÄ@ªº°ÝÃD(¦]¬°¤ÓÀWÁc¦aÀˬd)?

¦b¦a¼sªº¬ü°ê ³Ò¦à§x¹y ªá¶O«Ü¤j ¥¢Ápªº·|¤ñ¸û¦h À³¤]·|¦³·NÄ@ªº°ÝÃD?

ªü«¢! ³o®É¬ðµMı±o ¤¤¦ìPFS¸û°ª´N¬OÃĮĤñ¸û¦n¶Ü? ©Î³\°£¤FÃĮĥ~ ¦a²z ±wªÌ·NÄ@ Âå¯f¤¬°Êµ¥¦]¯À³£²o§è¨ä¤¤§a

µM¦ÓOSªº²Î­p ¥i¯à´N·|±µªñ²{ªp ¦]¬°¤£¥²¨ì°|Àˬd ¤@³q¹q¸Ü´N¥i¯à§¹¦¨¬d³X

§Ú­Ì¬Ý¤@¨Ç PFS ¡NOS ªºKaplan -Meier ¥Í¦s¹Ï¤U¤è ·|¦³¤@Äæ n at risk ªº¼Æ¦r OSªº ³q±`¤ñ¸û¤j ³]­­¸ê®Æ¤H¼Æ¸û¤Ö À³¤]¬O­ì¦]¤§£¸

Æ[¹îÃĮĪº¨}æÕ ­Y¥u¬Ý¤¤¦ìPFSªº¼Æ¦r®e©ö¥¢¯u ¬Ý´c¤Æ¤H¼Æªº¤ñ¨Ò©Î¤~¬OÃĮij̯u¹êªº§e²{

OS ªº¼Æ¦r´N¤ñ¸û«ÈÆ[ ¤]¸û¯à¥Nªí±wªÌ¦³¨S¦³Àò±o¸û¨Îªº¥Í¦s§Q¯q ¦ý»Ý­n«Üªø°lÂÜ´Á

822¸ÕÅç±wªÌ¦³µL¥¢Áp ©Î³\¤½¥q·í§½¬Oª¾¹Dªº ¹ï©ó ¤¤¦ìPFSªº¦ô­p ©Î¤w¸g¤FµM©ó¯Ý¤F§a

¶È¨Ñ°Ñ¦Ò

¨Ã½Ð¤j®a¿ãÅD«ü¥¿³o­Ó·Qªkªº¹ï©Î¿ù ©Î¬Oª¼ÂI¦b­þ ÁÂÁ¤j®a!

ªþªí :

OBI-822Á`¦s¬¡¾÷²v¸Õºâªí (228­Ó¸ÕÅç±wªÌ¤¤ °²³]¨C¶¥¬q¦³1 ¤H´c¤Æ ¥B¦³88­Ó³]­­¸ê®Æ(¬ù²¤¸m¤¤))

¨C­Óª½Ä檺Äæ¦ì¦WºÙ ¥Ñ¥ª¦Ü¥k¤À§O¬° ¡m n at risk §Y n( i ) ¡n,¡m d( i ) ¡n,¡m ¶¥¬q¦s¬¡¾÷²v §Y 1- d( i )/ n( i ) ¡n, ¡m Á`¦s¬¡¾÷²v ¡n

228 0 1.00000000 1.00000000

227 1 0.99559471 0.99559471

226 1 0.99557522 0.99118943

225 1 0.99555556 0.98678414

224 1 0.99553571 0.98237885

223 1 0.99551570 0.97797357

222 1 0.99549550 0.97356828

221 1 0.99547511 0.96916300

220 1 0.99545455 0.96475771

219 1 0.99543379 0.96035242

218 1 0.99541284 0.95594714

217 1 0.99539171 0.95154185

216 1 0.99537037 0.94713656

215 1 0.99534884 0.94273128

214 1 0.99532710 0.93832599

213 1 0.99530516 0.93392070

212 1 0.99528302 0.92951542

211 1 0.99526066 0.92511013

210 1 0.99523810 0.92070485

209 1 0.99521531 0.91629956

208 1 0.99519231 0.91189427

207 1 0.99516908 0.90748899

206 1 0.99514563 0.90308370

205 1 0.99512195 0.89867841

204 1 0.99509804 0.89427313

203 1 0.99507389 0.88986784

202 1 0.99504950 0.88546256

201 1 0.99502488 0.88105727

200 1 0.99500000 0.87665198

111 1 0.99099099 0.86875422

110 1 0.99090909 0.86085645

109 1 0.99082569 0.85295869

108 1 0.99074074 0.84506092

107 1 0.99065421 0.83716315

106 1 0.99056604 0.82926539

105 1 0.99047619 0.82136762

104 1 0.99038462 0.81346986

103 1 0.99029126 0.80557209

102 1 0.99019608 0.79767433

101 1 0.99009901 0.78977656

100 1 0.99000000 0.78187880

99 1 0.98989899 0.77398103

98 1 0.98979592 0.76608326

97 1 0.98969072 0.75818550

96 1 0.98958333 0.75028773

95 1 0.98947368 0.74238997

94 1 0.98936170 0.73449220

93 1 0.98924731 0.72659444

92 1 0.98913043 0.71869667

91 1 0.98901099 0.71079890

90 1 0.98888889 0.70290114

89 1 0.98876404 0.69500337

88 1 0.98863636 0.68710561

87 1 0.98850575 0.67920784

86 1 0.98837209 0.67131008

85 1 0.98823529 0.66341231

84 1 0.98809524 0.65551455

83 1 0.98795181 0.64761678

82 1 0.98780488 0.63971901

81 1 0.98765432 0.63182125

80 1 0.98750000 0.62392348

79 1 0.98734177 0.61602572

78 1 0.98717949 0.60812795

77 1 0.98701299 0.60023019

76 1 0.98684211 0.59233242

75 1 0.98666667 0.58443465

74 1 0.98648649 0.57653689

73

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/12/27 ¤U¤È 01:42:38²Ä 1474 ½g¦^À³
¦U¦ì¤j¤j:

¬ü°êFDA ¤w©ó103 ¦~11 ¤ë©³®Ö­ãOBI-833 ¶i¦æÁ{§ÉàPÅç¡A¹w­p©óµu´Á¶¡¥Ó½Ð¥xÆWIND¡A¨Ì¾Ú¥ý«eÁ{§ÉàPÅ禬®×¸gÅç¹w­p¦¬®×¤Î°lÂܮɶ¡¡A¹w¦ô©óµu´Á¶¡§¹¦¨Á{§É¤@´ÁàPÅç¡A°w¹ïªÍÀù¡B¤j¸zÀù¡B­GÀù¡B¯ØŦÀùµ¥¯f¤H¶i¦æÃĪ«¦w¥þ©Ê¤ÎÃĮĵû¦ô¡Fº¸«á©ó¥þ²y¶i¤JÁ{§É¤G´ÁàPÅç¡F¤¤´Á¶¡¶i¤JÁ{§É¤T´ÁàPÅç¡A¹w­p¥¼¨Ó·sÃĤW¥«¾P°â¡C(page 26)

­Ó¤H¸ÑŪ:¥¼¨Ó§¹¦¨ªÍÀù¡B¤j¸zÀù¡B­GÀù¡B¯ØŦÀùµ¥¯f¤HÃĪ«¦w¥þ©Ê¤ÎÃĮĵû¦ô«á ±q¯ØŦÀù¥ý°µ,¦]¯ØŦÀùÄÝ©óaggressive type of cancer ¦]Æ[¹î´Áµu ¦¬®×¤H¼Æ¤Ö,¤S¥i¥Î©t¨àÃÄ¥Ó½ÐÃÄÃÒ ,¥i¥[§Ö¤W¥«¤Î±ÂÅvªº®É¶¡,ªÍÀù¡B¤j¸zÀù¡B­GÀù¦]¶Ò¸ê¸êª÷¥R¸Î,À³¤]·|±µÄò¬ãµo ¤£·|µ¥¨ì¯ØŦÀù¬ãµo¦¨¥\¦A¬ãµo¨ä¥LÀù¯g,¥@¬É¤W¦³¦W¥Í§Þ¤½¥q³£¬O¦h½b»ôµo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¸ô¤H¥Ò10134573  µoªí®É¶¡:2014/12/27 ¤U¤È 01:24:36²Ä 1473 ½g¦^À³
®¥³ß¯Eª©¦U¦ì±M·~¤H¤hªº¥I¥X»P¤À¨É,822½T¹ê¬O¤@¶µ«Ü¦¨¥\ªº·sÃÄ,¤½¶}»¡©ú®Ñ¤w¸g¼gªº«Ü²M·¡¤F,¦pªGÁÙ¦b½èºÃ®`©È©Î¬Ý¤£À´ªº,¨ì³Ì«á³s´ö¥i¯à³£³Ü¤£¨ì¤F,¦Ñ¸Ü¤@¥y(§ë¸ê³£¦³­·ÀI½Ð¸Ô¾\¤½¶}»¡©ú®Ñ)
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/12/27 ¤U¤È 01:04:51²Ä 1472 ½g¦^À³
·PÁ¦U¦ì¤j¤j³Ìªñ´£¨Ñªº¸ê°T¤À¨É:

¦³Ãö12¤ë26¤é¤½§i¤WÂd»¡©ú®Ñ:§Ú§â833Ävª§Àu¶Õ±Ô­z¤À¦¨¦p¤U¨â¬q,°£¤F1¥~,½Ð¯S§O³Ìª`·N2(¤w¦b¥t¤@¶µ²£«~OBI-822 ¤W¦¨¥\ÅçÃÒ)

³o¥y±Ô­z¤£ª¾¦U¦ì¤j¤j¦p¦ó¸ÑŪ?

1¨Ï¥Î·s¿oªº¤Æ¾ÇÁäµ²ªk¨ÓÁpµ²Áާܭì(Globo H) »P¸üÅé³J¥Õ( ¥Õ³ïÃþ¬r¯À¡ADT-CRM197)¡A§Q¥ÎOBI ¤º³¡¬ÛÃö§Þ³N¡A

½T»{¨âªÌ³Ì¨Î¤ñ¨Ò¡A¥H¹F¨ì¦³®Ä´£¤É¤HÅé§K¬Ì¨t²Î¹ïÁާܭ쪺¿ëÃѯà¤O¡A±q¦Ó¹F¨ì¥D°Ê¦¡§K¬ÌªvÀøªº¥Øªº¡C

2 ³oÃþ«¬¤Æ¾Ç­×¹¢³J¥Õ½èªº§Þ³N¡A¸Ó¤½¥q¤w¦b¥t¤@¶µ²£«~OBI-822 ¤W¦¨¥\ÅçÃÒ¡A¨Ã¤w¦b¥xÆW¶i¤JÁ{§É¤T´ÁàPÅç¡C¥Ñ©ó¥Ø«e³oÃþ«¬ªºÀù¯gªvÀø¤è¦¡©|¥¼¦³¥ô¦ó²£«~¤W¥«¡A¦b¥¼¨ÓÀù¯gªvÀøªº»â°ì¤W¨ãµo®i¼ç¤O¡A¹ï±wªÌ¥Í²z¾÷¯à¸û¤Ö¯}Ãa©Ê¼vÅT¡A¹ï©óÀù¯g¯f¤Hªº¥Í¬¡«~½è¥ç¦³¥i§ïµ½¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/12/27 ¤W¤È 10:57:53²Ä 1471 ½g¦^À³
Iriswu ¤j

¸g±z¤@´£ Á×µ|¦¨¥»1.1% ¨º¸ò«ùªÑ¤T¦~ªºÃÒ©Òµ|3.75% ¤]«Üªñ¤F

·íµM¹ï¤j³¡¦ìªº¤j¤j¨Ó»¡ ©Î³\ÁÙ±oºëºâ¨ä¶¡ªº§Q¹ú±o¥¢

¹ï«ùªÑ¸û¤Öªº¤j¤j ©Î³\¨Ì²{¦æµ|¨î³W¹º ·|¦³¾Þ§@ÆF¬¡ªº¦n³B

ÁÂÁ±zªº´£¿ô!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GIriswu10136250  µoªí®É¶¡:2014/12/27 ¤W¤È 09:50:13²Ä 1470 ½g¦^À³
²q·Q¤j,³o­Óµ|¨îªº¤£½T©w©Ê·|³y¦¨§Úµ¥Á×µ|¤W«Ü¤jªºÅܼÆ.¦pªG«ö·Ó²{¦æªºµ|¨î,¾Þ§@¤W¥i¯à·|¦³1.1%(¨â¦¸¶R½æ+¨é°Óªº»ù®t)ªº¥æ©ö¦¨¥».«ö·ÓªL¥þª©¥»,«h¬O¦h¥X½æ¥X¦¨¥»ªº0.1%,¨âªÌ¦³11­¿.³Ì®tªº±¡ªp¦³¥i¯à¬O¥ý¥Îªº²{¦æªº¤èªkÁ×µ|,±N¨Ó(§Ú²q³Ì§Ö¬O2017¦~)¤S­n¥ÎªL¥þªºª©¥»¦Aú¤@¦¸µ|.¥u¬O¦h¤F¾Þ§@¤WªºÆF¬¡©Ê.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/12/27 ¤W¤È 09:08:55²Ä 1469 ½g¦^À³
Iriswu ¤j ÁÂÁ±z!

±zªº¸ÑŪ«Ü¦X²z ¸Ñ¨M²{¦³ÃÒ©Òµ|ªº°ÝÃD

·PÁÂ!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GIriswu10136250  µoªí®É¶¡:2014/12/27 ¤W¤È 09:01:26²Ä 1468 ½g¦^À³
§Ú­Ó¤Hªº¸ÑŪ¬O´£°ª¥æ©öµ|0.1%,½æ¥XªÑ²¼¨Æ´N¥ý¹w¦©0.1%.¦pªG±N¨Ó¤@¦~µ²ºâ¦pªG½ß¿ú.§A¥i¥H¦b©Ò±oµ|¥Ó³ø®É°h¦^¨Ó¤§«e©Ò¹wúªº0.1%. ·íµM¦pªG¬OÁÈ¿úªº¤H´N¤£·|¦A¥Ó³ø,©Ò¥H³o¼Ë´N¥i¥H©â¨ìªÑ¥«ÁÈ¿úªº¤Hµ|.¥u¤£¹L³o¼Ë°µ·|¤£·|80%ªº³£­n¥Ó³ø.¥u¦³20%¤£¥Î¥Ó³ø,½ß¿úªº¤HÁÙ­n°O±b.¤]¬OÆZ³Â·Ðªº.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/12/27 ¤W¤È 08:55:25²Ä 1467 ½g¦^À³
Âd¶R¦P·N¤WÂd«´¬ù¤é´Á¥´¤W¥h¤F

103¡B12¡B26

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/12/27 ¤W¤È 08:37:51²Ä 1466 ½g¦^À³
½Ð±Ð¤F¸Ñªº¤j¤j­Ì

"¯ó®×³W©w¡A¦bªÑ²¼¥X°â®É¡A«ö¥æ©ö»ù®æªº0.1%¥ý¦æ¦©Ãºµ|´Ú¡Aµ²ºâ®É¨Ö¤Jºî¦X©Ò±o©ÎÀç§Q¨Æ·~©Ò±o³]ºâ¬°­t"

³o¬O¤°»ò·N«ä?

¬O»¡0.1%¥ý¦æ¦©Ãºªºµ|´Ú ¥i±qºî©Òµ|ªº©Ò±o¤¤¦©°£³o¨Çµ|´Ú

ÁÙ¬O¨Ö¤Jºî¦X©Ò±o¦X¨Ö­pºâ ¦h°h¤Ö¸É

«eªÌ¬F©²¥i¯àµ|¦¬¦³´î¤ÖªººÃ¼{ «áªÌ¥i¯à¸û²{¦æµ|­t¬°­«

³o¼Ë¥i¦æ¶Ü? ÁÙ¬O¥t¦³¥L·N?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gmoncler4710135258  µoªí®É¶¡:2014/12/27 ¤W¤È 12:07:26²Ä 1465 ½g¦^À³
¬_«Ø»Ê»¡¡A±NÃÒ©Òµ|½Ò¼xÂk¹s«ä¦Ò¡A¥Á¶iÄҹΤU¶g¤@±N­«´£©Ò±oµ|ªk³¡¤À±ø¤å­×¥¿¯ó®×¡A´£¥X¡u´N·½¦©Ãº¡B¦X¨Ö¥Ó³ø¡vªºÃÒ¨é¥æ©ö©Ò±oµ|µ|¨î¡A¥H²Å¦X¶q¯à½Òµ|¡B²¤Æ½]¼xµ¥­ì«h¡C

¯ó®×³W©w¡A¦bªÑ²¼¥X°â®É¡A«ö¥æ©ö»ù®æªº0.1%¥ý¦æ¦©Ãºµ|´Ú¡Aµ²ºâ®É¨Ö¤Jºî¦X©Ò±o©ÎÀç§Q¨Æ·~©Ò±o³]ºâ¬°­t¡A¨S¦³§Kµ|ÃB³]­p©Ò²£¥Íªº¤HÀY¤á°ÝÃD¡A¥H²Å¦X¶q¯à½Òµ|¤Î´¶¹M½Òµ|­ì«h¡C

¥t¥~¡A¯ó®×¤]©ú©w¹Ò¥~ªk¤H¤ñ·Ó¦ÛµM¤H¿ì²z¡A¥iÁקK°²¥~¸êªºÁ×µ|¬y¹ú¡C¬_«Ø»Ê»¡¡A¥Á¶iÄҹέt³d¥ô¥H·Ç°õ¬FÄÒªº¤ßºA´£¥X­×ªkª©¥»¡A¶D¨D¥Á²³»{¦P¡C

--------------------

³o­Óµu´Á¤£·|¹L,¦ý¥i¯à¦¨¬°Á`²Î¤j¿ï®É¥Á¶iÄÒ¬Fµ¦,´«¨¥¤§,­Y2016§ï´Â´«¥N«h¥Ø«eÃÒ©Òµ|¥i¯à§¹¥þ¨ú®ø§ï¥H¦h¤d¤À¤§¤@ÃÒ¥æµ|¥N´À,¦b§ë¸êµ¦²¤¤W¥iª`·N¦¹ÁͶյo®i...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Grabbit10136567  µoªí®É¶¡:2014/12/26 ¤U¤È 12:01:16²Ä 1464 ½g¦^À³
Hi ­D§b¤j

§A´£¨Ñªº¸ê®Æ«Ü´Î¡A

¦ý¤§«e°Q½×¬O 142 ¬°´Á¤¤¤ÀªR±ø¥ó¡A³o§Ú­Ó¤Hı±o¥s°µ¸Ñª¼±ø¥ó»P´Á¤¤¤ÀªRµLÃö

±À´ú 284 «D ¹êÅç²Õ:¹ï·Ó²Õ = 2:1 ¥i¥H°£ºÉªº­¿¼Æ¡A©Ò¥H n=90 ¥i¥H®³¨Ó°Ñ¦Ò¯E¹©¡A

342 «h¦]¬°­n¦^±À n = 114 ªº¦U¶µ¼Æ¾Ú¡A§ó¥[§xÃø¡A

¥Ø«e¦¬®×¤H¼Æ¤w¹F¨ì­ì¨Óªº³]©w±¡ªp¤U¡A¦¬®×¤H¼Æ¼vÅT¤ÀªRªººÃ¼{¤w¸g¤£¥Î¦Ò¼{¡A

¥Ø«eªºÃö¥d¬O ?/180 ?/90 ¨âÃ䪺®t²§¡A

PFS´Nºâ¨ì¹F§Ú­Ìªº´Á±æ¡A¦ý¬O­Y¨â­Ó²Õ§Oªº±±¨î²v®t²§¨S¦³©Ô¶}ªº¸Ü¡A

¨ºªvÀøªº«H¿à°Ï¶¡±N¤£·|¤Ó¦n¡A¤]¬O®{³ÒµL¥\

¤@¤Á´Nµ¥¸Ñª¼

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/12/26 ¤W¤È 11:44:28²Ä 1463 ½g¦^À³
²q·Q¤j¡A¦U¦ì¤j¡A

²q·Q¤j±z³o¸ê®Æ¯uªº¬O¤Ó´Î¤F

¤p§Ì¦A¥J²Ó¾\Ū¤@¹MÀò¯q¨}¦h

¦A¦¸·PÁ¡I

²q·Q¤j´£¨Ñªº°Ñ¦Ò¸ê®Æ¡G

http://clincancerres.aacrjournals.org/content/15/17/5323.full

¤p§Ì¨Ì¥L­Ìªº©w¸q¥H¤Î¥Ø«e¹ï822ªº¤F¸Ñ­«·sºâ¤À¼Æ

GH+SSEA3+SSEA4Áp¦X§@¾Ô±Æ¦W¦b«e10¦W¨S°ÝÃD(HER2³£±Æ¦b²Ä¤»¦W¤F)

±j¯P«Øij¦pªG¦³¹w³Æúµ|3.75%ªº¥´ºâªº¤j¤j

¥i¥Hªá®É¶¡¦n¦nÅé·|¤@¤U¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­D§b10139065  µoªí®É¶¡:2014/12/26 ¤W¤È 10:06:59²Ä 1462 ½g¦^À³
https://www.ptt.cc/bbs/Stock/M.1408343067.A.CCB.html §@ªÌching0629 (Syameroke)

³o½g¬O°Q½×°ò¨È´Á¤¤¤ÀªR¡A¤p§Ì¤£¤~¾ÇÃѵu²L´£¨Ñµ¹¦U¦ì¤j¤j¬Ý¬Ý¯à§_¥Î¦¹¤èªk¸Õºâ¯E¹©¡IÁÂÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/12/26 ¤W¤È 09:52:45²Ä 1461 ½g¦^À³
Joseph DiMasi©M¥Lªº¹Î¶¤¦bTufts ¤j¾Ç±´°Q¦³ÃöÁ{§É¸ÕÅ窺¦¨¥\²v¨Ã¦bÁ{§ÉÃIJz¾Ç»PªvÀø¾ÇÂø»x¤Wµoªí

http://www.biotech-now.org/business-and-investments/inside-bio-ia/2010/11/clinical-trial-success-rates-recent-study-from-tufts#

¥H¤U¤ÀªR ¶È¨Ñ°Ñ¦Ò

1¤j¤À¤lÃĪ«½d³ò²[»\¡G肽¡B³J¥Õ½è¡B§ÜÅé¡B®Ö»Ä¡B¦hÁÞ¡B¦h¯×µ¥¡A¥D­n¥Î©óªvÀø¸~½F¡B·R´þ¯f¡B¤ß¸£¦åºÞ¯e¯fµ¥

¯E¹©¥Ø«e¯à¨«¨ì¤T´Á¸ÛÄݤ£©ö,±q¤å³¹ªí®æ²Î­pphase3¨ìNDA¤j¤À¤lÃĦ¨¥\¾÷²v74%(¦³¨ÇÃĦ]°Æ§@¥Î¤Ó¤j©Î¬OÀø®Ä¤£¯S§O¨S³q¹LFDA®Ö­ã) ¥Ó½Ð¨ì®Ö­ã¾÷²v96%

2ÁöµMÁÙ¨S¦³²Ä¤T¥NªºÁÞ¤À¤l·sÃÄ°Ý¥@¤Î²Î­p,­Ó¤H²z¸ÑÁÞ¤À¤l·sÃĦ]¦³©ú½T¼Ð¹v©Ê ,°Æ§@¥Î«D±`¤p,¾Ì³o¨âÂI³q¹L¾÷²v²z½×¤WÀ³·|¤ñ¤j¤À¤lÃÄÀu¨q,2013¦~¥Í§Þ¾ã¦X¨|¦¨¤¤¤ß¡]Si2C¡^­º®uÅU°ÝĬÃh¤¯ªí¥Ü¡A¥þ²y¥Í§Þ·sÃIJ£·~¤w¸g¶i¤J²Ä¤T­Ó¦a¥­½u¥@¥N¡]The Third Evolution of Global Pharma Horizons¡^¡AÄ~¤Æ¾ÇÃÄ¡B³J¥Õ½èÃĤ§«á¡A¥]¬AÁÞ¤À¤l¬ã¨s©Ò¶}µoªº§K¬ÌÀøªk·sÃÄ¡A¥i¯à³Ð³y¤U¤@ªi·sÃÄ­²©R¡C

¯E¹©¥[ªo ¯¬¯E¤Í·s¦~§Ö¼Ö ¥­¦w¦p·N

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSAM196910138913  µoªí®É¶¡:2014/12/26 ¤W¤È 09:20:14²Ä 1460 ½g¦^À³
¬Q¤Ñ¦¬¨ì¯E¹©¤jªÑªF§iª¾

3/23¤WÂd±¾µP!!!!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/12/26 ¤W¤È 08:32:45²Ä 1459 ½g¦^À³
¤p©_¤j ¥Î¥\¤SÅÞ¿è¥X²³ ¬Ý±zªº¤å³¹ ¥u·|Åý¤p§ÌÀWÀWÂIÀYºÙ¡¨Æg¡¨

¤p§Ì®É¶¡¯à¤O¦³­­ ¥u§l¦¬¬ã¨s¹ï§ë¸ê§PÂ_¦³À°§Uªºª¾ÃÑ©M¸ê®Æ

¤é¬Q³o¥÷¸ê®Æ §â¦U¼Ð¹v»PÃĮĦ³Ãöªº¶µ¥Ø °µ¾ãÅ骺µû¶q ¬°§Ú­Ì¦bª¾©¼ªº»â°ì¶}¤F¤@®°µ¡

¤£ª¾­þ¦ì¤j¤jª¾¹D(¤p§Ì¤£´±¤£·q¦aÂI¦W) ¬O§_¦³¤¶²Ð¦õ¾¯ªºÃþ¦üºô­¶ ¥i¥H¤À¨É¤j®a°Ñ¦Ò ¤p§Ì¥ý¦V±z­PÁÂ

MUC1 Áö¶Q¬°µû¦ôº]²´ ´N¦p¤p©_¤j©Ò¨¥ Á{§É©|¥¼¶Ç¥XÅå³ßªºµ²ªG

«e¤Ñ¤p§Ì©Ò´£ªº¨º¥÷³ø§i ¦³´£¤Î MUC1 ±M¤@©Ê¤£¨Îªº­ì¦] ¦ý¹ï¨ä¤WªºÁÞ¤À¤l«h¤©ªÖ©w

³oºØ»¡ªk ¥[¤W ¤§«e Cliff¤j ³s¦êªº»¡©ú ÁÙ¦³142¤Hªº¸Ñª¼±ø¥ó­YÄݯu Åý§Ú­Ì¹ï822§ó¦³«H¤ß

¦P®É ¤p§Ì¤]±N«ùÄòÃöª`³oÀÉÁÞ¤À¤l¬Ì­]ªºµo®i

¦ý³ø§i¤¤¦³´X³BÃöÁä¤Ó±M·~ ¤p§Ì¤O¦³¥¼¶e ²`©È»~¸Ñ «Ü·Q©ñ±ó°Õ

¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­D§b10139065  µoªí®É¶¡:2014/12/25 ¤U¤È 08:08:05²Ä 1458 ½g¦^À³
rabbit¤j:µ¹±z¤@­Ó¸ê®Æ°Ñ¦Ò¤@¤U

ºK¦ÛÁ{§ÉÂå®v¦p¦ó°õ¦æ²Ä¤T´ÁÁ{§É¸ÕÅç (Phase III clinical trials)¡@

²ø¨ä¿pÂå®v

¥x¥_ºa¥ÁÁ`Âå°|°üÀù¬ì

°ê¥ß¶§©ú¤j¾Ç¤½¦@½Ã¥Í¬ã¨s©Ò

²Ä¤T´Á§Z±_ÀùªºÁ{§É¸ÕÅ笰¨Ò¡A¨ä­ì¥»¼Ð·Ç¤Æ¾ÇªvÀøªº­·ÀI²v (l = hazard rate)¬°0.3¡A§Ú­Ì¥i¥H­pºâ¨ä¤¤¦ì¦s¬¡´Á (median survival)¬° ln (0.5)/l = 2.3¦~¡A²{¦³¤@Á{§É¸ÕÅç·sÃÄ¡A¥i¥H¨Ï­·ÀI²v­°¬°0.2¡A¦]¦¹¥i¥H­pºâ¨â²ÕªvÀøªº­·ÀI¤ñ­È¬° (£_ = 0.3/0.2)¡A°²³]¨â²Õ©Û¶Ò¬Û¦P¼Æ¶q¯f±w (Qc = QE = 0.5)¡A±Na³]¬°0.05¡Ab³]¬°0.1¡AÁ`¬ã¨s®É¶¡¬°5¦~ (T = 5)¡A¦Ó¯f±w©Û¶Ò®É¶¡¬°3¦~ (T0 = 3)¡A¦]¦¹§Q¥ÎLachinªº¤½¦¡¥i¥Hºâ¥XÁ`¦@©Ò»Ýªº¯f±w¼Æ¥Ø¬° 461 (¨C²Õ230¤H)¡A¦Ó¹w¦ôµo¥Í¨Æ¥ó¼Æ (event number) = 264¡CŪªÌ­Y¦³¿³½ì­pºâLachin¤½¦¡¡A¥i¥H¤Whttp://www.cct.cuhk.edu.hk/stat/survival/Lachin1981.htm#2¡A§Q¥Î½u¤W§K¶O³nÅé­pºâ§AªºÁ{§É¸ÕÅç©Ò»Ý­nªº¯f±w¼Æ¡C

©Ò¥H¸ÕÅç©Ò»Ýªº¯f±w¼Æ¥Ø©M´Á¤¤¤ÀªRµo¥Í¨Æ¥ó¼Æ¦n¹³¬O¤½¥q¦b³]­p¸ÕÅç®É¹w¦ô¤ñ­ì¥»¼Ð·Ç¤Æ¾ÇªvÀøªº­·ÀI²v¦A¥[¤W¤@¨Ç¼Æ¦rºâ¥X¨Óªº¡A¤]¦³½d¨Ò±z¬Ý¤@¤U§Æ±æ¹ï±z¦³À°§U¡AÁÂÁ¡C

¥t¥~²ø¨ä¿pÂå®vºô¯¸http://www.womencancer.com.tw/topic_r05.htm

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Grabbit10136567  µoªí®É¶¡:2014/12/25 ¤U¤È 06:29:27²Ä 1457 ½g¦^À³
Hi ¹«¤j

"±zªº·N«ä¬O«ü¦¬®×¹Lµ{¤¤¹F¤@¥b´c¤Æªº¤ÀªR¥s´Á¤¤¤ÀªR ¦¬®×§¹¦¨¤§«áªº¤ÀªRÀ³¸Ó´NÄÝ©ó´Á¥½¸Ñª¼~~§ÚÀ³¨S¸ÑŪ¿ù§a"

¤£¥i¥H³o¼ËÁ¿¡A­nÄYÂÔªº»¡: ¬O·íªì³]©w¤@­Ó¹w´Á M ¦~·|´c¤Æªº N ¤H¼Æ¡AN ¦A³]©w¤@­Ó¤ñ¨Ò L%¡A

·í N X L% ªº´c¤Æ¤H¼Æ¨ì¹F¡A´N¸Ñª¼¡A³o¥s°µ´Á¤¤¤ÀªR¡C

¤§«e 142 µL½× 172 ³£¤w¸g¬OÁ`¦¬®×¤H¼Æªº¹ï¥b¡A³o®É­Ôªº¸Ñª¼¡A´N¤w¸g¬O´Á¥½¤ÀªR¡A¤£¬O´Á¤¤¤ÀªR¡C

¥H¤W¬°¦Û¤v§äªº¸ê®Æ¡A­Y¦³¿ù»~ÁٽЧiª¾¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/12/25 ¤U¤È 05:27:48²Ä 1456 ½g¦^À³
¹«¤j¡A

¨ì©³¬O142¤H©Î172¤H¡A§Ú¤]¤£½T©w

¦ý¥i¥H½T©wªº¬O¡A¸ÕÅç²Õ»Ý­n¬ù70~80¤Hªº±wªÌ´c¤Æ¡A

¨ç¼Æ¦±½u¤~·|­°¨ì0.5¡A822ªºÃĮĤ~¨ì³»

¦pªG²{¦b¤£¨ì142¤Hªº¸Ü

¨ç¼Æ¦±½u¥i¯à¥u¦³­°¨ì0.2~0.3ªº¥¼§¹¦¨¹Ï«¬

¥u­n³o¥ó¨Æ¬O¯uªº

¤j®aªº­C½Ï¸`¹Ú·Q³£·|¦¨¯u

¦ý¥Ø«eÁ`´c¤Æªº¼Æ¦rªÖ©w¨S¦³¤H¥i¥H¥´Å¥±o¨ì

§Ú­ÌºÉ¶q±ÀºV´N¬O¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/12/25 ¤U¤È 05:12:41²Ä 1455 ½g¦^À³
²q·Q¤j¡A

ÁÂÁ±z¬Q¤Ñ¤U¤È´£¨ÑªºÄ_¶Q¸ê®Æ

¤p§Ì¨ØªA±z¨D¯uªººë¯«

¨Ì¥L­Ìªº¼Ð·Ç¥´¤À¼Æ¡Amuc1¯uªº«Ü±j

¦ýmuc1¨ì¥Ø«e¤w¸g¦³decades of yearsªº¬ã¨s¡A¤´µM¨S¦³Ãļt¦¨¥\

¤@­ÓÁÙ¨SIND¡A¥H¦â¦C³o¤@­Ó¦bphase1/2¡A®É¶¡³£ÁÙ¦­

¤p§Ì²{¦b¬Û«Hªº´N¬O822ªºÁ`´c¤Æ¤H¼Æ©MK-M¨ç¼Æ¡A

¨ä¥Lªº²{¦b­nµû¦ô¤´¤Ó»»»·¡A¥B»·¶W¹L¤p§Ìªº¯à¤O

´N¦p±z»¡ªº«ø¥Ø¥H«Ý§a¡I

ªp¥B¦b822ªº¤T´ÁÁ{§É¼Æ¾Ú¤½¥¬«á¡AGHªº±Æ¦WÁÙ·|¤j´T¶i¨B

¦Ó¥BGH¬O¥ÎÁp¶°§@¾Ôªº¡A±Æ¦WÁÙ¥i¥H©¹«e¡A³o¤@ÂI¯Î°|ªø¤£¥i¯à¤£ª¾¡C

ùØÀY´£¨Ñ¤FÂ×´Iªº¸ê®Æ¡A¦ý½Í½×ªº¥DÃD¤ñ¸ûÄYµÂ¡A¦³¿³½ìªº¯E¤Í¥i¥H°Ñ¦Ò¬Ý¬Ý¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¯ä¦Ñ¹«10139175  µoªí®É¶¡:2014/12/25 ¤U¤È 04:17:01²Ä 1454 ½g¦^À³
rabbit¤j¤j

±zªº·N«ä¬O«ü¦¬®×¹Lµ{¤¤¹F¤@¥b´c¤Æªº¤ÀªR¥s´Á¤¤¤ÀªR

¦¬®×§¹¦¨¤§«áªº¤ÀªRÀ³¸Ó´NÄÝ©ó´Á¥½¸Ñª¼~~§ÚÀ³¨S¸ÑŪ¿ù§a

1.¥i°Ñ¦Ò°ò¨ÈÁ{§É¹Lµ{¡GPI-88©ó2013¦~©³¦b¥xÆW¡BÁú°ê¡B¤j³°¡B­»´äµ¥25­ÓÂå¾Ç¤¤¤ß¡A¹F¦¨Á{§É¤T´Á500¦ì¦¬®×¥Ø¼Ð¡A¨Ã©ó2014¦~5¤ë¹F¦¨¥i¶i¦æ´Á¤¤¤ÀªRªº²Ä131­Ó¯f±w´_µo±ø¥ó¡A¹w­p7¤ë©³¡B8¤ëªì¤½§G¤ÀªRµ²ªG¡C©Ò¥H¯E¹©¦¬®×§¹¤F¡A­Y142¤H´c¤Æ¤´¥s´Á¤¤¤ÀªR

2.¤µ¦~Á{®ÉªÑªF·|¤W»¡¡G¤½¥q¤´µM¤£Â_ªº·|»PFDA¡ATFDA¶i¦æ¤¬°Ê·¾³q¡A¶i¦æ³Ì¦nªº¸Ñª¼¤ÀªR¡AµM¦Ó¨Ì¾Ú¹êÅç³]­p¡A´_µo¤H¼Æ¹F¨ì284¤H¤~¬O¹w­pªº¸Ñª¼ÂI¡A¤]¥i¯à©¹«e´£¡A¦]¬°ÃĮĦn¡A­nµ¥¨ì´_µo¤H¼Æ³o»ò¦h¹ê¦b«ÜÃøµ¥¨ì¡C

3.°Ñ¦Ò²Ä¤@°]¸g±M³X¡AÀ³¸Ó´N¦³µª®×¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GIriswu10136250  µoªí®É¶¡:2014/12/25 ¤U¤È 04:15:28²Ä 1453 ½g¦^À³
jack,½Ð°Ý§Ú¸òbill¦^µª£~£~ªº°ÝÃD.­þ¸Ì¿ù»~,½Ð§A«ü¥¿.¤£µMµo¨¥®É½Ð¤p¤ß¥Îµü.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Grabbit10136567  µoªí®É¶¡:2014/12/25 ¤U¤È 02:40:04²Ä 1452 ½g¦^À³
Hi ¦U¦ì

¤j®a¬O¤£¬O·d¿ù´Á¤¤¤ÀªR? (­Y¬O§Ú¿ù ½Ðªþ¤W¤@¨ÇÃÒ©ú§iª¾ §Ú·|«D±`·P¿E)

´Á¤¤¤ÀªR¬O³]©w¤@©w¦¬®×¤H¼Æ¨Ò¦p: 60% X (284 or 342) = 171 to 206 (A)

A ªº¤@¥b 86 to 103 ´_µo®É¡A¤~¥Ñ¿W¥ß¼fij·|¨M©w¬O§_°µ´Á¤¤¤ÀªR¡A°µ§¹¤ÀªRÁÙ­n¨M©w¬O§_¤½¶}°µ¸Ñª¼¨úÃÄÃÒ¡C

©Ò¥H²{¦b°Q½× 142 or 172 ´_µoªº±ø¥óµo¥Í®É¡A«ç·|¬O´Á¤¤¤ÀªR? ¬O´Á¥½¸Ñª¼¤F¤£¬O¶Ü?

¦Ü©ó 284 342¡A«Dªk»¡Âç²Mªº¡A§Ú­Ó¤H«Ü¦­ªº¥ß³õ´N¬O¿ï¾Ü Clinical ªº¸ê°T¨Ó¬Ý¡A

­YµL²á»¡¦^À³¦³¨Ï¤H¤£µÎªA¡A½Ð¨£½Ì¡A«D¥»·N

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDon10139533  µoªí®É¶¡:2014/12/25 ¤U¤È 01:51:48²Ä 1451 ½g¦^À³
davidh¤j¤j¬O¥¿½T¸ê°T

jackÀ³¸Ó¬O¦n·Nªº

¿ù»~ªº°T®§À³¸Ó¦³¤H¥X¨Ó«ü¥¿ ¥H§K»~¾É¤j®a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gjack10139694  µoªí®É¶¡:2014/12/25 ¤U¤È 01:34:44²Ä 1450 ½g¦^À³
·PÁÂdavidh¤j´£¥Xªº¼Æ¦r»P¤½¥qµo¨¥ºÞ¹D»¡ªk²Å¦X §Ú¦A¦¸±j½Õ§Æ±æ¯E¤Í­Ì¦³¥ô¦óºÃ°Ýª½±µ¥´¹q¸Ü½Ð±Ð¯E¹©¹ï¥~µo¨¥ºÞ¹D ¦pªG¤½¥q¤£Ä@·NµªÂШS¦³µª®× ¤~®³¨ìºô¸ô¤j®a¤@°_°Q½× ¥xÆW§ë¸ê¤H³£³ßÅwÅ¥¤p¹D®ø®§ ¤£¦V¤½¥q¨DÃҳ᳣̫·|¦YÁ« §Ú¬O¦n·N«o³Qxx §Æ±æ¯E¤Í³£¯à¤ß·Q¨Æ¦¨
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¯ä¦Ñ¹«10139175  µoªí®É¶¡:2014/12/25 ¤U¤È 01:28:28²Ä 1449 ½g¦^À³
¤p©_¤j¤j

¤§«e½Ð±Ð¹L±z¤@­Ó°ÝÃD

¦pªG´Á¤¤¤ÀªR¤H¼Æ¬O­q142¤H

«hK-M¦s¬¡¦±½uÂ÷0.5¤£´N«Ü»·«Ü»·¡H

davidh¤j¤j»¡²Ä¤@°]¸g³X°Ý±i¸³»¡´Á¤¤¤ÀªR±ø¥ó¬°142¤H

¥i§_³Â·Ð±z¨¯­Wµe¤@¤U

K-M¦s¬¡¦±½u·|ªø¬Æ»ò¼Ë¤l¡H

ÁÂÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gbill10135881  µoªí®É¶¡:2014/12/25 ¤W¤È 11:48:18²Ä 1448 ½g¦^À³
³o­Ójack¤j

©¿µM«_¥X¨Ó¥s°}

µ¥²³¯E¤Í¤ÞÀV¥ø¬ß®É

¤SÀtÁY¤£´±¥XÁn?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­D§b10139065  µoªí®É¶¡:2014/12/25 ¤W¤È 11:47:58²Ä 1447 ½g¦^À³
jack¤j:³o¬O°Ñ»P¸ÕÅ窺ºa¥ÁÁ`Âå°|ªº¤½§i¡A±z°Ñ¦Ò¤@¤U¡C·íµM§A¤]¥i¥H¥´¹q¸Üµ¹µo¨¥¤H°Ý²M·¡¦A¨ìª©¤W§i¶D¤j®a¡A¶°²³¤H¤§¤O»`¶°¸ê°T§Ú¬Û«H¨ä¥LŪªÌ¤]·|ÁÂÁ§A¡A¤£ª¾±zı±o¦p¦ó¡H

»O¥_ºa¥ÁÁ`Âå°|²Ä¤@¤HÅé¸ÕÅç©e­û·|²Ä 10 ¦¸·|ij¬ö¿ý ¤½§iª©

¶}·|®É¶¡¡G¤E¤Q¤E¦~¤Q¤@¤ë¤@¤é¤U¤È¤G®É¥¿

page 5

¡]¥|¡^²Î­p³¡¤À¡G

1. ¥»¸ÕÅç©ó 176 ¨Æ¥óµo¥Í·|°õ¦æ¤@¦¸´Á¶¡¤ÀªR¡A¨ä©Ò¹ïÀ³¤§ÅãµÛ¤ô·Ç¤§±Àºâ¤è¦¡À³¥H 176 °£¥H 284 ¦Ó«D 176 °£¥H 342¨Ó­pºâ¤§¡A½Ð­×¥¿¡C

2. ¥»¸ÕÅç¹w©w©ó²Ä¤@¦ì¨ü¸ÕªÌ¶i¤J¸ÕÅç 16 ­Ó¤ë«á±N¶i¦æª¼©Ê¼Ë¥»¼Æ¦Aµû¦ô¡F­pµe®Ñ½Ð²M·¡»¡©ú¦bµo¥Í²v§C¨ì¦h¤Ö¥H¤U·|¼W¥[¼Ë¥»¼Æ¡A¥çÀ³»¡©ú¼Ë¥»¼Æ¼W¥[¤§¤è¦¡¡C

3. ¥Ø«e¯e¯fª¬ªp¤À¼h¦]¤l¬O¤À¬°¨â¼h¡]CR vs.PR/SD¡^¡C­Y¦b³Ì²×¤ÀªR®É¡A¸ÕÅç²Õ»P¹ï·Ó²Õ¤§ PR ©Î SD ¤ñ¨Ò¤£¤@­P¡A®£¼vÅTÀø®Ä§PŪ¡C

½Ð±N PR »P SD ¤À¶}¡A§Y¨Ì¯e¯fª¬ªp¤À¬°CR, PR »P SD ¤T¼h¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gdavidh10137720  µoªí®É¶¡:2014/12/25 ¤W¤È 11:10:39²Ä 1446 ½g¦^À³
¥­¦w©]­è¹L¡A§Æ¥­¦w©]±a¨Óªº³ß¼Ö»P¥­¦w¯à¦bª©¤W©µÄò¤U¥h¡A³o­Óª©¤W¦³¤@¥i·R¤§³B¡A§Y²³¦h°ª¤HÄ@µL¨p±NÄ_¶Q«H®§¤Îµo²{»P¤j®a¤À¨É¡A¦b´²¤á§ë¸êª¾°T¤£¹ïºÙ¤§»Ú¡A¤£³×¬O·ø¤Þ»âªº©ú灯¡C§Æª©­±¥­¦w/³ß¼Ö/¤À¨É/ª¾©Êªºª^³ò¯à«ùÄò¨ÃÅܱo±o§ó¿@­§¡C

¦³Ãö啓°Ê¯E¹©´Á¤¤¤ÀªR®É¾÷(´_µo¤H¼ÆÀ³¬°¦h¤Ö©O?)¡A§Úµo²{¤@­Ó¤j®a³£³ßÅwªº¦n®ø®§¡A®ø®§¨Ó·½¬°­è¤~¬Ý¨ì2014/6/30~7/7 ²Ä¤@°]¸g¶g¥Z²Ä13´Á²Ä15­¶¡A¯E¹©±i¸³±M³Xªº¦^ÂÐ(Q6):OBI-822Á{§É­ì¶È»Ý284¤H¡A¦ý¬°®£¤¤³~¦³¤H¯Ê®u¡A¤£¥þµ{°µ§¹¡A¬G·¸¦¬¤F¬ù20%¡A¦@¦¬¤F342¤H¡A¦Ó´Á¤¤¤ÀªR啓°Êªº®É¾÷¬°284¤Hªº¤@¥b¡A§Y142¤H¡A³o¤ñ¤§«e¤j®a¹w´Áªº¤Ö¡A¬G¦Ü¤µ©|µL142¤H´_µo¡C§Ú·Q³o¬O¤j®a³£¼Ö·NÅ¥¨£ªº¦n®ø®§§a!¤]§Æ­É¦¹¦n®ø®§¡A¤j®a³£¯à¤ß¤¤¥Rº¡³ß¼Ö¡A¤]¨Ïª©¤WÅw´r»Pª¾©Êªºª^³ò¯àÄ~Äò¼Wªø¡CÁÂÁÂ!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gµ½¤H10137888  µoªí®É¶¡:2014/12/25 ¤W¤È 10:47:24²Ä 1445 ½g¦^À³
Jack¤j,

¦pªG±z»{¬°ª©¤Íªº°T®§¬O¿ùªº, ½Ð±z±N¥¿½Tªº°T®§¼g¥X¨Ó, ¨Ñª©¤Í°Ñ¦Ò. ª©¤Í·|·PÁ±zªº.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Grabbit10136567  µoªí®É¶¡:2014/12/25 ¤W¤È 10:15:04²Ä 1444 ½g¦^À³
Hi Jack,

µo¨¥¤Hªºµo¨¥­Y«D¤½¶}µoªí¡A³o¼Ëªº°T®§¤]¥s°µ"¤p¹D®ø®§"¡A¯ù¾l¶º«áÁÁ¨¥°Q½×½}¤F¡A

172 ¤H¬O Clinical ¬F©²ºô¯¸¥i¬dªº 342 ¤Hªº¥b¼Æ¡AÄÝ©ó¥Ø«e³Ì¦X²zªº±À¦ô¡A¤@ÂI³£¤£µL²á¡C

¦Ó³Ì«áÁ{§É¤ÀªR¡A¤]¤£·|¬OÁ{§É 342 ¤H´N§¹¥þªº³Q²Î­p¶i¥h¡A

¦]¬°Á{§É´Á¶¡µo¥Í«D¯f²zªº·N¥~¦Ó¥h¥@¡A³o¥²¶·³Q±Æ°£¡A©Ò¥H³Ì«á¤]¤£·|¤@©w´N¬O 342 ¤H¡C

¦ý§Ú­Ì¥i¥H»¡ 342 ¤H³o­Ó¼Æ¦r«ÜµL²á¶Ü?

¦ý§Ú­Ì¥i¥H»¡ 342 ¤H³o­Ó¼Æ¦r«ÜµL²á¶Ü?

¦ý§Ú­Ì¥i¥H»¡ 342 ¤H³o­Ó¼Æ¦r«ÜµL²á¶Ü?

§A¤~µL²á!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/12/25 ¤W¤È 09:44:20²Ä 1443 ½g¦^À³
½Ð±Ð jack ¤j

¬JµM±z»¡ "¯E¹©´Á¤¤¤ÀªR°ÝÃD ´_µo172¤H®Ú¥»´N¤£¹ï ³o¨Ç°ÝÃD¥i¥H½Ð°Ý¤½¥qµo¨¥¤H ¤@ª½¦b¤£¹ïªº°ÝÃD°Q½× ¯u¬OµL²á"

°²­Y¤j®aªº°T®§¬O¿ùªº ¥i§_½Ð±z¤À¨É¤@¤U±z¨Ó¦Ûµo¨¥¤Hªº°T®§? ¥ýÁÂÁ±z¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gjack10139694  µoªí®É¶¡:2014/12/25 ¤W¤È 09:28:53²Ä 1442 ½g¦^À³
ÃÒ©Òµ|¤£²M·¡¤£©ú¥Õ½Ð¤£­n°­§è³J®`¤H ¹ê¦b¬Ý¤£¤U¥h ¥þ¥x¥_°êµ|§½°ß¤@¯à¸ÑÄÀ²M¼ä23113711¤À¾÷1557¶À¤p©j ¯E¹©´Á¤¤¤ÀªR°ÝÃD ´_µo172¤H®Ú¥»´N¤£¹ï ³o¨Ç°ÝÃD¥i¥H½Ð°Ý¤½¥qµo¨¥¤H ¤@ª½¦b¤£¹ïªº°ÝÃD°Q½× ¯u¬OµL²á
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G£~£~10134649  µoªí®É¶¡:2014/12/25 ¤W¤È 09:13:22²Ä 1441 ½g¦^À³
·PÁ¤G¦ì¤j¤jªº¦^µª,³o­Óµª®×¥O§Ú«D±`ªº¿³¾Ä¡C

¦]¬°·í§ÚIPO¤§«áÄ~Äò«ù¦³¤Q¦~,°tªÑ¥i¯à¤@±iÅܤQ±i,

¦Ó§Ú¥u»Ý­nú²Ä¤@±iªºÃÒ©Òµ|,´N¬Û·í©ó3.75%ªº¤Q¤À¤§¤@,

¤]´N¬OÃÒ©Òµ|³Ñ0.375%¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GIriswu10136250  µoªí®É¶¡:2014/12/25 ¤W¤È 09:03:56²Ä 1440 ½g¦^À³
£~£~¤j,±zªº¨Ò¤l¬O¤£¥ÎúÃÒ©Òµ|,¦]¬°§A¿³Âd¶Rªº¨º¤@±i¦¨¥»100¤¸,¤WÂd«á½æ¥X¤]¬O100¤¸.¦Ü©ó¥t¥~°tªÑ±o¨º¥|±i,´N·|¦³¥|¸U¤¸ªºªÑ®§­n¨Ö¤J©Ò±o½Òµ|.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gbill10135881  µoªí®É¶¡:2014/12/25 ¤W¤È 08:49:57²Ä 1439 ½g¦^À³
¤j¤j

ÃÒ©Òµ|±Ä¥ý¶i¥ý¥X

¤WÂd«á½æ¥X5±i

²Ä¤@±i¬O¦b¿³Âd¶Rªº¡A­núµ|

«á­±°tªÑ©Ò±oÄÝ©ó¤WÂd«á¤~«ù¦³ªº¡A§Kú¡C(°£«D¤j¤á)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G£~£~10134649  µoªí®É¶¡:2014/12/25 ¤W¤È 08:42:09²Ä 1438 ½g¦^À³
§Úªº°ÝÃD¬O:¦b¿³Âd¶R¶i,IPO«á°£Åv°tªÑ,©Ò°tªºªÑ²¼½æ¥X®É»ÝúÃÒ©Òµ|¶Ü?¨Ò¦p,¬Y°²ªÑ²¼¦b¿³Âd§Ú100¤¸¶R¤J¤@±i,¤§«á±¾µP¤W¥«,öt¨ì500¤¸,¦pªG¦¹®É§Ú½æ¥X¥²¶·Ãº6¸UÃÒ©Òµ|¡C¦pªG¨S½æ,¤§«á°£Åv°tªÑ4000ªÑ,Á`¦@Åܤ­±i,°²³]ªÑ»ùÅܦ¨100¤¸,²{¦b§Ú¤­±i³£¥H100¤¸½æ¥X,¨º»ò¨C¤@±i³£¤£¥Îú¥ô¦óÃÒ©Òµ|¤F¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GIriswu10136250  µoªí®É¶¡:2014/12/25 ¤W¤È 08:05:05²Ä 1437 ½g¦^À³
ªÑ²¼ªÑ§Q¬O¨Ö¤J¦U¤H©Ò±oµ|¤¤. ¤ÀÃþ¤W¬OÄÝ©ó¤W¥«Âd¥H«áªºªÑ²¼. ¦]¬°¨S¦³ÃÒ©Òµ|ªº°ÝÃD.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G£~£~10134649  µoªí®É¶¡:2014/12/24 ¤U¤È 10:26:58²Ä 1436 ½g¦^À³
¡u¤WÂd«á°tªºªÑ²¼ªÑ§Q­n¦©ÃÒ©Òµ|¶Ü?¡v³o¥y¸Ü§ÚªºÀç·~­û¤]°Ý¹L§Ú,¦o»¡¦o°Ý°êµ|§½¤]°Ý¤£¨ìµª®×¡C©Ò¥H,¦pªG¦³¤¯¤H§g¤lª¾¹Dªº¸Ü,³Â·Ð¤À¨É¤@¤U,·P¿E¤£ºÉ!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/12/24 ¤U¤È 06:32:44²Ä 1435 ½g¦^À³
¨Ì¾Ú¯E¹©ªÑ§Q¬Fµ¦, ²{ª÷ªÑ§Q¥u­n¤£§C©ó10%«K²Å¦X ,²{ª÷ªÑ§QÀ³¤£¦h ,¦]¬°­n¬ãµo»Ý­n²{ª÷,¥D­nÁÙ¬O¥HªÑ²¼ªÑ§Q¬°¥D,ªÑ²¼ªÑ§Q°tªÑ§Öªº¸Ü´Á¬ß2016¯à¶}¨Ï°t, ¦]°ª»ùªÑ°tªÑ²¼¹ï¤pªÑªF±i¼Æ¤Öªº¤H¦³§Q,¦p¯àªø´Á«ù¦³,­@¤ßµ¥°tªÑ,ªÑ¼Æ¦h­¿¼Æ¼W¥[,¦p·í¦~ÂE®ü ¥x¿n¤@¼Ë ( °t¦h¤ÖªÑ²¼·íµM­n¬Ý·í¦~«×Àò§Q¸³ºÊ¨Æ·|ij¨M©w¤ÎªÑªF·|ªÑªFªº·¥¤Oª§¨ú °Q»ùÁÙ»ù)

£~£~¤j:¤WÂd«á°tªºªÑ²¼ªÑ§Q­n¦©ÃÒ©Òµ|¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G£~£~10134649  µoªí®É¶¡:2014/12/24 ¤U¤È 06:07:11²Ä 1434 ½g¦^À³
¦pªG¬O¤j¤á,¦pªG±N¨Ó4174¤j¦¨¥\,¨C¦~°t®§´N¨¬¥H¨Ï­Ó¤Hºî©Òµ|²v¹F¨ì40%,³øµ|®É¤£¦ý¤£¯à°hµ|,¦Ó¥BÁÙ¥²¶·¸É°t®§ªº23%ªºµ|¡C¨ì¨º®É­Ô,3.75%ªºÃÒ©Òµ|¥u¤£¹L¬Û·í©ó¤@¨â¦~ªººî©Òµ|¡C¿úÁȫܦhúµ|Åܦ¨±`ºA¡C¦pªG¨S¦³¨º»ò¤@¤Ñ,¤ñ¦p»¡4174¥¢±Ñ¤F,¨ì®É­Ô3.75%¤]¬O·L¤£¨¬¹D,¬Æ¦ÜÁ«·l§Kú¡C¦pªG¬O¬Ý¦nªº¤j¤á,¹ê¦b¬O¤£¥²¬°¦¹·Ð´o¡C¦Ü©ó®ü¤j¤á²{¦b½æ¥X¬O§_¨C­Ó¤áÀY¶W¹L99±i?ú15%?¦pªG¬O,§Ú·|»{¬°¥L¥¼¥²·|¶R¦^¡C¦]¬°§Úı±o³o¼Ë¾Þ§@¤£¬O«Ü©ú´¼¡C¦ý¬O,¦¨¥\ªº¤H¤]³\­pºâ§ó°ª©ú,³o¤@ÂI§ÚµL¸m³ñªº¾l¦a¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/12/24 ¤U¤È 05:07:37²Ä 1433 ½g¦^À³
§Ö¨â¦~«eªº¸ê°T »P²{¦b¸ê°T°µ®É¶¡ªº¦êÁp §Ú²×©ó©ú¥Õ¤@¨Ç°ÝÃDµª®×? ¯S§O¬O¼v¤ù³Ì«á¤@¥y¸Ü

http://mepopedia.com/forum/read.php?127,29464

1 Globo H KLH /QS21 »P Globo H DT /QS21 ³£¬OÄÝ©óªvÀø©Ê¬Ì­],®t§O¦b©ó Globo H DT /QS21¥Î©óÀù¯gÄÝ©ó

aggressive types of cancer

2 ¨º¤QºØÀù¯g¬O­P©RªºÀù¯g http://www.livescience.com/11041-10-deadliest-cancers-cure.html

3 ¦b¤QºØ­P©RªºÀù¯g¤¤¯E¹©¨Ï¥ÎGlobo H KLH /QS21 ¨ÓªvÀø¨ÅÀù»P§Z±_Àù ,¦pªG¯à¦¨¥\ªº¸Ü ­Ó¤H¦X²z±À´ú

Globo H DT /QS21 ¨Ï¥Î¦b¨ä¥L­P©RªºÀù¯g¦¨¥\¾÷²v§ó°ª,¨ÅÀù»P§Z±_ÀùÀ³ÄÝ©ó¥ý±´³¡¶¤

4 Globo H DT /C34 ¬O§_¥i¯à¥Î©ó¹w¨¾©Ê¬Ì­]¥Ø«eÁÙ¤£²M·¡,¦³«Ü¤j¥i¯à, ¦ý¼v¤ù³Ì«á¤@¥y¸Ü»¡Áٻݭn»áªøªº¤@¬q®É¶¡

5 ³\¦h¤H¬°¤F¸`µ|¦~©³«e½æ¥X §Æ±æ2015¦~ªì¶R¦^,¦pªG¦³1000­Ó¤pªÑªF¦³³oºØ·Qªk(2015¦~ªì¶R¦^ªº»ù´N¬O¦¨¥»»ù),

°²¦p¥­§¡»Ý¸É¦^3±i,¦b¤£ºâ¤j¤á¦^¸Éªº±¡ªp¤U2015¦~1¤ë5¤é¦Ü1¤ë16¤é¦@2¶g ¯à¦^¸É§¹²¦¶Ü?¤Hºâ¤£¦p¤Ñºâ

¦U¦ì¤j¤j¥i¸Õºâ¤@¤U¥H 250 350 400 ·í¦¨¥»¦Û¦æ¹w¦ô4174¤T¦~«áªº»ù¦ì,¥Hµ|²v3.75%­pºâ,ÃÒ©Òµ|ªº®t²§¨ä¹ê¬O¦b¥i

±µ¨ü½d³ò,¦pªG2015¦~1¤ë5¤é¦Ü1¤ë16¤é»Ý¥H§ó°ª»ù®æ¸É¦^ ¬O§_¦Eºâ?©Ò¿× :¥¢¤§ªF¶¨,¦¬¤§®á·®

¤ñ³ëÁöµM¥ý¦b¬Y¤@¤è­±¦³·l¥¢¡A¦ý²×¦b¥t¤@¤è­±¦³¦¨´N

¥H¤W¬O­Ó¤H²L¨£ ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù½Ð´£¥X§ó¥¿ §ë¸êª`·N­·ÀIºÞ²z

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/12/24 ¤U¤È 02:16:07²Ä 1432 ½g¦^À³
¤p©_¤j°Ê§@¯u§Ö ·PÁ±zªº¤À¨É

³o½g¤å³¹ ¤p§Ì§zÔ¬§]´Ç¬Ý¹L¤@¦¸ ©¿²¤±M·~²z½×³¡¥÷ ¥uÂ^¨ú¥i§ë¸ê§PÂ_ªº¸ê®Æ

¦]µ{«×¤Ó®t µLªk°µ­Ó¤H·Qªkªºªí­z

¦ý¦³¨Ç¹Ïªí ©Î¹ï±z¦³À°§U

http://www.pnas.org/content/109/1/261/F2.expansion.html

http://www.pnas.org/content/109/1/261/T1.expansion.html

http://www.pnas.org/content/109/1/261/F3.expansion.html

¥t¥~ÁÙ¦³¤@½g°Ñ¦Ò¤å¥ó

http://clincancerres.aacrjournals.org/content/15/17/5323.full

¬ÛÃö¹Ïªí¦C¦p¤U:

http://clincancerres.aacrjournals.org/content/15/17/5323/T3.expansion.html

http://clincancerres.aacrjournals.org/content/15/17/5323/F2.large.jpg

http://clincancerres.aacrjournals.org/content/15/17/5323/F3.large.jpg

²Ä¤@½g½×¤å¬O¯Î°|ªø½s¿è¼f®Öªº ¥i¨£¥L¤]ª¾¹D¸Ó¬Ì­] ¤£ª¾¥L¦³¦ó¬Ýªk?!

¦³¨S¦³ IND ¬O¸Ó¬Ì­]§¹³Æ»P§_ªºÆ[¹î­«ÂI

¥¦ªº¦õ¾¯ ±Ä¥Î Pam3CysSK4 FDA Á{§Éºô¯¸¤]§ä¤£¨ì ·|¤£·|¹J¨ì833ªº±¡ªp¤]¤£ª¾

´NÅý§Ú­Ì«ø¥Ø¥H«Ý§a!

¥H¤W¸ê®Æ ¶È¨Ñ°Ñ¦Ò ÁÂÁÂ!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/12/24 ¤U¤È 01:35:57²Ä 1431 ½g¦^À³
²q·Q¤j¡AJM¤j¡A¦U¦ì¤j¡A

¤p§Ì¬Q¤Ñ¨S¦³·d²M·¡¡A¥H¬°JM¤j©Ò´£ªº¡§§ÜÀù¬Ì­]¦³±æ2020¦~¤W¥«¦³®Ä¹ï§Ü7¦¨­P©RÀù¯g¡¨´N¬O¥H¦â¦CVAXIL³o®a¤½¥qªº²£«~Immucin¡A¸g²q·Q¤j°l®Ú¨s©³ªººë¯«¡A¤~ª¾¹D­ì¨Ó¤]¬O¤@­Ó§@¥Î¦bMUC1¤Wªº¬Ì­]¡A¦p²q·Q¤j©Ò¨¥¡A¡y¤Ö¼Æ¤Hªº®É¶¡ ´¼¼z ³£¦³­­ ¦³®É®e©ö³´¤JºD©Êªº¥DÆ[«äºû °ß¦³¤j®a¿n·¥©^Äm¤ß¤O ¼ö±¡°Ñ»P ©Î¤~¦³¸û±µªñ¨Æ¹êªº«ÈÆ[µ²½×¡z¡A­n§â¯E­ô°e¤W¤jÁp·ù¥´¥@¬É¤jÁÉ¡A¤j®aÁٻݦ@¦P§V¤O¡C

1.¨â­Ó³£¬O»¤µo§K¬Ì¨t²Îªº¬Ì­]¡A³£¬O¥HMUC1³o­ÓÁÞ³J¥Õ°µ¬°¼Ðªº¡A¨Ó¯}ÃaÀù²Ó­M¡A¨ä¤¤ÁÙ¨SINDªº³o¤@­Ó¬Ì­]ªº§Ü­ì¬OMUC1¤WªºÁÞ¤À¤l¡A»P¯E¹©ªº822³Ì¬Û¦ü¡A¦ý¶i«×¤ñ¸ûºC¡F¥H¦â¦CVAXIL³o®a¤½¥qªº²£«~Immucin¶i«×¤ñ¸û§Ö¡A¦bMyelomaªºphase1/2Á{§ÉÀò±o¤£¿ùªº¦¨ªG¡A2014¦~1¤ë¶i¦æ¤FMBCªºphase1/2Á{§É¡C

2.ÁÙ¨SIND³o¤@­Ó¡A»P822«Ü±µªñ¡A¶·­n¦X¦¨ÁÞ¤~¯à»s³y¬Ì­]¡A¦ý¤£ª¾¬O´X­Ó³æÁÞ¦X¦¨ªº¡A¹êÅç«Çùضq¤pÁÙ¥i¥H¡A¦pªG¬O¤ñ¸û¦hªº³æÁÞ¦X¦¨ªº¡A¨ì®É·|¦³¤j¶q¦X¦¨ªº°ÝÃD¡A¥i¯à»Ý­n¤¤¬ã°|ªº±ÂÅv¡A¤~¯à¤Æ¾Ç»Ã¯À¦X¦¨¡C¦Ü©ó¬Ì­]¦b¤HÅ骺¤ÏÀ³µ²ªG¦p¦ó¡AÁٻݭn«Üªø¤@¬q®É¶¡¤~¯à¦³¶i¤@¨Bªºµª®×¡C

3.¥H¦â¦CVAXIL³o®a¤½¥qªº²£«~Immucin¡A¤@´Á15¤H¦b°©Åè½Fªº¼Æ¾Ú¬Û·í¤£¿ù¡A«P¨Ï¥L­Ì°£¤F°©Åè½F¤§¥~¡A¶i¤@¨B°µMBCªºphase1/2Á{§É¡A¥¦ªº¬Ì­]ªº¤À¤l«¬ºA¬OPeptide(ÁY®ò»Ä)¡A¦X¦¨À³¸Ó¤£¬O°ÝÃD¡C

4.­«ÂI¨Ó¤F¡AMUC1³Qthe National Cancer InstituteºÙ¤§¬°¦b¬Ì­]µo®i¤W³Ì­«­nªº¦b¸~½F¤W¦³°ª«×ªí²{ªº¤T­Ó³J¥Õ½è¼Ð°O¤§¤@¡A¨º¨ì©³MUC1»PGHÁÞ®a±Ú¹ïÀù(·F)²Ó­M¦Ó¨¥¡A½Öªº¥\¯à©Ê¤ñ¸û°ª¡H©ÎªÌ»¡Àù(·F)²Ó­M¹ï­þ¤@­Óªº¨Ì¿à©Ê¤ñ¸û°ª(¨Ì¿à©Ê¶V°ª¥i¯àªí¥Ü¤H¼Æªí²{²v¶V°ª¡A²Ó­M¼Æ¦Ê¤À¤ñ¶V°ª¡AÀùºØÃþ¤À§G¶V¦h)¡H»¤µo§K¬Ì¨t²Î²£¥Í§ÜÅ骺§@¥Î®É¡A½Öªº¿ëÃѫפñ¸û°ª(¿ëÃѫ׶V°ª¡A°Æ§@¥Î¶V¤Ö¡A¤£·|»~±þ¥¿±`²Ó­M)¡H¤SMUC1¤£¬O·sªF¦è¡A¤w³Q¬ã¨s¦Ü¤Ö¤@¤G¤Q¦~¡A¦ý¤´µM¨S¦³¥ô¦óÃļtÀò±o¤T´Áªº¦¨¥\µ²ªG¡A¬O¤°»ò­ì¦]©O¡H¦]¦¹¡A¤W­z³o¨â¼Ë¬Ì­]¦³¾÷·|¶Ü¡H

5.¥Ø«e¦bª©¤W©Ò¦¬¶°¨ìªº¸ê®Æ¡A¤w¤W¥«©Î¦bÁ{§É¤G¤T´Á¦³¤£¿ùªº¼Æ¾ÚªºÃÄ¡A¦bMBCªvÀø¤W¡A¨ä§@¥Î¾÷Âà¹ï822³£ºc¤£¦¨«Â¯Ù¡A­n¹F¨ì10­Ó¤ë¥XÀYªº¤¤¦ì¼ÆPFS¦³¾÷·|¡A¦ý­n¹F¨ì20­Ó¤ëªº¥H¤WªºPFS¥²¶·¦b®ø·ÀÀù(·F)²Ó­Mªº§@¥Î¾÷Âà¤W¦³­«¤jªº¬ð¯}¡A¤W­z¨â­Ó¦bMUC1¤W§@¥Îªº¬Ì­]¬O¥Ø«e©Òª¾³Ì±j¤jªº¼ç¦bÄvª§ªÌ¡C

¦n®ø®§¬O¡A¯E¹©¶i«×¤w»»»»»â¥ý¡A¥BÃĮĦü¥G¤£¿ù¡A¥ý¤W¥«¥ýÁÈ¥ýĹ¡Aµ¥¥L­ÌÁ{§Éµ²ªG¥X¨Ó¤F¦A¨ÓPK¤]¤£¿ð¡C

¥H¤W«D±M·~ªº²q´ú¡A½Ð¤j®a¬Ý¬Ý´N¦n¡A¹ïµu¤¤´ÁªÑ»ù¨S¦³¼vÅT¡A²¦³º¯E­ô²{¦b¬O3¦Ê¦hªºªÑ»ù¤£¬O3¤d¦hªºªÑ»ù¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/12/24 ¤W¤È 10:25:35²Ä 1430 ½g¦^À³
À³¸Ó¬O³o½g³ø§i ¦³¿³½ìªº¤j¤j¥i°Ñ¦Ò ¤p§Ì­è§ä¨ì ¤]ÁÙ¨S¬Ý

http://www.pnas.org/content/109/1/261.full

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/12/24 ¤W¤È 08:53:26²Ä 1429 ½g¦^À³
¬Q©]¼g±o¤Ó¥^¥^ ¤p§Ì¦A¾ã¦X¸É¥R¤@¤U

¡§°²­Y¨ä¯àIND ­Ó¤H»{¬° ©Î±N¦¨¬°822ªº«l¼Ä?¡¨ ©Î³\³o­Ó±À½×¤U±o¤Ó¥DÆ[

1.¹«Åé¤ÏÀ³©_¨Î ©Î¦]¹«Åé°ª§Ü­ìªí²{²v °ªªº²Ó­M¼Æ¦Ê¤À¤ñ ¦ý¤HÅé©|¤£©ú?(À³»¡¤p§Ì¤£ª¾¹D ©Î³\¤j®a¶°¸s¤O¦A¬dÃÒ)

2.¸ÓÁÞ¤À¤l¬O§_©ö©ó¦X¦¨ ÁÙ¬O¤´¦b§ï¶i¦X¦¨§Þ³N?

3.Àù·F²Ó­M¬O§_¨ã¸Ó§Ü­ì Ãö«Y822¬O§_¤ñ¥¦¦³Àu¶Õ?

4.¸Ó¬Ì­]©Ò¤Þµoªº§ÜÅéºØÃþ¬°¦ó ¦³³ø¾É»¡³ø§i·|µn¦bPNAS¤W(http://www.pnas.org/) ¤p§ÌÁÙ¨S®É¶¡¬d¸ß

5.¬Ý°_¨Ó ³o­Ó¬Ì­]¦ü¥G­n¬D¾Ô¤@½u¥«³õ °²­Y¦p¦¹ ©Î±N¥HORR¬°¥D¼Ð ¶iµ{·|¤ñ¸û§Ö

­Õ­YÃĮīܦn ·|¤£·|¹³Lynparza¤@¼Ë ¥ÎÁ{§É¤G´Á¼Æ¾Ú ´NÀò±o§å­ã? °²¦p822 ÃĮĤ]³o¼Ë¦n À³¤]¥i®Äªk?

¤@¤Á³£¥¼©w ¤×¨ä©|¥¼IND( ? ¤p§Ì¥ÎMUC1©M Breast cancer ¨â­ÓÃöÁä¦r µL©ÒÀò)

§Ú·Q µ¥½T¹êIND«á ¦A¨Ó¯S§OÃöª`§a!

«D±M·~¦³­­¸ê®Æªº²q´ú ½Ð¤j®a¬Ý¬Ý´N¦n ÁÂÁÂ!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/12/23 ¤U¤È 11:19:21²Ä 1428 ½g¦^À³
¤p©_¤j ¦n¼F®`!

±z»¡±o¹ï·¥¤F À³¸Ó­n±µSSEA4 (©ÎGH ¡NSSEA3)§ÜÅé¤~¹ï

¡§Typically, these receptors(«üCARs )are used to graft the specificity of a monoclonal antibody onto a T cell ¡§

§Ú¬O±q³o­Ó¹Ï¥h·Qªº µ²ªG·Q¿ù¤Fhttp://en.wikipedia.org/wiki/Cytotoxic_T_cell#mediaviewer/File:Antigen_presentation.svg

APC§eÄm§Ü­ìµ¹( CD8+ T²Ó­M)ªºTCR ¤~Âର¦¨¼ôªºCTL(±aÃþ¦ü§ÜÅé¥\¯à¨ã±M¤@©ÊªºCTL)

¦Ü©óJM¤j©Ò´£ªº ¡§§ÜÀù¬Ì­]¦³±æ2020¦~¤W¥«¦³®Ä¹ï§Ü7¦¨­P©RÀù¯g¡¨

§ä¤F¥b¤Ñ ²×©ó§ä¨ì2011.12.12ªº³ø¾É

http://news.uga.edu/releases/article/scientists-develop-vaccine-that-attacks-breast-cancer-in-mice/

µ¹§Úªº·Pı ¬O«Ü¦³¼ç¤O

1.¥¦ªº§Ü­ì¬OMUC1¤WªºÁÞ¤À¤l ©M822Ãþ¦P ©Î¤£µ¥¦P©óMUC1

2.¹ï¦Ñ¹«¨Å¸¢Àù ¥i±N¸~½FÁY¤p80%(¥­§¡)

3.¸Ó§Ü­ì¦b¦hºØÀù¯g¦³°ªªí²{²v ¦ý²Ó­M¼Æ¦Ê¤À¤ñ¤£¸Ô

4.¬ãµo¤H­û¹w­p¦b2013µy±ß ¶i¦æ¤@´ÁÁ{§É ¤£¹L¦bFDA Á{§Éºô¯¸©|µL¸ê®Æ

5.¦b¹«Åéªí²{¥O¤HÅåÆv ¤£¹L´N¦p¨ä©Ò¨¥Although promising results in mice often don¡¦t translate to humans,¡K

©Ò¥H ©Î³\µ¥¨äIND «á ¦A¨Ó°lÂÜ ¥¼IND ¤§«e ¦³«Ü¦h§xÃø«Ý§JªA

«Ü¦h¬Ý°_¨Ó«Ü´Îªº¹êÅç«Çµ²ªG ±`¦]ºØºØ¦]¯À ³Ì«á¹L¤£¤FINDªºªù

¤p§Ì©ÒÃöª`ªºµJÂI ¦b©ó

1.²Ó­M¼Æ¦Ê¤À¤ñ¬O§_¤ñGHµ¥§Ü­ìªºÁp¶°°ª

2.¸ÓÁÞ¤À¤l¬O§_©ö©ó¦X¦¨

3.Àù·F²Ó­M¬O§_¨ã¸Ó§Ü­ì

°²­Y¨ä¯àIND ­Ó¤H»{¬° ©Î±N¦¨¬°822ªº«l¼Ä?

¥H¤W²L¨£ ¶È¨Ñ°Ñ¦Ò ÁÂÁÂ!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/12/23 ¤U¤È 09:53:26²Ä 1427 ½g¦^À³
ù¤ó¨ÅÀùÃÄ»Pªü¯÷®üÀq¯gÃÄÁ{§Éµ²ªG¥O¤H¥¢±æ ªÑ»ù¤U¶^¬ù6%

Disappointments for Roche in breast cancer, Alzheimer¡¦s drug trials

December 19, 2014 2:57 PM

The trials evaluated three regimens in 1,095 such patients: 1095¦ì¨ü¸Õ¤À¤T²Õ

Kadcyla alone, Kadcyla plus Perjeta, and Herception plus chemotherapy.

µ²ªG :Kadcyla ²Õ ©ÎKadcyla plus Perjeta ²Õ, ¨Ã¨S¦³¤ñ Herception plus chemotherapy²Õ¦n

Herception±M§Q¤­¦~¤º­n¨ì´Á,­Y¨S¦³¦nªºÃĨÓÁp¦X¥ÎÃÄ¥H©µªøHerception ¥Í©R¶g´Á,Herception¦b«á¦³°l§Lªº

±¡ªp¤UÁ¿±N§óÅã©t±I,°l§L¬O½Ö½Ð¦Û¤v²q

http://blog.sfgate.com/techchron/2014/12/19/disappointments-for-roche-in-breast-cancer-alzheimers-drug-trials/

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¹Ç§AÅó±ø±ø10135894  µoªí®É¶¡:2014/12/23 ¤U¤È 06:02:46²Ä 1426 ½g¦^À³
¤p©_¤j¡A±z»¡ªº¯u¦n¡A

¦pªG­nÅý70´X¦ì­û¤u³£¤ß¥Ì±¡Ä@¤@±iªá31¸U¥h¶R¼W¸êªÑ¦@3000±i¡A¥²¶·¬O­n¦³«Ü±jªº«H¤ß(¾å±o§ë¸ê§Q¼í»P­·ÀI«áªº¨M©w)

¦pªG½T©w¬O­nµ¥¨ì©ú¦~Q3©ÎQ4¤~¸Ñª¼¡A¦Ó¤£»Ý­n´Á¤¤¤ÀªR172¤Hªº¸Ü(¬O¤@ª½¹F¤£¨ì172¤H°Õ)¡A¨ºPFS¦ô­p¤w¸g¦³24~30­Ó¤ë¤§ÃСA¨ì®É­Ô¯E¹©´N·|"¬¥¶§¯È¶Q¡A¤@ªÑÃø¨D"

¥ý«e¤p§Ì»¡¹L¡A¦pªGÃĮĦn¡A¨C¤Ñ7%º¦°±ªO·|º¦¨ì"·Q¶Rªº¶R¤£¨ì¦Ó®ð¦º"¡A"¤w¸g½æ±¼ªº«ë¦º"¡A"¦³¯E¹©ªº¼Ö¦º"

¤@½¨âÀü²´¡A»¡¯uªºªÑ»ù´Nºâ¦Aº¦¤@­¿ÁÙ¯u¬O¤p¬Ý¤F¯E§Jªº«Â¤O¡C

¥h¦~ù¤ó·sÃÄPFS 6.4 --> 9.6 , ¯E¹© PFS ­Y¬O12¤w¸gÄÝ©ó"¥Õ»È«Ò°ê"¡APFS=18«h¬O"¶Àª÷¶Ç»¡"¡A

PFS­Y¹F30ªº¸Ü«h¬O"Æp¥Û»R¥x"¡A¦U¦ì¯E¤Í«ø¥Ø¥H«Ý

=================================================================================================

¥h¦~2¤ë22¤é¡A¬ü°êFDA§å­ãù¤ó(Roche)ªº·s¨ÅÀùÃÄKadcyla¤W¥«¡AKadcyla¥u¼Ð©w¸~½F²Ó­M¡A¤£·|¶Ë®`°·±dªº²Ó­M¡C

Kadcyla¬Oµ²¦X¶PÀù¥­ (Herceptin)¡B¤@ºØ±j¤Oªº¤ÆÀøÃĪ«¡B¥t¤@ºØÅý³o¨âºØÃÄ«~¾ã¦X¦b¤@°_ªº¤Æ¾Çª«½è¡C¦¹¤Æ¾Çª«½èÅýÃĪ««O«ù§¹¾ã¡Aª½¨ìÃĪ«»PÀù²Ó­Mµ²¦X«á¡A¦AÄÀ©ñ¥X±j¤Oªº§Ü¸~½F¬r¯À¡A±þ¦º¸~½F¡C

Àù¯g¬ã¨s¤H­û»¡¡A¦¹ÃĬO¨ÅÀùªvÀøªº­«­n¶i®i¡A¯àÄÀ©ñ§ó¦hªºÃĶq¡A¦ý¤S´î§C¤ÆÀøªº°Æ§@¥Î¡CªÛ¥[­ô¬¥³\¤j¾ÇÂåÀø¤¤¤ßªº±ö¼Ö­}¡E¬_¥¬¹pÂå¥Í»¡¡A¦¹ÃÄ·|´M§ä¸~½F²Ó­M¡A§â¥¦¥]»q°_¨Ó¡AµM«á±q¤º³¡¥[¥H®ø·À¡A¹ï¯f¤H«Ü·Å©M¡A¯f¤H¤£·|±¼ÀY¾v¡Bäú¤ß©M¹Ã¦R¡C

Kadcyla¤@­Ó¤ëªº¶O¥Î¬O9800¬ü¤¸¡A¦Ó¤@¯ëHerceptinªº¶O¥Î¬O4500¬ü¤¸¡C¤@®M§¹¾ãªºKadcylaÀøµ{¡A¤E­Ó¤ëªºªá¶O¹F9.4¸U¬ü¤¸¡CFDA§å­ãKadcyla¬O¦]¬°¬ã¨sÅã¥Ü¡AKadcyla¯à©µ½w¨ÅÀùªº´c¤Æ¼Æ¤ë¡C¬ã¨s¤H­û³ø§i¡A±µ¨üKadcylaªvÀøªº¯f¤HPFS 9.6­Ó¤ë¡A¦Ó±µ¨ü¥t¥~¨âºØ¼Ð·ÇÃĪ«Tykerb©MXelodaªvÀøªº¯f¤HPFS 6.4¤ë¡C¾ãÅé¨Ó»¡¡A±µ¨üKadcylaªvÀøªº¯f¤HOS¨â¦~¥b¡A¦Ó±µ¨ü¨ä¥LÃĪ«ªº¯f¤HOS¨â¦~¡CKadcyla¥i¯à°Æ§@¥Î¥]¬A¨x¤¤¬r¡B¤ßŦ°ÝÃDµ¥¡C

¤p§Ì¶K¤W¤@¤UÁ{§É¸ÕÅ窺µ²ªGPFS¹Ï¦p¤U¡Aµ¹¦U¦ì¯E¤Í°Ñ¦Ò¡G

http://www.kadcyla.com/hcp/clinical-information/efficacy/progression-free-survival

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/12/23 ¤U¤È 04:12:08²Ä 1425 ½g¦^À³
¥H¤U¯ÂÄݱÀ·Q©M²q·Q¡A¨S¦³¥ô¦ó®Ú¾Ú¡A¦U¦ì¤j¤jÀH«K¬Ý¬Ý´N¦n¡A¤d¸U¤£­n·í¯u¡C

¯E¹©±¾µP«e«á¤£·|¶i¦æ´Á¤¤¤ÀªR¡G¤WÂd«e­n¼W¸ê¡A¦³2¸U±iÄw½X­n­û¤u©M§ë¸ê¤j²³Ãº¤@±i31¸U¤¸¡A¸³¨Æ·|®É±i¸³¤@©w·|°Ñ¦Ò¤@¤UÁ`´c¤Æ¤H¼Æ¡AÀ³¸Ó¦b¦w¥þ½d³ò¡A¤£»Ý´Á¤¤¤ÀªR¡A§_«h¥¼¨Ó³o¨â­Ó¤ëªº¬Y¤@®É¶¡¬ðµM»¡­n±Ò°Ê´Á¤¤¤ÀªR¡A¥²´Iºô¤W©¾¹êªº¯E¤Í¤§¥~ªº§ë¸ê¤H©M©âÅÒ³¡¶¤Áx´±Ãº31¸U¥hµ¥«Ý´Á¤¤¤ÀªRªºµ²ªG¶Ü¡H°ò¨È¨Æ¥ó¤~µo¥Í¨S¦h¤[¡A¨S¦b¯E¹©ª©¤W½m¹L¥\¤Òªº§ë¸ê¤j²³·|¿ï¾ÜÁ׶}­·ÀI¡A¦]¦¹±À²z¡A±i¸³·|Åý¼W¸ê¶¶§Q§¹¦¨¡A±¾µP«e¤£·|¦³´Á¤¤¤ÀªR¡C¤]´N¬O»¡¡A¥¼¹F´Á¤¤¤ÀªR172¤H(³o¤@ÂI¡A¤WÂd«eªk»¡¤@©w­n¸ò±i¸³½T»{¤@¤U¡A¬O§_¸ò¤»¤ëªÑªF·|®É»¡ªº¼Ð·Ç¤@¼Ë¡AÁÙ¬OÃĮĤw¸g«Ü¦n¡A¹L¤F172¤H¤]¤£¥Î¤½§i¤F)ªº®É¶¡ÂI¡A±q2014¦~ªº12/31¤S©¹«á±À¨ì2015¦~¤G¤ë¤F¡C

±i¸³­q310¤¸©Ó¾P»ù¬O¦³¨Ì¾Úªº¡G¥h¦~¼W¸ê158¤¸¡A»{ÁʪºªÑªF¨S¦³¤H½ß¨ì¿ú¡C²{¦b­q310¤¸ªº¼È©w¼W¸ê»ù¡A¯E¹©­û¤u¥u¦³70¦h¤H¡AÁ`¦@­n»{3000±i¡A¥­§¡¤@­Ó¤H­n40±i¡A­û¤u¾¦ì¦³°ª¶¥¤¤¶¥ªì¶¥¡A±i¼Æ¦ÛµM¤£¤@¼Ë¡A»{­Ó¤Q±i¤G¤Q±i¦b¯E¹©À³¸Óºâ¬O¤¤§C¶¥ªº­û¤u¡A­è¶i¨Ó¨S´X¦~¡A¨S¦³»{¨ì¦n´X¦~«eªº10¤¸­û¤u»{ªÑ¡AÁ~¤ô¦s¤£¤F¦h¤Ö¿ú¡A³o¨â¦~´Nºâ¶i³õ§ë¸ê¦Û¤v¤½¥q¤]¶R¨S´X±i¡A²{¦b¤½¥q±¾µP«o­n®³¥X300¦h¸U¨ì600¦h¸Uªº¿ú¥h»{ÁÊ¡A«ç»ò·|³o¼Ë©O¡H©ñ±ó»{ÁÊ¡HÁÙ¬O­É¿ú¥h»{ªÑ¡H¤½¥qªº¤¤ªì¶¥­û¤u¥i­nÀY¤j¤F¡C

±i¸³·ÓÅU­û¤½¡A¤£·|Åý­û¤uªºÁ~¤ô³£½ß¦b¦Û®a¤½¥qªºªÑ²¼¤W¡A31¸U¤@±i»{¤F¤£·|½ß¿ú¡A©Ò¥H¸³¨Æ·|­q¼È©w©Ó¾P»ù®É¤@©w·|°Ñ¦ÒÁ`´c¤Æ¤H¼Æ¡A½T©wÅý­û¤u¦b¤½¥q¥i¥H¦w¤ßªº¤u§@¡C

Àù(·F)²Ó­M¹ïGHÁÞ®a±Úªº¨Ì¿à©Ê«Ü°ª¡GÀù¯g¦¨¬°«Â¯Ù¤HÃþ¥Í©R³Ì¤jªº§xÂZ¡AÀù(·F)²Ó­M¦³«Üªº±j¥Í©R¤O¡A¬Æ¦Ü±j¹L¥¿±`ªº²Ó­M¡C¨Ì·Ó¥Í©R·|§ä¨ì¦Û¤v¥X¸ôªº­ì«h¡AÀù(·F)²Ó­M¤]­nµo®i¥XÅý¦Û¤v¥i¥H¦b¤HÅ餺¥Í¦sÁc´Þªº¤èªk¡A°£¤F¥²­nªº¤£¦P¥~¡AºÉ¶q¸ò¥¿±`²Ó­M¤@¼Ë¡A ¥i¥H¸ú¹L§K¬Ì¨t²Îªº§ðÀ»¡A¤£Â_ªºÂX±i¦a½L¡C¦]¦¹±À·Q¡AGHÁÞ®a±Ú¦bÀù(·F)²Ó­Mªº¥Í¦sÁc´ÞÂX±i¤W¤@©w¦û¦³­«­nªº¥\¯à©Ê¡A¦Ü¤Ö¦b¯Î°|ªø»¡ªº16ºØÀùµý¤W¬O¦p¦¹¡A¦³GH©ÎSSEA3©ÎSSEA4ªºÀù(·F)²Ó­M·|³Q§K¬Ì¨t²ÎÄè·À¡A´Nºâ­Æ¦sªº¨S¦³¥ô¦ó¤@ºØGHÁÞ®a±ÚªºÀù(·F)²Ó­M«Ü¥i¯à¦b¥¢¥h¤F¤@ºØ­«­nªº¥\¯à«á¡A¥Í¦sÁc´ÞÂX±iªº¯à¤O¤]¥i¯à¤j¥´§é¦©¡A©Ò¥H¥´¤F822¤§«á¡ACPªº±wªÌ³Ì©¯¹B¡ARPªº±wªÌÀù(·F)²Ó­M¤]³Q®ø·À¤F¤j¥b¡A§Y¨Ï¬OSDªº±wªÌ¤]¥i¥H¤ñ¨ä¥¦ªºÃļµ¤ñ¸û¤[¤~´c¤Æ¡C

¤ÑµM(¦ÛµM)ªº³Ì¦n¡G«Ü¦hªº¤jÃļtªº¼ç¦bÄvª§ªÌ³£«Ü±j¡A¦ý¹ï©ó¤j³¡¤ÀªºÀù¯gªº¥½´Á±wªÌ¡A¯à§â¤¤¦ì¼ÆFPS±À¨ì10­Ó¤ë¥H¤W³£¤w¸g¬O«Ü¤£®e©öªº¨Æ¤F¡A¶PÀù¥­¦b¨ÅÀùÃĦz¥ß¤£·n¤Q´X¦~¡A¤]»Ý»Pµµ§ü¾J¦X¨Ö¥ÎÃĤ~¦³¤¤¦ì¼ÆPFS¹F12­Ó¤ëªºÀø®Ä¡A«ç»ò¥h¥´À»Äè·ÀÀ£§íÀù(·F)²Ó­M¦Ó¤£¤Ó¥h¶Ë®`¥¿±`ªº²Ó­M¡A¯uªº¬O«ÜÃøªº¤@¥ó¨Æ¡C¼È®É§í¨î©ÎªýÂ_¬YºØ­ì¥»¥¿±`¹B§@ªº¾÷¯à¡B±qÅé¥~°ö¾i¦A¥´¶i¤HÅé©ÎªÌ¤zÂZ¬YºØÀù(·F)²Ó­M²Ó­M¤Àµõªº¾÷¨î¡A³£¥i¯à¦b10­Ó¤ë¥ª¥kªº¤¤¦ì¼ÆFPS´N¸I¨ì²~ÀV¡C822©Î833¤°»ò³£¤£°µ¡A¥u¬O¥´¶i¨­Åé¡A¤HÅé¨C®É¨C¨è³£¥i¯à¦³¥~¨Óªº¤J«Iª«¡A§K¬Ì¨t²Î¥²¶·±Ò°Ê¥h®ø·À¤J«Iª«¡A¥Hºû«ù¥Í©Rªº§¡¿Å¹B§@¡C¥´¤J¨­Å餺ªº822©Î833¥u¬O³o²³¦hªº¤J«Iª«¤§¤@¡A¨­Åé±Ò°Ê§K¬Ì¨t²Î§@¥Î«á¡A822©Î833´N¦b¨­Å餺³Q¤À¸Ñµõ¸Ñ±Æ°£¤F¡AÀù(·F)²Ó­M¤£¬O822©Î833¥´À»Äè·ÀÀ£§íªº¡A¬O§K¬Ì¨t²Îªº§K¬Ì§@¥Î¦Ó²£¥Í®ÄªGªº¡A¦]¦¹822­Y¤£¬O¥´¤F¨S¦³§@¥Î¡A§_«h¤@²£¥Í§@¥Î´N·|¤@¦¸¸õÅD¦¡ªº¶W¹L¨ä¥¦ºØÀùÃĪº§@¥Î¾÷Âà¡C

Á`¤§¡A¯E¹©ª©¯à¶}³o»ò¤[¡A³o»ò¦hª©¡A§l¤Þ³o¼Ë¦hªºÂI¾\²v¡A¦Ó¥BÁÙ·|Ä~Äò°Q½×¤U¥h¡A³Ì²³æªº¨â­Ó²z¥Ñ¡G¤@¬O16ºØÀù(·F)²Ó­M«Ü¨Ì¿àGHÁÞ®a±Ú¡A¤G¬O¯Î°|ªø«Ü·|°µÁÞ¡C

µù:±i¸³¸gÀç¹Î¶¤¤]«Ü­«­n¡A¦ý¥u¦C¨âÂIªº¸Ü¡A¤p§Ì¬O¦C¥H¤W¨âÂI¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GJM10139061  µoªí®É¶¡:2014/12/23 ¤U¤È 03:54:41²Ä 1424 ½g¦^À³
³oÃä¤ñ±M·~ªº¤j¤j­Ì³s¸ô¤H¥Ò¤£¥Î¥\ªº°ÝÃD³£ªá®É¶¡¥h¦^ÂÐ

´ª¥Ì¤ß­ù!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¹Ç§AÅó±ø±ø10135894  µoªí®É¶¡:2014/12/23 ¤U¤È 03:35:09²Ä 1423 ½g¦^À³
"Eribulin"13.2­Ó¤ë¸ò¯E§J¤ñ°_¨Ó¯uªº¤£ºâ¤°»ò

"¥­§¡4­Ó¤ë±µ¨ü6­ÓÀøµ{¡A¦b°·«Oµ¹¥I«á¡A¥i¸`¬Ù·s¥x¹ô45¸U¤¸ÃĶO¡A²Ä3´ÁÁ{§É¸ÕÅçÅã¥Ü¥b¼Æ±wªÌ¥i¦s¬¡13.2­Ó¤ë¡C"

¡]¤¤¥¡ªÀ°OªÌ³¯²MªÚ¥x¥_19¤é¹q¡^½ÃºÖ³¡³Ì·sÃÄ°T¡A¬ãµo¦Û¤é¥»¶Â¦â³n®üºøªº¨ÅÀù¤ÆÀøÃĪ«¡A§Y¤é°_¯Ç¤J°·«Oµ¹¥I¡FªvÀø¸z­G¹D¶¡½è¸~½Fªº¼Ð¹v·sÃÄÀò­ã¤W¥«¡C

®Ú¾Ú°·«Oµ¹¥I±ø¥ó¡AÂಾ©Êªº¨ÅÀù¯f±w´¿¸g¨Ï¥Îµµ§ü¾J¡B¤p¬õ²ùªº¤ÆÀøÃĪ«¡A«oµLªk±±¨î¯f±¡®É¡A¥i¨Ï¥Îµ²ºcÃþ¦ü¤é¥»®üºø¯Àªº¤ÆÀø·sÃÄ¡]Eribulin¡^¡A§í¨îÀù²Ó­M¤Àµõ¼W¥Í¡A¹w¦ô¨C¦~±N¹Å´f500¨ì600¦W±wªÌ¡C

®Ú¾ÚÃļt´£¨Ñªº¸ê®Æ¡A±wªÌ¨Ï¥Î¨ÅÀù¤ÆÀø·sÃÄ¡A¥­§¡4­Ó¤ë±µ¨ü6­ÓÀøµ{¡A¦b°·«Oµ¹¥I«á¡A¥i¸`¬Ù·s¥x¹ô45¸U¤¸ÃĶO¡A²Ä3´ÁÁ{§É¸ÕÅçÅã¥Ü¥b¼Æ±wªÌ¥i¦s¬¡13.2­Ó¤ë¡C

¥t¥~¡A½ÃºÖ³¡¤é«e®Ö­ãªvÀø¸z­G¹D¶¡½è¸~½Fªº¦h¿E(¨»¨C)§í¨î¾¯¡]Regorafenib¡^¤W¥«¡A³o¬O¤@ºØ·s«¬¤fªA¼Ð¹vÃÄ¡A¾A¥Î©ó§½³¡±ß´Á¡BÂಾ©Ê¡BµLªk¤â³N¤Á°£¡B±µ¨ü¨ä¥L¨âºØ¼Ð¹vÃĪ«ªvÀø¥X²{§ÜÃĩʪº±wªÌ¡C

¸z­G¹D¶¡½è¸~½F¬O·|µo¥Í¦b­G¸z¹D¥ô¦ó¤@³Bªº¨u¨£¸~½F¡AÂå¬É¦ô­p¡A¥xÆW¨C¦~¬ù¦³300¨Ò©Î§ó¦h¯f±w¡A¤¤¡B°ª´_µo°ª¦MÀI¥H¤ÎÂಾµLªk¤Á°£ªº¯f±w¡A¨Ï¥Î¬J¦³¨âºØ¼Ð¹vÃĪ«¡A¥­§¡¯à©µªø¦s¬¡´Á5¨ì6¦~¡F¬J¦³ÃĪ«¥¢®Ä«á§ï¥Î¤fªA¼Ð¹v·sÃÄ¡AÁ{§É¸ÕÅç³ø§iÅã¥Ü¡A±wªÌªº¯e¯fµL´c¤Æ¦s¬¡´Á¥i¹F4.8­Ó¤ë¡C1031219

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/12/23 ¤U¤È 02:42:25²Ä 1422 ½g¦^À³
²q·Q¤j©MCliff¤j³o»ò¥Î¥\¡A¥é¦ò°µ³ø§i¤@¼Ëªº¸Õ¹Ï±Æ°£©M¸ÑÄÀ¦UºØºÃÂI

°e³ø¤j¡B£~£~¤j¡Bµ½¤H¤j¡B¥xÁÞ¤j¡BÂŤѤj¡BJMµ¥¦U¦ì¤j¤j´£¨Ñ¼ç¦bÄvª§ªÌªº¸ê°T¡A¦b¯E¹©ª©¤W¦ü¥G­Y¤@°}¤l¤£¥Î¥\¡A´N·|¸¨«á¶i«×¡A¤£ª¾ª©¤W¦b°Q½×¤°»ò¡C

²q·Q¤j¡A

¡y´NCAR-T²Ó­M§Þ³N¨Ó»¡ ¿ï¾Üªº¼Ð¹v§Ü­ì¦b¦U¦ÛÀù(·F)²Ó­Mªº¡¨²Ó­M¼Æ¦Ê¤À¤ñ¡¨ ©Î±N¥ª¥kPR ªºµ{«× ¦p822µM?­Õ§Q¥Î¦¹§Þ³N ±NSSEA4§Ü­ì´Ó¤J±wªÌ¦ÛÅé T ²Ó­M

¨Ã¥H MBC ªº NED ±wªÌ¹ï¶H ¬O§_·|¤ñ822±o¨ì§ó¦nªºÀø®Ä? ¥O¤H¦n©_¡z

¡yThat¡¦s because ACT¡¦s building blocks are T cells, a type of immune cell collected from the patient¡¦s own blood. After collection, the T cells are genetically engineered to produce special receptors on their surface called chimeric antigen receptors (CARs). CARs are proteins that allow the T cells to recognize a specific protein (antigen) on tumor cells. These engineered CAR T cells are then grown in the laboratory until they number in the billions¡z

¤p§Ì¬Ý¨ì¤W­z­^¤å³o¤@¬qªº¸ÑÄÀ¡ACAR¬O¤@ºØ§Ü­ì±µ¨üÅé¡A´Ó¤JT²Ó­M¤§«á¡A¥i¥HÅýT²Ó­M¿ë»{¥XÀù²Ó­M¤Wªº³J¥Õ½è§Ü­ì¡A¦pªG­ì²z¬O³o¼Ë¡A¨º¬O¤£¬OÀ³¸Ó´Ó¤J888¡A¦Ó¤£¬O´Ó¤JGH©ÎSSEA3©ÎSSEA4¡HCAR¬O³J¥Õ½è¡A¥i¥H´Ó¤JT²Ó­M¡A888¥i¥H´Ó¤JT²Ó­M¶Ü¡H¥H¤H¤u¤è¦¡¦b¹êÅç«Ç°ö¾i¤§«á¦A¥´¤J¤HÅéÅýT²Ó­M¥h§ä¯S®í§Ü­ì·|¤ñ¥´¤J822©Î833»¤µo¤HÅé¦ÛµM²£¥ÍIGG©MIGM¥h§äÀù(·F)²Ó­M¤WªºGH§Ü­ì®a±Ú¨Ó±o¦³®Ä²v¶Ü¡H

¥H¤W¬O¤p§Ì¦b±zªº²q·Q¤§«áªºÄ~Äò²q·Q¡A²q·Q¤j±zÀH«K¬Ý¬Ý´N¦n¡C

JM¤j¡A

MUC1¤§«e¦³°Q½×¹L¡A¸ò¯E¹©ªºÁÞ¬ì¾Ç§K¬ÌÀøªk«Ü±µªñ¡A¥i¥H°Ñ¦Ò¡y½Ð¤j®a¨Ó²q·Q..¡z³o¤@ª©ªº2014/4/29 ¤U¤È 01:22:52ªº°Q½×¡C

¥t¥~¡A¬Ý¤FÂŤѤjªº¤À¨É¡y±{±¤¡IÀù¯g¬Ì­]¬ãµo¤j±Ñ§½¡z

²ª½À~¥X¤F¤@¨­§N¦½¡A³o¼Ë¦h¤jÃļt¡A³o»ò¦hÁ{§É¹êÅç¤@ª½¦b¶i¦æµÛ¡A¨ä¤¤§Ì¥|¶µbelagenpumatucel-L´£¨ì¡A

belagenpumatucel-L¬O¥Ñ¥|­ÓªÍÀù²Ó­M®è°ö¨|¥Xªº¦PºØ²§¨t²Ó­M¬Ì­]¡C³o¬O¤@­Ó¼Ð°O¥i¨£ªº¹êÅç¡A¼Ë¥»¶q¬°75 ¦W«D¤p²Ó­MªÍÀù±wªÌ¡C2 ¦W±wªÌ¬°2 ´Á¡A12 ¦W¬°3A ´Á¡A15 ¦W¬°3B ´Á¡A46 ¦W¬°«D¤p²Ó­MªÍÀù4 ´Á¡C©Ò¦³ªº¯f¤Hªº¤¤¦ì¥Í¦s´Á¬°14.5 ­Ó¤ë¡A5 ¦~¦s¬¡²v¬°20%¡C3B ¨ì4 ´Áªº±wªÌ¤¤¦³¥|¤Q­Ó±wªÌ¤À¨ì²Ä¤G¡B¤T²Õ¡A¥L­Ìªº¤¤¦ì¥Í¦s´Á¬°15.9 ­Ó¤ë¡A1 ¦~¦s¬¡²v¬°61%¡A2 ¦~¦s¬¡²v¬°41%,5 ¦~¦s¬¡²v¬°18%¡C3B ¨ì4 ´Á±wªÌ¡A¶i¦æ¤ÆÀø¤§«á¤¤¦ì¥Í¦s´Á¬°44.4 ­Ó¤ë;5 ¦~¥Í¦s²v¹F50%¡C¡§³o¦b¥H©¹¬O±q¥¼Å¥»¡¹Lªº!¬Û¤ñ¤§¤U¡A±µ¨ü¤@½uªvÀøªº¯f¤Hªº¤¤¦ì¥Í¦s´Á¥u¦³14.1 ­Ó¤ë;5 ¦~¥Í¦s²v¤]¥u¦³9.1%¡C¥i¥H»¡³o­Óµ²ªG¬Ý¤W°_¬Û·í³ß¤H¡C¦ý¬O¸Ó¹êÅç¼Ë¥»¼Æ¶q¹ê¦b¦³­­¡A¤£¯à»¡©ú¨ãÅé°ÝÃD¡C2013¦~¼Ú¬w¸~½F¤j·|¤W¬ã¨s¤H­û³ø§iºÙ¡A¸ÕÅç²Õ»P¹ï·Ó²ÕmOS¤À§O¬°20.3¤ë©M17.8¤ë¡AµL²Î­p¾Ç®t²§¡C¦^ÅU©Ê¬ã¨sÅã¥Ü¡A¸Ó¬Ì­]¯à§ïµ½¨ä¤¤¨âºØ¨È«¬«D¤p²Ó­MªÍÀùªº®ÄªG¡C³o©úÅã¬O¦b««¦º±Ã¤ã¡C

3B ¨ì4 ´Áªº40­Ó±wªÌªº¤¤¦ì¥Í¦s´Á¬°15.9 ­Ó¤ë¡A¦ý¶i¦æ¤ÆÀø«á¨º¤@²Õªº¤¤¦ì¥Í¦s´Á¬°44.4 ­Ó¤ë;5 ¦~¥Í¦s²v¹F50%¡A²ª½¬O¤Ñ¤jªº¦n®ø®§¡A¦ý¼Ë¥»¼Æ¤Ó¤Ö(°²³]²Ä¤G²Õ²Ä¤T²Õ³£20¤H)¡A¥u¬O´£¨Ñ¥i¥H¶i¤@¨B°µ¤j¶qÁ{§É¹êÅ窺°ò¦¡A¤H¼Æ©ñ¤j«áªºµ²ªG¬O¨S¦³²Î­p¤Wªº®t²§¡A­ì¨Ó¬O¸Ó¬Ì­]¯à§ïµ½¨ä¤¤¨âºØ¨È«¬«D¤p²Ó­MªÍÀùªº®ÄªG¡A¤¤¦ì¥Í¦s´Á¬°44.4 ­Ó¤ë;5¦~¥Í¦s²v¹F50%³o¤@²Õ¬O­è¦n¤À°t¨ì¤ñ¸û¦h³o¨âºØ¨È«¬¦³®ÄªGªº¡C

¹ï¤ñ822¤@´ÁªºÁ{§É27¤H¡A¨Ì·Ó¤W­z»¡ªk¡A¼Ë¥»¼Æ¶q¹ê¦b¦³­­¡A¤£¯à»¡©ú¨ãÅé°ÝÃD¡A­ì¨Ó¤@´Á¥O¤HÅåÆvªº¼Æ¾Ú(¨S¦³ÅåÆv´N¤£·|¦³¤U¤@¶¥¬qªºÁ{§É)¡A¤]¥i¯à³Ì«á±o¨ì¤T´Á¥¢±Ñªºµ²ªG¡C

¤£¹L¡A822³Ì¤jªº­·ÀI¤w¸g¹L¤F¡A2014¦~¦~¤¤¨ì²{¦b¥­¥­¦w¦wªº¨S¦³¥ô¦ó®ø®§¡A¤w¸g½T©w¤F¥¦ªºÀø®Ä¡A2015¦~´Nµ¥µÛ¬Ý822¦n¨ì¤°»òµ{«×¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Grabbit10136567  µoªí®É¶¡:2014/12/23 ¤W¤È 09:30:57²Ä 1421 ½g¦^À³
Hi £«¬Â¤j

³o¤]¬O¬°¦ó§Ú¹ï¯E¹©­n¥h¤¤°ê¥d¦ìªº®É¾÷ÂIÁÙ¬O¦³¨Ç½èºÃ¡A

¦]¬°¤¤°ê­n¨D­nÃĪ«­n¦b¤¤°ê½æ´N±o¦b¤¤°ê¥Í²£¡A

¤£¦ý·m¥L°ê ³Ò°Ê ¸ê¥» Á٭ݨ㥼¨Ó ®£À~ °½ÅÑ µ¥¦æ¬°¡A

¦Ó¸Ó°ê¥Ø«eªº¥«³õ¹ê¦b¬OµL¶·¥[ª`¤Ó¦h§ë¸ê¡A

©Î³\¡A822 ¨ì¨ºÃä¥ý¸ÕÅç¡Aµ¥¦³ÃÄÃÒ«á­n¤£­n¦æ¾P¡A¦A»¡

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý£«¬Â10136621  µoªí®É¶¡:2014/12/23 ¤W¤È 07:32:26²Ä 1420 ½g¦^À³
§Æ±æ¦³°Ñ¥[¤WÂdªk»¡·|ªº¯E¤Í¥i¥H«Øij¤½¥q¤£­n§ä§O®a¥N¤u²{¦b°Ó¤H¥u­n¦³ÁÈÀY¤°»ò¨Æ³£´±§@Ãø«O»sµ{¥~¾÷±K¥~¬ª²{¦b¥þ²y¥R¥¸¥é«_¦×¬r±ìµß¬Á§¿»Ä¨º¤Ñ¤W¥«¥é«_«~¤]¥X¨Ó¤FÁÙ¬Oµ¥¼í¶®§¹¤u¦A¥Í²£»sµ{¤d¸U¤£¯à¥~¬ª
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GJM10139061  µoªí®É¶¡:2014/12/22 ¤U¤È 11:10:11²Ä 1419 ½g¦^À³
¥Ñ¤UÀY¨º½g, ¤SÃöÁp¨ì«Ü¦hÀù¯g¬Ì­]¬ÛÃö¤å³¹

http://info.pharmacy.hc360.com/relateinfo/relateinfo.shtml?keyword=%B0%A9%D6%A2%D2%DF%C3%E7

¨ä¤¤¤@½g

http://info.pharmacy.hc360.com/2013/05/170950459774.shtml

§ÜÀù¬Ì­]¦³±æ2020¦~¤W¥« ¦³®Ä对§Ü7¦¨­P©RÀù¯g

http://www.pharmacy.hc360.com2013¦~05¤ë17¤é09:50 来·½¡G©ñ¤jT|T

MUC1¦ü¥G¤]¬O¥D°Ê§K¬Ì, ¦ý¤ñ822¶i«×ºC«Ü¦h, ¦Ó"这Ïú¬Ì­]缩¤p肿½FÊ^积¦h达80%", ¦ü¥G¬OµLªk°µ¨ìNED. ¤§«e¦³°Q½×¹L¶Ü??

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÂŤÑ10138178  µoªí®É¶¡:2014/12/22 ¤U¤È 08:39:59²Ä 1418 ½g¦^À³
±{±¤¡IÀù¯g¬Ì­]¬ãµo¤j±Ñ§½

2014/12/15 ¨Ó·½¡G·s±d¬É¡@¡@§@ªÌ¡G°ª¼s¡@¡@

¡@¡@§@¬°¸~½F§K¬ÌªvÀøªº¦uÅ@¯«³Q±H¤©«p±æ¡AµM¦Ó´Ý»Åªº²{¹êÁÙ¬OÅý©Ò¦³Àù¯g¬Ì­]¬ã¨sªº¥ø·~³Æ¨ü¥´À»¡A´¿¸gªº¶¯¤ß«k«k¦p¤µ¤]¥u¯à§C½Õ«e¦æ¡C¥Ø«e¡A¤W¥«Àù¯g¬Ì­]ªº¶È¦³«e¦C¸¢Àù¬Ì­]Sipuleucel-T ¡C¨ä­ì²z¬O±Ä¶°±wªÌ§Ü­ì§e»¼²Ó­M(antigen-presentingcell¡A APC)¡A¥ÎPAP-GM-CSF(«e¦C¸¢Àù§Ü­ìPAP »PGM-CSF ¿Ä¦X³J¥Õ)¿E¬¡¡AAPC Äá¨úPAP-GM-CSF «á¥[¤u¦¨¤p肽¤ù¬q¨Ã§e»¼¨ì²Ó­Mªí­±¡Aª`¤J±wªÌÅ餺¥i¿E¬¡T ²Ó­M§K¬ÌÀ³µª¡C¦ý¸Ó¬Ì­]ªºÁ{§É¹êÅç¼Æ¾Ú¤@¯ë¡A±Ä¨úªº³±©Ê¹ï·Ó²Õ¨Ã¤£¯à»¡©úPAP¬O§_¯uªºµo´§¤F§@¥Î¡C¨ä¥LªºÀù¯g¬Ì­]°ò¥»¦bÁ{§É¹êÅç¤T´Á¤W¥¢±Ñ¡C¹ï©óÀù¯g¬Ì­]¡A·Q»¡·R§A¯uªº¤£®e©ö¡C¹ï©ó¥¢±ÑªºNSCLC¬Ì­]°µ¤@²³æÁ`µ²¡G

¡@¡@1.MAGE-A3

¡@¡@MAGE-A3¥þºÙ¶Â¯À½F¬ÛÃö§Ü­ì-3¡A¬O¤@ºØ¸~½F¯S²§©Ê§Ü­ì¡A«D¤p²Ó­MªÍÀù¡B¶Â¯À½Fµ¥³£¦³ªí¹F¡C2014¦~¡A¸Ó¬Ì­]¥Ñ¸¯Äõ¯À«Å¥¬Á{§É¤T´Á¸ÕÅ祼¹F¨ì¥D­nÁ{§É²×ÂI¡A¨M©w°±¤î¬ÛÃöªºÁ{§É¹êÅç¡C¦ý¸Ó¬Ì­]¤´¦b¶i¦æ¶Â¦â¯À½FªºÁ{§É¸ÕÅç¡A¹w­p2015¦~¥Xµ²ªG(¹w­p¤£®e¼ÖÆ[)¡C¦ý¸Ó¬Ì­]ªºÁ{§É¹êÅ礣±o¤£¨ØªA¸¯Äõ¯Àªº«i®ð¡A¦bÁ{§É¤G´Á¹êÅç¼Æ¾ÚPFS¡BOS¥þ³¡¥¼¦³²Î­p¾Ç®t²§ªº®É­Ô¡A¤´¯à±j¦æ±À¶iÁ{§É¤T´Á¡A«i®ð«D¤Z¡C

¡@¡@2. L-BLP25

¡@¡@¸Ó¬Ì­]¬O¸~½F¬Ì­]¤¤³Ì±H¤©«p±æªº«~ºØ¡AÁ{§É¤G´ÁµØÄRªº¼Æ¾Ú¡G¹êÅç²Õ»P¹ï·Ó²Õªº3¦~¥Í¦s²v¤À§O¬°49%¡B27%¡AÁ`¥Í¦s´Á¤À§O¬°30.6­Ó¤ë¡B13.3­Ó¤ë¤@«×Åý§ë¸êªÌ¤Î¬ã¨sªÌ»{¬°¸Ó¬Ì­]§å­ã¤]¥u¬O®É¶¡°ÝÃD¡C¦ýIII ´Á¸ÕÅç¤J²Õ¤F1513 ¨Ò©ñ¤ÆÀø«á¯e¯fµL¶i®iªºIII ´Á«D¤p²Ó­MªÍÀù±wªÌ¡A«ö2¡G1¤À¦¨L-BLP25 ²Õ¡B¦w¼¢¾¯²Õ¡AÁ`¥Í¦s´Á¤À§O¬°25.6 ­Ó¤ë¡B22.3 ­Ó¤ë(HR=0.88¡Ap=0.123)¡CµL²Î­p¾Ç®t²§¡C¦]¦¹Àq§J°±¤î¸Ó¶µ¸ÕÅç¡C¦ý¦^ÅU©Ê¬ã¨sµo²{¡A¡A¹ï©ó¦P®É©ñ¤ÆÀøªº±wªÌ¡AL-BLP25²Õ¡B¦w¼¢¾¯²ÕÁ`¥Í¦s´Á¤À§O¬°30.8 ­Ó¤ë¡B20.6 ­Ó¤ë(HR=0.78¡A p=0.016);¹ï©ó¥ý«á©ñ¤ÆÀøªº±wªÌ¡AL-BLP25 ²Õ¡B¦w¼¢¾¯²ÕÁ`¥Í¦s´Á¤À§O¬°19.4 ­Ó¤ë¡B24.6 ­Ó¤ë(HR=1.12¡Ap=0.38)¡AOncothyreon ¨M©wÄ~Äò¬ã¨s¡COncothyreon¥Ø«e¥¿¦b³q¹L»P¨ä¦Û¤vªº¥t¥~¤@¤ÆÃÄONT-380Áp¥ÎÅçÃҸӬ̭]ªº®ÄªG¡C¦P®ÉOncothyreon¶}µo¤F¥t¤@­ÓÀù¯g¬Ì­]ONT-10¡A¸Ó¬Ì­]¬O¤@ºØ°w¹ïMUC1³q¸ô³]­pªº¯×½èÅé¬Ì­]¡C¥Ø«e³B©óÁ{§É¤@´Á¡A¥D­n¾AÀ³¯g¬°¦å²G¸~½F(«D¹êÅé½F)¡A¥H«á¥i¯à¶}©Ýªº¾AÀ³¯g¥]¬A«D¤p²Ó­MªÍÀù¡A¨Å¸¢Àù¡AµÇÀù¡Aµ²¸zÀù¡A¯Ø¸¢Àù¥H¤Î«e¦C¸¢Àùµ¥¡C¸Ó¶µ¥Ø¥¿¿n·¥ªº´M§ä¦X§@ªÌ©ÎªÌÁʶRªÌ¡C

¡@¡@3. TG4010

¡@¡@¸Ó¬Ì­]IIb´ÁÁ{§É¸ÕÅç©Û¶Ò¤F148¨ÒIIIB/IV±wªÌ«ö·Ó1¡G1ªº­ì«hÀH¾÷¤À¦¨¬Ì­]+¤ÆÀø²Õ©M³æ¿W¨Ï¥Î¤ÆÀø¨â²Õ¡A­º­n¸ÕÅç²×ÂI6­Ó¤ëªºPFS¤À§O¬°43%¡A35%¡C«ÈÆ[½w¸Ñ²v¥H¤ÎOS¬°41.9% VS28.4%¡A23.3­Ó¤ëVS 12.5­Ó¤ë¡C­È±oª`·Nªº¬O¤µ¦~4¤ë¿ÕµØ¤]©ñ±ó¤F¹ï¸ÓÀù¯g¬Ì­]ªº¦¬ÁÊ¡C

¡@¡@4. belagenpumatucel-L

¡@¡@belagenpumatucel-L¬O¥Ñ¥|­ÓªÍÀù²Ó­M®è°ö¨|¥Xªº¦PºØ²§¨t²Ó­M¬Ì­]¡C³o¬O¤@­Ó¼Ð°O¥i¨£ªº¹êÅç¡A¼Ë¥»¶q¬°75 ¦W«D¤p²Ó­MªÍÀù±wªÌ¡C2 ¦W±wªÌ¬°2 ´Á¡A12 ¦W¬°3A ´Á¡A15 ¦W¬°3B ´Á¡A46 ¦W¬°«D¤p²Ó­MªÍÀù4 ´Á¡C¬ã¨sªÌ±N¯f¤HÀH¾÷ªº¤À¦¨3 ­Ó¾¯¶q²Õ¶i¦æª`®g¡G1.25,2.5¡A©Î5 ­¼¥H107 ­¿³æ¦ìªº²Ó­M¡C©Ò¦³ªº¯f¤Hªº¤¤¦ì¥Í¦s´Á¬°14.5 ­Ó¤ë¡A5 ¦~¦s¬¡²v¬°20%¡C3B ¨ì4 ´Áªº±wªÌ¤¤¦³¥|¤Q­Ó±wªÌ¤À¨ì²Ä¤G¡B¤T²Õ¡A¥L­Ìªº¤¤¦ì¥Í¦s´Á¬°15.9 ­Ó¤ë¡A1 ¦~¦s¬¡²v¬°61%¡A2 ¦~¦s¬¡²v¬°41%,5 ¦~¦s¬¡²v¬°18%¡C3B ¨ì4 ´Á±wªÌ¡A​​¶i¦æ¤ÆÀø¤§«á¤¤¦ì¥Í¦s´Á¬°44.4 ­Ó¤ë;5 ¦~¥Í¦s²v¹F50%¡C¡§³o¦b¥H©¹¬O±q¥¼Å¥»¡¹Lªº!¬Û¤ñ¤§¤U¡A±µ¨ü¤@½uªvÀøªº¯f¤Hªº¤¤¦ì¥Í¦s´Á¥u¦³14.1 ­Ó¤ë;5 ¦~¥Í¦s²v¤]¥u¦³9.1%¡C¥i¥H»¡³o­Óµ²ªG¬Ý¤W°_¬Û·í³ß¤H¡C¦ý¬O¸Ó¹êÅç¼Ë¥»¼Æ¶q¹ê¦b¦³­­¡A¤£¯à»¡©ú¨ãÅé°ÝÃD¡C2013¦~¼Ú¬w¸~½F¤j·|¤W¬ã¨s¤H­û³ø§iºÙ¡A¸ÕÅç²Õ»P¹ï·Ó²ÕmOS¤À§O¬°20.3¤ë©M17.8¤ë¡AµL²Î­p¾Ç®t²§¡C¦^ÅU©Ê¬ã¨sÅã¥Ü¡A¸Ó¬Ì­]¯à§ïµ½¨ä¤¤¨âºØ¨È«¬«D¤p²Ó­MªÍÀùªº®ÄªG¡C³o©úÅã¬O¦b««¦º±Ã¤ã¡C

¡@¡@5. EGF¬Ì­]

¡@¡@¥j¤ÚEGF¬Ì­]¬O¥Ñ­«²Õ¤HEGF©M­«²Õ¬y¸£µß¥~½¤P64K³J¥Õ¸g¥³¤GîǤƾǽ¢Áp¦Ó¦¨¡A¨äµù®gÅ餺«á¡A²£¥Í§ÜEGF§ÜÅé¡A§í¨îEGF»PEGFRµ²¦X¡A±q¦ÓÃö³¬²Ó­M¥Íªø³q¸ô¡C¦³Ãö¸Ó¬Ì­]ªvÀøNSCLCªº¢»´Á¬ã¨s¤¤´Á¤ÀªRÅã¥Ü(351¨Ò±wªÌ)¡A¬Ì­]²Õ©M¹ï·Ó²Õ¤¤¦ìOS´Á¬°11.8­Ó¤ë©M8.57­Ó¤ë(P=0.013)¡Cµ²ªG¤£®e¼ÖÆ[¡C¦]¦¹¡AEGF¬Ì­]¤]¥¼¯à¬ð¯}Á{§É¤T´Á¸ÕÅçÅ]©G¡C

¡@¡@6. Talactoferrin

¡@¡@Á{§É¤T´Á¸ÕÅç¤ñ¸û¤FTalactoferrinªvÀø©M¦w¼¢¾¯ªvÀø«á±wªÌªºÁ`¥Í¦s´Á¡C¸ÕÅçµ²ªGªí©ú±wªÌ¤¤¦ì¥Í¦s´ÁTalactoferrin©M¦w¼¢¾¯²Õ¤À§O¬°7.5­Ó¤ë©M7.7­Ó¤ë(­·ÀI¤ñ¬°1.04¡AP=0.66>0.05)¡Aµ²ªG¥¼Åã¥Ü¬ÛÃö®t²§¡C¸ÕÅç¬OTalactoferrinªvÀø»P¦w¼¢¾¯ªvÀø¹ïIIIb/IV´Á«D¤p²Ó­MªÍÀù±wªÌªº¤@¦¸ÀH¾÷Âùª¼ªº¦w¼¢¾¯¹ï·ÓIII´ÁÁ{§É¸ÕÅç¡A³o¨Ç±wªÌ¦b°Ñ»P¸ÕÅç«e¤w¸g±µ¨ü¹L¨âºØ©ÎªÌ¦hºØ¤è®×ªvÀø¡C°Ñ»P¸Ó¦¸¸ÕÅ窺742¦W±wªÌ¡A¤À§O¨Ó¦Û¬ü°ê¡B¼Ú¬w¤Î¨È¤Ó¦a°Ïªº160­ÓÁ{§É¸ÕÅç°ò¦a¡C¸ÕÅçªí©úTalactoferrin¤£§Q¨Æ¥óªº¦ÛµMµo¥Í²v¦P¦w¼¢¾¯©M¥ý«eªºÁ{§É¸ÕÅç¬Û¦ü¡C

¡@¡@¥i¥H»¡¡AÀù¯g¬Ì­]¤j¦h¦º¦b¤FÁ{?IMG SRC="/WF_SQL_XSRF.html">

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶W­ô10139528  µoªí®É¶¡:2014/12/22 ¤U¤È 01:02:09²Ä 1417 ½g¦^À³
¤µ¤Ñ¤W¥«Âd¥Í§Þ¦A«×¤jº¦,¯E¹©¥i¿×¸U¬õ¤§¤¤¤@ÂIºñ,¤£¹L³o¼Ë¤]¦n,§â¤@¨Çªü¬¶¥þ¬~¥X¥h,ªü¬¶¬Ý¨ì³o¼Ë¤@©w¨ü¤£¤F,¥i¥H¤jÁx¹w´ú¤U­Ó¤ë«ùªÑ¤H¼Æ1-5±iªº¤H¼Æ¤@¿õ¤j´î,¦Ñ¸Ü¤@¥y,ªÑ»ù¤£·|²æÂ÷°ò¥»­±¤Ó¤[,¨ä¥LªºªÑ¶Vº¦,´N¥Nªí¯E¹©ªº»ù­È¶V³Q§C¦ô,2e¦h¬üª÷±ÂÅvª÷ªº¼°±¡³£¯àªø¨ì±µªñ300,¨º»ò³æ³æ¥u¦³ºâ¤@¶µ¨ÅÀùªº60e¬üª÷ªº¯E¹©¬O¤£¾A­n¦b*30?¬O¤£¬O³o¼Ë§Ú¤£ª¾¹D?¤£¹LÁo©ú¤H¸Ó¶R¤°»ò¬Û«H¤j®a³£ª¾¹D
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/12/22 ¤U¤È 12:21:52²Ä 1416 ½g¦^À³
·PÁÂFaith¤j

¹ï¯E¹©ªº«H¤ß ¥D­n¬OCliff¤j ³s¦ê¤¤¬ã°|³ø§iªº¤À¨É»P±Ð¾É

ÁÙ¦³¤p©_¤j¬°§Ú­Ì±À´ú¨Ã²Î­p¤ÀªR¤¤¦ìPFSªºµ²ªG

µM¦Ó¦b822©|¥¼¸Ñª¼¤Î·s§Þ³N¤é·s¤ë²§ªº·í¤U

822»P¹ï¤âÃĪ«ªº¶i®i ©Î¦³¿à¤j®a«ùÄòªº§V¤O©MÃöª`

·PÁµ½¤H¤j©M¥xÁÞ¤j´£¨ÑLynparzaªº¸ê®Æ

¡§The FDA¡¦s approval is based on Phase II data in which the drug charted a 34% objective response rate for an average of 7.9 months.

Treatment with olaparib also led to progression-free survival (PFS) of 11.2 months versus 4.3 months on placebo.

¡KFor olaparib, the company is running concurrent Phase III trials in ovarian, gastric and breast cancers, hoping to win a string of approvals and cobble together a blockbuster.¡¨

Lynparza ¯à¥ÎÁ{§É¤G´Áªº¼Æ¾Ú ´NÀò±o§å­ã

À³¬O¼Ð¹v©Ê¡NÃĮĤΥ¼º¡¨¬ÃĪ« ¦Ó±o¨ì®Ö­ã?

¦³34%°Ñ»Pªº±wªÌ ¹F¨ìORR ÁöÁÙ¦³2/3ªº±wªÌ ¥¼¹FORRªº¼Ð·Ç

¦ý´N¤¤¦ìPFS¨Ó¬Ý À³ÁÙ¦³¤£¤Öªº±wªÌ ¬O³B©óSD¤@¬q®É¶¡

¥»¥H¬°ORR ¬O°w¹ïµû¦ô¤@½uÃĪ«©Ò³]­p ¦p¤µ«á½uÃĪ«¤]±Ä¦¹¼Ð·Ç

©Î³\¬O¹ï¥»¨­·sÃĪº«H¤ß ¤~¨Ï¥Î¤ñPFS §óÄY­Vªºµû¦ô¤è¦¡ Áö¦³¸ÕÅç®Éµ{ÁYµuªº®Ä¯q ¦ý¤]§ó®e©ö¦³¥¢±Ñªº­·ÀI

¦p¤µ³ø¾É¥ç´£¤Î ¸ÓÃIJ{¥¿¶i¦æ BRCA°ò¦]¬ðÅܧZ±_Àù¡B­GÀù¡B¨Å¸¢Àùªº¤T´ÁÁ{§É

¦³¸ê®ÆÅã¥Ü(¤£ª¾¥¿½T§_?)

¡§Mutations in BRCA1 and BRCA2 are uncommon, and breast cancer is relatively common, so these mutations consequently account for only five to ten percent of all breast cancer cases in women¡K.

Women with harmful mutations in either BRCA1 or BRCA2 have risk of breast cancer that is about five times the normal risk, and a risk of ovarian cancer that is about ten to thirty times normal. BRCA1 mutations typically confer a higher risk of breast and ovarian cancer in women than BRCA2 mutations.¡¨

¦³¦¹¬ðÅÜ°ò¦]ªº°ü¤k ¿©¨ÅÀù¤Î§Z±_Àùªº­·ÀI³£«Ü°ª ¦ý¤ñ¨Ò¤£°ª

¯E¹©»P¤§©Î³\¦U¦³¼Ð¹v¸s ­«Å|ªº¤ñ¨ÒÀ³¤£°ª ¦ý¤´­È±oÃö¤Áµo®i

°e³ø¤j¹ï©óCTL019¯«©_ÃĮĪº³ø¾É ¯uªº¦n¯«

¦ý¥J²Ó¤F¸Ñ¤§«á ©Î³\ÁÙ¦³¸ô­n¨«

¦³³o¨â­Óºô­¶ ©Î¥iÁA¸Ñ¨ä¤j­n

http://www.chop.edu/centers-programs/cancer-center/t-cell-therapy-ctl019#.VJVyXsAA

http://www.cancer.gov/cancertopics/research-updates/2013/CAR-T-Cells

¡§ The CD19 molecule is ubiquitously expressed throughout all stages of B-cell differentiation, but is not found on haemopoietic stem cells.

Since most B-cell leukaemias and lymphomas retain CD19 expression, it represents an excellent target for immunotherapy of these malignant disorders. ¡§

Àù¤ÆB²Ó­Mªº¶W°ª§Ü­ìªí²{²v ¤SÄÝ«D©TÅé½F §Î¦¨°ªCR %

µM³oºØªvÀø¤è¦¡ªº­­¨î ©Î¦b©ó­Ó¤H¤Æ

¥H°ò¦]­×¹¢§Þ³N±N§t¦³´c©Ê²Ó­Mªí­±§Ü­ìªº´O¦X°ò¦] ´Ó¤J¨C­Ó±wªÌªº¦ÛÅéT²Ó­M ®£»Ý­Ó§O¬°¤§

¥Ñ¤¶²Ð±oª¾ ³oºØÀøªk¬O¥H¤ÆÀøµL®Ä±wªÌ¬°¹ï¶H ©Î¦³¨äµLªk¤j¶q¦¬¯Ç¯f±wªº»Ùê

§Ú·Q °£«D§Þ³N¥i¥H¶i¨B¨ì§Q¥Î²§ÅéT²Ó­M¦Ó¤£·|³y¦¨±wªÌªº±Æ¥¸ §_«hÂ÷¤j¶qÀ³¥Î ¤j¶q¥Í²£ ©Î³\Áٻݮɤé (­Ó¤H°ò©óµLª¾ªº±ÀÂ_ ¤]³\¤w¦³§Þ³N¥i¥H¹F¦¨)

¥t¥~§Ú­Ì·Qª¾¹Dªº°ÝÃD ´N¬O¥¦¯à©µÄò¦h¤[¤£´_µo

¥Ñ©ó¦b¥¿±`ªº³y¦å·F²Ó­M¤W ¨Ã¥¼µo²{CD19 ¦]¦¹¤£·|³y¦¨§ðÀ»¥¿±`³y¦å·F²Ó­Mªº°Æ§@¥Î

¦ý³o¬O§_·N¨ý Àù·F²Ó­M¤W¤]¨S¦³CD19§Ü­ì?

°²¦p¦p¦¹ ³o»ò°ªªºCR²v ¨ä§@¥Î©Î³\¤]¥u¯àºû«ù¤@¬q®É¶¡ ¦p¬Y¨Ç¤ÆÀøÃĪ« ¦ÓµLªk²£¥Í®Úªvªº®ÄªG?

©Ò¥H

´NCAR-T²Ó­M§Þ³N¨Ó»¡ ¿ï¾Üªº¼Ð¹v§Ü­ì¦b¦U¦ÛÀù(·F)²Ó­Mªº¡¨²Ó­M¼Æ¦Ê¤À¤ñ¡¨ ©Î±N¥ª¥kPR ªºµ{«× ¦p822µM?

­Õ­Y§Q¥Î¦¹§Þ³N ±NSSEA4§Ü­ì´Ó¤J±wªÌ¦ÛÅé T ²Ó­M

¨Ã¥H MBC ªº NED ±wªÌ¹ï¶H ¬O§_·|¤ñ822±o¨ì§ó¦nªºÀø®Ä? ¥O¤H¦n©_

¥Ñ³o¨â­Ó¨Ò¤l

ÁöµM±i¸³»¡ GH µ¥§Ü­ì¦b MBC ±wªÌ¤¤ ¦³°ª¹F98%ªºªí²{²v

¦ýÁ{§É³]­p ¦p¦ó¨Ï¥~¤H§ó¯à²M·¡¤F¸Ñ822¼Ð¹vªvÀøªº©ú½T©Ê

¦b¥¼³Qº¡¨¬ÃĪ«ªº¥«³õ °ß¦³©ú½Tªº¼Ð¹vÃÄ®Ä ¤~¯à§l¤Þ¥@¬Éªº²´¥ú

¹ïFDA ¹ï±wªÌ Âå®v «OÀI¤½¥q ©Î±N§ó¦³»¡ªA¤O

¤í¯Ê±M·~°ò¦ªº¨¥½× »Ý­n±z¤j¤O«ü¥¿ ¤~·|Åý¤p§Ì¶i¨B

¬°¤F¦³¥þ­±ªºµø³¥ Åwªï¦³©Ò¥»ªºÅÞ¿èµû­z ¤£ºÞ±z¬O¸É¥¿ÁÙ¬O²§¨£

¤p§Ì³£±N·PÁ±zªº«ü¾É ÁÂÁÂ!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/12/19 ¤U¤È 10:51:44²Ä 1415 ½g¦^À³
²q·Q¤j

±z¤µ¤Ñ¯S§O·P©Ê³é^_^

¦³¦Ñ¯E¤Íªº¤ä«ù¯u¦n

³o¤@¸ô§Ú­Ì³­µÛ¯E¹©¤½¥q¦¨ªø....

§Ú³o´X¤Ñ¤]¤@ª½¦b«ä¦Ò

Maybe¤£°Ñ¥[©âÅÒ¤F

¦]¬°

­n¤¤ÅÒ¤£®e©ö

¦A¥[¤W»ù®t¤£¤j¡A·Qª½±µ§â­n©âÅÒªº³o´X±i¸Éº¡

´X¤Q¸U¹ï¤p§Ì¦Ó¨¥ÁÙ¦n

©Ò¥H¡A¤p§Ì¥þ®a³o´X±iªº¾÷·|¡AÅýµ¹¯E¤Í¤F

¯¬ºÖ¤j®a¤¤ÅÒ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/12/19 ¤U¤È 08:38:00²Ä 1414 ½g¦^À³
·íªì S.H ¤jÀ°§ÚÂà¶K¥»ª©®É

¤p§Ì´N»{¬°¯E¹©·|¬O¤@ÀÉ super highrise

«¢! ½Ð®ü²[§Úªº°g«H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gµ½¤H10137888  µoªí®É¶¡:2014/10/19 ¤U¤È 10:15:09²Ä 1413 ½g¦^À³
¤U­±³o«h·s»D, ¬L§i¤Ñ¤U, ½æÃĤ£¯à¥ú¾a¸ì¸ï, ÁÙ¬O­n¾a¹ê¤O - Àø®Ä.

¸¯Äõ¯À¥v§JÃļt¦b³°¾D»@ 150»õ¤¸³Ð¤Ñ»ù

Posted on 2014 ¦~ 09 ¤ë 21 ¤é by ±i®x·ì ¸ê®Æ¨Ó·½¡GÁp¦X·s»Dºô

­^°ê»sÃÄ¥¨ÀY¸¯Äõ¯À¥v§J¡]¤¤°ê¡^¤½¥q¡]GSKCI¡^¦b¤j³°¯A¶û°Ó·~¸ì¸ï®×¡A¤j³°´ò«nªø¨F¥«¤¤¯Å¤H¥Áªk°|¤µ¤Ñ«Å§P¡AGSKCI³Q§P³B»@ª÷¤H¥Á¹ô30»õ¤¸(¬ù·s¥x¹ô150»õ¤¸)¡A

³o¬O¨´¤µ¬°¤î¤j³°¶}¥Xªº³Ì¤j»@³æ¡A¸Ó¤½¥q¤¤°ê°Ï­t³d¤H°¨§J¡P¿à§Q¡]Mark Reilly¡^µ¥³Q§i¡A³Q§P³B¦³´Á®{¦D¤G¨ì¥|¦~¡C

·sµØªÀ¥ý«e³ø¾É¡A°¨§J¡P¿à§Q¦Û2009¦~1¤ë°_¡A¹ª°Ê¾P°â­û¤u¡u¤j¸v¸ì¸ïÂå°|¡BÂå¥Í¡vµ¥ÂåÀø³¡ªù¡A¿Ñ¨ú«Dªk©Ò±o¼Æ¤Q»õ¤¸¤H¥Á¹ô¡A

2012¦~´¿¥ý«á¦V¥_¨Ê¡B¤W®üµ¥¦a¤u°Ó¦æ¬F°õªk¤H­û©MÃö«Y¤H¦æ¸ì¡Aª½¦Ü2013¦~6¤ë³Q¬dÀò¡C

³ø¾ÉºÙ¡A¥h¦~7¤ë¡A¤j³°·í§½©ë¯d¸Ó¤½¥q¥|¦W³°Äy°ª¼h¡A«ü±±¸Ó¤½¥qªá¶O¤H¥Á¹ô30»õ¤¸¸ì¸ïÂå¥Í»P©x­û¡AÅýÂå°|©M¯f¤HÁʶR¸Ó¤½¥qªºÃÄ«~¡A

¨Ã§Q¥Î®È¦æªÀµ¥ºÞ¹D¡A±Ä¨ú¦æ¸ì©ÎÃÙ§Uµ¥§Î¦¡¡A¦V­Ó§O©x­û¡BÂå¥Í¤j¸v¦æ¸ì¡A¥H¥´¶}ÃÄ«~¦b·í¦aªº¾P°â¥«³õ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/10/16 ¤U¤È 01:51:37²Ä 1412 ½g¦^À³
¹Ç§AÅó±ø±ø¤j¡A

¡K¨ä¤¤ªº1/3¹ï·Ó²Õ114¤HÀ³¸Ó³£¤w¸gµo¯f¡K³o¥y¸Ü¤£¹ï¡APFS¤¤¦ì¼Æªº©w¸q­n¦A½T»{¡A°²³]¹ï·Ó²Õªº¤¤¦ì¼ÆPFS¥u¦³4­Ó¤ë¡A7¤ë·í¤ë¦¬®×ªº¹ï·Ó²Õ¨ì10¤ë©³¤]¤£¨ì¤@¥bªº¤H´c¤Æ¡A©Ò¥H²{¦b¹ï·Ó²Õ¨S¦³114¤H¨º»ò¦h´c¤Æ¡A¨Ì·Ó¡y¤é²±µû¦ô³ø§i¡z¨º¤@ª©ªº±À¦ô¡A¨Ì¤£¦Pªº±¡¹Ò°²³]¡A¨ì9¤ë©³ªº¹ï·Ó²Õ´c¤Æ¤H¼Æ¦b84~99¤H¤§¶¡¡A¦³¿³½ì¥i°Ñ¦Ò¡C

¡K¦ý¬O®É¶¡©¹«á¤S¶i¤J¤@­Ó¤ë¡A¥­§¡ªºPFS = X + 1, ¦ý¹ï©óOBI-822ªºPFS¤Ï¦Ó¼W¥[¬O 1 X 3/2 = 1.5..

¤p§Ì¬Ý¤£À´³o­I«áªºÅÞ¿è¬O¤°»ò¡AµLªk´£¨Ñ¥ô¦ó«Øij¡A¤p§Ì¥Î¤ñ¸û­W¤Oªº¤è¦¡¡A¨Ì·Ó¤¤¦ì¼ÆPFSªº©w¸q¡A±q2010¦~¨Ó¦¬®×ªº¤H¼Æ¨ì2013¦~6¤ë©³ªº¦¬®×¤H¼ÆºCºC±À¡A±À¥XªºPFS¤¤¦ì¼Æ¤]¥²©w»P¹ê»Úªº¼Æ¦r¦³»~®t¡A¦³¿³½ì¥i¥H°Ñ¦Ò¡y¤é²±µû¦ô³ø§i¡z¨º¤@ª©¡C

²¦Ó¨¥¤§¡A²{¦b¨C¼W¥[¤@­Ó¤ëªº®É¶¡¨S¦³«Å¥¬172¤H°µ´Á¤¤¤ÀªR¡A¹êÅç²ÕªºPFS¤¤¦ì¼ÆFPS´N·|¼W¥[¶W¹L1­Ó¤ë¡A¦Ü©ó822¼W¥[¤@­Ó¤ëªºPFS­È¦h¤Ö»ù­È¡A¬Û«H¦U¦ì¤j¤j¦Û¦³¦Û¤vªººâ½L©Î­pºâ¾÷¥i¥Hµû§P¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶À¤jÄ_10132519  µoªí®É¶¡:2014/10/16 ¤U¤È 01:31:20²Ä 1411 ½g¦^À³
°£¤F¯E¹©³Ð·s°ª ÁÙ¦³¤@¤ä ·|³Ð·s°ª «ø¥Ø¥H«Ý.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¹Ç§AÅó±ø±ø10135894  µoªí®É¶¡:2014/10/16 ¤U¤È 01:19:41²Ä 1410 ½g¦^À³
¥xÁÞ¤j¡A

ÁÂÁ±zªº»¡©ú¡A¤@´Áªº¼Æ¾Ú§Ú³£«Ü²M·¡°Õ¡C§Úªº·N«ä¬O«ü²{¦b¤T´Áªº¹êÅç¼Æ¾Ú¡A°²³]342¤H¥Ø«e¥­§¡¹êÅç¸g¹L¤é´Á¬OX­Ó¤ëªº¸Ü¡A¨ä¤¤ªº1/3¹ï·Ó²Õ114¤HÀ³¸Ó³£¤w¸gµo¯f¡C342¤H¤¤ªº2/3¹êÅç²Õ228¤H¦³¤Ö³¡¤À±wªÌµo¯f¡A¦ý¬O¤´¥¼¹F¨ì¨ä1/4ªº57¤H¡A¤w­P©óµo¯f¤H¼Æ³£ÁÙ¥¼¹F¨ì114+57=171¤HÁ`¤H¼Æ342¤Hªº¤@¥b¡A¨Ì³W¹º¬OµL¶·¶i¦æ´Á¤¤¤ÀªRªº¡C

¦ý¬O®É¶¡©¹«á¤S¶i¤J¤@­Ó¤ë¡A¥­§¡ªºPFS = X + 1, ¦ý¹ï©óOBI-822ªºPFS¤Ï¦Ó¼W¥[¬O 1 X 3/2 = 1.5¡AÁöµM§Ú¤£ª¾¹D¥Ø«eOBI-822¤T´Á¤j·§ªºPFS¬O¦h¤Ö¡A§Ú·Qªí¹F¬O¦pªG¤@ª½¨ì©ú¦~Q2³£µL»Ý´Á¤¤¤ÀªRªº¸Ü¡A¹ï©óOBI-822 PFS±N¬O¬Û·í¦³®Äªº¥[¤À

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/16 ¤U¤È 12:40:59²Ä 1409 ½g¦^À³
¹Ç§AÅó±ø±ø¤j:

³o¤@ÃD­n°Ý¤p©_¤j¥L¦³²`¤J¬ã¨s

OBI822/OBI821¬O¥Ñ¬ü°êª¾¦WÀù¯g¤¤¤ßMemorial Sloan Ketterin(MSKCC)§ÞÂà¦Ó¨Ó¡A®Ú¾Ú¸Ó¤¤¤ß·íªì¤p³W¼Ò°w¥½´Á¨ÅÀù¯f±wªº¸ÕÅçµ²ªGÅã¥Ü¡A4¦~(48­Ó¤ë)¤º¥ÎÃįf±w41%¥¼´c¤Æ¡A 48%±wªÌÄ~Äò¦s¬¡¶W¹L9¦~¦Ü10¦~(¥uÆ[¹î10¦~)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¹Ç§AÅó±ø±ø10135894  µoªí®É¶¡:2014/10/16 ¤U¤È 12:00:29²Ä 1408 ½g¦^À³
¦U¦ì¤j¤j¡A

¤p§Ì°²³]¥Ø«e¨C¹L¤@­Ó¤ë¡A¬O§_·N¿×µÛOBI-822 PFS¤S¥i±À¶i¼W¥[1.5­Ó¤ë©O?

¤p§Ì¬O¥Î2/3¹êÅç²Õ¡A1/3¹ï·Ó²Õ¤H¼Æ¦ô­pªº

¹êÅç²Õ 1 X 3/2 = 1.5

½Ð«ü±Ð¡AÁÂÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/15 ¤U¤È 05:30:32²Ä 1407 ½g¦^À³
1¤¤¥¡¬ã¨s°|°ê®a¥Í§Þ¬ã¨s¶é°Ï¥þ°Ï³¾Àý¹Ï·¥¬°§§Æ[ (2016¦~¤¤±Ò¥Î),¥¼¨ÓTFDA ­¹«~ÃĪ«ºÞ²z¸p·|¦b°ê®a¥Í§Þ¬ã¨s¶é°Ï¤º,

ÁÙ¦³°ê®a¹êÅç°Êª«¤¤¤ß,¯Î±Ò´f°|ªø±À°Ê°ê®a¥Í§Þ²£·~,¥\¤£¥i¨S

2¥D­n«Ø¿vª«¦p¤U

A.¥ÍÂåÂàĶ¬ã¨s¤¤¤ß B.®Ö¤ß¥DÃD¬ã¨s¤¤¤ß C.³ÐªA¨|¦¨¤¤¤ßD.¥Íª«¸ê°T¤¤¤ß E.¥Íª«§Þ³N¶}µo¤¤¤ß F.­¹«~ÃĪ«ºÞ²z¸p G.°ê®a¹êÅç°Êª«¤¤¤ß

3¯Î±Ò´f°|ªø»¡:³o¦¸BIOUSA¡]¬ü°ê¥Í§Þ¡^µû¦ô¡A¥xÆW¬ã¨s±ø¥ó³Ì¦n¡A¦bªk³W¡B¸êª÷¡B¤H¤~¡BÀô¹Ò»P¿ïÃD¤W¡A§Ú­ÌªºÀô¹Ò¬Oº¡¦nªº¡A¦¨¥\¬O¿ð¦­ªº¨Æ¡C¦bÀô¹Ò¤W¡A¥xÆW¤H¤f±K¶°«×¥þ¥@¬É²Ä¤G¡A¥B¦³µo®i¥Í§Þªº¶é°Ï¡Fªk³W­±¤S¸ò°ê»Ú±µ­y¡A§Ú­Ì¦³©M¬ü°ê¤@¼Ëªºªk³W¡A¹ªÀyµo®i¥Í§Þ·~¡F¦b¤H¤~¤W¡A¤£¥u¬O¥Í©R¬ì¾Ç¡A¤Æ¾Ç¡BÂå¾Ç¡B»s³y¤uµ{¡BºÞ²z¡Bªk«ß»P¦æ¾P¤H¤~¡A¥Í§Þ©Ò»Ý­nªº¤H¤~¥þ³¡³£¦³¡C¯à°÷µo®i¥Í§Þªº°ê®a¡A¥xÆW¦U¤è­±ªºµo®i³£¬O¨ã³Æªº¡A¥xÆW¸êª÷§ó¬O«D±`¥R¸Î¡A¥h¦~¬ü°ê¥Í§Þ·~§ë¸ê¸êª÷¬ù¤T¤Q¦Ü¥|¤Q»õ¬ü¤¸¡A¥xÆW«h¦³¤Q¤­»õ¬ü¤¸¡A¤µ¦~¤]¬O¤@¼Ë¡A§Ú­Ì¤ñ¬ü°ê¤p«Ü¦h¡A¦ý¹ï¥Í§Þ²£·~ªº§ë¸ê«o¬Û·í°ª¡Aªí¥Ü¥xÆW¤H¹ï³o²£·~¬O¦³«H¤ß»P¼ö±¡ªº¡A³o¬O¦n²{¶H¡C

4 ¥Ø«e¶i¤J¤@¤G¤T´ÁÁ{§ÉÃĪ«¬ù120¦hÁû,20´XÁû·sÃÄ¥¿¦b¶i¦æ²Ä¤T´ÁÁ{§É¸ÕÅç¡A­Y±q©ÎµM²v¨Ó¬Ý¡A¦³¤@¥bªº¾÷²v·|¦¨¥\

±N¶W¹L±i¸³»¡ªº3Áû·sÃĦ¨¥\¥xÆW´N¶i¤J¯à¬ãµoÃĪ«ªº°ê®a,³oªÑ¯à¶q¥¼¨Ó¤T¦~·|Ãzµo,§O©¿µø³o¤@¤d¸üÃø³{ÁͶÕ

http://gao.sinica.edu.tw/shiwusuo/engineering/sample/Biotech.pdf

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/10/15 ¤W¤È 08:15:17²Ä 1406 ½g¦^À³
¥xÁÞ¤j

·PÁ±zÀ°¤j®a¾ã²zªº¸ê®Æ

¥[¤WCliff¤j§ä¨ìºÃ¦ü888ªº¸ê®Æ

§q(§Ô¤£¦í³Û¤@Án~~¤ÓÆg¤F)

·PÁ»{¯u.¨¯­Wªº¤j®a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/14 ¤U¤È 11:49:47²Ä 1405 ½g¦^À³
¦U¦ì¤j¤j:

1 ¥H¯E¹©ªº¬ãµo§Þ³N°t¦X¾Ç³N³æ¦ì»PÂå¾Ç¤¤¤ßªº¬ã¨s¯à¤O¥[«ù ,¥[¤W°w¦¸¦h4°w ¾¯¶q¦h20·L§J,§ÜÅé«ùÄò®É¶¡¤ñ¤@´Áªø,¦p¤j®a©Ò¨¥¨C¹j3­Ó¤ë¦A¥´¤@°w, Åý¯f±w«O¦³§ÜÅé,´Á±æ±µªñ¤@¯ë¤H¥­§¡¹Ø©R(µ¥¦Pªv¡ )©Î¤¤¦ì¼ÆÁ`¦s¬¡´Á¯à¹F8¦~¥H¤W(¦p¤@´ÁÁ{§É¤@¼Ë®ÄªG)¥Ø«e³Ì¦nªºHER2¶§©ÊÂù¼Ð¹vÃÄ2014¦~9¤ë¤U¦¯¤½§iÁ`¦s¬¡´Á¬ù56.5­Ó¤ë(¬ù4.6¦~) PFS 18.7­Ó¤ë ,

Perjeta,Herceptin and docetaxel chemotherapy(56.5­Ó¤ë) PK Herceptin and chemotherapy (40.8­Ó¤ë) median PFS 18.7 ­Ó¤ë PK 12.4 ­Ó¤ë

2 Åý¥½´Á¨ÅÀùÅܦ¨ºC©Ê¯f¯f±w¥i±µªñ¤@¯ë¤H¥­§¡¹Ø©R(Ãzµo©Ê·sÃÄ)©Î¤£¯àªv¡¦ý¥i©µ¹Ø(¾_¾Ù©Ê·sÃÄ)¬OOBI822§V¤O¥Ø¼Ð

3 ª½±µªv¡¥½´ÁÀù¯g(¥P¤¦§®ÃÄ)¬OOBI833§V¤O¥Ø¼Ð,¦pªG¯à§ä¨ì§ó¦nªº¦õ¾¯,ÅýIGG§ÜÅé±q3¦Ü6­Ó¤ë ©µªø¦Ü¥H¦~¬°³æ¦ì­pºâ,

«K¦³¾÷·|ªv¡¥½´ÁÀù¯g

4 OBI822 OBI833 ¤]¦³¾÷·|¹ï¦­´Á¨ÅÀùª½±µªv¡ OBI833°w¹ï¸û¥û®«ªºÀù¯g¦pªÍÀù ¯ØŦÀù ­GÀù¤Î§@¬°¹w¨¾©Ê¬Ì­]

5 °|ªø¥x¤jºtÁ¿µû¦ô OBI822«e­±¬ãµoªº´XºØÀù¯g¦pªGÀø®Ä¯S§O¦n¤£±Æ°£ Out label usage ª½±µÀ³¥Î¨ì¨ä¥¦¤Q´XºØ

Àù¯g©Îª½±µ¥Î¦b¥¼±oÀù¯g¤§¹w¨¾©Ê¬Ì­]¨Ï¥Î

¥H¤W¬O¹ï¥xÆW¯E¹©ªº´Á¬ß,´£¨Ñ°Ñ¦Ò,¨Ã½Ð¹LÂo¸ê°T,¸Ô¥[§PÂ_,ºÞ±±§ë¸ê­·ÀI ¦p¦³¿ù»~½Ð´£¥X§ó¥¿

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G£~£~10134649  µoªí®É¶¡:2014/10/14 ¤U¤È 10:41:08²Ä 1404 ½g¦^À³
PhaseIªº¨º¨Ç¯f±w,¦n¤F´N¦n¡C­Y¦n¤F,¹L´X¦~ÅÜ®t¤F,À³¸Ó«ùÄò°l¥[,·íºC©Ê¯fÅý¥LÄ~Äò¬¡,¦Ó¤£À³¸Ó¥áµÛÅý¥L«ùÄò´c¤Æ,¤@ÃäÆ[¹î´c¤Æ¤@Ãä²Î­p¡C³oºØ¯f±w«ùÄò¥´´N·|«ùÄò¬¡¡C©Ò¥H,§Ú»{¬°¯f±w¤À¤TºØ,¨ä¤@¥´§¹¤E°w´N«ùÄòNED,¨ä¤G¥´¤E¯u¥²¶·Ä~Äò¨C®æ¤@¬q®É¶¡¥´¤@°w¥iÁקK´c¤Æ,¨ä¤T¥´¤E§¹¥þµL®Ä¡C²Ä¤GºØÀ³µø¬°ºC©Ê¯f,´N¹³¿}§¿¯f¤@¼Ë¤@½ú¤l»Ý«ùÄò¥´ª½¨ì²×¦Ñ¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p±¶10135877  µoªí®É¶¡:2014/10/14 ¤U¤È 10:25:54²Ä 1403 ½g¦^À³
¤E°w¥H¤W®£©È¬O¥|´Á¤~¦³¾÷·|¹êÅç,²{¦b3´ÁÀ³¤´¦b¤E°w¤º
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G£~£~10134649  µoªí®É¶¡:2014/10/14 ¤U¤È 09:33:46²Ä 1402 ½g¦^À³
¨S¿ù!À³¸Ó«ùÄò¥´,§â·s²£¥Íªº¨ãGHªºÀù²Ó­M©MÀù·F²Ó­M¥´±¼,¥i¥H§â³o¨Ç¯f±w·íºC©Ê¯f±w¡C¤£À³¸Ó¥´¤E°w´N°±!³o­Ó°±¯u­n©R!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÂŤÑ10138178  µoªí®É¶¡:2014/10/14 ¤U¤È 09:22:35²Ä 1401 ½g¦^À³
Phase 1 : 5¦~¥H¤W20/27(74.07%), 8¦~¥H¤W15/27(55.56%)

Gb5¦b¤@¯ë¨ÅÀù²Ó­Mªºªí²{²v¹F77.5%¡A¦Ó©ó¨ÅÀù·F²Ó­M«h¬°62.5%¡C

74.07%»P77.5%«Ü±µªñ, 55.56%»P62.5%¤]«Ü±µªñ, ªí¥Ü¬Æ»ò·N¸q©O?

¬O§_ªí¥ÜOBI-822/821¤]¯à®ø·À±a¦³Gb5ªºÀù²Ó­M©MÀù·F²Ó­M©O?

­Ó¤Hªº²q´ú¡@³oªí¥Ü¥Îªº¾¯¶q©M°w¼Æ¤£°÷¡@¦pªG°÷ªº¸Ü¡@°£¤F¢±­Ó¤@¦~´_µo¡@¢±­Ó¨â¦~´_µo¤§¥~ªº¸ÕÅç¹ï¶H¡]¥i¯à¨S¢Õ¢ÖÃþ§Ü­ì¡^À³¸Ó¨ä¥Lªº¢²¦~¡@¢³¦~¡@¢´¦~¡@¢µ¦~¡@¢¶¦~´_µoªº¹ï¶H³£·|¤j´T¼W¥[¦s¬¡´Á¡D

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GIriswu10136250  µoªí®É¶¡:2014/10/13 ¤W¤È 10:05:15²Ä 1400 ½g¦^À³
«D±`»{¦P²q·Q¤jªº¬Ýªk.¬ì¾Ç´N¬O¬Ý¼Æ¾Ú.µ¥¦³¦nªº¼Æ¾Ú¤j®a¦A¨Ó¼ÖÆ[¸ÑŪ¥i¯à¤ñ¸û¦n.«Ü¤£§Æ±æ¦A¬Ý¨ì°ò¨Èªºª¬ªp­«ºt.§Ú­Ó¤H¬O¹ïªÑ²¼§Ù·V®£Äߪº.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p±j10137673  µoªí®É¶¡:2014/10/13 ¤W¤È 08:44:46²Ä 1399 ½g¦^À³
Serenity¡¦s Journey

¤j®a¦n¡I§Ú§Æ±æ¤@¤Á¶¶§Q¡C¨º§A¯àÅé·|¨ìªº¯¬ºÖ±z¦¬¨ìªº¨C¤@¤Ñ¡C§Ú¦^¨ì®a¸Ì¡A±qMDACC©M§Ú©Ò¦³ªº´ú¸Õ¦^¨Ó¤F·¥¦nªº¡I·PÁÂ¥D¡I¥­¦w¤F¡I XOX¥­ÀR

´ú¸Õµ²ªG¦n¹³«Ü¦n

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/10/13 ¤W¤È 08:40:14²Ä 1398 ½g¦^À³
«D±`·PÁ¤j®aªº¸ê®Æ ¤×¨äCliff¤jªº¿@ÁYºëµØª©

ªø¤[¥H¨Ó §xÂZªº°ÝÃD¶°¤¤¦b822¨ì©³¦³¦h¦n

¬JµM§Ú­Ìª¾¹DGHµ¥¤TºØ§Ü­ì¦s¦b±wªÌªº¤ñ¨Ò·§ªp

¤]¬ù²¤ª¾¹DGH±wªÌªº¶§©Ê²Ó­M¼Æ¤ñ¨Ò¤Î¤¤¦ì¼Æ

¤p§Ìªº·Qªk Â\Àú¦bCliff¤j(ÁöµM¨S©ú»¡) £~£~¤j »P ¤p©_¤j¤§¶¡

°²¦p822§ÜÅé¥u¯àµ²¦X¨ã¦³GHµ¥§Ü­ìªºÀù²Ó­M ¨Ã§â¥¦µõ¸Ñ

¥BµL¨ä¥L¤Þµo§Ú­Ì¤£ª¾ªº¾÷¨î¥i¥H®ø·À¨ä¥L¤£¨ãGHªºÀù²Ó­M

¨º»ò¬O§_´N¬O»¡ ±wªÌGHªº¶§©Ê²Ó­M¼Æ¤ñ¨Ò¤Î¤¤¦ì¼Æ ¹ï©ó§PÂ_ÃÄ®Ä ´N¬Û¹ï¦³°Ñ¦Ò»ù­È

¤HÅé¬O½ÆÂøªº Àù²Ó­Mªº¥Íªø²¾Âà¾÷¨î §K¬Ì¨t²Îªº§ÜÀù¤è¦¡ ¬ì¾Ç®a³£¤´¦b¬ã¨sºN¯Á¤¤

¹L¥h¦³³\¦h ª¾¨ä¤@ ¤£ª¾¨ä¤GªºÁ{§É¥¢±Ñ ¥i¯à¬O¹B®ð¤£¦n ±N¦¸­n¼vÅT¦]¤l»~»{¬°¥D¦]¤l ªºµ²ªG

²¦³º¤HÅé¥Í¤Æ¤ÏÀ³¤´¦³³\¦h¥¼ª¾ ©Ò¥H·sÃĶ·¥HÁ{§É¸ÕÅç¨Ó´ú¸Õ¨ä¦b¤HÅ餤ªº¾ãÅé¤ÏÀ³ªí²{

¤j®a´Á±æ³£«Ü°ª

°²¦p822¯à±N±wªÌ¥Ñªì¤J¸ÕÅç®Éªº«DNED ÂରNED ¨º¯uªº¬O¥P¤¦§®ÃĤF

¤p§Ì¹ï¯E¹©ªº´Á±æ ¥u§Æ±æ¥L¤ñ²{¦æÃĪ«±j¤W50%´Nº¡·N¤F

¦ý³o¥i¯à¤w¬O«ÜÃøªº¼Ð·Ç¤F

¤p§Ì¬O¹ï¬ì¾Ç¬O°È¹ê¬£ «D®öº©¬£

¦ý¹ï¤@ºØ»â°ì¤F¸Ñ¦³­­ §Ú¶É¦V©ó¸Ñª¼«á¦A¨Ó®öº©

«D±M·~ªº·Qªk ½Ð¤j®a¯º¯º´N¦n ÁÂÁÂ!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/10/13 ¤W¤È 08:38:49²Ä 1397 ½g¦^À³
S¤p©j

excellent

28¤ÀÄÁ«e

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gµ½¤H10137888  µoªí®É¶¡:2014/10/13 ¤W¤È 01:58:08²Ä 1396 ½g¦^À³
«D±`·PÁª©¥Dªº®¦¼w, Åý¯E¹©¦b¤W¥«Âd«á, ¤´µM«O¯d¥»ºô, Åý²³¯E¤Í¦b¥»ºôÄ~Äò¶°«ä¼s¸qªº°Q½×, »P¯E¹©¤@°_¦¨ªø§§¤j.

¯E¹©³o¦W¦r¨ú±o¤Ó¦n¤F - í©T§§¤j.

¥xÁÞ¤j,

¦Ñ¯Î¦b±z¹Ú¤¤ªº«üÂI, "¨ÅÀù¥½´ÁÃÄOBI-822¥¼¨Ó¦³¤T±ø©R¹B¨«¦V", ¦¹©R¹BÀ³¸Ó¬O«ü¥½´Á¨ÅÀù±wªÌªº©R¹B.

A. ª½±µªv¡¥½´Á¨ÅÀù : ©R¹B¦nªº¥½´Á¨ÅÀù±wªÌ, ¥»¨­ªº§K¬Ì¨t²Î¤´µM°·¥þ, ¥i¯à¦û55%~60%.

B. Åý¥½´Á¨ÅÀùÅܦ¨ºC©Ê¯f, ¯f±w¥i±µªñ¤@¯ë¤H¥­§¡¹Ø©R : ©R¹B¤£¿ù, ¥»¨­ªº§K¬Ì¨t²ÎÁٺⰷ¥þ, ¥´§¹ªvÀøªº9°w, ¥H«á¨C3­Ó¤ëÀˬd¤@¦¸, »Ý­n®É¦A¸É¥´¤@°w.

C. ¤£¯àªv¡, ¤]¤£¯àÅý¥½´Á¨ÅÀùÅܦ¨ºC©Ê¯f, ¦ý¥i©µ¹Ø : ©R¹B¸û®tªÌ, ¥»¨­ªº§K¬Ì¨t²Î¤w¤£°·¥þ, »Ý­n´M¨D¨ä¥¦¦X¾AªºÃÄ, ©Îµ¥¥H«áOBI-888¦¨¥\¤W¥«.

´¼Àºªº¯ØŦÀù·sÃÄPEP02 (Merrimack MM-398), Merrimack¦A±ÂÅvµ¹Baxter(outside the U.S. and Taiwan)ªº·s»D, §Ú¤]¬Ý¹L.

Merrimack¤jÁÈ, ´¼ÀºªºÀò§QÁöµM¤]¸òµÛ¼W¥[, ¤£¹L¤´µM¬O±i¸³»¡ªº"¤p½T©¯", ¦pªG¥H«á¦¨¥\¤W¥«, ¾P°â¶q¦p¦ó, ¤´¦³«ÝÅçÃÒ, ²¦³º¤£¬O³Ì¦nªº¯ØŦÀùªvÀøÃÄ.

ÁÙ¬O¯Î°|ªø©M±i¸³¦³²´¥ú©M¶¯§Ó, ­n³Ð¥ß¦Û¤vªº¥xÆW«~µP, ¤é¤l¤@¤Ñ¤Ñªº¼õ¹L, ²×±N¨£ÃÒ¯E¹©¦bÀù¯g·sÃĪº©_´º©M©_ÂÝ.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/12 ¤U¤È 09:51:41²Ä 1395 ½g¦^À³
Faith¤j «Ü¦³³Ð·N ÃĤ£¦b¦h ¦³ÁÞ«hÆF

¦A¸É¥R2­Ó

ÃĤ£¦b¦h ¦³¹v«hÆF

ÃĤ£¦b¦h ¦³®Ä«hÆF

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/10/12 ¤U¤È 09:36:28²Ä 1394 ½g¦^À³
¸É¥R

¥xÁÞ¤j

±zÆF·P¨Ó¤F¤§«á

¤å«ä¬u´é¤U

¼g±o¯uªº«Ü¦n

¤åµ§§ó¤W¤@¼h¼Ó¤F

Æg

·PÁÂ¥»ºô¤Îª©¥D

¥H«á¤j®a¤´¥i¦b¦¹°Q½×

¥H«eªº¸ê®Æ¤S¥i«O¯d¤U¨Ó

Åý¤j®a¨£µý¯E¹©ªº¦¨¥\¾úµ{

¤WÂd«áªº¤@¤Á¤@¤Á±N§óºëªö

¥[ªo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/12 ¤U¤È 09:30:35²Ä 1393 ½g¦^À³
¦U¦ì¤j¤j:

¦³¤@«h·s»D«Ü­«­n¤j®a©¿²¤¤F,´¼Àº¥H2.2»õ¬ü¤¸¦b¤G´ÁÁ{§É®É§â¯ØŦÀùÃÄMM-398±ÂÅvµ¹MERRIMACK ,MERRIMACK §¹¦¨¤T´ÁÁ{§É«á¦A¥H9.7»õ¬ü¤¸¦A±ÂÅvµ¹BAXTER,¤T´Á±ÂÅv ¤G´Á±ÂÅvª÷ ®t 4.4­¿ ´¼Àº¦pªG¾Ç¯E¹©²{¼W¦Û¦æ°õ¦æ¤T´ÁÁ{§É«á¦A±ÂÅvÀ³¥i¦h225»õ¶i±b,Á¤ÁÙ¬O¦Ñªº»¶,¤@Áû¤pÃĤT´Á±ÂÅvª÷±µªñ10»õ¬ü¤¸ (Á`¦s¬¡´Á¼W¥[1.9­Ó¤ë 6.1­Ó¤ë ¤ñ 4.2­Ó¤ëp=0.012)

MM-398 Áp¦X 5-fluorouracil and leucovorin (¹êÅç²Õ¥ÎÃÄ)

5-FU and leucovorin (¹ï·Ó²Õ¥ÎÃÄ)

As a monotherapy, MM-398 had a 4.9 month median overall survival but did not achieve a statistically significant advantage compared to the control arm.

³æÃÄMM-398ªvÀø¤¤¦ì¼ÆÁ`¦s¬¡´Á4.9­Ó¤ë»P¹ï·Ó²Õ¤ñ¸û¥¼¹FÅãµÛ®t²§

¥¼¨ÓOBI822 ¨ÅÀù¤Î§Z±_Àù ÁÞ´¹¤ù¦× ¬r±ìµß¯À ¼Ú¤é±ÂÅv©Î¦æ¾P¦X§@ ªÑªF±N±H¤©«p±æ

https://propthink.com/merrimack-baxter-tie-pancreatic-cancer-drug

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/10/12 ¤U¤È 08:21:04²Ä 1392 ½g¦^À³
·PÁª©¥D

³o¨ÇÄ_¶Qªº¸ê®Æ¤]¥i«O¯d¤U¨Ó

¦A¦¸·PÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/10/12 ¤U¤È 06:59:18²Ä 1391 ½g¦^À³
¥xÁÞ¤j

±z§Î®eªº«D±`¦n

¦³¥y¸Ü»¡

¤s¤£¦b°ª ¦³¥P«h¦W ¤ô¤£¦b²` ¦³Às«hÆF

¥H«á­n¦h¥[¤@¥y

ÃĤ£¦b¦h ¦³ÁÞ«hÆF¡C«¢«¢«¢

·PÁ±zµL¨pªº¤À¨É

ªü¬Â¤j ¨ì¤é¥»­Y¦³¾÷·|­nÀ°¦£«Å¶Ç¯E¹©³á

·Q¦^¥xÆW®É ÅwªïÀH®É¦^¨Ó ³o¸Ì­YµL°Q½×°Ï¤F

§Ú­ÌMobil 01¡u¯E¤Í­Ñ¼Ö³¡¡v¨£

¨ä¹ê¤½¥q¤W¥«Âd«á¥»ºôÁÙ¬O·|«O¯d°Q½×°Ïªº¡A

Åwªï«B·sª¾Ä~Äò¦b¦¹§@°Q½×¡A¥»ºôÁÙ¬O«ÜÅwªï¦U¦ìªº¡AÁÂÁ¡IBYª©¥D

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G£~£~10134649  µoªí®É¶¡:2014/10/12 ¤U¤È 05:18:13²Ä 1390 ½g¦^À³
¤p©_¤j!«D±`ÁÂÁ±z¸Ñ´b¡C©Ò¥H¦³³o¨ÇÁÞÃþ¼Ð»xªº²Ó­M¯S§O´c¬r,¯àÄè·À¥¦­Ì´N¯S§O¦³¥Î¡C´Ý¯dªº­è¦n³£¬O¯Ê¥F³oÃþÁÞÃþªº,¤]¬O¤ñ¸û¤£¨º»ò¥i©Èªº¡C³o¬O§Ú¥~¦æ¤Hªº²z¸Ñ,ÁöµM¥~¦æ,¦ý¬O¿ï¾Ü¹ï¤F©ÒÁȪº¿ú«o¤@¤ò¤]¤£¤Ö¡C¨º¨Ç¬ì¾Ç®a©ÎÂå®v°µ¥X­«­n°^Äm,¦pªG¨S¤j¶q«ùªÑ,¤]¤£¤@©wÁȤñ§Ú­Ì¦h¡C«D±`·PÁ³o¨Ç¬ì¾Ç®a,Âå®v¥H¤Îª©¤W¤j¤j¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý£«¬Â10136621  µoªí®É¶¡:2014/10/12 ¤U¤È 04:13:51²Ä 1389 ½g¦^À³
¯E¹©¬O§Ú¶Rªº²Ä¤@¤ä¥¼¤W¥«ªÑ²¼,¥»¨Ó¥u·Q©ñ3¦~.²{¦b¸g¹L¦U¦ì¤j¤j¤£Â_¤ÀªR§ä¸ê®Æ,«H¤ß¸òµ½¤H¤j¤@¼Ë¦Ê¤À¦Ê,·Q­n¸ò¯E¹©¤@°_¦¨ªø§â´¤Ãø±o¾÷·|.¹L¤@¬q®É¶¡¥i¯à´N¦^¤é¥»,³oªO­±¤]ÀH¯E¹©¤WÂd®ø¥¢,À³¸Ó¨S¦³ªO­±¥i¥H¦A°Q½×¯E¹©,·|¥Ã»·°O±o¦U¦ì¤j¤j!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/10/12 ¤U¤È 03:51:16²Ä 1388 ½g¦^À³
£~£~¤j¡A

´I¶°«×¤w¸g«Ü±µªñ¡A¦ý²Ó­M¼Æ¦Ê¤À¤ñ¤~¯àºë·Ç¶Ç¹F³oÆ[©À

NED¬OPET±½ºËªº»ö¾¹Åã¥Ü

¬y¦¡²Ó­M»ö¬O·LÆ[ªº²Ó­M¼Æ¦ôºâ

Àù²Ó­M©MÀù·F²Ó­M¦b«Ü§Cªº¤ô·Ç¤U¡APETÀË´ú¤£¥X¨Ó

¥B¦³GH¨t¦CªºÀù²Ó­M©MÀù·F²Ó­M³QÄè·À«á

Àù²Ó­Mªº¼W¥Í¯à¤O·|´î®z

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/12 ¤U¤È 03:49:56²Ä 1387 ½g¦^À³
Y¬Â¤j:

¥¿¬Oµ½¤H¤jªº¶K¤å,¥t¥~¤@ª©¤é²±µû¦ô³ø§i ,§Ú7¤ë8¤é¤È9ÂI39¤À¶K¤å½Í¨ì·F²Ó­M,µ½¤H¤j¦b1®É¦h«K¶K¥X¤@½g§óºë±m¶K¤å,

¥i¨£¥L¦­¤w¯Ý¦³¦¨¦Ë,¥»¦¸¥L¤Ñªù¬}¤§®È«á,«e´X¤Ñ¦b¥»ª©¶K¤å»y­«¤ßªø,¨â½g¶K¤å¬Û®t¨â­Ó¦h¤ë,»á¦³²§¦±¦P¤u¤§§®

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý£«¬Â10136621  µoªí®É¶¡:2014/10/12 ¤U¤È 03:13:32²Ä 1386 ½g¦^À³
Phase 1 : 5¦~¥H¤W20/27(74.07%), 8¦~¥H¤W15/27(55.56%)

Gb5¦b¤@¯ë¨ÅÀù²Ó­Mªºªí²{²v¹F77.5%¡A¦Ó©ó¨ÅÀù·F²Ó­M«h¬°62.5%¡C

74.07%»P77.5%«Ü±µªñ, 55.56%»P62.5%¤]«Ü±µªñ, ªí¥Ü¬Æ»ò·N¸q©O?

¬O§_ªí¥ÜOBI-822/821¤]¯à®ø·À±a¦³Gb5ªºÀù²Ó­M©MÀù·F²Ó­M©O?

(³o¬Oµ½¤Hªº¶K¤å,¥xÁÞ¤j«üªº¬O³o¬q§a!)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GCliff10135274  µoªí®É¶¡:2014/10/12 ¤W¤È 01:22:58²Ä 1385 ½g¦^À³
·PÁ¤p©_¥S¡I¹ê¦b«Ü©êºp¡A­«·s§ó¥¿©ó«á¡C¡]³o´N¬O¤W¯Z®É¶K¤åªº«á¿ò¯g¡^

2014/10/11 ¤U¤È 05:21:43ªº¨º¤@½g¶K¤å¡A³Â·Ðª©¥D§R°£¡A¥H§K²V²c¡A·PÁ¡I

I.2008¦~½×¤å¡GTable.1¡GGH¡BSSEA-3

¡]i¡^GHªí²{²v¡G53­ÓÀËÅ餤¡A28­ÓÀËÅç¤FGH&SSEA-3¡A¥t13­Ó¥uÀËÅçGH¡C28+13=41

¨ÅÀù²Ó­M¡G ¤H¼Æªí²{²v¡G61¢M¡]25/41¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G? ¢M¡]24.4-79.2¢M¡^

¨ÅÀù·F²Ó­M¡G¤H¼Æªí²{²v¡G20¢M¡]8/40¡Aµù¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G? ¢M¡]9.7-71.0¢M¡^

µù¡G41­ÓÀËÅ餤¡A¦³¤@­ÓÀËÅ餣§tCD24-CD44+¦¸¸s¡A³Q§P©w¬°¤£¬O·F²Ó­M¡A©Ò¥H41-1=40¡C

¡]ii¡^SSEA-3ªí²{²v¡G53­ÓÀËÅ餤¡A28­ÓÀËÅç¤FGH&SSEA-3¡A¥t12­Ó¥uÀËÅçSSEA-3¡C28+12=40

¨ÅÀù²Ó­M¡G ¤H¼Æªí²{²v¡G77.5¢M¡]29/40¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G? ¢M¡]24.3-70.4¢M¡^

¨ÅÀù·F²Ó­M¡G¤H¼Æªí²{²v¡G62.5¢M¡]25/40¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G? ¢M¡]5.0-58.4¢M¡^

II.2012±M§Q¤å¡GTable.3¡GSSEA-3¡BSSEA-4

¡]i¡^SSEA-3ªí²{²v¡G35­ÓÀËÅé

¨ÅÀù²Ó­M¡G ¤H¼Æªí²{²v¡G71.4¢M¡]25/35¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G40.5¢M¡]24.3-70.4¢M¡^

¨ÅÀù·F²Ó­M¡G¤H¼Æªí²{²v¡G65.7¢M¡]23/35¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G24.3¢M¡]5.0-58.4¢M¡^

¡]ii¡^SSEA-4ªí²{²v¡G35­ÓÀËÅé

¨ÅÀù²Ó­M¡G ¤H¼Æªí²{²v¡G91.4¢M¡]32/35¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G43.7¢M¡]4.0-78.1¢M¡^

¨ÅÀù·F²Ó­M¡G¤H¼Æªí²{²v¡G88.6¢M¡]31/35¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G37.1¢M¡]5.6-83.6¢M¡^

¥H¤W¡C

­n»¡GH¡BSSEA-3©ÎSSEA-4¦bÀù¡]·F¡^²Ó­M¤¤©Ò¦ûªº¤ñ¨Ò¦³¦h¤Ö¡A­n¬Ý¬O«ü¡u¤H¼Æªí²{²v¡vÁÙ¬O«ü¡uÀù¡]·F¡^²Ó­Mªº²Ó­M¼Æ¦Ê¤À¤ñ¡v¡A³o»ò¤ÖªºÀËÅé¼Æ°Ñ¦Ò´N¦n¡A¤Ó°õµÛ©ó¼Æ¦r·|¦³¿ù»~´Á«Ý¡Aµ¥342¦ìªº¼Æ¾Ú¥X¨ÓÀ³¸Ó·|¤ñ35¦ì¡B40¦ì¡B53¦ì¨Ó±o¦³·N¸q¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G£~£~10134649  µoªí®É¶¡:2014/10/12 ¤W¤È 12:00:54²Ä 1384 ½g¦^À³
½Ð°Ý:¡u²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡v¬O§_¬Û·í©ó§Ú­Ì«UºÙªº¡u´I¶°«×¡v?¨º»ò,¬Ý°_¨Ó¤£½×¬OÀù²Ó­M©ÎÀù·F²Ó­M³£¦³¤@¤j¥b¥´¤£¨ì,´Nºâ±¡ªp¦nªº70%¤]ÁÙ¦³30%¥´¤£¨ì¡C¨º»ò¦p¦ó¥X²{NEDªºª¬ºA?¬O§_¥´±¼¤@¥b¤§«á,³Ñ¤Uªº§K¬Ì¨t²Î¦³¯à¤O¶i¦æ²M°£?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/10/11 ¤U¤È 10:59:20²Ä 1383 ½g¦^À³
·PÁÂCliff¤jªº¤@¦¸¸Ñ¨M¡I

¦£¤¤¿ù¶K¤F¤@±Æ¼Æ¦r

Table1¨Ã¨S¦³´£¨Ñ²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡A¥u¦³range

¦ýSSEA3¦b2012±M§Q¤å¤S¥X²{¤@¦¸

¥u¦³G-H¨S§ä¨ì

¦ý³o¹ï©ó¾ãÅ骺Æ[©À¼vÅT¤£¤j¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GCliff10135274  µoªí®É¶¡:2014/10/11 ¤U¤È 05:21:43²Ä 1382 ½g¦^À³
¤@¦¸¸Ñ¨M¡C

I.2008¦~½×¤å¡GTable.1¡GGH¡BSSEA-3

¡]i¡^GHªí²{²v¡G53­ÓÀËÅ餤¡A28­ÓÀËÅç¤FGH&SSEA-3¡A¥t13­Ó¥uÀËÅçGH¡C28+13=41

¨ÅÀù²Ó­M¡]Non-BCSCs¡^¡G¤H¼Æªí²{²v¡G61¢M¡]25/41¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G25¢M¡]24.4-79.2¢M¡^

¨ÅÀù·F²Ó­M¡]BCSCs¡^¡G¤H¼Æªí²{²v¡G20¢M¡]8/40¡Aµù¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G8¢M¡]9.7-71.0¢M¡^

µù¡G41­ÓÀËÅ餤¡A¦³¤@­ÓÀËÅ餣§tCD24-CD44+¦¸¸s¡A³Q§P©w¬°¤£¬O·F²Ó­M¡A©Ò¥H41-1=40¡C

¡]ii¡^SSEA-3ªí²{²v¡G53­ÓÀËÅ餤¡A28­ÓÀËÅç¤FGH&SSEA-3¡A¥t12­Ó¥uÀËÅçSSEA-3¡C28+12=40

¨ÅÀù²Ó­M¡]Non-BCSCs¡^¡G¤H¼Æªí²{²v¡G77.5¢M¡]31/40¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G29¢M¡]24.3-70.4¢M¡^

¨ÅÀù·F²Ó­M¡]BCSCs¡^¡G¤H¼Æªí²{²v¡G62.5¢M¡]25/40¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G25¢M¡]5.0-58.4¢M¡^

II.2012±M§Q¤å¡GTable.3¡GSSEA-3¡BSSEA-4

¡]i¡^SSEA-3ªí²{²v¡G35­ÓÀËÅé

¨ÅÀù²Ó­M¡]Non-BCSCs¡^¡G¤H¼Æªí²{²v¡G71.4¢M¡]25/35¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G40.5¢M¡]24.3-70.4¢M¡^

¨ÅÀù·F²Ó­M¡]BCSCs¡^¡G¤H¼Æªí²{²v¡G65.7¢M¡]23/35¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G24.3¢M¡]5.0-58.4¢M¡^

¡]ii¡^SSEA-4ªí²{²v¡G35­ÓÀËÅé

¨ÅÀù²Ó­M¡]Non-BCSCs¡^¡G¤H¼Æªí²{²v¡G91.4¢M¡]32/35¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G43.7¢M¡]4.0-78.1¢M¡^

¨ÅÀù·F²Ó­M¡]BCSCs¡^¡G¤H¼Æªí²{²v¡G88.6¢M¡]31/35¡^¡F²Ó­M¼Æ¦Ê¤À¤ñªº¤¤¦ì¼Æ¡]¹ê»Ú½d³ò¡^¡G37.1¢M¡]5.6-83.6¢M¡^

¥H¤W¡C

­n»¡GH¡BSSEA-3©ÎSSEA-4¦bÀù¡]·F¡^²Ó­M¤¤©Ò¦ûªº¤ñ¨Ò¦³¦h¤Ö¡A­n¬Ý¬O«ü¡u¤H¼Æªí²{²v¡vÁÙ¬O«ü¡uÀù¡]·F¡^²Ó­Mªº²Ó­M¼Æ¦Ê¤À¤ñ¡v¡A³o»ò¤ÖªºÀËÅé¼Æ°Ñ¦Ò´N¦n¡A¤Ó°õµÛ©ó¼Æ¦r·|¦³¿ù»~´Á«Ý¡Aµ¥342¦ìªº¼Æ¾Ú¥X¨ÓÀ³¸Ó·|¤ñ35¦ì¡B40¦ì¡B53¦ì¨Ó±o¦³·N¸q¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/10/11 ¤U¤È 01:51:13²Ä 1381 ½g¦^À³
¥xÁÞ¤j¡A

®Ú¾Ú2008ªº½×¤å©M2012ªº±M§Q¤å

²Ä2ÂI©M²Ä3ÂI¦³­×¥¿ªº¥²­n

¤H¼Æ¦Ê¤À¤ñ©M²Ó­M¼Æ¦Ê¤À¤ñ¬O·N¸q¤£¦Pªº

³o¹ï¸ÑŪ¯E¹©¬Û·í­«­n

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GCliff10135274  µoªí®É¶¡:2014/10/10 ¤U¤È 08:38:31²Ä 1380 ½g¦^À³
¦n¤£®e©ö¦³­Ó¤£¥²¤W¯Zªº©]¡ALet¡¦s get something new¡K¡K

¦Ñ¸Ü¤@¥y¡A¤£·Q¬Ýªº½Ð¦Û¦æ¸õ¹L¡A¤£¼vÅT±zªºÅv¯q

·íGlobo H ±q²Ó­M½è²¾¦Ü²Ó­M½¤ªí­±ªí²{®É¡Aªí¥Ü²Ó­M¥¿³vº¥Àù¤Æ¡C¬O¤°»òª«½è­t³d¥¿±`»P¥¦µ²¦X¹B°e¨ì²Ó­M½¤ªí­±¡H­n¥ý§ä¥X¨Ó¤~¦³¿ìªk°µ¶i¤@¨B¬ã¨s¡CSSEA-4¤]¬O¬Û¦P¡A¥x¤j¤Æ¾Ç¬ã¨s©Ò¬x¹©¶v³Õ¤h2013¦~6¤ëªº¬ã¨s¤w¸g§ä¨ìFKBP4¡]FK-506 binding protein 4¡^­t³dµ²¦X¹B°eSSEA-4¡F¤Sµo²{FK-506·|¼vÅTFKBP4¡A©Ò¥H½Õ¸`FK-506¥i¥H½Õ¸`SSEA-4¡C¡]°Ñ¦Ò¸ê®Æ1.&2¡^

¦P®É¥L¤]¹B¥Î¤HÃþ³J¥Õ½è´¹¤ù¡Aµo²{234ºØ±`¥Îªº³J¥Õ½è¤¤¡]²{¦¨¶R¨Óªº³J¥Õ½è´¹¤ù¡^¦³13ºØ³J¥Õ½è·|»PGlobo Hµ²¦X¡C¦A¶i¤@¨B§Q¥Î»Ã¯À§K¬Ì´ú©w¡]ELISA¡^¡A§tGlobo H¤Î¦PÃþª«ªºÁÞ´¹¤ù¨â¹D¤âÄò¡Aµo²{¥u¦³artemin (ART©ÎºÙARTN)·|»PGlobo H¦PÃþª«µ²¦X¡A¦Ó¥BART¬O»P¦³Gb3®Ö¤ß¡]Gb3 in core¡^ªºGlobo H¦PÃþª«µ²¦X³Ì±j¡A¤]´N¬O»PGb3¡BGb4¡BGb5¡]SSEA-3¡^¡BGlobo Hµ²¦X¡C³o¬O¥þ¥@¬É­º¦¸µo²{ART·|»PGlobo Hµ²¦Xªº¬ã¨s³ø§i¡]°Ñ¦Ò¸ê®Æ1.¡^¡C

³o¤@¬q²Ó¸`ªº³¡¤À­n¬Ý¥þ¤å¤~¦³¡A°Ñ¦Ò¸ê®Æ1.¥u¯àŪ¨ìºK­n¡C¦Ü©óartemin (ART)¬O§_¤]§êºtÃþ¦üFKBP4¤§©óSSEA-4ªº¤¬°Ê¨¤¦â¡A§âGlobo H±q²Ó­M½è¹B°e²¾©¹²Ó­M½¤¥hªí²{¡A¥Ø«e©|µL¤H´£¥X§ó¸Ô²Óªº¬ã¨s³ø§i¡A§Ú·Q³oÀ³¸Ó¬O¯Î¹Î¶¤ªº¬ã¨s¥Í­Ì¤U¤@¶¥¬qªº½×¤å¬ã¨sÃD¥Ø¤§¤@¡C

²Ä¤@¦¸Å¥¨ìartemin¥H¬°¬O·sªF¦è¡A¨S·Q¨ì¥¦¦­´N¬O¸~½F¾Ç³N¬É¤d¤Ò©Ò«üªº­««×¶ûºÃ¥Ç¡A¦h¦~¨Ó¤w³Q¦h¦¸«ü»{»P³\¦hÀù¯gªº´c¤Æ¦³Ãö¡A´N¬O¨S¤Hµo²{¥¦¸òGlobo H¦³Ãö¡C¡]¤@¸s½M¤l§â¶H¤ú¡B¶H»L¡B¶H»ó¡B¶H§À¤Ú³£ºN¹M¤F¡A´N¬O¨S¦³¤H»¡¥X³o¬O¤@ÀY¶H¡I¡^¥i¯à¬O¦]¬°¨S¦³¤@Áçªkµ{¦¡§Ö³t»sÁÞ¤ÎÁÞ´¹¤ù§Þ³N¡A¥u¯à¦bªù¥~±r«Þ¡AµLªk¤@¿sªù¤º°ó¶ø¡C

Artemin ÄÝ©ó¤@ºØ°Ê±¡¿E¯À¡]Estrogen¡^¦³Ãöªº¯«¸gÀç¾i¥Íªø¦]¤l¡AÄÝ©óGDNF¡]Glial cell line-derived neurotrophic factor family of ligands ¡^¥|ºØ¦¨¤À¤¤ªº¤@ºØ¡A¯àµo¥X«H¸¹«P¦¨²Ó­M¦s¬¡¡B¤À¤Æ¡B¦¨ªøªº³J¥Õ½è¡C¦b¥¿±`²Õ´¤¤¡A°£¤F¦b¯«¸g²Õ´¤¤¦s¦b¡A¤]³Qµo²{°ª«×ªí²{©ó¤p¸£¡Bµ²¸z¡BÄáÅ@¸¢¡B¤l®c¡B­G¡BµÇ¡B®ðºÞ¡B­L¨à¸£¡B¯×ªÕ²Õ´µ¥¡C¦bÀù²Ó­M®è¤¤·|°ª«×ªí²{©óª½¸zÀù¡BÄáÅ@¸¢Àù¡B¤l®c¤º½¤Àùµ¥²Ó­M®è¡A¤¤«×ªí²{©ó¯ØŦÀù¡B¨ÅÀù¡]¦³¥|®è¡F¤T®è¬OER¶§©Ê¡A ¤@®è¬OER³±©Ê¡^¡A¤Ö¶qªí²{©óªÍÀù¡B­GÀù¡]¥t¤@®è¡^¡Bµ²¸z¡]¥t¤@®è¡^¡AÄáÅ@¸¢¡]¥t¤@®è¡^¡B¨xÀùµ¥²Ó­M®è¡]°Ñ¦Ò¸ê®Æ4¡^¡C

¹L¥h¤­¡B¤»¦~¨Ó¡A³°Äòµo²{artemin»P¨ÅÀù¡B¤l®c¤º½¤Àù¡BÄáÅ@¸¢Àù¡B­¹¹DÀù¡BªÍÀù»P¯ØŦÀùµ¥Àù¯gªº´c¤Æ¡BÂಾ¦³Ãö¡]°Ñ¦Ò¸ê®Æ3¡^¡C¦ý¨s³º¬O¤£¬OÂǥѵ²¦XGlobo H«á¡Aª½±µ©Î¶¡±µ§âGlobo H¹B°e¨ì²Ó­Mªí­±¡A³y¦¨Globo H୤ƨӫP¦¨ÀùÅÜ¡A¥Ø«eÁٯʤF´X¶ô«÷¹Ï¡C¦Ü¤Öªí­±¤W¬Ý°_¨Ó¡A¤W­z³o¨ÇÀù¯g¤W³£¥]§t¦bGlobo ¢Ö¥i¯à¦³®Äªº¨º16ºØÀù¯g¦W³æùØ¡C¥¼¨Óªº¤é¤lùØ¡A¥i¯à·|¦³·sªº¬ã¨s¥X¨Ó¡A¬x¹©¶v³Õ¤hªº½×¤å¤]¤w¸g°Ý¥@§Ö¶W¹L¤@¦~¥b¡C

¦b¹êÅç«Çùصo²{artemin·|³y¦¨BCL2°ò¦]¹L«×ªí²{¦Ó¨Ï²Ó­M®è¤£©ö­ä¤`¡]¤£¦´¡^¡F®e©ö©ó¥­­±©Î¥ßÅ骺°ö¾i°ò²¾¦æ©Î«I¥Ç¡A¤£¥²Áã©w¡F¨Ï²§Åé²¾´Ó¡]Xenograft¡^ªº¦Ñ¹«¨­¤WªºMCF-7¨ÅÀù²Ó­M®è§ó©ö¥Íªø¡F¡K¡K¤@°ïÁj¦ËÃø®Ñ¡C¦bÁ{§É¤W¡Aarteminªºªí²{»PÀù¯gÁ{§É¤À´Á¡]stage¡^§eÅãµÛ¬ÛÃö¡A»PHER-2(+)§e°ª«×¬ÛÃö¡F¦ý»P±wªÌ¦~ÄÖ¡B¸~½F¤j¤p¡B¯Å¼Æ¡]grade¡^¡BER¡Bprogesterone¡]¶ÀÅé¿E¯À¡^µL¬ÛÃö¡C¦Ó¥Bartemin¶V¬OÅãµÛªí²{ªÌ¡A¾ãÅé¦s¬¡²v¡]overall survival¡FOS¡^¶V®t¡C¡]°Ñ¦Ò¸ê®Æ4¡^¡]stage¬O«üÀù²Ó­M¬O­ì¦ìÀù©Î¬O¤w¸gÂX´²¨ì¨­Åé¨ä¥L²Õ´¡Fgrade¬O«üÀù²Ó­M¦bÅã·LÃè¤U§e²{ªº¤À¤Æ±¡§Î¦nÃa¡^

2011¦~¦³¬ã¨sµo²{artemin·|»P¤HÃþ°ò¦]TWIST1²£¥Í¦@ÀٮĪG¡]synergy¡F´N¬O1+1>2ªº·N«ä¡^¡A³y¦¨ER(-)¨ÅÀù±wªÌÂಾ¤Î¤£¨}ªº¹w«á¡]°Ñ¦Ò¸ê®Æ5¡^¡A©Ò¥H­YARTªº­PÀù¯à¤O¬OÂÇ¥ÑGlobo H¨Óµo´§¡A¨º´N­ì²z¦Ó¨¥¡A§ÜGlobo H¨t¦CÃĪ«À³¸Ó¹ï³o­Ó§ÜÃıڸs·|¦³®Ä¡C

¡]TWIST1°ò¦]­t³d¤HÅé²Ó­M»s³yDNA®É¡A§áÂন¬°ÂùÁ³±Ûª¬¡A­Y¸Ó°ò¦]µo¥ÍÅܤơA»s³y¥X¨ÓªºDNA¤£§eÂùÁ³±Ûª¬¡A¬O°ò¦]¬ðÅܪº¤@ºØ¡C°ò¦]¬ðÅܬO±`¨£ªº­PÀù­ì¦]¤§¤@¡^

HER-2¶§©Êªº¨ÅÀù±wªÌ¥HHerceptinªvÀø®É¡A¦³¤@©w¤ñ¨Òªº±wªÌ·|¦³§ÜÃÄ©Ê¡A2014¦~¦³¬ã¨sµo²{»PArtemin¦³Ãö¡]°Ñ¦Ò¸ê®Æ6¡^¡CARTN±j¨îªí²{ªºµ²ªG¦b¥ÍÅ餺/¥ÍÅé¥~³£­°§CHER2(+)Àù²Ó­M¹ïtrastuzumab¡]Herceptin¡F¶PÀù¥­¡^ªº±Ó·P«×¡A¬Û¤Ï¦a¡A¥ÎsiRNA¡]¤p¤ù¬qªº®ÖÁޮֻĤzÂZ§Þ³N¡^§í¨îARTN¡A·|«P¶itrastuzumabªºÀø®Ä¡C«á¤Ñ©Ê¹ïtrastuzumab¦³§ÜÃĩʪº¡A¨äARTNªºªí²{·|¼W¥[¡F­YARTN´î¤Ö®É¡A«h«ì´_¹ïtrastuzumabªº±Ó·P©Ê¡CÃhºÃ¬O³z¹L¥[±jBCL2°ò¦]ªº¤è¦¡¨Ó¨Ï±o¨ÅÀù·F²Ó­M¤£©ö­ä¤`¡]apoptosis¡^¡C©Ò¥H¦P¼Ë¹D²z¡A§ÜGlobo H¨t¦CÃĪ«¤]¦³¥i¯à¹ï³o­Ó§ÜÃıڸs¦³®Ä¡C

°Ñ¦Ò¸ê®Æ¡G

1¥xÆWºÓ³Õ¤h½×¤å¥[­È¨t²Î¡G±´°Q§Ü­ì©ÊÁÞÃþSSEA-4¤ÎGlobo H¤§µ²¦X³J¥Õ ¬x¹©¶v ¡]¤¤¤å¡^http://handle.ncl.edu.tw/11296/ndltd/56105589827731305044 ÂI¿ï¡uºK­n¡v

¡§Investigation of SSEA-4 Binding Protein in Breast Cancer Cells¡¨,¡]­^¤å¡^ J. Am. Chem. Soc., 2013, 135, 5934-5937.<

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/10 ¤W¤È 11:05:04²Ä 1379 ½g¦^À³
¤p©_¤j Cliff¤j ¦U¦ì¤j¤j

¥H¤U¸ê°T­«·s¾ã²z ´£¨Ñ°Ñ¦Ò,¨Ã½Ð¹LÂo¸ê°T,¸Ô¥[§PÂ_ ¦p¦³¿ù»~½Ð´£¥X§ó¥¿«Øij

1 ÁÂÁ§A­Ìªº¸Ñ»¡,¤£ºÞ¬O53¤H 35 ¤H 40 41¤H ³o¤£¬O­«ÂI,­«ÂI¬O­n§ä¨ì¤@¨Ç¸ê°T¸É¨¬¥H©¹¤j®a¤£¬O«Ü²M·¡SSEA4¦b¨ÅÀù·F²Ó­M»P«D¨ÅÀù·F²Ó­Mªºªí²{¦Ê¤À¤ñ,§Ú«Ü§C½Õ§e²{ªº­ì¦]¬O­nÅýªì¤W¥»ª©¤£¤[ªº¯E¤Í¯à¬ÝÀ´,¨ä¹ê¤Ó²ÓªºªF¦è¤£¬O§Ú­Ì¥i¥H¿s¨ä°ó¶ø,¥D­n´x´¤Globo H SSEA3 SSEA4¨ÅÀù·F²Ó­M»P«D¨ÅÀù·F²Ó­Mªºªí²{¦Ê¤À¤ñ§Y¥i (¥u­n¯à§ä¨ìÀù²Ó­M»P·F²Ó­M¨ÃÄè·À¥¦Àù¯g´N¦³ªv¡ªº¼ç¤O)

2 Globo H¦b¤@¯ë¨ÅÀù²Ó­Mªºªí²{²v61¢H¡A¦b¨ÅÀù·F²Ó­M¬°20¢H¡FSSEA3 ¦b¤@¯ë¨ÅÀù²Ó­Mªºªí²{²v77.5¢H¡A¦b¨ÅÀù·F²Ó­M62.5¢H¡CSSEA4 ¦b¤@¯ë¨ÅÀù²Ó­Mªºªí²{²v91.4¢H¡A¦b¨ÅÀù·F²Ó­M88.6¢H¡C

3¬Ý°_¨ÓGlobo H¤ñ¨Ò¦n¹³¤Ö¤@ÂI ¨ä¹ê¨C­ÓÀù²Ó­M»PÀù·F²Ó­M¦³¤T­Ó¯S®íªºÁޯ׽èSSEA3¡BGlobo H¡B SSEA4, ¦³¨Ç¦³¨â­Ó, ¦³¨Ç¥u¦³¤@­Ó ,¦³¨Ç¤T­Ó³£¦³,¦³¨Ç¤T­Ó³£¨S¦³, (¥u¦û1%), ¥u­n¦³¤@­Ó´N«Ü¨¬°÷,²¦³º¥@¤W¦³¥H·F²Ó­M¬°¼Ð¹vªºÃĦn¹³ÁÙ¨S¥X²{

3Àù·F²Ó­M©w¸q

Stem cells are defined as a group of cells with the capacity for self-renewal and for differentiation into multiple lineages to generate different types of cells and tissues. As both malignant tumors and normal tissues contain heterogeneous populations of cells, the existence of cancer stem cells which play a key role in tumor growth and maintaining tumor heterogeneity has been proposed. CSCs possess the capability of stem cells to multiply and differentiate into their progenitors, display resistance to chemotherapy and radiation therapy ¡]CSCs¡^Àù·F²Ó­M³Q©w¸q¬°¤@¸s²Ó­M ,³o¤@¸s²Ó­M¦³¦Û§Ú§ó·s©M ¤À¤Æ¦¨¦hºØÃШtªº¯à¤O¨Ã²£¥Í¤£¦PÃþ«¬ªº²Ó­M©M²Õ´¡C¥Ñ©ó´c©Ê¸~½F»P¥¿±`²Õ´³o¨âºØ¤¤§t¦³²Ó­Mªº²§½è¸sÅé¡AÀù¯g·F²Ó­M¦b¸~½F¥Íªø©Mºû«ù¸~½Fªº²§½è©Êªº§êºtÃöÁ䨤¦â¤w³Qµo²{¡C¸~½F·F²Ó­M¾Ö¦³Ác´Þ©M¤À¤Æ¬°¥¦­Ìªº«eÅé²Ó­Mªº¯à¤O¡A¨Ã®i²{©è§Ü¤ÆÀø©M©ñ®gªvÀø

4¥u­n¯à§ä¨ìÀù²Ó­M»P·F²Ó­M¨ÃÄè·À¥¦Àù¯g´N¦³ªv¡ªº¼ç¤O

5 OBI pharma observer 9¤ë3¤é¬ö¿ý

A½T©wOBI822 ¹ï©óGlobo ¨t¦CÁާܭìSSEA3 SSEA4 Globo H ³£¦³Binding(§ÜÅé»P§Ü­ìµ²¦X«á²£¥ÍÄè·À§Ü­ìªº¤ÏÀ³)

B Globo-H Ceramide

Globo-Hà­¤Æ(Ceramide)¬OÀù²Ó­M¥Î¨ÓÅõºÈ§K¬Ì²Ó­M§@¥Îªº¨¾¿m¨t²Î¡A¥i¥HÅýÀù²Ó­M¦s¬¡¡A¸ú¹L¨­Åé§K¬Ì²Ó­Mªº§ðÀ»¡C¦Ó¥´¤JªºOBI-822¤SºÙ¬°¤Ï¨¾¿m¨t²Î¡A¥L¥i¥HÅý¦¹¨t²ÎµLªk¹B§@¡AÅý¦ÛÅé§K¬Ì²Ó­M¥i¥H»´ÃPªº±þ¦ºÀù²Ó­M¡C

CÀù¯g²Ó­M´_µo¾÷¨î--Àù·F²Ó­M(Cancer Stem Cell)

Àù¯g´_µo­ì¦]¦b©ó¨­Å馳©Ò¿×ªºÀù·F²Ó­M(Cancer Stem Cell)¡A¤§«eªº¤ÆÀø±þ¦ºÀù²Ó­M¡A¦ý¬O¤´µLªk±þ¦ºÀù·F²Ó­M¡C¤¤¥¡¬ã¨s°|¬ã¨sµo²{¡A¦bÀù¯g·F²Ó­M¤W­±µo²{¦³Globo-H, SSEA-4, SSEA-3¡A¥NªíOBI-822¤£¶È¥i¥H±þ¦ºÀù²Ó­M¡AÁÙ¥i¥H±þ¦ºÀù·F²Ó­M¡C

6 ¤¤¬ã°|¬ã¨s GLOBO H , SSEA3 , SSEA4 ³£¦³¦bÀù²Ó­M»PÀù·F²Ó­Mªí²{

ÁÞ¤À¤l±´°w¤£¥u¥i¥H°lÂÜÁÞ³J¥Õ¡AÁÙ¥i¥H°lÂÜÁޯ׽è¡A¤@¶}©l½Í¨ì¦b³J¥Õ½è¤W§ä¤£¨ì¯u¥¿¦nªº¼Ðªºª«¡Aµ²ªG«o¦bÁޯ׽è¤W§ä¨ì¤F¡A³o­Óµo²{¬O·sªº¬ð¯}¡A¦bÀù²Ó­M©MÀù¤Æªº·F²Ó­M¤Wµo²{¤T­Ó¯S®íªºÁޯ׽èSSEA3¡BGlobo H¡B SSEA4¡A¬O¥¿±`²Ó­M©Ò¨S¦³ªº¡A³o´NÅý§Ú­Ì·Q¨ìÀù¯g¬Ì­]ªº³]­p¡C(¥H¤W¯Î°|ªø¤@¤p¬q½Í¸Ü)

7 Àù·F²Ó­M¬°Àù²Ó­MªººØ¤l,Àù¯g¬O·F²Ó­M¯e¯f

8¦Ü¤Ö¦³70¡ã80%¯f¤Hªº§Z±_Àù²Ó­M¦s¦bGlobo H ¤Î¨ä«eÁÍÁޯ׽èGb5 (SSEA3)ªºepitopes¡C´¹¤ù´ú©wµo²{¡A¤£¤Ö§Z±_Àù¯f¤H¦å²M¤¤¥i¥H§ä¨ì¹ï§ÜGlobo H©ÎGb5 (SSEA3)ªº¦Ûµo©Ê§ÜÅé¡AÃÒ¹êGlobo Hªº½T¥i¥H¤Þµo§Z±_Àù¯f¤Hªº§ÜÅé§K¬Ì¤ÏÀ³¡Cepitopes ¨ì©³¬O¤°»ò·N«ä:§Ü­ì¨M©w¦ì(epitope)¬O«ü§Ü­ìªí­±¤W¨M©w§Ü­ì¯S²§©Êªº¤Æ¾Ç°ò¹Î¡C§Ü­ì¨M©w¦ì¥i³Q§K¬Ì¨t²Î¦p§ÜÅé¡BB²Ó­M©ÎªÌT²Ó­M©ÒÃѧO (¨Ì¾ÚWIKI)

9 Cliff¤j:

the ranges of SSEA-3 or SSEA-4 expression represented by the percentage of positive cells within total cancer cells ªº·N«ä¬O SSEA-3 or SSEA-4ªí²{ªº½d³ò¬O¥H¥þ³¡Àù²Ó­M¤º¶§©Ê²Ó­Mªº¦Ê¤À¤ñ¨Ó§e²{

10 ¬y¦¡²Ó­M³N¡]Flow CytoMetry¡AFCM¡^¬O¹ïÄa²G¤¤ªº³æ²Ó­M©Î¨ä¥L¥Íª«²É¤l,³q¹LÀË´ú¼Ð°Oªº¿Ã¥ú«H¸¹¡A¹ê²{°ª³t¡B³v¤@ªº²Ó­M©w¶q¤ÀªR©M¤À¿ïªº§Þ³N¡Cflow cytometer¬y¦¡²Ó­M»ö¤SºÙ¿Ã¥ú¿E¬¡²Ó­M¤À¿ï¾¹¡B¿Ã¥ú¬¡¤Æ²Ó­M¤ÀÃþ­p,²{¥Nªº¬y¦¡²Ó­M»ö¨C¬í¥i¥H¹ê®ÉÀË´ú´X¤d­ÓÁû²É¡A¨Ã¥B¥i¥H¥D°Ê¤ÀÂ÷¨ã¦³¤£¦P¯S©ÊªºÁû²É¡C( Æ[¹îÀù²Ó­M)

11 ¤p©_¤j´£¨Ñ¨ÅÀùHER2¶§©ÊÂù¼Ð¹v¶P¯e§´PFS OS ¦±½u¹Ï¨Ñ°Ñ¦Ò ¸ÓÃÄ9¤ë¤½§G PFS OS ­Ó¤Hµû¦ôÁÙ¤£·|«Â¯ÙOBI822

http://www.ccgh.com.tw/CK/ck_MedMaintain2/download/iperj..pdf

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/10/10 ¤W¤È 12:10:01²Ä 1378 ½g¦^À³
¥xÁÞ¤j¡ACliff¤j¡A

·PÁ´£¨Ñ¸ê°T¡A¤ß¤¤ªººÃ´bÁŵM¶}®Ô

²¦Ó¨¥¤§¡A¯E¹©ªºGH¨t¦Cªº¤TºØÃÄ¡A822¡B833¡B888­n¹ï¥I16ºØÀù¯g

´N¬OºÉ¤H¨Æ¡AÅ¥¤Ñ©R

ºÉ¤H¨Æ´N¬O§ä¥X³Ì¨Îªºª`®g¦¸¼Æ¡A¬IÃĶ¡¹j®É¶¡¡A¥Î³Ì¾A·íªº¦õ¾¯¥H»¤µo³Ì¨Î½è¶qªºIGg¡BIGm¡A¥Î³Ì§Cªº¦¨¥»¦X¦¨GHµ¥µ¥

Å¥¤Ñ©R´N¬O¦ÛµM¬Éªº¹B§@ªk«h¡A¦³¨ÇÀùºØªºªºGH¨t¦Cªº¤H¤f¤ñ¨Ò°ª¡A¤]¨Ç¤ñ¸û§C¡F¦³¨Ç¤HªºGH¨t¦Cªí²{°ª¡A¦³¨Ç¤Hªí²{§C¡A¬Æ¦Ü¨S¦³¡C

¦ý³oµ·²@¨S¦³´î·l¯Î°|ªøªº°¶¤j¦¨´N¤Î¯E¹©ªº¤£¦P¤ZÅT¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GCliff10135274  µoªí®É¶¡:2014/10/9 ¤U¤È 06:47:01²Ä 1377 ½g¦^À³
¤p©_¥S¡A·PÁ¡I

¤@¨Ç¥ý«e¹ïGH¦bÀù¯g²Ó­M¤À¥¬ª¬ªpªº¤£¸Ñ»P²q´ú¡A¨ä¹ê¦­´N¦b¨º½g2008¦~½×¤å´N¦³¤F³o¨Ç±Ô­z¡A°¾°¾§Ú·í¦~¥u°½ÃiŪ¤F¤¤¬ã°|ªº¤¤¤å·s»D½ZºK­n¡A¨S±qÀYŪ¹L©Ò¥H¤£³q¡C¨â­Ó¤ë«e§ä¨ì±M§Q¤å¥ó¤]¨S¥þ¬Ý§¹¡C

¥¼¨Ó822¤W¥««á°t¦X¥ÎÃÄ«eªºÁÞ´¹¤ù´ú¸Õ¡AGH©ÎSSEA-3©ÎSSEA-4Áp¶°§t¶q¸û°ªªÌ¶V¬O´c©Ê¡A¦ý¤]¥i¯à¹ï822©Î833¶V¦³¤ÏÀ³¡F¨º¤TªÌ§t¶q¬Ò§CªÌ¡A¬Æ¦Ü¥þ¹sªÌ¡]¡u·s¡v¤T³±Àù¡^ªÌ´N¨SÂá¤F¡C

·s¦Wµü¡G¡u·s¤T³±Àù¡v¡A±N½Ï¥Í¡A2017¦~¡C

¦b2008¦~½×¤åTable1ªí®æ¤U¤èµù¸Ñ¤Î¤º¤å±Ô­z¡G

53­ÓÀËÅ餤¡A¦³28­ÓÀËÅç¤FGH&SSEA-3¡A¥t13­Ó¥uÀËÅçGH¡AÁÙ¦³¥t12­Ó¥uÀËÅçSSEA-3¡C

ÀËÅçGHªºÀËÅéÁ`¼Æ¬O41­Ó¡A¨ä¤¤25­Ó¶§©Ê¡FÀËÅçSSEA-3ªºÀËÅéÁ`¼Æ¬O40­Ó¡A¨ä¤¤31­Ó¶§©Ê¡F

¨ºSSEA-4©O¡H«D¥»½g½×¤å¬ã¨s­«ÂI¡A©Ò¥H¨S´£¨ì¡C¦b±M§Q®Ñ«á¬q¦³¸É¥R¤@¨Ç¸ê®Æ¡A¦ý¨S¦A¦C¥X·sªº°Ñ¦Ò¤åÄm¡C¡]¤´¬O2008¦~½×¤å¡^

±M§Q¬O2009/8/6´£¥X¥Ó½Ð¡Aµo¥¬¤é¬O2012/9/18¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GJM10139061  µoªí®É¶¡:2014/10/9 ¤U¤È 05:19:08²Ä 1376 ½g¦^À³
´Nºâ¦bªvÀø«áªº·í¤U¥i¹F0Àù·F²Ó­M,¤]¤£«OÃÒ¥H«á´N¤£·|¦A²£¥ÍÀù·F²Ó­M. ´N¸ò§Y«K°·±dªº¬YA²{¦b¨­Å餺0Àù·F²Ó­M,¤]¤£«OÃÒ¬YA¥H«á¤@©w¤£·|±oÀù¯g--§_«h³o¥@¤W®Ú¥»¤£·|¦³Àù¯gªº¥X²{¤F.

©Ò¥H­n¨DªvÀø¨ì0Àù·F²Ó­M,¦b§Ú¬Ý¹ê½è·N¸q¤£¤j,¨º¨Ç²Î­p¼Æ¦r¤~¬OÀø®Äªº­«ÂI.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/10/9 ¤U¤È 03:11:06²Ä 1375 ½g¦^À³
Cliff¤j¡A¥xÁÞ¤j¡A¦U¦ì¤j¡G

1.¤p§Ì½T©wÀËÅé´N¬O¤TÁ`¨º53¦ì±wªÌ¡A2008ªº½×¤å¥Î¨Ó¤ÀªRGH©MSSEA-3¡A2012¦~ªº±M§Q¥Ó½Ð«h¤ÀªRSSEA-3©MSSEA-4¡C¼Ë¥»¦~ÄÖªº½d³ò´X¥G¤@­P¡A³Ì­«­nªºÃÒ¾Ú¬O2008©M2012ªº¨â­Ó¼Ë¥»½s¸¹BC0264©MBC0266¡A¹Ï«¬¬O¤@¼Ò¤@¼Ë¡C

2.2008ªº½×¤å¡A¤ÀªRGHªºfrequency(¦³GHªº¼Ë¥»¤ñ¨Ò)¡A¥u¥Î¤F41¦ì¡A¨ä¤¤¦³25¦ì¦³GH¡ASSEA-3«h¥Î¤F31/40(77.5%)¡A¤£ª¾¤°­ì¦]¡A53­Ó¼Ë¥»ªºÀËÅé¨S¦³¿ìªk¥þ³¡®³¨Ó¤ÀªR¡C2012ªº¥u­n¤ñ¸ûSSEA-3©MSSEA-4¡A¬Y¨Ç¼Ë¥»¥i¯à¤£¯à¥Î¡A¦³¨Ç¼Ë¥»¬J¨S¦³SSEA-3¤]¨S¦³SSEA-4¡A¨S¦³¤ÀªRªº¥²­n¡A°²³]ÁÙ¬O¸ò2008¦~¤@¼Ë¦³41­Ó¼Ë¥»ªºÀËÅé¥i¥Î¡A¦³SSEA-4ªº¼Ë¥»¹F34/41(83%)¡A¤]¬O¶W¹LGH©MSSEA-3¡C

3.2008¦~¤ÀªRGH©MSSEA-3ªº¨Ò¤l¡G

For example, tumor from patient BC0145 contained 17.1% BCSCs that were negative for Globo H, whereas 43.8% of the non-BCSCs expressed Globo H. In patient BC0240, Globo H expression was detected in 66.4% of non-BCSCs and 23% of BCSCs.

³oªí¥Ü(°t¦XSupporting Informationªº¹Ï2/8)¡A¼Ë¥»BC0145ªº¨ÅÀù¸~½F¤¤¦³17.1%

¬OÀù·F²Ó­M(¨C­Ó¼Ë¥»¤ñ¨Ò³£¤£¦P)¡A¦b·F²Ó­MªºGHªí²{¬O¹s(¤@­Ó·F²Ó­M³£¨S¦³GH)¡A¦b«D·F²Ó­M«h¦³43.8%(ª`·N¡A¤´¦³56.2%ªº«D·F²Ó­M¨S¦³GH)¡C¼Ë¥»BC0240ªº¨ÅÀù¸~½F¤¤¦³12%¬OÀù·F²Ó­M(¨C­Ó¼Ë¥»¤ñ¨Ò³£¤£¦P)¡A¦b·F²Ó­MªºGHªí²{¬O23%¡A¦b«D·F²Ó­M«h¦³66.4%¡C­ì¤å§â¦³GHªº²Ó­MºÙ¬°GH positive¡A¨S¦³ªººÙ¬°GH negative ¡A¥Îexpression level¨Óªí¥Ü¬YÀËÅ馳Áާܭ쪺Àù²Ó­M¤ñ¨Ò¡C§Y¨Ï¦b¦U¤è­±ªí²{³£³Ì°ªªºSSEA-4¡A¬Y­Ó¼Ë¥»¦bBCSC¤W¦³SSEA-4ªºªí²{ªº¤ñ¨Ò³Ì°ª¥u¦³83.6%(´N¬O¨S¦³100%) ¡A©Ò¥H¦pCliff¤j©Ò»¡ªº¡A¨C­ÓÀËÅ餤©Ò§tªºGlobo H©ÎSSEA-3©ÎSSEA-4¶q³£¤£¤@¼Ë¡A±q§C±Æ¨ì°ª¨Ó§ä¤¤¦ì¼Æ¡A¦ý¤¤¦ì¼Æ³£¨S¦³¶W¹L50%¡C

4.Cliff¤j»¡¡G¡yµ²ªG©Ò¦³ªºP value³£¤j©ó0.001¡Aªí¥ÜSSEA-3¡BSSEA-4¦b¨ÅÀù²Ó­Mªº¤À¥¬¤£¦]Á{§É´Á§O¡BHER-2 receptor¶§/³±©Ê¦Ó¦³®t§O¡z¡AP value¦h¤F¤@­Ó0¡AÀ³¸Ó¬O0.01¡A¤@¯ë¼eÃPªº¥Î0.05¡AÄY®æªº¥Î0.01¡A2012ªº¸ê®Æ¥u¦³ ER¥X²{0.0128¡AÁÙ¬O¤£°÷ÅãµÛ¡C³o­Óµ²½×»¡¡A¦b¨ÅÀù¤W¡AÁާܭ쪺expression level©M³\¦h­«­nªº¨ä¥¦ÅܼƵLÃö¡A¦]¦¹¤£ºÞ¬OER¶§©Î³±©Ê¡AHER+©Î-¡AGH¨t¦CÁާܭ쪺expression leve¥u¸ò±wªÌ¦Û¨­©Òªí²{¬ÛÃö¡A¦pªGGH¨t¦CªºÁÞ§ÜÅé´N¥u»{¦³GH¨t¦CªºÀù²Ó­M©ÎÀù·F²Ó­M¡A¥B¯à°÷®ø·À¥¦¡A¨º°£¤F¨ÅÀù¤£¤À¤T³±©Ê©ÎER©ÎHER¥~¡A¨ä¥¦15ºØÀù¯g¤]¥i¯à¤£¤À¥û¤£¥û´c¤F¡A­«ÂI¬O­n¦³¨¬°÷ªºGH¨t¦CªºÁާܭìexpression level¡C

5.¤p§Ì·Qªí¹Fªº¥t¤@­ÓÆ[ÂI¡A¥i¯à·|Åý¬Y¨Ç¯E¤Í¥¢±æ¡A·Ó½×¤åªºªí­z¡A¨S¦³¤@­Ó¼Ë¥»ªºÀËÅ骺Àù²Ó­M©ÎÀù·F²Ó­M¤WªºGH©ÎSSEA-3©ÎSSEA-4ªºexpression level¹F¨ì100% ¡A©Î³\¤T­ÓÁp¶°«á·|¹F¨ì90%¥H¤W¡A¨º¬O¤Ö¼Æªº©¯¹BªÌ¡AS¤p©j¥i¯à¬O¨ä¤¤¤§¤@¡A´Nºâ¦p¦¹¡A¤]¤£¬O¦Ê¤À¦Ê¡A¥L©Î¦o¦bªvÀø«á·|¹F¨ìNED¡A¦ýÅ餺ÁÙ¬O¦³Àù²Ó­M©ÎÀù·F²Ó­M¡A¦ý¥i¯àPFS©ÎOS¥i¥Hªø¨ìÅý¥L©Î¦o¥i¥H²×¦Ñ¡A¦Ó¤£¬O¦]Àù¯g¦Ó¥h¥@¡A¦ý¦]¬°Àù·F²Ó­Mªºexpression levelªº¤¤¦ì¼Æ¦b­Ó§OGH¨t¦C¤£¨ì50%(¤T­ÓÁp¶°À³¸Ó¤¤¦ì¼Æ¥i¥H¶W¹L50%¡A²qªº)¡A¦]¦¹¡A¹L¥bªº¤H¡A¦b¬Y­Ó®É­Ô¡AÃĮĹL¤F¡A¨S±þ¦ºªºÀù·F²Ó­M·|¦A«×Ác´Þ¼W¥Í¡A¤]·|¬Ý¨ì¯e¯fªº¶i®i¡A¤ñ¸û©¯¹Bªº±wªÌ¦³¸û°ªªºexpression level(¦h°ª¤~¥s°ª¡A¨S¤Hª¾¹D)¡A¨­Å骺Àù²Ó­M©MÀù·F²Ó­M·|³Q¥´¨ì§x¦u¦b¤è¤o¤§¦a¡A±wªÌ¨­Å骬ªp¥i¯à«ì´_¨ì¥i¥H¥Î¦Û¨­ªº§K¬Ì¤O¨ÓÀ£¨î¥¦¡A¦]¦¹·|¦³«Üªø«ÜªøªºPFS¤ÎOS¡C

¥H¤W¬O¤p§Ì¬yÄý¤F¨â½g½×¤åªº·P·Q¡A»P¹ê»Úªº±¡ªp¥²¦³¤£¤pªº¥X¤J¡A§Æ±æ¤£¼vÅT¨ì¦U¦ì¤j¤jªº§ë¸ê§PÂ_¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦sªÑ­P´I10136213  µoªí®É¶¡:2014/10/9 ¤U¤È 02:48:45²Ä 1374 ½g¦^À³
¦h¦æ¤£¸q¥²¦ÛÀÅ »¡ªº¦n ¨C­Ó¤H³£À³¸Ó¦n¦nÀË°Q¦Û¤v

爲¤FÅý¦Û¤v¶RªºªÑ²¼ÁÈ¿ú ¨C¤Ñ­J¨¥¶Ã»y ¶Ã½s¬G¨Æ ¤Ñ¤Ñ³y¤f·~ ¤Ñ¤Ñ¦³Ãa·Qªk ¨C¤Ñ­A¤ß¾÷·Q³]­p§O¤Hªº¤H ³Ì«á¤]¬O¦h¦æ¤£¸q¥²¦ÛÀÅ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶À¤jÄ_10132519  µoªí®É¶¡:2014/10/9 ¤U¤È 01:39:32²Ä 1373 ½g¦^À³
¦h¦æ¤£¸q¥²¦ÛÀÅ ¬Ý¬Ýª÷½Ã ö^Ügªñ¤éªÑ»ù ¬Ý¬Ý°µ¤½¯q³]¥ß­ð¼úªº¤¨­l¼Ù ¤@­Ó¦b°µ¤½¯q ¤@­Ó¦b¦¬¨í­é¹Ü §ë¸ê¤H¸C«G²´·ú µ¹©^ÄmªÀ·|¤½¯qªº¥ø·~¥D¹ªÀy´xÁn µ¹¤£§ð¤£¸qªºµs­ê·íÀY´Î³Ü. ¤ä«ù¯E¹© ¤¤¸Î ¬ÝªÅ ª÷½Ã ö^Üg
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GCliff10135274  µoªí®É¶¡:2014/10/9 ¤U¤È 12:45:09²Ä 1372 ½g¦^À³
§ó¥¿:

¤W¤å¡uµ²ªG©Ò¦³ªºP value³£¤j©ó0.005¡Aªí¥ÜSSEA-3¡BSSEA-4¦b¨ÅÀù²Ó­Mªº¤À¥¬¤£¦]Á{§É´Á§O¡B²O¤Úµ²«I¥Ç»P§_¡BER receptor¶§/³±©Ê¦Ó¦³®t§O¡C¡v¬O¿ù»~ªº

À³§ï¬°¡G

¡uµ²ªG©Ò¦³ªºP value³£¤j©ó0.001¡Aªí¥ÜSSEA-3¡BSSEA-4¦b¨ÅÀù²Ó­Mªº¤À¥¬¤£¦]Á{§É´Á§O¡BHER-2 receptor¶§/³±©Ê¦Ó¦³®t§O¡C¡v

­ì¤å¥Îµü¬O¡u¡K¡Kno significant correlation ¡K¡K¡v

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GCliff10135274  µoªí®É¶¡:2014/10/9 ¤U¤È 12:22:12²Ä 1371 ½g¦^À³
¦P·N¤p©_¥S¬Ýªk¡Aı±o¨º35¤HªºÀËÅé¬O¨Ó¦Û©ó¨º53¤H¡A´N±M§Q®Ñ¤ºªº±Ô­z¤]¬O¥u¦³³o¤@½g2008¦~¡u©¥Ä¦ÁÞÂà´«–¡¡vªº°Ñ¦Ò¨Ó·½¡A¥u¬O¤£ª¾¹D¦óºØ¦Ò¶q¥u¨ú¤F¨ä¤¤35¦ì°µSSEA3¤ÎSSEA4¤ÀªR¡C¤£¹L¡Aª`·N¨ì¤U­±³o¬qPage30¤U¤èªº±Ô­z¡G

¡uExpression of SSEA-3 and SSEA-4 in Breast Cancer and BCSCs¡G

The expression of Globo H in BCSCs, but ¡K¡K¡K(Chang W-W. et al., (2008) Proc Natl Acad Sci USA 105(33):11667-11672, incorporated herein by reference in its entirety.) ¡v

³o¥yincorporated herein by reference in its entirety¡Aªí¥Ü¬O±q°Ñ¦Ò¸ê®Æ´O¤J¥H±o¨ä§¹¾ã©Ê¡C©Ò¥HÀ³¸Ó¬O±q³o½g(2008) Proc Natl Acad Sci USA 105(33):11667-11672¤å³¹¾ã²z¥X¨Ó¡A¦A¥[¤JSSEA-4¸ê®Æ¡C¦]¬°¤W­z¤å³¹¨S°Q½×SSEA-4¡C¦ý¬O¥Ó½Ð±M§Q®É¡A·íµM­n§âSSEA-4¥]¬A¶i¥h¡C

¡u¥h±¼¤£§t¦³SSEA-3¤ÎSSEA-4ªº¡v¡A¥u³Ñ¤U§t¦³SSEA-3©ÎSEA-4ªº°µ¤ÀªR¡A¬O§Úªì¨Bªº±À´ú¡A²Ó¸`¤W¡A¸ê®Æ¦³­­¡A»Ý­n®É¶¡¾ã²z·Q·Q¡C

°ò¥»¤W¤£¥i¯à¬°¤F¥Ó½Ð±M§Q¦A­«±Ò·sªº¸ÕÅç¡A¤@©w¬O¥H²{¦³¤âÃ䪺¸ê®Æ¾ã²z°e¼f¡C

¥xÁÞ¥S¡G¡u·|¤£·|¬O53¤H¤¤¥h±¼¤£§tGlobo H «á³Ñ¤U35¤H¨Ó¤ÀªR SSEA3 SSEA4¦b¨ÅÀù·F²Ó­M»P«D¨ÅÀù·F²Ó­Mªºªí²{¦Ê¤À¤ñ¡H¡v©Î³\¦³¥i¯à¡A¦ý¬OÁ{§É·N¸q¬O¤°»ò©O¡H¤j®a¶°«ä·Q·Q¡A§Ú¨Sµª®×¡C

¥ýÂç²M¤@¤U¨â­Óªí®æªº¸ê®Æ¤º®e¡G

¤p©_¥S¡A§Úı±o¤£ºÞ¬O¡u©¥Ä¦ÁÞÂà´«–¡¡v¨º½gªºSupporting Information ªºTable S1ªº¡uGlobo H expression range, %¡v©Î¬O¡u±M§Q®Ñ¡v¨º½gªºTABLE 2ªº¡uSSEA4 Percent cells with expression Median¡]range¡^¡v³£¬O¥Hrange§e²{¡A¦Ó«D©T©w¼Æ¦r¡A¬°¤°»ò¡H¦]¬°¨C­ÓÀËÅ餤©Ò§tªºGlobo H©ÎSSEA-3©ÎSSEA-4¶q³£¤£¤@¼Ë¡A¦³§C¨ì0¢M¡A¤]¦³°ª¨ì77.1¢Mªº¡A©Ò¥H¦Û°ª¦Ó§C±Æ¤U¨Ó¡A´N¦ÛµM¦³¤FMedianªº¼Æ¦r¡C¨ºP value°µ¤°»ò¥Î¡H

¬O·Q¥Î²Î­pªºt test¨Ó¤F¸ÑSSEA-3¡BSSEA-4¦b¤£¦Pªºstage¡BNode involvement¡BERªºÃöÁp©Ê¦³¨S¦³²Î­p¤Wªº·N¸q¡Aµ²ªG©Ò¦³ªºP value³£¤j©ó0.005¡Aªí¥ÜSSEA-3¡BSSEA-4¦b¨ÅÀù²Ó­Mªº¤À¥¬¤£¦]Á{§É´Á§O¡B²O¤Úµ²«I¥Ç»P§_¡BER receptor¶§/³±©Ê¦Ó¦³®t§O¡C©Ò¥H±z«e¤Ñ¦³Ãö³æ¦ìªº°ÝÃD¡Aµª®×¬O¡u¦Ê¤À¤ñ¡v¢M.¡]±M§Q®Ñ¤Wªº­ì¤å¬OIn Table2, the ranges of SSEA-3 or SSEA-4 expression represented by the percentage of positive cells within total cancer cells¡^

¸ê®Æ¦³­­¡A·í¤¤ºÃÂI¤´¦h¡A¤j®a¦A·Q·Q¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶À¤jÄ_10132519  µoªí®É¶¡:2014/10/9 ¤W¤È 09:27:45²Ä 1370 ½g¦^À³
·í°È¤§«æ (¤W¥«Âd)Á׶}³s³Ó¤å·§©ÀªÑ¥H«O¦w±d
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/9 ¤W¤È 09:15:16²Ä 1369 ½g¦^À³
§ó¥¿:

1²@§J¬ù¥i»s³y¥X33°wOBI822

Cliff ¤j:

·|¤£·|¬O53¤H¤¤¥h±¼¤£§tGlobo H «á³Ñ¤U35¤H¨Ó¤ÀªR SSEA3 SSEA4¦b¨ÅÀù·F²Ó­M»P«D¨ÅÀù·F²Ó­Mªºªí²{¦Ê¤À¤ñ

¤£½×¨º¤@ºØ SSEA4 SSEA3 GloboH ³£¦³¦b¨ÅÀù·F²Ó­M»P¨ÅÀù²Ó­Mªºªí²{,¥u­n¯àÄè·À¨ÅÀù·F²Ó­M,¨ÅÀù´N¦³ªv¡ªº¼ç¤O

SSEA4 SSEA3 GloboH ¦b¨ÅÀù²Ó­Mªºªí²{²v

SSEA4 (91.4%) >SSEA3 (77.5%)>GloboH(61%)

SSEA4 SSEA3 GloboH ¦b¨ÅÀù·F²Ó­Mªºªí²{²v

SSEA4 (88.6%) >SSEA3 (62.5%)>GloboH(20%)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/9 ¤W¤È 08:57:00²Ä 1368 ½g¦^À³
µ½¤H¤j:

³o¦ì¾Ç¥Í¤Ñ¨Ï¨Ó¨ó§U¯Î°|ªø, ÅýGlobo H©M¨ä¥LÁÞ¤À¤l(¦pSSEA-4©ÎSSEA-3µ¥)¯àí©wªº¤j¶q¥Í²£,¯u¬O¤Ñ¦ö¥xÆW

OBI Pharma ObserverºtÁ¿¬ö¿ý:

¥H«eÁÞ¤À¤l¦X¦¨­nªá¤F¨â­Ó¬ã¨s¥Í18­Ó¤ëªº»s³y¡A¦@99­Ó¨BÆJ¡A¤~¯à±o¨ì10²@§J¡A°ª¦¨¥»¡A°ª¯Ó®É¡C¯Î±Ò´f°|ªø¤Sªá¤F¬ù5~6¦~ªº®É¶¡Ä~Äò§ïµ½»sµ{¡AºÙ¬°§ï¨}¦¡¤@Áçªk(Modified One-Pot)¡A¤@Áçªk¬ù»Ý2¤p®É¡A¨C§J¦¨¥»¤´°ª¹F20¸U¬ü¤¸¡C«á¨Ó¯Î°|ªø¦A§V¤O¬ã¨s»Ã¯À¤Æ¾Ç¦X¦¨ªk(Chemo-Enzymatic Method)¡A§Q¥Î¨­Å骺»Ã¯À´£·Ò¥X¨ÓÁÞ¦X¦¨¡A¥Ñ©ó¥h±¼«OÅ@°ò¡A¥i¥H¤j¶q¸`¬Ù¦¨¥»¡A¦]¦¹¨C§Jªº¦¨¥»­°§C¨ì1,000¬ü¤¸¥H¤U¡C¦Ó²{¦b­Y­p¤J«Ø¼t¦¨¥»Åu¾P¡A²{¦bªº¦¨¥»¬°¨C§J1¸U¬ü¤¸(«D³Ì²×²£«~)

­Ó¤H¬ù²¤­pºâ:

1§J¬O1000²@§J 1²@§J¬O1000·L§J OBI822¨C°w¥Î¶q30·L§J 1²@§J¥i»s³y¥X333°w,,¥@¬É¦U¤j¥Í§Þ¤½¥qª¾¹DÁÞ¤À¤l¬Ì­]ªº¼ç¤O,¥u¬O¦X¦¨ÁÞ¤À¤l«D±`§xÃø,¥u¦n©ñ±ó,OBI822 §C°Æ§@¥Î §C¬r©Ê ¦¨¥»±±¨î±o©y,±M§Q¼h¼h«OÅ@,¤S¨ã¤T­ÓÁÞ¤À¤l¼Ð¹v(³£¦³¦b¨ÅÀù²Ó­M»P·F²Ó­Mªí²{) ´Á«Ý¯E¹©¯à¦¨¬°Àù¯g·sÃĪº©_´º

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gµ½¤H10137888  µoªí®É¶¡:2014/10/9 ¤W¤È 02:34:10²Ä 1367 ½g¦^À³
¥xÁÞ¤j

§Ú9¤ëªì¬O¨ì±i®a¬É®È¹C, ¬°¤F¬Ý"¤Ñªù¬}"ªº©_´º, ¥i±¤¦¹ª©¤£¯à¶Ç·Ó¤ù. ¶À¤s§Ú¤]¥h¹L, Á`µ²: ±i®a¬É¤ñ¶À¤s§ó­È±o¤@¹C.

§Ú¥H«e´¿¼g, ¥xÆWªº¦UºØ²£·~, ¦b¦U­Ó®É´Á³£¦³¥@¬É²Ä¤@ªº²£·~©M¼t°Ó¥Nªí,

¨Ò¦p¥Ø«eªº¥x¿n¹q, ÂE®ü, ¤j¥ß¥úµ¥, ¥¼¨Óªº¤Q¦~, ¥xÆWªºÀù¯g·sÃIJ£·~, ·|¤£·|¤]¥X²{¤@¤G®a¥@¬É¯Åªº¼t°Ó©O?

¤Ñªù¬}¬O¥@¬É©_´º¤§¤@, §Ú´Á±æ¥¼¨Óªº¤Q¦~, ¯E¹©¯à¦¨¬°Àù¯g·sÃĪº©_´º, ³o©Î³\¬O§Ú¹C¤Ñªù¬}¤§«áªº"¥P¤H°U¹Ú"§a!?

¯Î°|ªø¦b¤G¦¸ºtÁ¿¤¤(¥x¤j©M²M¤jªººtÁ¿)³£»¡"ÁÞÃþ¤@Á禡µ{¦¡¦Xµ{ªk"¤£¬O¥Lµo©úªº, ¬O¥Lªº£¸¦ì¾Ç¥Íµo©ú«á±Ð¥Lªº, ¥Î¯Î°|ªøªº¦W¸q¥Ó½Ð±M§Q.

¯Î°|ªø»¡, ¥Lªº¾Ç¥ÍÅܦ¨¥Lªº¦Ñ®v, ¥i¨£¯Î°|ªø¦h»ò¦Ñ¹êÁ¾µê, ¤]«D±`¹ªÀy¦~»´¾Ç¤l.

¯Î°|ªø»¡, ¥L¦³¤@¦ì­×³Õ¤hªº¾Ç¥Í, °µ¤F¥|¦~ªº¹êÅç, ¨S¦³¤@¦¸°µ¦¨¥\, §Oªº¾Ç¥Í³£°µ¦¨¥\¤]®³¨ì³Õ¤h¾Ç¦ì.

³o¦ì¾Ç¥Í¦Ç¤ß¤F, ¥h§ä¯Î°|ªø½Í, ·Q©ñ±ó³Õ¤h¾Ç¦ì. ¯Î°|ªø°Ý¥L, §Aªº¿³½ì©M±Mªø¬O¬Æ»ò? ¾Ç¥Íµª: ¼Æ¾Ç©M¹q¸£.

¯Î°|ªø´N§â¥L´X¦~¨Ó¬ã¨sÁÞÃþ¦X¦¨ªº£¸½cµ§°O¥»¥æµ¹¾Ç¥Í, ³o¦ì¾Ç¥Í±N³o½c¸ê®Æ±a¦^®a, ³¬ªù¤@­Ó§«ô¤£¨£¤H.

¤@¶g«á, ³o¦ì¾Ç¥Í¥h§ä¯Î°|ªø, ³ø§i¥L¤w¸g°µ¦n¤F, ¯Î°|ªø¤£¤Ó¬Û«H, ¸g¹L¹q¸£¹ê»Ú¾Þ§@«á, ½T¹ê¥i¦æ.

«á¨Ó¯Î°|ªø¤S¬ã¨s§ï¨}¦¨²{¦bªºÁÞÃþ»Ã¯À¤@Á禡µ{¦¡¦X¦¨ªk. ³o¦ì¾Ç¥Í¥Î¤@¶g­×¦¨³Õ¤h, «á¨Ó¤]³QÄ«ªG°ªÁ~¸u½Ð¨ì¬¥§üÁF·í°ª¶¥µ{¦¡³]­p¸g²z.

¯Î°|ªøªº¤W­zºtÁ¿, Åý§Úı±o³o¬O§_"¤Ñ¦ö¥xÆW", ¦Ñ¤Ñ¦w±Æ¤F³o¦ì¾Ç¥Í(¤Ñ¨Ï)¨Ó¨ó§U¯Î°|ªø, ÅýGlobo H©M¨ä¥LÁÞ¤À¤l(¦pSSEA-4©ÎSSEA-3µ¥)¯àí©wªº¤j¶q¥Í²£,

¤~¯àí©w¤j¶q¥Í²£¦³®Ä¤S¦³¸gÀÙ»ù­ÈªºOBI-822/821©MOBI-833/832, ¯E¹©¥H«á¤~¦³¥i¯à¦¨¬°Àù¯g·sÃĪº¥xÆW©_ÂÝ.

7¤ë19¤é¤§«e, §Ú¹ï¯E¹©¥u¦³80%ªº«H¤ß, 7¤ë19¤éÅ¥¤F¯Î°|ªøªº"¬Ì­]®Úªv¨ÅÀù ¥¼¨Ó¤£¬O¹Ú"ªººtÁ¿¤§«á,

¹ï¯E¹©ªº«H¤ß°¨¤W¼W¥[¬°100%, ¦Û¦¹¤§«á§Y³{§C¥[½X¶R¶i, ¤]­n¨Ä¨Äªº¾Ç£«¬Â¤jªø©ê, "¤@¥Í¥u­n¤@¦¸´N°÷¤F".

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/10/8 ¤U¤È 11:42:16²Ä 1366 ½g¦^À³
¥xÁÞ¤j¡A

35¤Hªº¼Ë¥»©M53¤Hªº¼Ë¥»À³¸Ó¬O¦P¤@­Ó¨ú¼Ë

¦]¬°2008ªº½×¤å©M2012¥Ó½Ð±M§Qªº½×¤å©Ò¥Îªº¨ä¤¤¤@­Ó¼Ë¥»

½s¸¹BC0264¸¹½X©M¹Ï«¬¬O¤@¼Ëªº

¥ý°µG-H©MSSEA-3µM«á¦A¥[¤JSSEA-4°µ¤ñ¸û

percent Cells with expression

§Úªº²z¸Ñ¬O¡G¤£¦Pªº±wªÌªº¨Ò¦pSSEA-3ªºÀù²Ó­M©ÎÀù·F²Ó­M¤¤¦³SSEA-3ªº¦Ê¤À¤ñ

·N«ä´N¬O¡A³o35­Ó¼Ë¥»¤¤¨S¦³¤@­Ó¼Ë¥»ªºÀù²Ó­M©ÎÀù·F²Ó­M¤¤ªºSSEA-3©ÎSSEA-4ªºªí²{¹F¨ì¦Ê¤À¦Ê¡A¦³¨ÇÀù²Ó­M©ÎÀù·F²Ó­M¬O§¹¥þ¨S¦³SSEA-3¤ÎSSEA-4ªº¬Æ¦Ü¥i¯à³sG-H³£¨S¦³¡C

¥H¤W¬O§Úªº²z¸Ñ¡A¦³¿ù½Ð«ü¥¿¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/8 ¤U¤È 11:24:38²Ä 1365 ½g¦^À³
¤p©_¤j

À³¸Ó¥ýÂç²M³o35¦ì¤Hªº¸ê®Æ»P53¤Hªº¸ê®Æ¬O§_¬°¦P¤@§å¨ü¸Õ ©Î¬O¦U¦Û¿W¥ß,¦pªG¬O§R°£,¦]¤ñ¨Ò¬ù3¦¨ (18/53),¦ü¥G¤£¤Ó¥i¯à ¦]¬°¦³ Globo H SSEA3 SSEA4 ³o¤TºØÁÞ¤À¤lªº¤ñ¨Ò°ª¹F99%, ¦pªG¦P®É¥h±¼ SSEA3 SSEA4 ³o¤GºØÁÞ¤À¤lªº¤ñ¨Ò¤@©w¤]·|«Ü°ª,¤£¥i¯à¥u¦³3¦¨,¯à¥h§R°£3¦¨ªí¥ÜSSEA3 SSEA4¦b¨ÅÀù·F²Ó­M»P«D¨ÅÀù·F²Ó­MÀ³ªºªí²{¤ñ²v¤£°ª¤~¦³¥i¯à

2 ¤j³¡¥÷¤H³£ª¾¹D Globo H »PSSEA3 ¦b¨ÅÀù·F²Ó­M»P«D¨ÅÀù·F²Ó­MÀ³ªºªí²{¤ñ²v,SSEA4 ²z½×¤W·|¤ñGlobo H »PSSEA3 ¦b¨ÅÀù·F²Ó­M»P«D¨ÅÀù·F²Ó­MÀ³ªºªí²{¤ñ²v§ó°ª,¦]¬°±M¤@©Ê°ª ,¥H«e¦U¦ì¤j¤j¤]¦b¦³°Q½×SSEA4 DT /C34 °µ¬°¨ÅÀù¬Ì­]°t¤è,«á¨Ó¯E¹©¬ãµoOBI833 ( Globo H DT /C34) ¤@©w¦³¹D²z ,( ¥´3­Ó¨ÅÀù·F²Ó­M»P«D¨ÅÀù·F²Ó­M¤ñ¥´1­Ó¦n)

3 ¥»ª©7¤ë15¤éµ½¤H¤j¨º½g»y­«¤ßªøªº¶K¤å¥i¦A¦^¨ý¤@¤U,¥L³Ìªñ¶À¤s¤§®ÈÀ³¦³¹J¨£¥P¤H«üÂI°g¬z

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/10/8 ¤U¤È 10:49:08²Ä 1364 ½g¦^À³
¥xÁÞ¤j¡A

¤£¬O§â¨S¦³SSEA3¥B¨S¦³SSEA4ªº¼Ë¥»¥h±¼

³o¼Ë¯d¤U¨Óªº¼Ë¥»ªºSSEA3©ÎSSEA4ªº¦Ê¤À¤ñ·|¤ñ¸û°ª¶Ü

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/10/8 ¤U¤È 10:09:27²Ä 1363 ½g¦^À³
¥xÁÞ¤j

·PÁÂ

Cliff¤j

­Y±zÀH®É°lÂܨì¤W¦¸´£¨ì¤wµ²®×ªº¤HÅéÁ{§É¹êÅçµ²ªG¤§´Á¥Zµoªí

¤]¬ß±z¤£§[¤À¨É

·PÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/8 ¤U¤È 05:55:28²Ä 1362 ½g¦^À³
Cliff¤j:

§A»¡³o35¦ìªº¸ê®Æ¤ÀªR¬O53¦ì¨ÅÀù±wªÌÀËÅé¡A¥h±¼¤£§t¦³SSEA-3¤ÎSSEA-4ªº¤§«á¡A¦A°µªº¶i¤@¨B¤ÀªR,¦pªG¬O³o¼Ë

³o35¦ì¯f±wªº¨ÅÀù·F²Ó­M»P«D¨ÅÀù·F²Ó­MÀ³¸Ó³£³£¤£·|ªí²{SSEA-3¤ÎSSEA-4 ,¬°¤°»ò³o35¦ìªº¸ê®Æ¤ÀªR¤¤SSEA-3¤ÎSSEA-4¦b¨ÅÀù·F²Ó­M»P«D¨ÅÀù·F²Ó­Mªí²{¦Ê¤À¤ñ·|¨º»ò°ª?§A¦b¨º¤@­¶¤åÄm¬Ý¨ì¥h±¼¤£§t¦³SSEA-3¤ÎSSEA-4 ? ½Ð¨ó§U¤j®a¸Ñ´b?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/8 ¤W¤È 09:30:49²Ä 1361 ½g¦^À³
Cliff ¤j:

ÁÂÁ§A´£¨Ñ¸ê°T»P«ü¥¿

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/10/8 ¤W¤È 09:21:37²Ä 1360 ½g¦^À³
¥xÁÞ¤j,Cliff¤j

«D±`·PÁÂ!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GCliff10135274  µoªí®É¶¡:2014/10/8 ¤W¤È 08:09:53²Ä 1359 ½g¦^À³
«e½g´£¨Ñªº¸ô®|¤£©öÂI¥X¡u©¥Ä¦¿}Âà´«–¡¡v¥þ¤å¡G

Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575305/

¦Ü©óSupporting Information¡A«h¶·©¹¤å³¹¥½ºÝ²¾°Ê¦ÜACKNOWLEDGMENTS¤W¤è

§ä¨ì¡G

¡uCorrected Supporting Information:

Click here to view. ¡v

ÂI¤J¤U¸üPDFÀÉ¡A¬ÝPage 7/8 Table S1.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GCliff10135274  µoªí®É¶¡:2014/10/8 ¤W¤È 02:08:21²Ä 1358 ½g¦^À³
103/10/8 am

¤p©_¤j¡G

¥xÁÞ¥Sªº¸ê®Æ¨Ó¦Û©ó¯Î°|ªø¦V¬ü°ê¥Ó½ÐGlobo H±M§Qªº¤å¥ó

¦]¬°§ì¨ì¤FHTML®æ¦¡¡A©Ò¥HÄæ¦ì¥þ¶Ã¡A§ï¬ÝPDF®æ¦¡¡A¨º¨Ç¬n±¼ªºªí®æ´N³q³q¦^¥¿¤F¡C

https://docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US8268969.pdf

PDF ²Ä31­¶ªºTable 2 & 3 ³q³q¥ß¥¿¯¸¦n

¨ä¹ê³o¨Ç35¦ìªº¸ê®Æ¤ÀªR¡AÀ³¸Ó¨Ó¦Û©ó¦­¥ý¤TÁ`¥~¬ì«\§Ó¸ÛÂå®v´£¨Ñªº53¦ì¨ÅÀù±wªÌÀËÅé¡A¥h±¼¤£§t¦³SSEA-3¤ÎSSEA-4ªº¤§«á¡A¦A°µªº¶i¤@¨B¤ÀªR¡C¦b¥Ó½Ð±M§Q®É¡A³q³q³Q©ñ¶i¥h¡C

­ì©l¥Zµnªº½×¤å´N¬O©¥Ä¦¿}Âà´«酶ªº¨º¤@½g¡A¦A¥[¤WSSEA-4¸ê®Æ«á¡A©Ò°µªº¶i¤@¨B¤ÀªR¡C

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575305/ ¥þ¤å

http://www.genomics.sinica.edu.tw/index.php/tw/news/news-archives/197-2009-09-08-09-12-55

¤¤¤å·s»D

¥þ¤åùØÁÙªþ¦³supporting information¡AÂI¿ïAbstract¤W¤è¨º¤@­Ó¾î±ÆùتºSI¡A¶i¥h¤U¸üPDFÀÉ¡A§äpage 7/8¡A´N¦³­ì©lªº53¥óÀËÅé¤ÀªR¡A¾Ú¦¹¦A°µSSEA-3¤ÎSSEA-4ªº¤ÀÃþ¤ÀªR§Y¦¨¡C

µ¹¦³¤ß¤F¸Ñªº¤H°Ñ¦Ò¡A¤£·Qª¾¹D¤]µL§«¡AµLÃöªÑ»ù¡A¤£¼vÅTÅv¯q¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/7 ¤U¤È 11:32:14²Ä 1357 ½g¦^À³
¤p©_¤j:

³æ¦ì: percent Cells with expression median

¤¤¤å¤£ª¾¦pªG½Ķ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/7 ¤U¤È 11:13:47²Ä 1356 ½g¦^À³
1 OBI822¦b¬ü°êMSKCC¤@´ÁÁ{§É¦s¬¡²v: 5¦~¥H¤W20/27 (74.07%), 8¦~¥H¤W15/27(55.56%), 9¦~¥H¤W13/27(48.15%) ±À´ú1998¦Ü1999¦~¤@´ÁÁ{§ÉÀ³¤w¥´¨ì¨ÅÀù·F²Ó­M, ¥u¬O·í®É¨S¦³¥h©â¦å¬ã¨s,§_«h¤£¥i¯à¥½´Á¨ÅÀù¯à¬¡¨º»ò¤[

2 ¨ÅÀù²Ó­Mªºªí²{²v

SSEA4 (91.4%) >SSEA3 (77.5%)>GloboH(61%)

3 ¨ÅÀù·F²Ó­Mªºªí²{²v

SSEA4 (88.6%) >SSEA3 (62.5%)>GloboH(20%)

4 OBI822 ¤@¦¸¥´Globo H SSEA3 SSEA4 ¤T­Ó¨ÅÀù·F²Ó­M»PÀù²Ó­M, °w¦¸¦h4°w ¾¯¶q¦h20·L§J IGM ¥ý¥X¨Ó¥´¨ÅÀù²Ó­M»P·F²Ó­M4¦Ü6¬P´Á,¼Ä¤H³QÄè·À¤@¤j¥b«á IGG ¦A¥X¨Ó¥´¨ÅÀù²Ó­M»P·F²Ó­M3¦Ü6­Ó¤ë,À³·|¬O¤@³õºë±mªºÄè·À¾Ô

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/10/7 ¤U¤È 11:07:44²Ä 1355 ½g¦^À³
¥xÁÞ¤j,½Ð¸û¤@¤U

expression median ªº³æ¦ì¬O¤°»ò?

·PÁÂ!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/7 ¤U¤È 10:43:56²Ä 1354 ½g¦^À³
Faith ¤j:

¤£¬OA¬ã¨s B¬ã¨s

¬O A¶µ B¶µ C¶µ D¶µ §Ú¤À¶µ±Ô­z ¦U¦Û¿W¥ß

SSEA-3 (³Ìªñ§ä¨ìªº¸ê°T±µªñ2008¦~¬ã¨s ¥H35¦ì¯f±w¬°¹ï¶H)

Total 35 27 36.4 (1.4-66.4) 77.1

Non-BCSCs 35 25 40.5 (24.3-70.4) 71.4

BCSCs 35 23 24.3 (5.0-58.4) 65.7

²Ä¤@¶µ¬O ¨ÅÀù¯f¤H¼Æ 35 ¤H ¦³27 ¤H¦bSSEA3 ¦³ªí²{(¶§©Ê)¦Ê¤À¤ñ 27/35=77.1%

²Ä¤T¶µ¬O expression median ªí²{¤¤¦ì¼Æ ²Ä¥|¶µ¬O (Range)½d³ò ²Ä¤­¶µ¬O¥þ³¡¯f¤H¤¤¦bSSEA3¶§©Ê¦Ê¤À¤ñ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/10/7 ¤U¤È 10:26:25²Ä 1353 ½g¦^À³
²Ä¤@­Ó°ÝÃD¸É¥R»¡©ú

A»PB¬O¦P¤@­Ó¹êÅ禳¤£¦Pªºµo²{¡H¨Ã¤À¦¨Abc...

ÁÙ¬O¦U¦Û¿W¥ßªº¹êÅç¡H

¥ç©Î¬O¥u¤º®e¦³ÂI¤£¤@¼Ëªº¹êÅç¡H

©Î¬O....

·PÁÂ@@

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/10/7 ¤U¤È 10:09:38²Ä 1352 ½g¦^À³
¥xÁÞ¤j ·PÁÂ

½Ð±Ð´X­Ó°ÝÃD

1.±z´£¨ì

¡u2008¦~³¯¹a¬z°Æ¥D¥ô¤Î·F²Ó­M¹êÅç«Ç­t³d¤H´å¥¿³Õ¯S¸u¬ã¨s­ûªº¦X§@¤U¡A®i¶}Globo H©óÀù¯g·F²Ó­Mªº±´°Q¥H¬y¦¡²Ó­M»ö§Þ³N¡A°w¹ïGlobo H¥H¤Î¨ä¤­¤À¤l«eÁÍÁޯ׽èGb5¡]¤SºÙSSEA3¡^¦b¨ÅÀù·F²Ó­Mªí­±ªºªí²{§@¤ÀªR

A¬ã¨s³ø§iÅã¥Ü¡A¥H¶q¦Ó¨¥¡AGlobo H¦b¤@¯ë¨ÅÀù²Ó­Mªºªí²{²v¹F61% ¡A©óÀù·F²Ó­M¬°20%¡F

B¬ã¨s³ø§iÅã¥Ü¡A¥H¶q¦Ó¨¥ Gb5 (SSEA3)¦b¤@¯ë¨ÅÀù²Ó­Mªºªí²{²v¹F77.5%¡A¦Ó©ó¨ÅÀù·F²Ó­M«h¬°62.5%¡C¡v

½Ð°Ý¤åÄm¸ê®Æ¤¤¬O§_¦³´£¤ÎA¬ã¨s»PB¬ã¨sªº®t§O¦ó¦b¡H

2.¤p§Ì¤£§÷¡A²Ä¤@­Ó¼Æ¾Ú¥Nªí´X¦ì¡A½Ð±Ð¨ä¥¦¼Æ¾Ú¥Nªí¤°»ò¡H

Total 35 27 36.4 (1.4-66.4) 77.1

Non-BCSCs 35 25 40.5 (24.3-70.4) 71.4

BCSCs 35 23 24.3 (5.0-58.4) 65.7

¥H¤W ¬Û¤¬¤Á½R ·PÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/7 ¤U¤È 07:16:55²Ä 1351 ½g¦^À³
¦U¦ì¤j¤j:

2008¦~8¤ë¤¤¬ã°|·F²Ó­M¹êÅç«Ç­t³d¤H´å¥¿³Õ¸ÑÄÀ¡AÁöµMÀù¯g·F²Ó­M¥u¥e©Ò¦³Àù²Ó­Mªº1%¡A¦ý¬O¥¦·|¨ÏÀù²Ó­M¼W¥Í¡A¤]·|¤À¤Æ¥X¤l¥N²Ó­M¡A³ôºÙÀù¯g¥Íªøªº·½ÀY¡F¦pªG¤£¡A¸Ñ¨M±¼Àù¯g·F²Ó­M¡AÀù²Ó­M´N¥i¯àµLªk®Úªv¡C©Ò¥H¥HÀù¯g·F²Ó­M§@¬°§ÜÀùªº¥D­n¼Ðªº¡A¬O³Ì·sªº¬ã¨sÁͶաC(¤¤¬ã°|2008¦~´N¤wµo²{Àù¯g·F²Ó­M§@¬°§ÜÀùªº¥D­n¼Ðªº)

­Ó¤H»{¬° ¯E¹©ªºOBI822 833 ³Ì®Ö¤ßªº¤T­Ó°ÝÃDµª®×¬O¦pªG¬OªÖ©wªº OBI822 833±N·|¬O¾_¾Ù¥þ²yªº·sÃÄ,¥Ø«e¥þ²y¤w¤W¥«ªº¨ÅÀùÃĪ«©Î¬ãµo¤¤ªºÃĪ« (¬Ý¤£¨ì¥HÀù¯g·F²Ó­M§@¬°§ÜÀùªº¥D­n¼Ð¹v) OBI822 833 ¤@¦¸§ä¨ì¤T­ÓÀù·F²Ó­M»PÀù²Ó­M¼Ð¹v

¥H¤U¸ê°T´£¨Ñ°Ñ¦Ò,¨Ã½Ð¹LÂo¸ê°T,¸Ô¥[§PÂ_ ¦p¦³¿ù»~½Ð´£¥X§ó¥¿«Øij

1OBI822 833¬O§_¹ï©óGlobo¨t¦CÁާܭìSSEA3 SSEA4 Globo H³£¦³Binding (§ÜÅé»P§Ü­ìµ²¦X«á²£¥ÍÄè·À§Ü­ìªº¤ÏÀ³)

OBI pharma observer¬ö¿ý ½T©wOBI822 ¹ï©óGlobo ¨t¦CÁާܭìSSEA3 SSEA4 Globo H ³£¦³Binding

­Ó¤H±À´ú§ÜÅé¶qÀ³·|¦b©ú¦~¸Ñª¼«áµoªí¤åÄm¤@¨Ö¤½§i , OBI 833 ·|¦b§¹¦¨¤@´ÁÁ{§É«áµoªí¤åÄm«á¤½§i

2 GLOBO H , SSEA3 , SSEA4 ¬O§_³£¦³¦bÀù²Ó­M»PÀù·F²Ó­Mªí²{

2008¦~³¯¹a¬z°Æ¥D¥ô¤Î·F²Ó­M¹êÅç«Ç­t³d¤H´å¥¿³Õ¯S¸u¬ã¨s­ûªº¦X§@¤U¡A®i¶}Globo H©óÀù¯g·F²Ó­Mªº±´°Q¥H¬y¦¡²Ó­M»ö§Þ³N¡A°w¹ïGlobo H¥H¤Î¨ä¤­¤À¤l«eÁÍÁޯ׽èGb5¡]¤SºÙSSEA3¡^¦b¨ÅÀù·F²Ó­Mªí­±ªºªí²{§@¤ÀªR

A¬ã¨s³ø§iÅã¥Ü¡A¥H¶q¦Ó¨¥¡AGlobo H¦b¤@¯ë¨ÅÀù²Ó­Mªºªí²{²v¹F61% ¡A©óÀù·F²Ó­M¬°20%¡F

B¬ã¨s³ø§iÅã¥Ü¡A¥H¶q¦Ó¨¥ Gb5 (SSEA3)¦b¤@¯ë¨ÅÀù²Ó­Mªºªí²{²v¹F77.5%¡A¦Ó©ó¨ÅÀù·F²Ó­M«h¬°62.5%¡C

C¤¤¬ã°|2013¦~8¤ëÂç²M¤FSSEA-4»PÀù¯gªºÃöÁp¡A¤]½T»{­Y´î¤ÖÀù²Ó­M¤W¤§SSEA-4ªí²{¶q¡A©Î¨Ï¨­Åé²£¥Í¹ï§ÜSSEA-4¤§§ÜÅé¡A¥i¥H¦³®Ä­°§C¸~½F²Ó­M´c¤Æ¤§¾÷²vSSEA-4¬O¨ÅÀù¬Ì­]ªº¼Ð¹vÁÞ¤À¤l¡A¦]¬°¥¦¨ã¦³¤@¤ÁÁÞ¤À¤l¬Ì­]ªº³Ì¨Î±ø¥ó¡ASSEA-4³oºØÁÞ¤À¤l¡A°ª«×ªºªí²{©ó¨ÅÀù²Ó­M¤Î¨ÅÀù·F²Ó­M¡A¤×¨ä¬O·íÀù²Ó­M¶}©l´c¤ÆÂಾªº®É­Ô

D Comparison of SSEA4 and SSEA3 expression in BCSCs and non-BCSCs

Population patients No. expression median (Range)Total

Non-BCSCs «D¨ÅÀù·F²Ó­M BCSCs¨ÅÀù·F²Ó­M

SSEA-4 (³Ìªñ§ä¨ìªº¸ê°T ¥H35¦ì¯f±w¬°¹ï¶H)

Total 35 34 41.4 (0.5-77.1) 97.1

Non-BCSCs 35 32 43.7 (4.0-78.1) 91.4

BCSCs 35 31 37.1 (5.6-83.6 ) 88.6

SSEA-3 (³Ìªñ§ä¨ìªº¸ê°T±µªñ2008¦~¬ã¨s ¥H35¦ì¯f±w¬°¹ï¶H)

Total 35 27 36.4 (1.4-66.4) 77.1

Non-BCSCs 35 25 40.5 (24.3-70.4) 71.4

BCSCs 35 23 24.3 (5.0-58.4) 65.7

3 Àù·F²Ó­M¬O§_¬°Àù²Ó­MªººØ¤l

¬ì§Þ³¡ ¬ì§Þ¤jÆ[¶é : Àù²Õ´ªººØ¤l¡VÀù·F²Ó­M

http://scitechvista.most.gov.tw/zh-tw/Articles/C/0/1/10/1/50.htm

Cancer: a disease of stem cells Àù¯g¬O·F²Ó­M¯e¯f

http://www.eurostemcell.org/factsheet/cancer-disease-stem-cells

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p±¶10135877  µoªí®É¶¡:2014/10/7 ¤U¤È 04:01:33²Ä 1350 ½g¦^À³
¦³¤@ºØªF¦è¥s°£Åv°tªÑ,°£«D¹³ªi§J®L¤½¥q(¤Ú«D¯Sªº¤½¥q)¤@ªÑ20¸U¬üª÷¾ú¦~¨Ó¤Ö¦³°tªÑ®§(40¦~¨Ó²b­È¦¨ªø4000­¿)
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2014/10/7 ¤U¤È 02:50:26²Ä 1349 ½g¦^À³
¸É¥R¤@¤U..

·Q¨ì·í®É¬°¦ó½Ä°Ê.«Øij³o­Ó¹w´ú..

¦]¬°¨º®É¦³¤@­Ó¥ú.¤@ª½¦b³ÛEPS.EPS.Á«¿úªº¤½¥qµ¥µ¥......

·í¯E¹©¶}©l¦³ EPS ®É.¦³ÂI¾á¤ß¦³¬y°Ê©Êªº°ÝÃD..

----¦]¬°ªÑ»ù¥i¯à°ª¨ì¤@¯ë§ë¸ê¤H.¤pªk¤H¶R¤£°_¤F..«¢«¢«¢

----­È¤j©].ºÎ¯v¤£¨¬.­J¨¥¶Ã»y.·q½Ð­ì½Ì..¥h¸É¯v¤F..

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/10/7 ¤U¤È 02:44:57²Ä 1348 ½g¦^À³
°e³ø¤j

·PÁÂ

¯u§Æ±æ³o¨Ç²q´ú¥i¥H¦¨¯u

ǢǢǢ~~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2014/10/7 ¤U¤È 02:31:01²Ä 1347 ½g¦^À³
Faith¤j..

¥u¬O¬Ý¨ì µL±¡¯u¹ê ªººô­¶¦³³sµ²¥»ª©(¤é²±µû¦ô³ø§i)¹w´ú¯E¹©¥¼¨ÓªÑ»ù.

´N¦b³o«Øij¤@­Ó¿ï¶µ. µL±¡¯u¹êª©¤j¥i¯à¤]¬Oı±o¤Ï®t°÷¤j.´N±µ¨ü¤F..

104¦~¶}©l

822¨ÅÀù³¡¤À­n¥þ²y3´Á.¨ä¥L¾AÀ³¯g¤]¦³¥i¯à¤ñ·Óª½±µ2-3´Á

833§Öªº¸Ü104¦~©³«e¥i¯à1´Áµ²§ô¨ì2´Á¶}©l.

¨ä¥L888.868.858.¤]³£¦³¶i«×

¤pªº²q´ú§ë¤J¶W¹L¤@­ÓªÑ¥»ªº¾÷·|«Ü¤j.¤]«Ü§Æ±æ¥L¶W¹L..

³o¨Ç¸ÕÅç¸g¶Oªá±o¥X¥hªí¥Ü¶i«×¶¶§Q.ªÑ»ù¤]À³¸Ó¤ÏÀ³»ù­È..

¦b102¦~¼W¸ê»¡©ú®Ñ.¤½¥q¹w­p¦Û105¦~°_±N¦³À禬¤ÎÅv§Qª÷¦¬¤J2.5-3»õ¬ü¤¸

²q´ú104¦~822Åv§Qª÷À³¸Ó¥i¥H½T©w.105¦~¤~¦³¾÷·|»{¦Cñ¬ùª÷..

¦A¥[¤W822¼Æ¾Ú¤½¥¬.¥xÆWÃÄÃÒ.

¥H¤W§Q¦h¤ÏÀ³¦b105¦~ªºªÑ»ù1000¤¸À³¸Óºâ§C¦ô¤F.

¥H¤W·íµM³£¬O²qªº..

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý£«¬Â10136621  µoªí®É¶¡:2014/10/7 ¤U¤È 01:28:11²Ä 1346 ½g¦^À³
ªì´ÁªºÀù¯g·F²Ó­Mªí­±°£¤F¦³Globo Hªºªí²{¡AÁÙ¦³¤j¶qªºSSEA-3»PSSEA-4ªí²{¡C¦¹¨âºØÁާܭì¤]ÁõÄÝ©óGlobo-¨t¦C¡C¦¹¥~¡ASSEA-3»PSSEA-4¤£¥u¦bÀù¯g·F²Ó­M¦³ªí²{¡A¦bÀù¯g²Ó­M¤¤¤]¦³ªí²{¡C

¹ï¦¹·sµo²{¡A§Ú­Ì§Q¥Î³o¤TºØÁާܭì·f°t¥Õ³ï¬r¯À¬ðÅÜÅé (DT-CRM 197) ¥H¤Î¦õ¾¯¨Ó³]­p·sªº§Ü¨ÅÀù¬Ì­]¡A´Á±æ¥i¥H¼W¥[Àù¯g¬Ì­]ªº®Ä¯à¡C§Ú­Ìªº¬ã¨sµo²{¡AGlobo H-DT¥i¥H»¤µo¤j¶q¥i¿ëÃÑGlobo H, SSEA-3, and SSEA-4 ªº§ÜÅé¡C§Q¥ÎSSEA-4-DT²£¥Íªº§ÜÅ馳«Ü°ªªº±M¤@©Ê¡C¥t¤@¤è­±¡ASSEA-3¥H¥Õ³ï¬r¯À¬ðÅÜÅ鬰¸üÅé³J¥Õ©Ò»s¦¨ªº¬Ì­]¡A»PGlobo H¥H¤ÎSSEA-4¬Û¤ñ¡A¥Ñ©ó¯Ê¤Ö©¥Ä¦ÁÞ(fucose)©Î³è²G»Ä(sialic acid)¡A²£¥Íªº§ÜÅé±M¤@©Ê«h¸û®t¡C¥O¤H¿³¾Äªº¬O¡A³o¤TºØ¬Ì­]©Ò²£¥ÍªºIgG³£»·°ª©óIgM¡A¦]¦¹¡A¦¹¤@¬Ì­]ªº«ù¤[©Ê¬O¥O¤H´Á«Ýªº¡C

(¥Ñ¦¹¥i¬Ý¥Xobi-833ªº±N¨Ó©Ê¤£¥i¤p¬Ý)¶È¨Ñ°Ñ¦Ò.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/10/7 ¤W¤È 08:28:50²Ä 1345 ½g¦^À³
¥xÁÞ¤j ·PÁÂ

°e³ø¤j

§A«ç»ò³Q¼Ðµù¦b³o½g·í¤¤¤F

"4174 ¯E¹©¥¼¨ÓªÑ»ù¹w´ú¡G ¯E¹©·|º¦¨ìXXXX¤¸¦¨¬°¡y¥xÆW¤§¥ú¡z¶Ü¡H"

(½Ð¯E¤Í¦³¿³½ìªº¦Û¤v»`´M,¸ê°T¦³§ó·s,§Ú¤£·Q³Q·í¦¨ª£ªÑ¤H,©Ò¥H³o½g¹w¦ôªº»ù¿ú§Ú¥ÎXXXXªí¥Ü)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥xÁÞ10138776  µoªí®É¶¡:2014/10/6 ¤U¤È 09:55:54²Ä 1344 ½g¦^À³
¦U¦ì¤j¤j:

OBI822 ªº¥¼¨Ó ¦b©óBinding »P cancer stem cell

Binding ¦b Physical sciences ¦ÛµM¬ì¾Ç¤W¦³³\¦h©w¸q

Binding antibody ©w¸q¦p¤U (¨Ì¾Úºû°ò¦Ê¬ì)

Binding antibody, an antibody that has a reaction when combined with an antigen, possibly eliminating it (·í§ÜÅé»P§Ü­ìµ²¦X¦b¤@°_®É²£¥Í¤F¤ÏÀ³,¥i¯à¬OÄè·À§Ü­ìªº¤ÏÀ³)

§Ú¥H·í§L¥´¹v¬°¨Ò¤£ª¾¬O§_¦X¾A: ¤l¼u¬O§ÜÅé ¹v¬O§Ü­ì,®gÀ»«á¦p¥¿¤¤¬õ¤ß10¤À ¤¤²Ä¤G°é8¤À ¤¤²Ä¤T°é6¤À ²Ä¥|°é4¤À ²Ä¤­°é2 ¤À °é¥~ 0¤À , §ÜÅé»P§Ü­ìµ²¦X¦b¤@°_®É²£¥Í¤F¤ÏÀ³´N¬O¯È¹v¯}¬},¨Ì¯}¬}¦ì¸m ±o¨ì¤£¦P¤À¼Æ,¦p¦P¤l¼uK¨ì¹v®É¼uÃĴݯd¦b¯È¹v¯}¬}¤W(§ÜÅé¶q) ¥¿¤¤¬õ¤ß¬O§_´N¬O¥´¨ì¨ÅÀù·F²Ó­M?

Binding antibody : Binding¬O¦æ®eµü (ÂH¶K¦b¤@°_ µ²¦X¦b¤@°_ ¸j¦b¤@°_)

¯E¹©ªºOBI822 833 888 µ¥²£«~¬O§_¯à¦b¥ÍÂå¥v¤W¦W¯d¦b©ó

1 OBI822 833 888 ¬O§_¹ï©óGlobo ¨t¦CÁާܭ쳣¦³Binding

2 GLOBO H , SSEA3 , SSEA4 ¬O§_³£¦³¦bÀù²Ó­M»PÀù·F²Ó­Mªí²{

3 Àù·F²Ó­M¬O§_¬°Àù²Ó­MªººØ¤l

¥H¤W¤T¶µ¦pªG¬OªÖ©wªº ,¯E¹©ªºOBI822 833 888 µ¥²£«~±N·|¦b¥ÍÂå¥v¤W¯d¦W

¤¤¬ã°|°ò¦]Åé¬ã¨s¤¤¤ß¬ã¨s­û§d©v¯qªí¥Ü¡A¡u±Ù¯ó¤£°£®Ú¡A¬K­·§j¤S¥Í¡v¡A¤S»¡¡u¾à¸é¥ý¾à¤ý¡v¡A¦pªG§Ú­Ì¥u¬O°w¹ï¨ÅÀù²Ó­M¥h°µªvÀø¡A®ÄªG©¹©¹¤£¬O«Ü¦n¡A¤ÏÆ[­Y¯à±q§ó·½ÀYªº¨ÅÀù·F²Ó­M¤U¤â¡A¦¨¥\ªº¾÷·|´N¤j¦h¤F¡C

¥Ø«e¥u¬O¤pªi®ö,¦pªG¯à²`¤JÁA¸ÑBinding »Pcancer stem cell ¤~¯à¹wª¾¥¼¨Ó®ü¼S¬O§_¨ÓÁ{,¤µ¤Ñ¤£¤U­Ó¤Hµ²½×, ¯d¤U¤@¨ÇªÅ¶¡Åý¦U¦ì¤j¤j¥h·Q¹³

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÂŤÑ10138178  µoªí®É¶¡:2014/10/6 ¤U¤È 01:07:32²Ä 1343 ½g¦^À³
°e³ø¤j §ÚÆZ»{¦P§AªºÆ[ÂI ¥D¤O·Qª®À»ªº¹ï¶H¬O§ë«H°òª÷ .²¦³º¹ï´²¤á¨Ó»¡4¦Ê¦h¤¸ªºªÑ²¼¤£¬O´¶Ã¹¤j²³³£¶R±o°_¤]´±¶Rªº.¦ý§Úı±o±q3¦Ê¥ª¥k¶}©l¤Wº¦ À³¸Ó¬O¥D¤O¤w¸g¶}©l¤À¬q±À¤ÉªÑ»ù.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/10/6 ¤W¤È 11:44:39²Ä 1342 ½g¦^À³
­ì¨Ó¦p¦¹¡A³o¸Ìªº¯E¤Í³£³o»ò¤j©@(±i¼Æ¦h©Î©ê±o¤[)

Iriswu¤j»¡¡G¡yS F¤j±z²q¿ù¤F,§Úªº«ùªÑ¬Û«H¤ñ³o¸Ìµo¨¥ªº99%ªº¤H³£°ª¡z¡A¡ybill¤j,§Úª¾¹D±zªº«ùªÑ¤£¤Ö,§Úªº«ùªÑ¤ñ±zÁÙ°ª¡z

Faith¤j»¡¡G¡y³o¤]¬O¬°¤°»ò§Ú¦­±N«ùªÑ¥þ´«¦¨¯E¹©ªº­ì¦]¡A¡]§Ú¥i¤]¤£¬O¤p©@ªºªÑªF...«¢«¢«¢¡^¡z

¤ý£«¬Â¤j»¡¡G¡y§Ú«ùªÑº¡2¦~,²Ä¤@§å¶R¶i10±i¥H438¤¸­è¦nì§Q6­¿¡z

°e³ø¤j»¡¡G¡y¤pªº§ë¤Jªº¦¨¥»¬O¤£¨ì¤d¸U.¦ý¬O¦¨¥»§¡»ù94¶ô¦h¡A§O¦]¬°§Ú³ßÅw¶Ã²q.´N§â§Ú¬Ý±o¤Ó¤p©@.¡z

Ãø©Ç¯E­ô¦¨¥æ¶q´î¤Ö¤F¡A°£¤F¤jªÑªF¥~¡A­ì¨Ó³Q¥²´Iºôªº¯E¤Íµ¹Âê½X¤F¡C

Iriswu¤j¡Abill¤j¡AFaith¤j¡A¤ý£«¬Â¤j¡A°e³ø¤j¡A¯E­ô¼È®É¨S¤°»ò·sÂA¨Æ¡Aª©­±¸û§N²M¡A¶}­Ó¤pª±§µ¡A½Ð¨£½Ì¡C

¤p§ÌÁöµM±i¼Æ¤£¦h¡A©êªÑ®É¶¡¤]¨S¨º»òªø¡A¦ý¥Î¥\ªºµ{«×¬O¸ò¤j®a¤@¼Ëªº¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¹Ç§AÅó±ø±ø10135894  µoªí®É¶¡:2014/10/6 ¤W¤È 10:54:22²Ä 1341 ½g¦^À³
ÁöµM¤£¬O³Ì·sªº¸ê°T¡A¤£¹L·Å¬G¦Óª¾·s¤@¤U¡C

®Ú¾Ú¥x¥_µØ·s§ß½üªÀ¤µ¦~5/1³ø¾É,¥xÆWªñ¦~ªº§Z±_Àù¿©±w²v¬O¨C¦~1200¾l¤H¡A¬Û¹ï©ó¤j¸zÀù¨C¦~¬ù¤@¸U¤H,¾ãÅé¨Ó»¡§Z±_Àùªº¤­¦~ªº¦s¬¡²v¬O30% ¡Astage 1ªº¤­¦~¦s¬¡²v¥i°ª¹F90%¡Astage 2¬ù65%¡Astage 3¬ù35%¡Astage 4«h¥u¦³10% ¡C

¥Ø«eªºªvÀø¤èªk¥ý¤â³N¡A§âÀù²Ó­MºÉ¥i¯àªº²¾°£¡A¦P®É°µ¤Á¤ù¤À´Á¡A±µµÛ°µ¤Æ¾ÇªvÀø(Carboplatin+Paclitaxel)¡C¤Æ¾ÇªvÀøºâ¬O«D±`¦³®Ä¡A¬ù 70%~80%ªº¯f¤H¦³ªvÀø®ÄªG¡A¦ý¨Ã¤£¯àªv¡¡A¬ù 80%·|´_µo¡A¥B¬O¤ÏÂЪº´_µo¡A´_µoªº¶¡¹j®É¶¡³vº¥ÁYµu¡A©M§ÜÃĩʦ³Ãö¡C²Ä¤@¦¸´_µoªº®É¶¡¤j·§¬O2¦~¡AµM«á1¦~¡A6­Ó¤ë¡A2­Ó¤ë¡C¸¡µÄ¦³«Ü¦h´åÂ÷ªÅ¶¡¡AÀù²Ó­MÀHµÛ²Õ´²G¨ì³B¹C¨«¡A´²ªº«Ü§Ö¡A«á´Á³£¸¡µÈ¡A¸z¤l¤£°Ê¡C

ªñ10¦~³°Äòµo²{¡A¦³¨ÇÀù²Ó­M¦³¨ä¯S¦³ªºÁޤƪ«(carbohydrate antigens)¡A¬O¥¿±`²Ó­M©Ò¨S¦³ªº§Ü­ì¡C§Z±_Àù¡B¨ÅÀù¡BÄáÅ@¸¢Àù¤ÎªÍÀùµ¥²Ó­Mªºªí­±¡A³£¦³¤@ºØ¯S®íÁÞÃþGlobo H¡C·sªºªvÀø¬O§Q¥Î¥X²{¦bÀù²Ó­Mªí­±ªº¯S©wÁÞÃþ¡uGlobo H¡v»s¦¨¬Ì­]¡A±wªÌ¬I¥´¬Ì­]«á·|²£¥Í§ÜÅé¡A¨Ã¿Eµo¤HÅé«Ü±jªº§K¬Ì¤ÏÀ³¡A¹ï§ÜÀù²Ó­M¡A¦ý¤£·|¶Ë¤Î¥¿±`²Ó­M¡CÁ{§É¸ÕÅç©ó102¦~©³¶}©l¦¬®×¡A¥Ø«e¦¬®×40¾l¤H¡A¹w­p¨â¦~¤º¦¬®×110¦W±wªÌ¡A¥Hµû¦ô§Z±_Àù¬Ì­]ªºÀø®Ä¡A¦¬®×¹ï¶H¥²¶·¬O²Ä¤G´Á¨ì²Ä¥|´Á¡A¤w±µ¨ü¹L¼Ð·ÇªvÀø¡B¥¿¦b°lÂܪº§Z±_Àù±wªÌ¡AÁ`¦@­n¬I¥´12¦¸¬Ì­]¡A¤£¦¬¶O¥Î¡A§Æ±æµ²®×¦¨ªG¯à§e²{©µªøÀù¯g§Z±_Àù´_µoªº®É¶¡©Î¬O¹w¨¾´_µo¡C

¥Ø«e±µ¨ü¬Ì­]ª`®gªº40¾l¤H¡A¹ï¬Ì­]ªº­@¨ü©Ê³£ºâ¤£¿ù¡A¤Ö¼Æ¦³µu¼Èªº§½³¡¬õ¼ö©Îªø¯l¤l¡A¨S¦³³y¦¨¨ä¥L¶Ë®`¡C¤w±µ¨ü¹L¼Ð·ÇªvÀøªº¤H¤~¥i¥H°Ñ¥[¦¹Á{§É¸ÕÅç¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p±j10137673  µoªí®É¶¡:2014/10/6 ¤W¤È 08:41:25²Ä 1340 ½g¦^À³
¤p¹D®ø®§.¯E¹©¦b°¨°º¬ö©ÀÂå°|§Z±_ÀùÀù¤G´Á¦]®ÄªG¤Ó¦n.¾É­P§Z±_ÀùÀù¯f±w¤j¶q´é¤J.¨ä¥LÂå°|¦¬¤£¨ì¯f±w.¤£ª¾¦³­þ¦ì¤j¤j¯àÃÒ¹ê.ÁÂÁÂ
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/10/6 ¤W¤È 07:20:33²Ä 1339 ½g¦^À³
°e³ø¤j

Áo©ú Æg

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2014/10/6 ¤W¤È 12:35:05²Ä 1338 ½g¦^À³
¤pªº§ë¤Jªº¦¨¥»¬O¤£¨ì¤d¸U.¦ý¬O¦¨¥»§¡»ù94¶ô¦h.

§O¦]¬°§Ú³ßÅw¶Ã²q.´N§â§Ú¬Ý±o¤Ó¤p©@.

9¤ë¥H¨Óªº¤Wº¦.«Ü¥i¯à¦p¦¿´ò¶Ç¨¥ªº.¥u¬O·mÄw½XªººÆª¯®ö.

¦ý³oªiªº¥D¤O·Qª®À»ªº¹ï¶H.À³¸Ó¤£¬O¤@¯ë´²¤á.²¦³º¤w¸g400¦h¶ô

¦Ó¬O¤WÂd«e.¥u¯à¦b®Ç¬y¤f¤ôªº§ë«H.°òª÷.¥~¸êµ¥..

©Ò¥H4.5¦Ê¤ÑÀI.Å]©G...¥i¯à¤p¬Ý¤F³oªi¥D¤Oªº³g¤ß..

¤WÂd«e¦æ±¡À³¸Óº¡¥iÆ[ªº.¦Ó¥B¤½¥qÀ³¸Ó¤]·|°t¦Xºt¥X.

¦b¾A·íªº®É¶¡µo¥¬¤@¨Ç§Q¦h..

²¦³º³o¦¸¤WÂd¤@¸U¦h±iªÑ²¼¥i¶Ò±oªº¸êª÷¤ñ¾ú¦~ªº15¸U±iÁÙ¦h.

¦Ó¥B¥i¯à¬O»{¦Cñ¬ùª÷«e³Ì«á¤@¦¸¦VªÑªF­n¿ú..·íµM¬O¦h¦h¯qµ½¤F..

¥H¤W¤pªº¤S¦b¶Ã²q¤F...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/10/5 ¤W¤È 10:15:37²Ä 1337 ½g¦^À³
Faith¤j ÁÂÁ±zªº¤ä«ù©MÃö¤ß

¤p§ÌÀRÀq ¥D­n¬O¨S·Qªk¦nÁ¿ ¤£¬O¤£Ãö¤ß

¤p§Ì²{¦b¤]©M¤j®a¤@¼Ë --- µ¥«Ý¸Ñª¼

¦Aµøµ²ªG ¨Ó½Õ¾ã¦Û¤v«ùªÑªº°t¸m¤ñ­«

ÁÂÁ±z ¤]ÁÂÁ¤j®a´£¨Ñªº¸ê°T

¯¬ºÖ¤j®a³£¤jÁÈ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/10/5 ¤W¤È 10:15:11²Ä 1336 ½g¦^À³
µ½¤H¤j

±z¤ÀªRªº¬Û·í²`¤J

¦³²´¥ú¡B¦³«e¤

³o¤]¬O¬°¤°»ò§Ú¦­±N«ùªÑ¥þ´«¦¨¯E¹©ªº­ì¦]

¡]§Ú¥i¤]¤£¬O¤p©@ªºªÑªF...«¢«¢«¢¡^

¥t¤@½g¦³¤H°Ý¨ì¡G¥¼¸Ñª¼ªºªì¨B¤ÀªR¦ó®É¤½§G

­Ó¤H²q´ú¡G­Y¤½¥q¦³°µªì¨B¤ÀªR¡A±N·|¦b³ÌÁo©úªº®É¶¡ÂI¤½§i

¤°»ò¬O³ÌÁo©úªº®É¶¡ÂI¡H´N¯dµ¹¯E¤Í­Ì°Ê°Ê¸£¤F

¯E¤Í­Ì¡G°µµ½¨Æ¬OÀH®ÉÀH¦a¡B¦¹®É¦¹¨è¡A¥i¤£¬Oµ¥¨ì....¤~....

¥[ªoÅo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gµ½¤H10137888  µoªí®É¶¡:2014/10/5 ¤W¤È 12:13:32²Ä 1335 ½g¦^À³
£«¬Â¤jªº¦W¨¥: "¤@¥Í¥u­n¤@¦¸´N°÷¤F". ¦³²´¥ú¦³ÁxÃÑ, §ë¸ê¨ì¹ïªº¼Ðªº, ¯uªº¤@¥Í¥u­n¤@¦¸´N°÷¤F.

¬Ý¬Ý¤¨¦ÑÁó·íªìNT30¤¸¦Y¤U¥xÆW¯E¹©ªº©Ò¦³ªÑÅv, ¤~´X¦~ªº®É¶¡, Àò§Q¤w¸g13.6­¿, ¶W¹L200»õ¥x¹ô.

­«ÂI¬O, ¦Ü¤µ¤@±i³£¨S½æ, ÁÙ¨C¦¸³£°Ñ»P²{ª÷¼W¸ê.

¥H«e¦³¯E¹©ªº¬Y¨Ç¸g²z¤H´î¤Ö«ùªÑ, ¤@¨Ç³Ð§ë¤½§i½æ¥X«ùªÑ, ¤]¬O¦³¨Ç¤j¤jµo¤åĵ§i¯E¤Í­n¤p¤ß, ¦p¤µÃÒ©ú¥L­Ì³£½æ¿ù¬Ý¿ù¤F.

¤]³\¤£¯à»¡¥L­Ì½æ¿ù, ¦]¬°¥i¯à¦³¥L­Ì­n½æªº­ì¦], ¥ª¤âÂà¥k¤â, ¦ý¬O¤£¦Pªº¤H?

¤]¦]¬°³o¨Ç³Ð§ë¦b¤@¦Ê¦h¤¸, ¤G¦Ê¦h¤¸¤À§å½æ±¼, ³Q¥ýª¾¥ýıªºÁo©ú¿ú¤À§å±µ¨«Âê¦í, ¥[¤W²³¯E¤ÍªºÂêªÑ, ³y´N³o¤@ªi¤Wº¦®ÉÀ£¤O«D±`»´.

¦Ó³o¨Ç¥ýª¾¥ýıªºÁo©ú¿ú, ¥L­Ìªº¥ø¹Ï¤ß©M®æ§½¤S¦p¦ó©O? ¬O§_¤]¹³¤¨¦ÑÁ󪺶¯¤ß§§§Ó? ©Î¦p£«¬Â¤j»¡ªº "¤@¥Í¥u­n¤@¦¸´N°÷¤F"?

§Ú¤£ª¾¹D, ¦ý¬O¥L­Ì·|¤@¨B¤@¨Bªº¹º½u¸ô¹Ïµ¹§ë¸ê¤j²³¬Ý, Åý§ë¸ê¤j²³§PÂ_©M¿ï¾Ü.

¦³¤H¾á¤ß400¦h¤¸¬O§_¤Ó¶Q, «ç»ò¶R±o¤U¤â, ·|¤£·|¹³¥x·LÅé©Î°ò¨È¤@¼Ë¸y±Ù¦A¸y±Ù, ¶^¦^¤G¦Ê¦h¤¸©Î¤@¦Ê¦h¤¸?

¦pªG¯E¹©ªº¨ÅÀùÃĦ¨¥\¤F, ¤£¶È¦¨¥\¤W¥«, 5¦~«á¦¨¬°¥þ²yªº¨ÅÀù¯f±w©MÂå¥Íª§·mªº¼öªùÃÄ,

ºâºâEPS¬O¦h¤Ö¤¸, ªø´Á§ë¸êªºªk¤H©M¥ýª¾¥ýıªºÁo©ú¿ú·|µ¹¥¦¦h¤Ö­¿ªº¥»¯q¤ñ, ªÑ»ù·|º¦¨ì¦h¤Ö¤¸?

¥H438¤¸­nº¦¨ì5¦~«áªº»ù¦ì, ½u¸ô¹Ï­n«ç»ò¹º?

¦³¤H¥Î¯E¹©ªº¥«­È©M¥@¬É¤jÃļtªº¥«­È¬Û¤ñ, ù¤ó(Roche)ªº¥«­È¬ù¬üª÷2500»õ, ¥x¹ô7.5¥ü¦h.

ù¤óªºªÑ¥»¬ù¬üª÷69»õ, ¥x¹ô¤G¤d¦h»õ, ¯E¹©¬O¥x¹ô15»õ. ù¤óªºªÑ»ùUS36.03¤¸, ºâ¦¨¥x¹ô¬ù1096¤¸.

²{¦bªº¯E¹©·íµM¤£¯à©Mù¤ó¬Û¤ñ, ¯E¹©²{¦b¬O¤p©@, ¦pªG¨ÅÀùÃĦ¨¥\, ·|ºCºCÅܦ¨¤¤©@,

¦pªGOBI-833¤S¦¨¥\, ·|Åܦ¨¤¤¤j©@, ¥H«áªºÀç¾lÂà¼W¸êªº¼W­È¤~»¤´b°g¤H.

5¦~«á, OBI-833ªºÀø®ÄÀ³¸Ó¤w¸gª¾¹D¤F, ¦pªG¯uªº¤ñOBI-822§óÀu²§, ¯E¹©ªº»ù­È¤S·|¼W¥[¦h¤Ö­¿?

¦³¹Ú³Ì¬ü, ­n¤£­n³v(¿v)¹Ú, ½ÐÂÔ·V¦Ò¼{«á¦A¤U¨M©w.

¯E¹©¦pªG¯uªº¦¨¥\, ¥@¬É©Êªº¥Í§Þ§ë¸ê¸êª÷·|¤£·|Âà¦V?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý£«¬Â10136621  µoªí®É¶¡:2014/10/4 ¤U¤È 04:33:26²Ä 1334 ½g¦^À³
§Ú«ùªÑº¡2¦~,²Ä¤@§å¶R¶i10±i¥H438¤¸­è¦nì§Q6­¿,§Ú·Q³o½ú¤l¨S¿ìªk¦A§ä²Ä¤G­Ó¯E¹©,©Ò¥H¨M¤£»´©ö½æ±¼,¤@¥Í¥u­n¤@¦¸´N°÷¤F.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gµ½¤H10137888  µoªí®É¶¡:2014/10/4 ¤U¤È 02:47:56²Ä 1333 ½g¦^À³
¤j«Ó¤j¼gªº¯u¦n, "¿Ã¤õ¤§¥ú«ç»ò¸òµq¤ë¤§©ú¤ñ", §Î®eªº¤Ó¦n¤F.

¯E¹©ªº°ò¥»­±, Cliff¤j, rabbit¤j, ¤p©_¤j, ¥xÁÞ¤j, °e³ø¤j, ¤Î¦U¦ì¤j¤jªº°Q½×, ²³¯E¤Í³£¤w¸g¼ô±x¤F.

«Ü·|ötªº¤pötªÑ, öt¤@¤jªi¬q«á, Á`·|¦^ÀÉ20%, 30%, ¬Æ¦Ü50%¾ã²z¬~½L, Åý¨S¦³«H¤ßªºµu½uÄw½X¤U¨®, µM«á¦Aöt.

¨ì¥Ø«e¬°¤î, ¯E¹©¤£¬O¤pötªÑ, ¥¦¬O¦³ªø»·¼ç¤OªºÃ­°·ªÑ, ©Ò¥H¥¦ªº¨«¶Õ¬Oº¦¤@ªi¬q«á, ·|¦^Àɾã²z¤@¬q®É¶¡, µM«á¦Aº¦.

°£«D±z¬O¦p rabbit¤j¤§«e»¡ªº"¯«ªº¾Þ§@ ", ¦³¶W¤Hªº¥»»â, ½æ¦b¨C¤@ªi¬qªº¬Û¹ï°ªÂI, ¦bªi¬qªº¬Û¹ï§CÂI¶R¦^,

§_«h, ´N¨Ä¨Äªº¾Ç£«¬Â¤j, ©ê¨c¤Q¦~, Àò§Q¤Q­¿¥H¤W???

¯E¹©¦b¤WÂd«á©M¸Ñª¼¼Æ¾Ú¤½§G«á, ·|¤£·|Åܦ¨ötªÑ? ¦V¤Wöt©O? ©Î¦V¤Uöt©O? ´±¤£´±, ­n¤£­n°Ñ»P³o³õ²±·|,

´N¬Ý±zªºÁo©ú¤~´¼©M¤ß¯Ý¸£¤Oªº§à¾Ü.

¸Ñª¼¼Æ¾Ú¤½§G®É¥i¯à¤w¸g¤WÂd, ¦V¤Wöt, ±z·|·m¤£¨ì, ¦V¤Uöt, ±z·|½æ¤£±¼, ¯u¬O¨âÃøªº§à¾Ü.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/10/3 ¤U¤È 05:01:59²Ä 1332 ½g¦^À³
²q·Q¤j

±z²×©ó¤W¨Ó´«®ð¤F

§Ú¥H¬°±z¤U¨®¤F°Ç...«¢«¢«¢¡]¶}­Óª±¯º½Ð¨£½Ì¡^

§Ú¤ä«ù±zªº¬Ýªk

»P§Úªº·Qªk¤@­P

¯E¤Í­Ì

¤@°_Ä~Äò¥[ªo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G²q·Q10136148  µoªí®É¶¡:2014/10/3 ¤U¤È 04:12:44²Ä 1331 ½g¦^À³
¹ï¤£°_

¤p§Ì¥u¬O·Q§â³o­Óª©±À«e Åý¥¦§K©ó³Q®É¶¡²T¨S¦Ó¤w

¤j®a¹ï©ó½èºÃªº¨¥½× Á`¬O¤£Åwªï

¦ý¬O¤p§Ìı±o¨¥¤§¦³ª«ªº¤Ï¤è ¤~¯àÂç²M¦Û¤vªºª¼ÂI

¤£³ßÅw¤Ï¤è«äºû ¤H¤§±`±¡

¤£¹L¤]¤Ï¬M¥X§Ú­Ì¦]¤£½T©w ¤£§¹¥þ¤F¸Ñ©Ò±a¨Óªº«H¤ßµJ¼{

°²¦p§Ú­Ì¦³«H¤ß ¬O¤£¥Î­p¸û§O¤H¥ô¦ó¡¨ªÅ¤è¡¨¨¥½×ªº

·íµM ¹ï©ó¡¨¦h¤è¡¨ªº¨¥½× ©Î¤´±o¤p¤ß¨DÃÒ«á¦A±µ¨ü

¤]³\§Ú­Ì¦h¦³³o¼Ëªº¸gÅç

¹ï¬Y¨Ç¨Æª«¶V¤F¸Ñ §Ú­Ì´N¤ñ¸û®e©ö¤À¿ë¤å³¹ªº¥i«H«×

©Ò¥H§Ú­ÌÁÙ¬O­n§V¤O§l¦¬ª¾ÃÑ ¤@²´´N¥i¬Ý¬ï¤å³¹ªº¥iŪ©Ê

¤p§Ì¸Û¼°¦a«Øij¤j®a

½Ð§O¤Ï¹ï¦³®Ú¾Ú ¦³Å޿誺¤Ï¤è¨¥½×

¤]§OÅý¤Ï¤è¦]ÅU¼{¦ÓÀRÀq

§_«h§Ú­Ì±N·|¥¢¥h¹ï¬Y¨Ç¨Æª«§ó¥[²M·¡»{ÃѪº¾÷·|

¹ï¤£°_¤F ¤j®a

¦³«_¥Ç³B ½Ð±z®ü²[ ÁÂÁÂ!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý£«¬Â10136621  µoªí®É¶¡:2014/7/16 ¤W¤È 10:11:40²Ä 1330 ½g¦^À³
§Ú»Pµ½¤H¤jªº·Qªk¬Û¦P,§ë¸êªÑ²¼¤×¨ä¥Í§ÞªÑ»â¾É¤H«Ü­«­n,¦pªG¼Ðªº¶R¹ï¤F,´N§â¥¦·í¤@¥÷¨Æ·~ªø´Á«ù¦³,§Ú¥H«e»¡¹L§â¥¦·í«OÀI5¦~´Á.10¦~´Á,ì§Qµ´¹ï¤ñµu½u¶]¨Ó¶]¥h¦n,¦ýµ¥ÃĮĵ²ªG¥X¨Ó®É,ªÑ»ù¥i¯à¤£§C,¤j®a¤¬«j.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gµ½¤H10137888  µoªí®É¶¡:2014/7/15 ¤U¤È 11:44:10²Ä 1329 ½g¦^À³
Hi, Rabbit¤j,

±q±zªº¶K¤å, »{Ãѱz¬O¥M¸q¥¿¤H§g¤l, ¦]¦¹¦A»P±z²á¤@¨Ç¿v¹Úªº¤º¤ß¸Ü. ¤]´Á±æ¤j®a¤@°_¬ã¨s°Q½×, ¤¬§U¦X§@, ¤@°_¦¨ªø.

§Ú­Ì³£ª¾¹D, ¥ô¦óÀu¨}ªº²£«~, ³£»Ý­n±j¦Ó¦³¤Oªº¦æ¾P¨t²Î, ¤~¯à³Ð³y°ªÀ禬©M°ªÀò§Q.

¦U¦æ¦U·~³£¦³§Q¯q¤Äµ²ªº¶Â·t­±, ¤@­Ó·s²£«~·Q¦bµu®É¶¡¥´³q¥|­±¤K¤èªº¥«³õ, ¹ê«D©ö¨Æ.

±i¸³À³¸Ó¦­¤w¦Ò¼{¨ì¥¼¨Óªº¦æ¾PÃøÃD, ©Ò¥H¸u½Ð¶ÀÁ`·í°õ¦æªø, ¦Ü©ó¶ÀÁ`ªº¯à¤O¦p¦ó, ¥u¦³µ¥®É¶¡ÅçÃÒ.

§Ú­Ì¤]ª¾¹D, OBI-822/821Âಾ©Ê¨ÅÀù·sÃÄ, ¥xÆWªºÃÄÃҳ̧Ö2016¦~©³©Î2017¦~ªì¤~¯à®³¨ì, 2017¦~²Ä¤G©Î¤T©u¤~¯àÀò±o°·«Oµ¹¥I.

¦Ü©óFDAªºÃÄÃÒ, §ó¤£ª¾¦ó®É¤~¯à®³¨ì, ¦pªG¤@¤Á³£«ö¥¿±`ªºÁ{§Éµ{§Ç¨«, ¥i¯à2020¦~¤~¯à®³¨ìFDAªºÃÄÃÒ.

¦]¦¹¯E¹©ªºªÑ»ù¤£¬Oµu®É¶¡·|¤jº¦¨ì¤d¤¸©Î¥O¤H¿e¥Øªº»ù®æ, ¥u¬O¥Ø«e¥xÆWªº¥Í§ÞªÑ, ÁÙ¨S¦³¤H®³¹LÀù¯gÃĪºÃÄÃҩΦ³¥÷¶qªºFDAªºÃÄÃÒ,

¦pªG°ò¨È Ä_ÄÖ ´¼Àº³£¯à¶¶§Q¦pÄ@ªº®³¨ì¥xÆW©MFDAªºÃÄÃÒ, ÁöµM¥L­Ìªº«e´º¤£¨£±o«D±`«GÄR, ¦ý¬O¬O¥xÆWªº²Ä¤@¨B, ¬O²Ä¤@±iFDAªºÃÄÃÒ,

ªÑ»ùÀ³¸Ó·|¦³¤ÏÀ³, ¾ãÅé¥Í§ÞªÑ¤]¥i¯à¦³¥t¤@µf·s®ð¶H.

§Ú³Ìªñ¦³¤@ºØÅ鮩, ¬°¦ó§Ú¨S¦³²´¥ú©MÁxÃѦb¤Q¦h¦~«e¶R¶i¥x¿n¹q ¤j¥ß¥ú Ápµo¬ì©ÎÂE®ü, ¨Ãªø©ê¤Q¦h¦~»P¥L­Ì¤@°_¦¨ªø.

²{¦bªº¥xÆW¦³­þºØ²£·~ªº­þ´X®a¤½¥q, ¬O¤Q¦h¦~«eªº¥x¿n¹q ¤j¥ß¥úµ¥, ¥i¥HÅý§Ú­Ì¦w¤ßªº©ê¤Q¦~¥H¤W, »P¥L¤@°_¦¨ªø?

§ÚÁÙ¦bµ¥®É¾÷¥[½X¶R¯E¹©, ¤£¬Oµ¥»ù®æ, ¬Oµ¥OBI-822¨ÅÀùÃĽT©w¤£·|¥¢±Ñªº®É¾÷. §Ú¤ñ¸û±ß»{ÃѯE¹©, ©Ò¥H§Úªº¥­§¡¦¨¥»¦b260¤¸¥ª¥k,

¤£¹³£«¬Â¤j¨º»ò©¯ºÖ, ¦¨¥»¨º»ò§C, ¤£¹L¦pªG¯E¹©·|¦¨¥\, ¤Q¦~«á´N¤£¦b¥G¦¨¥»¬O100¤¸©Î400¤¸¤F.

§Ú¹ï¯E¹©¦³«H¤ßªº´X­Ó­ì¦]:

1. ¯Î°|ªø ±i©À·O©M¤¨¦ÑÁ󹳤£¹³¤Q¦h¦~«eªº±i©¾¿Ñ ªLÄ£­^ ½²©ú¤¶ ³¢¥x»Ê?

2. °¨°º¬°¦ó­nªá¼Æ¤d¸U¤¸¨ó§U¯E¹©°µ§Z±_Àùªº¤G´ÁÁ{§É¸ÕÅç? °¨°º¬°¦ó¤£±N¼Æ¤d¸U¯dµ¹­û¤u¥[Á~©Î°µ·Oµ½À°§U®z¶Õ¤H¥Á?

°¨°º¥i¯à¤w¸gª¾¹DOBI-822/821¯à°÷±Ï¨ÅÀù¥½´Áªº¯f¤H? ©Ò¥H­n°µ§ó¤jªº·Oµ½¨Æ·~.

3. Globo H¬O1983¦~Hakamori±Ð±Â¦Û¤HÅé¨ÅÀù²Ó­MMCF-7¤¤µo²{ªºÁÞ¯×Ãþ, ¥þ²y¨º»ò¦h¦³¦Wªº¤jÃļt,

¬°¦ó¤@ª½¨S¦³¤H¯à¥Î¥¦¬ãµoÀù¯g·sÃÄ? ¥i¨£¯Î°|ªø«D¤Z¤H¤]!

4. ´X¤Ñ«e§Ú¾ã²zªº¸ê®Æ, ¦A¶K¤@¦¸:

Phase 1 : 5¦~¥H¤W20/27(74.07%), 8¦~¥H¤W15/27(55.56%)

Gb5¦b¤@¯ë¨ÅÀù²Ó­Mªºªí²{²v¹F77.5%¡A¦Ó©ó¨ÅÀù·F²Ó­M«h¬°62.5%¡C

74.07%»P77.5%«Ü±µªñ, 55.56%»P62.5%¤]«Ü±µªñ, ªí¥Ü¬Æ»ò·N¸q©O?

¬O§_ªí¥ÜOBI-822/821¤]¯à®ø·À±a¦³Gb5ªºÀù²Ó­M©MÀù·F²Ó­M©O?

¦pªGOBI-822/821¦³³o»ò¦nªºÀø®Ä, OBI-833/832ªºÀø®Ä¤S¦p¦ó©O?

¦pªGOBI-833/832ªºÀø®Ä¯uªº¤ñOBI-822/821§ó¦n, «h10¦~«áªº¯E¹©·|¬O¬Æ»ò¼Ëªº¤½¥q©O?

³o´N¬O§Ú«e­±¼gªº"¬°¦ó§Ú¨S¦³²´¥ú©MÁxÃѦb¤Q¦h¦~«e¶R¶i¥x¿n¹q ¤j¥ß¥ú Ápµo¬ì©ÎÂE®ü", ¨S¦³¬Ý¨ì¤Q¦~«áªº»·´º.

¥H«e¤w¸g¿ù¹L¾÷·|, ¦pªG²{¦b¦³Ãþ¦üªº¾÷·|, ­n¤£­n´±¤£´±§ì¦í©O?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Grabbit10136567  µoªí®É¶¡:2014/7/15 ¤U¤È 06:21:51²Ä 1328 ½g¦^À³
Hi µ½¤H¤j¡A¤d¸U§O»¡¶û±ó¡A­Y§Ú¤§«e¦³¥ô¦óªº¸Ü»yÅý§A¦p¦¹·Pı¡A¨ºµ´«D§Ú¥»·N¡C

¹ï©óÃĪ«¥«³õªºµû¦ô¡A§Ú­Ó¤HÁÙ¬O°í«ù "«O¦u"¡A¨ÓÄ~Äò¬Ý Herceptin (ªü¶P) ªº¾P°â¸ê®Æ¡C

http://www.gene.com/about-us/investors/historical-product-sales/herceptin

Genentech ªººô­¶³ø§i¬O 1998 - 2008 ªü¶P U.S. Annual Selling¡A¥Ñ¨C¦~¦U©uªº¾P°âÁͶըӬݡAÃĪ«¨S¦³¬Æ»ò©ô¤£©ô©u¡A¨C©u³£¦³¬Û·í¥­§¡ªº¾P°â¡C1998¦~¤£¥h²z·|¡Aªü¶P 1999¦~ "¥u" ½æ¤F 1.837e ¬ü¤¸¡C

http://www.forbes.com/sites/simonking/2013/07/15/the-best-selling-drugs-since-1996-why-abbvies-humira-is-set-to-eclipse-pfizers-lipitor/

ªü¶P³Ì«e¤Q¦~¾P°â²Ö¿n: 222.24e¡A³Ìªñ¤­¦~306.25e¡A¦¹¤å³¹¬° 2013 ¦~µoªí¡CÁ`Åé 15¦~½æ¤F 528.49e¡C

¯E¹©­Y¦¨¥\¤W¥«¡A¥Îªü¶Pªº¦¨ÁZ¨Ó­n¨D¯E¹©ªº¦æ¾P¹Î¶¤¡A¤j®aı±o¹L¥÷¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©_10138298  µoªí®É¶¡:2014/7/13 ¤U¤È 01:37:28²Ä 1327 ½g¦^À³
³Ìªñ¥Í§ÞªÑ±þÁn¾_¤Ñ¡A§Ú¬ðµM·Q¨ì¤F§ë¸ê¯E¹©ªº´X­Ó¦n³B¡G

1.ªÑ¥«ªñ¸UÂI¤F¡A¥«³õ³£¦b²q°ê»ÚªÑ¥«¬O§_µû»ù¹L°ª­n¤ÏÂà¤F¡A¦ý¯E¹©ªº822«ùÄòµo´§ÃĮĤ¤¡A§ë¸ê»ù­È¥u¸ò¦Û¤vªºÃĮĦ³Ãö¡A¸ò¥þ²y´º®ðµLÃö¡A¤]¸ò¬ü°ê©ú¦~¤É®§Ãö«Y¤£¤j¡C

2.«Ü¦hªº·sÃĪѳ£­n¤£Â_¦aµ¥®ø®§¨Ó¨M©w¸ÓªÑ­n¶R­n½æ¡A¨Ò¦p¥«­È¥Ø«e¥«­È³Ì¤jªº°òX¡A¸¹ºÙ¦³900»õ¥x¹ôªº¥«³õ¡A7/27´N­n¤½¥¬µª®×¤F¡A«ç»ò§ë¸ê¤HÀ~¦¨³o¼Ë¡AªÑ»ù³£º¦¤F¦n´X­¿¡A¤£·Q¬Ý¤@¤Uµª®×¶Ü¡H¥t¥~§Ü¥Í¯ÀªºF-¤ÓX¡A³£¤w¸g½T©w¥i¥H§ð¶i¼s¤jªº¤¤°ê¥«³õ¡A¦ýªø½u¤jªÑªF¨C¤Ñ½æªÑ²¼¡A®M¨c¤F±¾µP«á©Ò¦³¶i³õªº§ë¸ê¤H¡FÁÙ¦³¯ØŦÀùªº´¼X¡A³£¤w¸g½T©wÃĮĤF¡A¦Ó¥B¬OFDA·|§å­ãªº·sÃÄ¡A¨½µ{ª÷µ¥µÛ¶i±b¡AªÑ»ù«o¬O¨£§Q¦h¤jº¦«á¦A¦^¨ì°_º¦ÂI¡C¬Ý°_¨Ó§ë¸ê³o¨Ç¥Í§ÞªÑ³£«Ü²Ö¡A­n¤£Â_¦a¸ò¤jªÑªF¡B¥D¤O¤Î¥«³õªº®ø®§§@¾Ô¡C¦ý¯E¹©¤£¥Î¡A¨S¦³´Á¤¤¤ÀªRªº®ø®§´N¬O¦n®ø®§¡A´Nºâ¦³´Á¤¤¤ÀªRªº®ø®§¡A¤]¥u»Ý­n¬Ý¬O¦ó®É¤½§i¡A¦A¨Ó±À¦ô¤@¤UPFS¡A¦A¨Ó¸ò¥Ø«e³Ì¦nªº¨ÅÀùÃÄ18.5­Ó¤ë¤ñ¸û¬Ý¬Ý¡C

3.ªk¤H­nµ¥±¾µP«á¡Aµ¥Á{§Éµ²ªG¦³§ó¶i¤@¨Bªºµ²ªG¤~·|¶i³õ¡A¯E¤Í¤w¸g¥ý¦b²î¤W¡A¥B®³¨ìªº°T®§¸òªk¤H¡B¥D¤O¦P¨B¡A¤£©È³Q§|±þ¡A¥B¯E¤Í¦³«Ü¦h±M·~¡B¼ö¤ßªº¤j¤j¡A¥i¥H®Ú¾Ú°T®§¨Óµû¦ô¥«³õªº¯u¯u°²°²¡A¥Hªï±µ©ú¦~¤¤µª®×ªº¤½¥¬¡A³Ì­«­nªº¬O¡A¦pªG´Á¤¤¤ÀªR¤@ª½¨S¦³»Ý­n°õ¦æ©Î¤ñ¸û±ßªº®É¶¡¤~°õ¦æ¡A¨º©ú¦~¤½¥¬µª®×®É¡A±N¬O¯E¹©ªø¦hªº¶}©l¡A¦Ó¤£¬O§Q¦h¥XºÉ¡C

«Ü¦h¤H·|ı±o§K¬ÌÀøªk¬O¦p¦¹¥ý¶iªºÂåÀø¬ì§Þ¡A°ê¥~ªº¤jÃļt³£ÁÙ¨S¦³¨ú±o¨M©w©Êªº³Ó§Q¡A¥xÆW¦³¥i¯à¶Ü¡H¯E¹©¦³¥i¯à¶Ü¡H¸U¤@¥¢±Ñ©O¡HªÑ»ù·|¶^¨ì­þ¸Ì¡H¨º±q¥t¤@¤è­±¨Ó¤Ï°Ý¡A¸U¤@¦¨¥\©O¡H­n¥X¦h¤Ö¿ú¥Ø«e¦b²î¤Wªº¤H¤~Ä@·N½æµ¹§A¡H

§Ú«Ü¦n©_¡A¯Î°|ªø7/19­n°µªººtÁ¿¡A¤@©w­n·Ç³ÆÁ¿½Z¡A¨º¨Æ«e»Ý¤£»Ý­n¥ý°Ý¤@¤U±i¸³¡A¥Ø«eªº´_µo¤H¼Æ¦³¦b¹w´Á¤§¤º¶Ü¡H

§ë¸ê½Ð¶q¤O¦Ó¬°¡AÁ{§É¼Æ¾Ú¥H¤½¥q¤½§i¬°·Ç¡AÁȨì¤j¿ú¤£§Ñ¦^õXªÀ·|¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GShabu10135634  µoªí®É¶¡:2014/7/13 ¤W¤È 10:44:11²Ä 1326 ½g¦^À³
¦Ó¥B¯Î±Ò´f°|ªøÁÙÂI¦W¤F°ò¨ÈPI-88...³o¬O·t¥Ü......7/27¤j®a¨Ó²q²q
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G£~£~10134649  µoªí®É¶¡:2014/7/13 ¤W¤È 12:25:39²Ä 1325 ½g¦^À³
§Ú»{¬°¯u¥¿ªºÃÄ´N¬O¯S®ÄÃÄ,¤]´N¬O¯à°÷®Úªv¯e¯fªºÃÄ¡C¥«­±¤W¥½ÀùªºÃĤj¦h¬O½w©M¯f±¡©Î©µ«á´_µo®É¶¡ªºÃÄ¡COBI-822¥¼¨Ó¦³¾÷·|¦¨¬°¥@¬É¤W²Ä¤@­Ó¥½Àù¥b¯S®ÄÃÄ¡C©IÀ³7/19°·±d°ª®p½×¾Â¯Î±Ò´fºtÁ¿ªºÃD¥Ø:¡u¬Ì­]®Úªv¨ÅÀù ¥¼¨Ó¤£¬O¹Ú¡v¡C

§Ú»{¬°­n½æ´N¶X²{¦b½æ¤@½æ,¦]¬°²{¦b¬O¤ñ¸û¤£½T©wªº®É­Ô¡C¦pªG¦³¤@¤ÑªÑ»ù¤W¤d®É,µ´¹ï¤£­n½æ,¦]¬°¨º®É­Ôªí¥Ü:1.¤£¤î¨ÅÀù¦³®Ä,¥u­n²Ó­M½¤¨ãGLOBO-HªºÀù¯g¥þ³¡¦³®Ä¡C2.¤£¤î¥xÆW±o±Ï,¥þ²yªº¯f±w³£·|±o±Ï¡C3.EPS·|¤W¤d,ªÑ»ù·|¤W¸U!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý£«¬Â10136621  µoªí®É¶¡:2014/7/12 ¤U¤È 11:04:21²Ä 1324 ½g¦^À³
¤µ¤Ñ¹ï¯Î±Ò´f»¡:¥xÆW¥Í§Þ§Y±N±È¤ýµP³o¥y¸Ü,«ä¦Ò¤F¤@¤Uª½Ä±§i¶D§Ú,¯Î±Ò´f¬O«Ü«O¦u内¦Vªº¤H,·|»¡¥X³o¥y¸Ü¥Nªí³o¤ýµP¦¨¥\²v¤£¥u°ª¦Ó¥BÃĮīD±`¦n,¤j®a«ä¦Ò¬Ý¬Ý.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý£«¬Â10136621  µoªí®É¶¡:2014/7/12 ¤W¤È 09:38:53²Ä 1323 ½g¦^À³
§Úªº·Qªk¸òµ½¤H¤j©MFaith¤j¤@¼Ë­n¶R´N¶R³Ì¦n,©Ò¦³¥Í§ÞªÑ§Ú³Ì¬Ý¦n¯E¹©,¦¨¥»±q70¤¸90¤¸¦Ü293¤¸³£¦³¹ï±i©À·O.¯Î±Ò´fªº±M·~²`«H¤£ºÃ.¤¤¸Î¤]¤£¿ù¦ý«ùªÑ¸û¤Ö.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/7/12 ¤W¤È 09:15:47²Ä 1322 ½g¦^À³
¤p§Ì´¿¥þ¼Æ¾Ö¦³¤¤¸Î

«á¨Ó¥þ´«¦¨¯E¹©

§Ú¤]¨S°ò¨È

¥u¬O·|Ãö¤ß¥Í§Þªº¯ß°Ê

§Úª¾¹D½äª`«Ü¤j

¦ý¦]¬°¬Û«H¡B©Ò¥H°í«ù

¯E¹©¦b¤Q¦~«eÁp¦X³ø¥Z¹L¤@¦¸·s»D§Ú´N¦b§ä¥L¤F

¬O¤£¬O¤d¨½°¨

´N­@¤ßµ¥«Ý¤F

¤j®a¤@°_¥[ªoÅo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/7/12 ¤W¤È 09:07:31²Ä 1321 ½g¦^À³
µ½¤H¤j¡GÁÂÁ§AºëÅPªº¤ÀªR

¤p§Ì¤]¦³»P§A¦P¼Ëªº±À´ú

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gµ½¤H10137888  µoªí®É¶¡:2014/7/12 ¤W¤È 03:14:14²Ä 1320 ½g¦^À³
Hi Rabbit ¤j,

©]²`¤HÀR, »P±z²á¤@¨Ç¿v¹Úªº¤º¤ß¸Ü, §Æ±æ±z¤£·|¶û±ó.

¦]¬°Faith¤jªº¶K¤å:

Faith10138335 µoªí®É¶¡:2014/7/8 : "§Ú±q°ò¨È«Å¥¬­n´Á¤¤¤ÀªR®É, ´N¦Ê«ä¤£±o¨ä¸Ñ, ³£¤w¦¬§¹®×¤F, ÁÙ¦]¨ì¹F´_µo¤H¼Æ¶i¦æ´Á¤¤¤ÀªR, ³o¤¤¶¡¨S¦³¥Ù¬Þ¶Ü? ¤£ª¾¦³¨S¦³­þ¦ì¤j¤j¥i¸Ñµª?"

§Ú¦³¬Ý¹L°ò¨Èªº³ø¾É, ©Ò¥H¼g¤F¤@¨Ç»¡©ú, §Æ±æ¯à¸ÑµªFaith¤jªººÃ°Ý. §Ú­Ì³£ª¾¹D, ¯E¹©硏µoªºÀù¯g·sÃÄ, ³£¬O¥HGlobo H¬°¥D¶b, ¥Ø«e¨S¬Ý¹L³ø¾É»¡¨xÀù²Ó­M¬O§_¦³Globo H.

¦]¦¹, ¯E¹©¬O¤£·|硏µo¨xÀù·sÃÄ. §Ú¼g: "¦pªG¯E¹©¤]¯à硏µoªvÀø¨xÀùªºÃÄ, ¨­»ù±N¼W¥[¤@­¿¥H¤W." ¬O¿ù»~ªº°²·Q.

§Ú¨S¦³¶R°ò¨ÈªºªÑ²¼, §Ú¹ï¯E¹©¦³«H¤ß, ©Ò¥H«ùªÑ¥H¯E¹©¬°¥D, ¤¤¸Î¬°»², ¥Hªø´Á§ë¸êªº¤ßºA, ·Q¸ò¯E¹© ¤¤¸Î¤@°_¦¨ªø, °£«D¥L­Ì¥¢±Ñ¤F.

§ÚÁÙ¦bµ¥¥[½Xªº®É¾÷, ¤£¬O»ù®æ, ¬O®É¾÷, ¦pªG¯E¹©·|¦¨¥\, ¥H«áªºªÑ»ù·|º¦¨ì¤d¤¸¥H¤W, ¦b¥G¬O300¤¸¶R¶i©Î400¤¸¶R¶i¶Ü? ¥Ø«e¶i¤J¾ã²z´Á, ´NÅý¥¦¾ã²z, ²M¬~¨S¦³«H¤ßªºÄw½X.

¹ï¯E¹©¦³«H¤ß, ¬O°ò©ó¹ï¯Î°|ªø ±i©À·O©M¤¨¦ÑÁóµ¥³»¦yºë­^¦³«H¤ß, ·íµM¤]¬Ý¤F¦³Ãö¯E¹©ªº¦UºØ¸ê°T, §PÂ_OBI-822/821Âಾ©Ê¨ÅÀù·sÃĪº¦¨¥\¾÷²v«D±`°ª, ¥¼¨Óªº¥«³õ«D±`¤j,

¬O¥Ø«e¥xÆW©Ò¦³¯à¶R½æªº¥Í§Þ·sÃĬãµo¤½¥q¤¤, ³Ì­È±o§ë¸ê, ¤U½äªº. Á`¤§, §Ú«Ü»{¦P±zªº¬Ýªk, ¤]«D±`·PÁ±z®É±`¶K¤@¨Ç·sªº¸ê°T»P¤j®a¤À¨É.

OBI-822/821ªºÂಾ©Ê¨ÅÀùÃĦpªG¦¨¥\®³¨ìÃÄÃÒ, ¨ä»ù­ÈÀ³¤£¥u¤d¤¸¯àº¡¨¬, ´NÅý¥«³õ¥h¨M©w¥¦ªº»ù­È§a. §Ú·Q ¨º®Éªº¯E¹©, ±N¦¨¬°¦³¿ú¤H©Mªk¤H°l³v§ë¸êªº­º¿ï.

¦]¬°¨ÅÀùÃÄ·|¦¨¥\, §Z±_ÀùÃĤ]À³¸Ó·|¦¨¥\? ´X¦~«á, OBI-833, 888ªº¨ä¥LÀù¯gÃĤ]¥i¯à·|¦¨¥\? ÁÙ¦³ÁÞ´¹¤ùÀËÅç¸Õ¾¯µ¥, Áo©úªº¦³¿ú¤H©Mªk¤H´N·|¦ôºâ¯E¹©ªºªø´Á»ù­È.

¨º®Éªº¯E¹©¤£¦A¬O°µ¹Ú´Á, ¦Ó¬O¦³¹ê½èÀò§Q, Ãzµo©ÊªºÀò§Q¦¨ªø´Á, ¦ÓªÑ»ùÁ`¬O´£«e¤ÏÀ³¥¼¨ÓªºÀò§Q, ´N¹³¤j¥ß¥ú, ¦³¤H¦ô¤µ¦~EPS100¤¸, ©ú¦~EPS120¤¸, ªk¤H¤w±NªÑ»ù³Û¨ì3000¤¸.

¥H¤Wªº°²·Q»Ý­n®É¶¡¦ÒÅç, ¹ï¯E¹©¦³«H¤ß, ·Q¿v¹Ú¤U½äªÌ, ´N­@¤ßµ¥«Ý¯E¹©¤½¥q¶}­»Âb¼y¯¬®bªºÅw©I³õ´º¬O§_·|¨ÓÁ{!?

¥H¤W¯ÂÄÝ­Ó¤Hªº²q·Q . ¥ô¦ó§ë¸ê³£¦³­·ÀI, ½Ð¦Û¦æ§PÂ_·V«ä«á¦b¤U¨M©w.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Grabbit10136567  µoªí®É¶¡:2014/7/9 ¤U¤È 06:15:33²Ä 1319 ½g¦^À³
http://iknow.stpi.narl.org.tw/Post/Read.aspx?PostID=9705

Y2012 Y2013 (³æ¦ì¡G»õ¬ü¤¸)

03.Herceptin Roche HER2+¨Å¸¢Àù 62.83 65.57

11.Xeloda Roche ¨Å¸¢Àù,µ²ª½¸zÀù 16.24 16.29

13.Afinitor Novartis¨Å¸¢Àù ¡Ð 13.09

19.Zoladex AstraZeneca¨Å¸¢Àù, «e¦C¸¢Àù 10.93 9.96

¥Ñ¦¹¸ê®Æ¥i¥H¬Ý¥X¡A¯E¹©§Gªº§½¦b¥«³õ¤W¬O¦h»òªºÃe¤j¡AµL½×¬O°µ¹Ú¤]¦n¡A­n¤£­n¿ï¾Ü¦b³o±ø²î¤W¡A³£¬O¥Ñ§A¦Û¤v¨M©w¡A

Á`¤§¡Aµ¥«Ý¤W ¤jÁp·ù¥«³õ ªº ¯E¹© ¡A¦U¦ì¦³»Ý­n¬°¥¦²{¦bªºªÑ»ù¤Ñ¤Ñ¾á¤ß¶Ü?

§O¬Ý¤F°ò¨ÈªºªÑ»ù´N©Á©Á¤£¥­©Î¸r¼}¡A¥¦ªº»ù­È¦¨¥\«á©Î³\¬O 800 ¡A¦ý¥«³õ©Î³\´N¬O¥uµ¹¥¦ 800¡A±Æ¦æº]¤W¡A¨xÀù¦b­þ¸Ì?

¯E¹©­Y¦¨¥\®³¨ìÃÄÃÒ³s 1000 ³£¨S¦³¡A¨º¤j®a§â²{¦b¾á¤ßªº¤O®ð¯dµÛ¨Ó¥hªÑªF·|¤j©ñ¬¶¦æ¾P³¡ªùÁÙ¤ñ¸û­È±o¡C

P.S. §ë¸ê¥Í§Þ¦³ÁÈ¿ú¡A§O§Ñ¤F°µ·Oµ½¡A¦æ¤½¯q¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GFaith10138335  µoªí®É¶¡:2014/6/28 ¤U¤È 04:52:09²Ä 1318 ½g¦^À³
1.¸³¨Æ·|¨Mij¤é´Á:103/06/27

2.ªÑªFÁ{®É·|¥l¶}¤é´Á:103/07/23

3.ªÑªFÁ{®É·|¥l¶}¦aÂI:¥x¥_É]´°¤Æ«n¸ô¤G¬q97¸¹11¼Ó(¤¸´IÃÒ¨é±Ð¨|°V½m¤¤¤ß)

4.¥l¶°¨Æ¥Ñ:

¤@¡B³ø§i¨Æ¶µ

(1) ­×­q¡y¸³¨Æ·|ij¨Æ³W«h¡z³¡¥÷±ø¤å®×¡C

¤G¡B°Q½×¨Æ¶µ

(1) ­×­q¡y¤½¥q³¹µ{¡z³¡¥÷±ø¤å®×¡C

(2) ­×­q¡yªÑªF·|ij¨Æ³W«h¡z³¡¥÷±ø¤å®×¡C

(3) ­×­q¡yÃö«Y¤H¡B¯S©w¤½¥q¤Î¶°¹Î¥ø·~¥æ©ö§@·~µ{§Ç¡z³¡¥÷±ø¤å®×¡C

(4) ­×­q¡y¸³¨Æ¤ÎºÊ¹î¤H¿ïÁ|¿ìªk¡z³¡¥÷±ø¤å®×¡C

¤T¡B¿ïÁ|¨Æ¶µ

(1) ¸É¿ï¿W¥ß¸³¨Æ¤G®u¤Î¼W¿ï¸³¨Æ¤@®u¡C

¥|¡B¨ä¥L°Q½×¨Æ¶µ

(1) ¸Ñ°£¥»¤½¥q¸³¨ÆÄv·~¸T¤î¤§­­¨î®×¡C

¤­¡BÁ{®É°Êij¡C

5.°±¤î¹L¤á°_©l¤é´Á:103/06/24

6.°±¤î¹L¤áºI¤î¤é´Á:103/07/23

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
12345678¤U¤@­¶³Ì«á¤@­¶

         

¡@

§Ú¡@¡@­n¡@¡@¦^¡@¡@À³¡@¡@¥»¡@¡@¸Ü¡@¡@ÃD

·| ¡@­û¡G

  

§@ ªÌ ¡G

 

¬ÛÃöªÑ²¼¤½¥q¦WºÙ ¡G

¥xÆW¯E¹©¥Í§Þ

¤º¡@ ®e¡G

¡@
½Ð¥ýµn¤J ­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹ ¡@
¡@

°Q½×°Ï¬ÛÃö³W©w¡G
    1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
    2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C


¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178   ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѠ ¬ÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ  ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß  ¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!